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Abstract
Chondroitin sulfate (CS), a member of the glycosaminoglycan family of linear polysac-
charides, is involved in the formation and maintenance of neuronal networks. CS has
dual roles in regulating neuronal morphology: promoting or inhibiting neuronal out-
growth, depending on the context. A single sulfated epitope, CS-E, is capable of
inducing both types of activity.
Members of the neurotrophin (NT) family of growth factors are required for CS-
E-induced neurite outgrowth in hippocampal neurons. Here, we demonstrate that
CS is capable of forming ternary complexes with NTs and their receptors. These
complexes were discovered using a novel, carbohydrate microarray-based approach
that allows for the rapid screening of such interactions. To support these findings,
we computationally determined the CS-E-binding site of the complexes, suggesting a
structural basis for the interaction. In addition, we showed that CS-E is capable of
attenuating NT signaling in cells, consistent with our computational and microarray
data. This is the first demonstration that CS-E is involved in NT signaling and that
CS is capable of supporting multimeric signaling complexes.
In addition to stimulating growth factor signaling, CS has been known to repul-
sively guide retinal ganglion cell (RGC) axons for over twenty years. However, its
function in vivo is unknown. RGCs are the only neuron type that transmits visual
information to the brain, and their guidance, which maps a topographic projection
of the retina to the superior colliculus (SC), is tightly regulated. Here, we show that
CS-E is required for the proper formation of this topographic order. CS-E, but not
the other major sulfation patterns, is a repellent guidance cue for RGC axons, with
a graded activity profile from low to high along the dorsal-ventral axis of the retina,
viii
congruent with EphB3 expression. EphB3 binds specifically to CS-E with physiolog-
ically relevant affinity, and is required for CS-E-mediated guidance. CS-E-null mice
have defects in topographic mapping in which ventral axons form ectopic termina-
tions medial to their correct location in the SC. These results indicate that CS is a
repulsive guidance cue required to map the dorsal-ventral axis of the retina along the
lateral-medial axis of the SC. This is the first report of a non-protein topographical
guidance cue.
ix
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1Chapter 1
Glycosaminoglycan Structure and
Function
1.1 Introduction
Carbohydrates are an essential component of life. From the simplest organisms to the
most complex, carbohydrates play diverse and essential roles in biology. Carbohy-
drates exist as simple sugars and complex polysaccharides known as glycans. Glycans
mediate cell-cell and cell-matrix interactions critical for the development and func-
tion of complex organisms. Specifically, a linear glycan family, glycosaminoglycans
(GAGs), fulfills myriad functions in vivo that range from providing structure to tis-
sue, such as in the vitreous humor of the eye, and facilitating joint lubrication and
movement,1,2 to multiple roles in cell signaling and development. For instance, gly-
cosaminoglycans are involved in angiogenesis,3 axonal growth,4 tumor progression,5,6
metastasis,5,7 and anti-coagulation.8,9 Furthermore, loss of normal GAG function
is implicated in a human diseases, including an overgrowth and tumor-susceptibility
syndrome, Simpson-Golabi-Behmel dysmorphia (SGBD), and multiple hereditary ex-
ostoses (MHE), which causes the formation of multiple bony tumors in children.10,11
GAGs are large (typically 10–100 kDa), highly charged, and heterogeneously sul-
fated molecules composed of repeating disaccharide units of alternating uronic acid
(d-glucuronic acid (d-GlcA) or l-iduronic acid (l-IdoA)) and hexosamine (d-N -
acetylgalactosamine (d-GalNAc) or a d-N -acetylglucosamine (d-GlcNAc)). GAGs
are generally located on the cell surface or in the extracellular matrix and are at-
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Figure 1.1: Representative structures of the glycosaminoglycan family. The structures can
be further elaborated by sulfation at the indicated positions. R = H or SO–3, R’ = H, Ac,
or SO–3.
tached to a protein core as a post-translational modification.12 Members of the GAG
family, chondroitin sulfate (CS), dermatan sulfate (DS), heparan and heparin sulfate
(HS), hyaluronic acid (HA), and keratan sulfate (KS), vary subtly in stereochemistry,
length, and sulfation pattern.
The principle taxonomic difference between the GAG family members is the struc-
ture of the repeating disaccharide unit (Figure 1.1). CS, the most abundant GAG
in the nervous system,13 is composed of a repeating d-GlcA-β(1 → 3)-d-GalNAc-
β(1 → 4) disaccharide. DS has a very similar structure to that of CS, differing only
in the stereochemistry of the C -6 position of the uronic acid. KS, unique among the
GAGs, does not contain uronic acid and is instead composed of a d-Gal-β(1→ 4)-d-
GlcNAc-β(1→ 3) disaccharide motif. HA is the only unsulfated GAG, and contains
a d-GlcA-β(1→ 3)-d-GlcNAc-α(1→ 4) disaccharide motif. HS and heparin contain
a repeating l-GlcA-α(1→ 4)-d-GlcN-α(1→ 4) disaccharide motif, as well as l-IdoA-
α(1→ 4)-d-GlcN-α(1→ 4). Sulfation provides further structural diversity. A simple
octasaccharide can have greater than 1, 000, 000 possible sulfation patterns.14
Sulfation is spatiotemporally regulated in vivo, and the sulfation pattern lies at
the heart of GAG bioactivity.15–19 For example, the expression of 6-O-sulfated HS
is graded from high to low along the proximal-distal axis of the developing chick
wing bud.20 Fibroblast growth factor 10 (FGF-10), which is essential for limb induc-
tion and apical ectodermal ridge maintenance, requires 6-O sulfation for activity.21,22
3Therefore, the precise spatial control of HS sulfation is necessary for proper develop-
ment of the chick wing. Moreover, the expression of CS sulfotransferases required for
the biosynthesis of the highly sulfated CS are temporally regulated during early post-
natal development in the mouse cerebellum,23 and CS expression is upregulated in the
glial scar following central nervous system (CNS) injury.24,25 This suggests that the
fine structure of GAGs, and not just bulk electrostatics, is essential to understanding
their activity.
1.2 The Role of Glycosaminoglycans in Neuronal De-
velopment
The development of the mammalian central nervous system proceeds through roughly
four major steps: (1) the patterning of the neural tube, (2) generation of neurons from
neural stem cells and their migration to genetically predetermined destinations, (3)
extension of axons and dendrites toward target neurons to form neuronal circuits,
and (4) formation of synaptic contacts. These developmental processes are regulated
by a number of morphogens, growth factors, axon guidance molecules, and adhesion
molecules; and, an increasingly large body of data indicates that GAGs are function-
ally involved in all of the major stages of neural development via interactions with
these proteins. For example, CSPGs have been implicated in regulating the migration
of neural crest cells.26,27 Endogenous CSPGs and HSPGs are enriched in the growth
environment of neuronal stem cells, and both are required for the normal neuronal
specification of mouse embryonic stem cells.28–30 Both CSPGs and HSPGs have been
shown to modulate the growth and guidance of axons and dendrites. Both GAG
types have been shown to act as both an attractant and a repellent guidance cue and
both positively and negatively modulate axonal outgrowth.31 HSPGs, and possibly
CSPGs, may play functional roles in synapses.32 In the neuromuscular junction, the
synapse formed between the nerve terminal of a motor neuron originating in the spinal
cord or hindbrain and a skeletal muscle fiber, almost all proteins have been shown to
4CS CS 
Inhibition Stimulation 
+ CS 
- CS 
+ CS 
- CS 
Figure 1.2: Dual roles for chondroitin sulfate in neurite outgrowth. Depending on the
context, CS can either promote (right) or inhibit (left) neurite outgrowth. It has been
shown that the CS-E motif can act in both capacities, suggesting the difference in phenotype
depends on neuron-type specific interactions with CS.
bind HSPGs and CSPGs, and HSPGs are prevalently expressed in this region.32–35
The functional scope of GAGs in the developing nervous system is very broad, and
while CSPGs and HSPGs are involved in similar processes, the role that each GAG
serves in development is quite different.
1.2.1 Chondroitin Sulfate in Neuronal Development
CSPGs are thought to play important roles in various cellular events in the formation
and maintenance of the neuronal network.36,37 These proteoglycans are commonly
thought to act as a barrier during neural development;31 however CSPGs have also
been shown to promote neuronal growth in certain contexts (Figure 1.2).38–40 The
dual roles for CSPGs are likely due to differences in the CSPG-binding factors on neu-
ron surfaces, as the proteoglycans neurocan and phosphacan have both been shown
to have bifunctional neurite outgrowth activity.13 Later studies with CS molecules of
defined structure demonstrated that a particular sulfated epitope, CS-E (Figure 1.3),
is capable of promoting and inhibiting neurite outgrowth.15,41 Furthermore, sulfation
can specify the outgrowth phenotype. In some contexts, CS-E and CS-D, another
sulfation motif with the same overall charge as CS-E but in a different spatial ar-
5rangement, stimulate neurite outgrowth but have different effects on neuronal mor-
phology.42 Here, we discuss the current understanding of the molecular mechanisms
underlying these processes.
1.2.1.1 Chondroitin Sulfate Is a Repulsive Guidance Cue
There are many examples of CSPGs forming boundaries for elongating axons and
influencing axonal pattern formation. During development, strong immunostaining
for CS often localizes to territories thought to act as barriers to migrating neurons
or extending axons, such as the posterior sclerotome,43,44 the dorsal midline of the
spinal cord and the optic tectum,44 and the epidermis and basal lamina of innervated
skin.45 CSPGs are expressed at the interface of the somites and the notochord in
embryonic zebrafish, and CS is required to constrain the projection of spinal motor
axons ventrally in order to establish the midsegmental ventral motor nerves.46 The
role of CS in guiding developing axons is discussed in greater detail in Chapters 4
and 5.
CS is also known to serve a significant role in inhibiting adult neural regenera-
tion.41,47–50 CSPGs are upregulated after injury in the CNS25 and inhibit regeneration
in vivo.51 At the site of injury, a glial scar develops containing CSPGs and other ex-
tracellular matrix molecules.52 CS-C and CS-E are overexpressed in the glial scar,
whereas CS-A is the dominant sulfation pattern in the uninjured CNS.49 Upregulation
of highly sulfated CSPGs is actually beneficial in the repair of injured spinal cords
and in the recovery of motor function during the acute phase after the injury. CSPGs
spatially and temporally controls the activity of infiltrating blood-borne monocytes
and resident microglia.53 However, at later stages in wound repair, the presence of
CSPGs becomes deleterious. Removal or blockage of CS chains, by enzymatic diges-
tion or treatment with an anti-CS-E antibody, can improve axonal regeneration.41,48
Like other inhibitory proteins, CSPG-mediated inhibition depends on activation of
RhoA and conventional protein kinase Cs (PKCs).54–57 Recently, specific neuronal re-
ceptors for CS have been identified, including receptor protein tyrosine phosphatase σ
(RPTPσ) and Nogo receptor (NgR) family members.58,59 RPTPσ, NgR1, and NgR3
6were found to interact with heavily sulfated CS motifs, such as CS-D and CS-E, with
approximate K
D
values between 3.0–0.1 nM. Interestingly, both RPTPσ and the NgR
family members also interact strongly with heparin, and RPTPσ appears to be more
selective for CS-E and heparin than other oversulfated CS motifs, while NgR binds
to these GAGs with approximately equal affinity.59
In culture, RPTPσ−/− mutant and NgR1−/−;NgR3−/− double-mutant neurons
show reduced inhibition by CSPGs, and RPTPσ−/− or NgR1−/−;NgR3−/− mutant
mice show enhanced axonal regeneration post-injury.58,59 Regeneration in NgR1−/−;
NgR3−/−;RPTPσ−/− triple mutant mice was further enhanced while single NgR mu-
tants did not exhibit any additional regeneration.59 These results suggest that there is
functional redundancy among CSPG receptors. While RPTPσ and NgR exhibit sim-
ilar responses to GAGs, the proteins have significantly different CS-binding regions.
The GAG-binding site of RPTPσ is in the first immunoglobulin (Ig)-like domain
in its sequence, and the first two Ig domains comprise the minimal stable unit for
GAG binding.60 However, GAG binding in the NgR family members occurs near
the C-terminal capping domain and requires the juxtamembrane stalk domain, which
contains a highly conserved cluster of basic amino acid residues (see also, Appendix
B).59 Perhaps unsurprisingly, little primary sequence homology exists between these
two domains suggesting that a specific arrangement of basic amino acids in the ter-
tiary structure is all that is required for CS-binding activity, rather than a specific
consensus sequence (see also, Chapter 2).
Whether or not either of these proteins interact with CS to affect development
remains unclear. In contrast, the chick ortholog of RPTPσ, CRYPα, has been shown
to promote intraretinal axon growth through HS.61 HSPGs have also been implicated
as ligands for CRYPα in the topographic mapping of retinal axons. Chicks that
excreted soluble CRYPα had defects in axon targeting along the anterior-posterior
axis of the tectum.62 CRYPα is expressed by developing neurons throughout the
retinotectal projection,63 in a pattern congruent with CS;64 however, an inhibitory
role for CRYPα has not been established. In addition, HS has been shown to act
as a growth-promoting ligand for RPTPσ in P8 mouse dorsal root ganglion (DRG)
7neurons in vitro, suggesting the two ligands induce opposing neuronal activity through
the same receptor.60
1.2.1.2 Chondroitin Sulfate Stimulates Neuronal Growth
While CS has been shown to inhibit neuronal growth in a variety of contexts, it also
promotes neurite outgrowth. CS does not always exclude the entry of axons;44,65 in
fact, CS expression coincides with developing axon pathways in some cases.38,64,66
Furthermore, evidence from in vitro studies suggests that CSPGs,67,68 CS,39,69 and
synthetic CS analogs15,70 promote rather than inhibit neurite outgrowth.
There is some evidence to suggest that the growth-stimulatory/growth-inhibitory
effects of CS are highly dependent on the local molecular milieu. For example, in the
thalamocortical system, CS has been shown to exhibit both stimulatory and inhibitory
effects on thalamic axons.71 Thalamic axons project from the thalamus, through
the cerebral wall within the subplate to their appropriate target neurons within the
cortical plate. CS immunostaining increases as the thalamic axons travel through the
subplate and in the cortical plate when the axons extend to their target neurons.66,72,73
When cultured onto living slices of mouse forebrain, thalamic neurons are inhibited
by slices from the cortical plate and stimulated by slices from the intermediate zone
and subplate. In both instances, these effects were sensitive to enzymatic digestion
of the CS chains via chondroitinase ABC (ChABC) treatment or the addition of
soluble CS.71 It is striking that CS can affect both growth-stimulatory and inhibitory
responses in the same neuron type depending on the local environment. These findings
suggest that local CS-binding molecules are responsible for the differential response
to CS from these neurons. On the other hand, it is possible that the different cortical
layers express different CS sulfation patterns, which bind to a unique set of molecules
and initiate divergent signaling pathways.
Unfortunately, the role of sulfation was not examined in this context, as later
studies have shown that the sulfation motifs on CS can drastically affect its activity.
Indeed, CS polysaccharides enriched in the CS-D and CS-E sulfation motifs (Fig-
ure 1.3) have been shown to have different growth-promoting effects on developing
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Figure 1.3: The structures of the common sulfation patterns of chondroitin sulfate
hippocampal neuron morphology.68,74–76 CS-D was found to increase the number
of neurite-bearing neurons in culture and the average length of their processes. In
contrast, CS-E dramatically increased the growth of a privileged long process bound
to become an axon.76 In other words, polysaccharides enriched in the CS-E motif
favors the growth of an axon-like projection, whereas CS-D-enriched polysaccharides
favors dendrite-like processes. Other CS motifs, such as CS-A, -B (DS), and -C did
not have a significant effect on neurite outgrowth. Similarly, DS has been shown to
increase the formation of dendritic outgrowth in cortical neurons while HS promotes
axonal growth.69,77 In some contexts, GAGs have been shown to lower growth cone
adhesion to the substratum.39 It has been proposed that dendritic growth requires
higher adhesion.78 Thus, GAGs which lower adhesion of a specific neuron type may
favor axon growth over that of dendrites.
One problem with these studies is that the role of sulfation motifs cannot be con-
clusively ascertained using heterogeneous CS polysaccharides, due to the presence of
various sulfation motifs of different lengths. To address this problem, CS tetrasac-
charides bearing homogeneous sulfation patterns were synthesized and used as a sub-
stratum for hippocampal neuronal culture. CS-A, -C and unsulfated tetrasaccharides
had no apparent effect on neurite outgrowth, while CS-E tetrasaccharides promoted
the growth of a single neurite.15,70 Preliminary studies show that CS-D tetrasac-
charides increased the growth of dendrites, but did not favor axons like CS-E (S.-G.
Lee and L. C. Hsieh-Wilson, unpublished data). Unlike the heterogeneous polysac-
9charides which can vary in length, degree of sulfation, and the patterns of sulfation,
synthetic tetrasaccharides allow for the direct comparison between the motifs. For
example, CS-D has the same overall charge as CS-E but displays a different sulfation
pattern and has remarkably different activity (Figure 1.3). These differences suggest
that CS interacts with proteins in a defined ligand-binding site where the particular
spatial arrangement of the ligand is required to make the appropriate contacts with
amino acid residues on the protein, and CS-binding proteins are not merely electro-
static sinks for negatively charged GAGs. Indeed, a disulfated CS motif that has not
been observed in nature, termed CS-R, with sulfation at the 2- and 3-O positions
of GlcA, did not have an observable effect on neurite outgrowth, despite having the
same overall charge as CS-D and -E.15 Soluble growth factors, known to affect neurite
outgrowth, have been shown to interact with highly sulfated CS structures and are
suspected to be responsible, in part, for the growth-promoting activity of CS.15,79 For
example, both midkine (MK) and brain-derived neurotrophic factor (BDNF) selec-
tively bind to CS-E at physiologically relevant concentrations and have been shown
to induce neurite outgrowth in vitro. Moreover, inhibiting either the growth factor
or its cell-surface receptor using function-blocking antibodies prevents CS-E-induced
outgrowth.15 Presumably, CS may induce neurite outgrowth by increasing the local
concentration of specific growth factors to the cell surface via specific, oversulfated
motifs, thereby increasing local signaling (See also, Chapter 2).
1.2.1.3 Summary
These findings suggest that stimulation and inhibition of neurons by CS proceeds
through different mechanisms that are highly dependent on sulfation. Increasing
evidence suggests that differences in the CS sulfation pattern are sufficient to have
different effects on neuronal morphology. Studies with synthetic tetrasaccharides have
demonstrated that the difference cannot be attributed to other factors, such as charge
or length. Interestingly, differences in CS fine structure are not strictly responsible
for the dual activities of CS. Indeed, the CS-E sulfation motif can promote either
axonal growth or inhibition depending on the context. This, and other evidence,
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suggests that the combination of the cellular milieu and spatiotemporally regulated
sulfation determines what activity CS will have in vivo. As our understanding of the
factors and CS-binding partners that regulate these processes increases, so will our
understanding of the structural determinants that affect CS activity.
1.2.2 Heparan Sulfate in Neuronal Development
Traditionally, HSPGs were thought to be growth stimulatory while CSPGs were
thought to be growth inhibitory. As the preceding discussion has demonstrated,
this is not accurate. Just as CS has been shown to have bifunctional roles in promot-
ing axonal growth, the neuritogenesis activity of HS depends on the cellular context.
Indeed, investigators have discovered diverse activities for HS. Genetic mutation of
enzymes required for HS biosynthesis have greatly facilitated our understanding of
the roles and importance for this class of GAG. In particular, studies using dally mu-
tants in Drosophila and Nestin-Cre+;Ext1lx/lx conditional knockout mice have been
invaluable for understanding the role of HS in morphogenesis and axon growth and
guidance.
1.2.2.1 Neuro- and Gliogenesis
HS helps regulate and differentiate neuronal and glial progenitors. Neurogenesis is
regulated by several growth factors and morphogens. HS binds many of these secreted
factors, including fibroblast growth factors (FGFs), Wingless (Wnt), and Hedgehog
(Hh).80,81 In the developing rodent nervous system, regions of high HS expression
correspond to regions of high mitotic activity where HS-binding proteins, such as
FGF, are known to play important regulatory roles. HSPG transcripts are primarily
seen in areas that contain proliferating neuronal and glial progenitors such as in
ventricular zones of the developing forebrain, midbrain, and hindbrain areas.82
In vivo evidence for HS involvement in cell growth and differentiation can be seen
in mutation of the division abnormally delayed (dally) locus in Drosophila. Loss of
dally, a gene coding for a Drosophila glypican, causes alterations in specific patterns
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of cell division in the larval brain.83 These mutants also had morphogenic defects
in many tissues, including the wing, genitalia, eye, and antenna. The first evidence
that HSPGs influence growth factor signaling in vivo came from analysis of dally
mutants.84 This mutation has been shown to affect Decapentaplegic (Dpp), FGF,
and Wingless (Wg) signaling.
Evidence for the requirement of HS in mammalian neuro- and gliogenesis comes
from Nestin-Cre+;Ext1lx/lx conditional knockout (cKO) mice. These mice lack the
enzyme responsible for polymerizing the HS chain and do not synthesize HS in neural
progenitor cells, and their progeny, as early as E9.5.85,86 These mice have severe
malformations in the caudal midbrain-cerebellum region including the apparent lack
of inferior colliculus and cerebellum, an abnormally small cerebral cortex, and the
absence of the olfactory bulbs.85 These defects are similar to the phenotypes caused by
a hypomorphic Fgf8 allele and a natural Wnt1 allele called swaying,87,88 suggesting a
role for HS in activating these pathways and facilitating their extracellular distribution
during normal neurogenesis. Moreover, loss of HS resulted in reduced proliferation in
the cerebral cortex.
The Nestin-Cre+;Ext1lx/lx cKO mice suggest that HS is significant for specific de-
velopmental signaling effects, in particular FGF8 morphogenic signaling, rather than
affecting more general cellular activities such as adhesion and migration. These re-
sults demonstrate that HS is an essential signaling molecule in neuro- and gliogenesis.
In addition to the gross loss of normal morphogenesis, these mice also displayed severe
defects in axonal guidance.
1.2.2.2 Axonal Guidance
A role for HS in axon guidance has been suggested since the 1990s.89,90 Since then,
genetic experiments in several model systems have shown that HS is required for axon
guidance.91 Indeed, phenotypes of Nestin-Cre+;Ext1lx/lx cKO mice revealed that the
role of HS in axon guidance in mice is unexpectedly pervasive. Nestin-Cre+;Ext1lx/lx
cKO mice show severe defects in commissural fiber tract development. The three ma-
jor commissures in the forebrain, the corpus callosum, hippocampal commissure, and
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anterior commissure, are all absent in Nestin-Cre+;Ext1lx/lx cKO mice.85 The defects
are somewhat similar to that of mutant mice in which the guidance molecules Slit1
and Slit2 are ablated,92 suggesting the possibility that the lack of HS disrupts signal-
ing necessary for the formation of forebrain commissures. A recent study showed that
phenotypes of Hs2st−/− and Hs6st1−/− mice, which lack the sulfotransferase enzymes
needed to sulfate the 6-O and 2-O positions of the GlcN and IdoA moieties of HS
(Figure 1.1), closely match those of Slit1−/− and Slit2−/− embryos, respectively, indi-
cating a possible functional relationship.93 In contrast, perturbation of FGF signaling
also causes the lack of forebrain commissures.94,95 As HS is known to be involved in
both guidance signaling by the Slit/Robo system and by FGF signaling, the mecha-
nism by which the forebrain commissures are lost likely involves loss of both functions.
Indeed, recent studies have shown that Hs6st1 has Slit-independent functions and the
data implicate a role for FGF signaling.93
HS plays a direct role in axon guidance at the optical chiasm of the retinal axon
trajectory. In the optical chiasm, retinal axons cross the midline and project into
the contralateral tectum. In Nestin-Cre+;Ext1lx/lx cKO mice, these axons project
ectopically into the contralateral optic nerve.85 The phenotype is similar to that of
Slit1−/−;Slit2−/− double-mutant mice.96 Slit proteins are a family of secreted repul-
sive guidance molecules.97 In the optical chiasm, Slit1 and Slit2 act cooperatively to
guide retinal axons to contralateral sides.96 Slit proteins bind HS and HS promotes
Slit-Robo interaction. Moreover, Slit requires HS in explant assays.98 The physio-
logical role of HS in Slit-mediated axon guidance has been demonstrated by genetic
interaction experiments using Slit2 and Ext1 null alleles.85 Although little guidance
defects were found in Slit2−/− mice, due to the intact Slit1 function, a reduction of
one Ext1 allele in Slit2−/− background causes profound retinal axon misguidance,
as observed in Slit1−/−;Slit2−/− double-mutant mice and Nestin-Cre+;Ext1lx/lx cKO
mice.85 Such a strong dosage-sensitive genetic interaction between Slit and Ext1 in-
dicates that HS plays a physiologically essential role in Slit-mediated retinal axon
guidance. Again, HS fine structure is important for guidance through the chiasm.
The sulfotransferase mutants Hs2st−/− and Hs6st1−/− have similar phenotypes to
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those of Slit1−/− and Slit2−/−, respectively.93,99 Additionally, Hs6st1−/− retinal ax-
ons are less sensitive to Slit2 repulsion than wild-type axons.99 Expression of the
sulfotransferases coincides with Slit expression domains where axons make pathfind-
ing errors in HS mutant mice. Together, this suggests that Slit1 and Slit2 each bind
to distinct HS sulfation motifs to affect signaling and guidance.
Detailed analyses of individual axon tracts would likely reveal more guidance
defects in both Nestin-Cre+;Ext1lx/lx cKO and sulfotransferase mutant mice. Axons
of the fasciculus retroflexus, a fiber tract connecting the limbic forebrain and the
midbrain, have been shown to be defasciculated in Nestin-Cre+;Ext1lx/lx cKO mice.
The pathfinding of these axons is regulated by semaphorin 5A (Sema5A), which binds
HS.100 Extension of sensory axons from dorsal root ganglia into the spinal cord is also
disrupted in Nestin-Cre+;Ext1lx/lx cKOmice. As such, the role of HS in axon guidance
seems to be quite pervasive. In addition to the aforementioned guidance molecules
for which the requirement of HS has been demonstrated in vivo, there are probably
other molecules and guidance events that require HS, such as in Ephrin-A3/EphA
signaling.101
1.2.2.3 The Role of HS Sulfation
Phenotypic comparison between Ext1 mutants and mutants of HS modifying enzymes
that catalyze steps downstream of Ext1 can provide genetic evidence for the role of
sulfation of HS in vivo. One problem with this approach is that, for the steps in
which multiple enzyme isoforms are present, the absence of phenotype in a given
knockout mouse model may be due to the compensatory effect by other isoforms. In
particular, the 3-O- and 6-O-sulfotransferase genes have at least five and three known
isoforms, respectively.102 This is also a potential issue with NDST, although Ndst1
is the predominant gene among the four Ndst genes in many tissues.103 On the other
hand, C5-epimerase and 2-O-sulfotransferase are encoded by single genes, Glce and
Hs2t, respectively, which makes comparison of phenotypes more straightforward.
Another potential problem is the difference in the nature of gene inactivation be-
tween constitutive and conditional knockout systems. Cells in constitutive knockout
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mice have been adapted to the null environment from the beginning of embryogenesis,
whereas cells in conditional knockout mice may represent an acute phase of adapta-
tion. Thus, one should be cautious in comparing phenotypes of constitutive and
conditional knockout mice. Keeping these limitations in mind, phenotypic compari-
son between different HS mutant mice have been very informative in understanding
the in vivo significance of HS sulfation.
Brain phenotype has been fairly well characterized in Ndst1−/− mice.103 In com-
parison to Nestin-Cre+;Ext1lx/lx cKO mice, penetrance of phenotypes in Ndst1−/−
mice is lower and their expressivity variable. This may be due to the compensatory ac-
tion of other isoforms. Also, craniofacial defects due to systemic ablation of the gene
complicate the interpretation of brain phenotypes. However, the brain phenotype
of strongly affected Ndst1−/− mice substantially overlaps with Nestin-Cre+;Ext1lx/lx
cKO mice. Ndst1−/− mice display agenesis of olfactory bulbs, the lack of the hip-
pocampal and anterior commissures, and microcephaly.103 These findings support
the notion that sulfation is critical to HS activity.
Analysis of C. elegans animals lacking C5-epimerase, 6-O-sulfotransferase, and
2-O-sulfotransferase showed distinct, as well as overlapping axonal and cellular guid-
ance defects in specific neuron classes.104 These findings are consistent with Hs2st−/−
and Hs6st1−/− mice which have similar, but less severe, axon guidance phenotypes
as Nestin-Cre+;Ext1lx/lx mice. Interestingly, the major brain defects due to loss of
morphogenic signaling in Nestin-Cre+;Ext1lx/lx and, to a lesser extent, Ndst1−/− mice
were not observed in either the sulfotransferase mutants or in Glce−/− mice.105 This
suggests that the activity of certain morphogens may be less sensitive to HS sulfation
than axon guidance molecules, such as Slit. However, mice or flies that lack Glce,
Hs2st, or Hs3st either have very early patterning defects or die perinatally.80,105–107
This suggests an important and pervasive developmental role for particular HS sulfa-
tion motifs.
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1.2.3 Summary
Overall, the phenotypes of HS mutant mice indicate that the major role of HS in vivo
is the modulation of signaling by morphogens and guidance molecules. Phenotypic
comparison among different HS mutant mice have helped define the physiological
requirements of specific HS fine structures. Data obtained thus far suggest that phys-
iological requirements for fine structure in morphogenesis are not as stringent as that
inferred from biochemical binding experiments. However, care should be taken when
interpreting these results, as other GAGs or sulfation patterns may have compen-
satory activity. In contrast, sulfotransferase mutants suggest that Slit activity is
dependent on the pattern of HS sulfation, and differences in HS sulfation can spa-
tiotemporally regulate protein activity. Presumably, perturbing enzymes responsible
for CS biosynthesis would demonstrate the importance of CS in vivo and validate in
vitro data suggesting an important role for CS and CS sulfation in neuronal develop-
ment.
1.3 Glycosaminoglycan Biosynthesis
Most of the enzymes participating in GAG biosynthesis have been identified. In
nature, GAGs, with the exception of HA, are covalently linked to a core protein via
an O-glycosidic bond to a serine residue to form a proteoglycan (PG). Virtually all
mammalian cells produce PGs which are either inserted in the plasma membrane
or excreted into the extracellular matrix (ECM).108 Proteoglycans can vary in the
length, type, and number of GAG chains.109 Nascent PGs, after chaperone-mediated
folding in the endoplasmic reticulum (ER), are transferred to the Golgi apparatus
where GAG biosynthesis occurs.110 The first step towards CS/DS and HS/heparin
PGs is the coupling of xylose (Xyl) from uridine diphosphate-xylose to selected serine
residues in the PG core protein (Figure 1.4). Studies with synthetic peptides have
not defined a single consensus sequence for chain initiation; however, the sequence of
a-a-a-a-Gly-Ser-Gly-a-b-a, where a = Glu or Asp and b = Gly, Glu, and Asp, has been
identified.111 Other properties of the protein, such as proximity to other substituted
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Figure 1.4: Biosynthesis of the linkage region tetrasaccharide of chondroitin and heparan
sulfate. Addition of the first hexosamine commits the intermediate to either CS or HS.
sites, downstream sequences, or secondary structure may also be important for GAG
initiation and the subsequent differentiation of CS/DS or HS/heparin chains.112
The Xyl residue is further modified by two Gal units and a GlcA added by three
distinct transferases.102,113 The resulting tetrasaccharide is common to CS/DS and
HS/heparin, and is termed the linkage region. The linkage region can be modified by
transient phosphorylation of the Xyl residue or sulfation of one or both Gal residues.
It has been suggested that phosphorylated Xyl may regulate subsequent GAG mod-
ification.110 Sulfation of the Gal residues has been found in CS/DS chains but not
HS/heparin,113 although the role of this modification is unclear. In the case of CS/DS,
a GalNAc residue is transferred to the tetrasaccharide. For HS/heparin biosynthesis,
the linkage region is modified by GlcNAc. This is the committing step that determines
whether the nascent PG will be CS or HS.
1.3.1 Chondroitin Sulfate Biosynthesis
After the initial addition of a GalNAc residue to the linkage region, polymerization
of the CS chain continues by the alternating addition of GlcA and GalNAc from
the UDP sugars in the Golgi (Figure 1.5).114 Polymerization occurs in a highly
organized manner, with both GalNAc and GlcA transferases acting in concert to
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form chondroitin chains up to 70 kDa, or larger.
Sulfation of the resulting chains is effected by three different families of transferases
that elaborate the C4 or C6 positions of GlcNAc residues, or the C2 hydroxyl of GlcA.
Most of the CS found in vivo is found as the monosulfated CS-A or CS-C motifs (Fig-
ure 1.3). The oversulfated CS-D and CS-E motifs are the next most prevalent forms,
although they are much less common than CS-A and CS-C. Other oversulfated CS mo-
tifs have been found in marine organisms,42,115 however the existence of these motifs in
mammals has not been demonstrated. All the sulfotransferases in GAG biosynthesis
require 3’-Phosphoadenosine 5’-phosposulfate (PAPS), as a cofactor. Three distinct
GalNAc 4-O-sulfotransferases (C4ST1–3; known as Chst11, Chst12, and Chst13, re-
spectively) have been cloned and characterized.116–118 These enzymes are homologous
to the human natural killer cell carbohydrate antigen 1 (HNK-1) sulfotransferase that
produces the HNK-1 epitope by the transfer of a sulfate to the C3 position of ter-
minal GlcA residues in the sequence GlcAβ1,3Galβ1,4GlcNAc.119 In addition to the
HNK-1 sulfotransferase and the enzymes involved in CS biosynthesis, two additional
4-sulfotransferases (GalNAc-4ST1 and GalNAc-4ST2, or Chst8 and Chst9), which
add a sulfate group to terminal GalNAc residues on N - and O-linked oligosaccha-
rides, also belong to this family. Truncated versions of these enzymes can transfer
sulfate groups to internal residues in desulfated chondroitin.119
Sulfation at the C6 position of GlcNAc is catalyzed by two isoforms of C6ST
(Chst3 and Chst4),120 members of the GST (Gal/GlcNAc/GalNAc sulfotransferase)
family of enzymes.121 To date, seven different members of the GST family have been
identified in humans, most being GlcNAc-6-sulfotransferases.121 Mice targeted with
a deletion in the Chst3 gene show > 90% loss of the CS-C motif in the spleen.122 The
disappearance of the CS-D motif in the brain and cartilage of the Chst3-deficient mice
revealed that this structure was generated by the enzyme. By contrast, levels of CS-
E in the spleen and brain were unaffected, showing that 6-O-sulfation of 4S-GalNAc
is catalyzed by a separate enzyme. Like specific HS sulfotransferase mutants, brain
development appeared normal in Chst3−/− mice, but the number of CD62L+CD44low
T lymphocytes was significantly decreased.
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Figure 1.5: Biosynthesis of chondroitin sulfate. After polymerization of GalNAc and GlcA
units, sulfotransferases further modify the structure. Shown here are the biosynthetic routes
to the common A, C, D, and E motifs. Mixtures of several motifs can be found on natural
CS chains. See Figure 1.9 for key to monosaccharide representations.
The enzyme that synthesizes CS-E motifs from CS-A is GalNAc4S-6ST, also
known as Chst15. This enzyme is also responsible for sulfating the C6 position of
GalNAc(4S) regions of DS, and GalNAc(4S) residues at the non-reducing terminal of
CS and DS.123,124 Unlike many of the other sulfotransferases, which have several iso-
forms, Chst15 may be the sole enzyme responsible for the synthesis of GalNAc(4,6S)
residues in CS and DS, as Chst15−/− mice have no apparent expression of this pat-
tern.125 Expression of this GalNAc4S-6ST may be regulated during the development
of the brain,23,126 mast cells,127 and early mouse embryos.128 Knockdown of Chst15
in hippocampal neurons induced the formation of multiple axons and reduced the
length of the longest neurite, consistent with the known role of CS-E in promoting
the growth of a single neurite over dendritic growth.129
Like CS-E, CS-D is another highly sulfated form of chondroitin that is synthesized
by a single sulfotransferase. CS/DS2ST (uronyl 2-O-sulfotransferase, UST) transfers
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a sulfate group from PAPS to the C2 position of GlcA or IdoA.130 IdoA is frequently 2-
O-sulfated, generating IdoA(2S)-GalNAc(4S). Sulfation at the C2 position of CS only
produces CS-D.110 Interestingly, while expression of Chst15 decreases during postnatal
development in the mouse cerebellum, expression of UST increases, suggesting the
resulting oversulfated motifs play different roles in development.23 On the other hand,
knockdown of either UST or Chst15 resulted in disrupted migration of cortical neurons
and had similar effects on hippocampal morphology.129,131 These results suggest that
some processes are more sensitive to sulfation than others.
1.3.2 Heparan Sulfate Biosynthesis
Elongation of the HS/heparin chain is catalyzed by the HS polymerases EXT1 and
EXT2, which append GlcA and GlcNAc to the growing chain (Figure 1.6). Further
elaboration of the resulting polymers is initiated by N -deacetylase/N -sulfotransferase
(NDST), a bifunctional enzyme, which modifies selected GlcNAc residues. As N -
sulfation is required for further modification, the NDST isozymes are responsible for
the overall sulfation pattern of the HS/heparin chain. The N -sulfated domains occur
predominantly in contiguous sequences with a minor proportion of N -acetylated dis-
accharides.132 These highly sulfated S-domains are normally distributed in a fairly
uniform manner in HS, separated by unmodified N -acetylated regions with low sul-
fation.133 These N -sulfated/N -acetylated/N -sulfated (SAS) domains are a common
feature of HS and are thought to be important in growth factor binding.132,134–136
Four mammalian NDSTs have been identified. Transcripts of NDST1 and NDST2
have a broad spatiotemporal distribution, while NDST3 and NDST4 are mostly ex-
pressed in embryo.137 However, evidence suggests that the expression of the NDSTs
are translationally controlled,138 therefore the transcript levels may not reflect the
amount of protein. Two of the NDST isozymes have been deleted in mice, suggest-
ing NDST1 is the predominantly active form in most tissue, while NDST2 defects
have a restricted phenotype in which only HS from connective-tissue mast cells are
affected.139 The sulfotransferase domain of NDST1 has been crystallized,140 and used
as a template to create homology models of the other NDSTs.141 The structures re-
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Figure 1.6: Biosynthesis of heparan sulfate. After polymerization of GlcNAc and GlcA
units, sulfotransferases further modify the structure. See Figure 1.9 for key to monosaccha-
ride representations.
veal that the shape and pattern of charge in the putative substrate-binding site differs
across the four isoforms, suggesting a basis for the observed differences in substrate
specificity.141–143
After N -sulfation, selected GlcA residues are converted to IdoA, followed by 2-
O-sulfation of the C2-position of the resulting IdoA, or less often to GlcA, by the
C5-epimerase-2-O-sulfotransferase (2-OST) complex.144,145 2-O-sulfated uronic acids
are almost exclusively found in contiguous N -sulfated domains of the polysaccharide.
The next modification is sulfation at the 6-O position of GlcN. Three 6-OSTs have
been identified.146 While these isozymes have similar substrate specificities, with
only minor differences in target preference,147 they show different spatial expression
in adult mice.146
HS/heparin can be further modified by 3-O-sulfation of GlcNAc residues. This
rarest modification is catalyzed by at least six related sulfotransferases.148–150 3-O-
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sulfation is required for the interactions of heparin with antithrombin and the gD
envelope protein of herpes simplex virus 1.149 It is known that HS modified by 3-
OST1 and 3-OST5 display anticoagulant activity, whereas HS modified by 3-OST3
and 3-OST5 serve as entry receptors for herpes simplex virus 1.149,151,152 Interestingly,
3-OSTs show sequence homology with the N -sulfotransferase domain of the NDSTs.
A 3-OST3/PAP/heparin ternary structure has been solved, revealing key amino acids
required for substrate recognition.153 Interestingly, only a pair of residues are respon-
sible for differentiating the substrate specificities of these isoforms, and mutating these
residues has been shown to alter the substrate specificity.154
1.3.3 Biological Implications of Glycosaminoglycan Biosynthe-
sis
The inherent heterogeneity of GAG chains is a product of non-template-based biosyn-
thesis.155 However, a recent study found that the CS proteoglycan bikunin has a
defined sequence. Bikunin is a simple proteoglycan consisting of a single CS chain
appended to a 16-kDa core protein. The carbohydrate motif is heterogeneous in size
and composition, with 27–39 saccharides and a molecular mass of 5.5–7.1 kDa. De-
spite the apparent heterogeneity, bikunin has two ordered domains: a sulfated domain
consisting of a CS-A tetrasaccharide followed by two tetrasaccharides each composed
of an unsulfated and CS-A sulfated disaccharide, and a non-sulfated domain between
6–22 residues long.156
The presence of an ordered sequence motif in bikunin suggests that other, more
complex, proteoglycans could also have conserved domains. The technical challenge
of sequencing GAGs, and our current understanding of the biosynthetic mechanisms,
limit our understanding of GAG fine structure. Despite the apparent heterogeneity
of GAGs, the differences in the spatiotemporal expression of the various sulfotrans-
ferase isoforms indicates that sulfation is tightly regulated in vivo. As described above
(Section 1.2), the expression of HS sulfotransferases 2-OST and 6-OST1 are spatially
regulated to correspond to Slit1 and Slit2 activity, respectively.93,99 Moreover, reports
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indicate that HS tissue-specifically regulates the reactivity of the FGF-FGFR inter-
action.157,158 Thus, the spatiotemporal expression and fine structure of HS appear
to be as important for the induction of specific biological processes via Slit or FGF
signaling as the expression of the Slits/Robo or the FGFs/FGFRs themselves.159
Similarly, enzymes responsible for the sulfation of CS, Chst14, UST, and Chst15,
which are responsible for the CS-B (DS), CS-D, and CS-E sulfation patterns, have
very different expression profiles. Expression of Chst14 and UST increased through-
out development whereas Chst15 expression decreased during postnatal development.
Moreover, expression levels of UST and Chst15 correlated inversely in many cell types
and neurons.23 These data are consistent with in vitro data that implicates CS-E in
axonal growth and CS-D in dendritic growth. Therefore, the spatiotemporal regula-
tion of CS may help facilitate neuronal development.
Together, the data indicate that broad sulfation motifs, such as 2-O- versus 6-O-
HS sulfation or CS-E versus CS-D motifs, are essential for GAG function in many
instances. GAG sulfation appears to be regulated by the spatiotemporal control of the
expression of these enzymes, and rare isozymes with limited expression may further
control GAG fine structure. Unfortunately, beyond the regulation of expression of
specific sulfotransferases, little is known about the factors that influence the fine
structure of CS and HS. This is especially true for CS. For example, the biosynthetic
basis for the sulfated domain of bikunin is currently a mystery.
Through in vitro chemoenzymatic synthesis of heparin oligosaccharides, much
has been learned about the substrate specificity of the various HS sulfotransferase
isoforms.160–162 Understanding the substrate specificity profile for the various CS
sulfotransferases would help predict general properties of the resulting chains (e.g., the
average distribution of highly sulfated motifs). For instance, the action of NDST in HS
biosynthesis is known to result in SAS domains of alternating high and low sulfation.
This knowledge helped demonstrate that these domains are important for binding
to various proteins, such as the chemokines and FGF/FGFR complexes.132,134–136 In
contrast, much less is known about how blocks of sulfation are distributed in CS (see
also, Appendix B). Therefore, improving our understanding of GAG biosynthesis will
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Figure 1.7: The helical conformation of glycosaminoglycans. GAGs adopt a semi-rigid,
extended helical structure both in solution and in solid state. Counterions can affect the
helical symmetry.
help uncover the role of fine structure in GAG activity.
1.4 Glycosaminoglycan Structure
The three-dimensional structure of GAGs has been examined by x-ray crystallogra-
phy, fiber diffraction, NMR, and computational modeling. These studies have revealed
that GAGs exist in an extended and semi-rigid structure in solution, with different
helical symmetries for different GAGs (Figure 1.7). Unlike proteins, GAGs are not
known to display or fold into any particular tertiary structure.163 The main struc-
tural parameters affecting the topology of GAGs are the glycosidic torsion angles (φ,
ψ) and the conformation of the hexapyranose ring of the monosaccharides. Several
studies have shown that the CS monosaccharides, as well as the GlcNAc residues of
HS, exist almost exclusively in the 4C1 conformation. IdoA, on the other hand, can
exist in four major conformations: 4C1, 1C4, 2S0 and 0S2. Each of these conforma-
tions are essentially equienergetic,155 and vary depending on the substitution pattern
of the residue, as well as the GlcN residue bound to its non-reducing end.164 For
CS, the helical structure also depends on the sulfation patterns and on the type of
bound counterion (Table 1.1). HS and heparin, on the other hand, show relatively
conserved φ and ψ angles. NMR studies on a series of modified heparins with sys-
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Figure 1.8: Kinks develop in the helical conformation of long glycosaminoglycans. The
best-fit structures of heparin oligosaccharides of increasing length using a combination of
analytical ultracentrifugation, synchrotron x-ray scattering, and constrained modeling.166
As the length of heparin increases, kinks begin to form in the secondary structure. Similar
effects have been predicted for CS polysaccharides.167
tematically altered substitution patterns indicate that all derivatives, regardless of
sulfation pattern, exhibit similar glycosidic bond conformations.165
The conformational information for GAGs was obtained for smaller, purified
oligosaccharides. However, natural GAG polysaccharides are significantly longer than
these fragments. Maintaining the extended structure in solution as the chain length
increases seems implausible. Several experimental studies suggest that chondroitin
sulfate may take a semiflexible coil conformation in solution,168,169 characterized by
an intrinsic persistence length in the range of 45–55 Å.168 Using a combination of an-
alytical ultracentrifugation, synchrotron x-ray scattering, and constrained modeling,
predicted structures for heparin developed kinks in the helical conformation as the
length increased above nine disaccharide units (Figure 1.8).166 Similarly, modeling
studies predict a similar kinked structure for long CS polysaccharides.167
The conformation of GAGs changes relatively little upon binding to a protein, as
comparison of heparin conformations bound to a variety of proteins, obtained from
heparin-protein crystal structures, were very similar to the solution structures.166 In-
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stead, proteins likely find a suitable region of the GAG to bind. These observations
could have a number of implications for GAG-protein binding. The kinked structure
of long GAG chains should have the effect of reducing the number of bound proteins
that can simultaneously bind a chain, relative to the extended conformation. Simi-
larly, the kinked structure may impose a limit on the length of viable GAG-binding
sites on proteins. Since chains larger than nine disaccharides long begin to develop
random kinks in the secondary structure, it is unlikely that proteins or protein-protein
complexes will require very long oligosaccharides for binding activity, as the proba-
bility of finding the GAG in the favorable binding conformation is likely to be low.
1.5 Conclusion
Glycosaminoglycans are an important class of molecules with diverse biological roles.
Some evidence suggests that the structural diversity afforded by variations in stereo-
chemistry and sulfation accounts for the range in activity (see Chapter 2). However,
the diversity of GAG structures that have been explored remains low. The main chal-
lenges in studying GAGs are the difficulty in obtaining homogeneous samples of de-
fined length and sulfation, and elucidating sequence information. This is particularly
true of CS. While the nature of heparin biosynthesis, and the expression of recombi-
nant HS sulfotransferases makes obtaining certain heparin oligosaccharides practical,
obtaining homogeneous samples of CS remains much more challenging. Although CS
oligosaccharides with various sulfation motifs have been prepared synthetically, the
process is challenging and time consuming. In addition, a biosynthetic route to CS
has yet to be demonstrated, and the requisite sulfotransferases are poorly character-
ized. As such, a structural understanding of CS, and especially the higher-sulfated
motifs, lags woefully behind heparin. In the following chapters, the development of
novel chemical tools for studying CS is described. Using a general, multi-pronged ap-
proach, we hope to develop a methodology for the elucidation of the structural basis
for CS activity in a number of fundamental biological processes. Later, we apply these
tools to understand the role of CS in growth factor signaling and axonal guidance.
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1.6 Appendix
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Figure 1.9: Symbolic representations of monosaccharides and proteins in Figures 1.4, 1.5,
and 1.6
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Table 1.1: Helical structure of GAGs155
GAG Helical symmetry Axial rise per disaccharide unit (nm)
CS-A 21 0.98 (Ca+2 )
32 0.94–0.96 (Na+)
CS-C 21 0.93 (low pH)
32 0.95–0.96 (Ca+2 )
83 0.98 (Na+)
Heparin 21 0.82–0.84 (Na+ or Ca+2 )
0.87 (Na+)
HS 21 0.93 (Na+)
0.84 (Ca+2 )
DS 21 0.94–0.97 (Na+)
32 0.95 (Na+)
83 0.92–0.93 (Na+)
KS 21 0.95 (Na+)
HA 21 0.98 (Na+ or low pH)
32 0.94–0.95 (Ca+2 )
43 0.84, 0.93–0.97 (Na+)
43 double helix 0.82 (K+ or low pH)
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Chapter 2
Glycosaminoglycan Interactions with
Growth Factors
2.1 Introduction
Most, if not all, of the biological activities of GAGs described in Chapter 1 are a
consequence of specific GAG-protein interactions. Glycosaminoglycans bind hun-
dreds of proteins, many of them growth factors required for proper development.
Unfortunately, compared to interactions between other proteins or nucleic acids, the
molecular characterization of GAG-protein binding is in a primitive state. Only a
handful of crystal structures of GAG-bound proteins have been solved, and very few
interactions for GAGs other than heparin have been characterized. For example,
only a limited number of CS-binding proteins have been identified and the structural
determinants of binding have not been elucidated, despite the prevalence of CS in
the nervous system. Growth factor binding is perhaps the best described biological
activity for GAGs, and the understanding of HS function in growth factor signaling
has reached an impressive level of mechanistic sophistication. For example, HS has
been shown to act as a co-receptor for FGF and other proteins. Studies with FGF
and chemokine family members have revealed the basis for heparin-protein interac-
tion at the molecular level: crystal structures for heparin and FGFs, both together,
and in complexes with FGF receptors, provide insight into the mechanisms for sig-
naling pathway activation; and, mutagenesis studies with chemokines help predict
the molecular requirements of HS required for binding. Given the similarities be-
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tween CS and HS, it may be possible that a deep understanding of the interactions
with heparin and growth factors can help inform or predict the molecular basis of
CS-protein binding. Indeed, many heparin-binding proteins also interact strongly to
certain highly sulfated CS motifs. Here, we will examine this possibility by comparing
known growth factor-GAG interactions, then explore the possibility that CS may act
as a co-receptor for the neurotrophin family of growth factors.
2.2 Lessons Derived from Heparan Sulfate-Growth
Factor Interactions
2.2.1 FGFs
Interactions between HS and members of the FGF family are very important and are
possibly the most studied aspect of GAG biology. HS interacts with most of the 23
members of the FGF homologous factors, which include FGFs 1–10, 15–23, midkine
(MK), hepatocyte growth factor (HGF), and pleiotrophin (PTN) (Figure 2.1).159 As
expected, the HS-FGF interaction is significantly electrostatic in nature; and, pro-
teins with reduced electropositive charge, such as FGF-21 (Figure 2.1), have little
affinity for HS.159 However, electrostatics alone are not necessarily predictive of rel-
ative binding affinity, as FGF-7 has higher relative affinity to heparin than FGF-8
despite carrying less overall electropositive charge (Figure 2.1C and D).21
A crystal structure of heparin tetra- and hexasaccharide bound to FGF-2 revealed
the nature of the binding interaction.170 Heparin binds to FGF-2 along a shallow
groove in the protein surface with most of the ligand exposed to solvent. Neither the
sugar nor the protein undergo a significant change in conformation. This mode of
binding is consistent with its role in juxtaposing components of the FGF signaling
pathway. Key interacting residues with the heparin tetrasaccharide include Asn28,
Lys120, Arg121, Lys126, Gln135, and Lys136 (Figure 2.1A).170 FGF-2 requires both
2-O- and 6-O-sulfation to support mitogenic activity.171
FGF-4 also requires both 2-O- and, especially, 6-O-sulfation for full biological ac-
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Figure 2.1: Structures of various FGF family members depicted as the solvent-accessible
±5 kbT/e electrostatic potential surface and ribbon representations. There is a strong corre-
lation between electropositive potential and GAG binding.159 (A) FGF-2 binds strongly to
heparin (orange). (B) FGF-4 elicits different responses when bound to heparin than HS.135
Key heparin-binding residues are colored in cyan for A and B. (C) In addition to heparin,
FGF-7 binds to DS which can potentiate its activity.172 (D) FGF-8 is a morphogen with
HS-dependent activity. (E) FGF-18 has high affinity to heparin. (F) FGF-21 has little
GAG-binding activity.
tivity, but, unlike FGF-2, neither are required to support mitogenic activity.171,173,174
Residues required for heparin binding to FGF-4 were identified via mutagenesis. Both
FGF-4 and FGF-2 engage heparin along a similar surface of each protein. Interest-
ingly, the residues corresponding to Asn28 and Gln135 in FGF-2 are substituted by
hydrophobic residues in FGF-4, and other FGF-4 residues in the HS-binding site
would clash with an N -sulfate group according to the conformation of FGF-2-bound
heparin. These, and other, differences provide physical justification for the observed
differences between the proteins in their ability to engage heparin.171,173,174 The
residues Asn89, Lys183, Asn184, Lys188, Arg192, and Lys198 make critical contacts
with heparin (Figure 2.1B).173
Together, these data indicate that the specific arrangement of residues along the
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Figure 2.2: HS interacts with a number of morphogens such as BMP-2 (A), BMP-3 (B),
BMP-6 (C), BMP-7 (D), Hh (E), Wnt-8a (F), and TGF-β1 (G). For each morphogen,
the ±5 kbT/e electrostatic potential plotted on the solvent-accessible surface and ribbon
representation are depicted.
binding surface can modulate the selectivity of proteins for a particular sulfation
motif. The structures of the FGFs show that HS binds on the surface, accessible to
the solvent. This feature is likely important for the formation of ternary complexes
with FGFRs.
2.2.2 Morphogens
FGFs are involved in diverse roles in developmental and physiological processes in-
cluding cell proliferation, differentiation, morphogenesis, and angiogenesis, and HS
is required for many of them.163 For example, neonatal Nestin-Cre+;Ext1lx/lx (Nes-
EXT1 ) cKO mice have severe defects in the midbrain-hindbrain region, characterized
by the absence of a discernible inferior colliculus and cerebellum,85 likely due to loss of
FGF-8 signaling. In fact, this phenotype is similar to that caused by a hypomorphic
Fgf8 allele.87
In addition to FGF-8, HS binds to other important morphogens such as bone
morphogenic protein (BMP), Hh, transforming growth factors-β1 (TGF-β1) and -β2,
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and Wnt (Figure 2.2). Morphogens are long-range signaling molecules that pattern
developing tissue in a concentration specific manner. Broadly, HSPGs have dual roles
in morphogen biology, affecting both the signaling and the movement of morphogens.
More specifically, interactions with HSPGs are thought to modulate several aspects of
morphogen signaling. HS may increase the cell-surface concentration of morphogens
and may be directly involved in signaling as a component of the active receptor sig-
naling complex.175–179 However, understanding the role of HS in morphogen signaling
is made complicated by the fact that HS affects morphogen spreading, so it is of-
ten unclear if reduced signaling after loss of HSPG is due to loss of the co-receptor
function or perturbed morphogen movement. HSPGs are required for the spreading
and signaling of Decapentaplegic (Dpp, a TGF-β homolog),176,180 and the long-range
spreading of Hh and Wnt.175,176,180,181 On the other hand, loss of HS causes an expan-
sion of the activity range of FGF-8 in zebrafish embryo, presumably by the reduced
sequestration of FGF-8 by HS.182 In addition, HS may reduce the rate of internaliza-
tion and clearance.180,183 While quantitative imaging and biophysical studies will be
needed to determine the exact roles of HSPGs, the multiple functions they control
underscore their importance.
Very little is known about the molecular basis for GAG-morphogen binding. How-
ever, the structures of the morphogens suggest that GAGs bind to the surface of the
protein at electropositive regions of the protein, similar to FGFs. Interestingly, these
proteins have significantly less electropositive surfaces than either the FGFs or the
chemokines (Figure 2.2), suggesting that the morphogens may not require highly sul-
fated regions of HS to achieve high-affinity binding. Furthermore, the differences in
surface topology among these structures underscores the flexibility with which HS is
able to engage proteins. Very little information about the sulfation requirements of
the morphogens, and Hs2st and Hs6st1 mutants have no obvious morphogenic de-
fects. On the other hand, Sulf1, an HS 6-O endosulfatase, regulates Wingless gradient
formation in the developing wing of Drosophila.184
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Figure 2.3: CC and CXC chemokines interact with heparan sulfate. Each chemokine, is dis-
played with the ±5 kbT/e electrostatic potential plotted on the solvent-accessible surface and
ribbon representations. Residues identified to interact with HS/heparin are shown as cyan
sticks. (A) CCL2 residues Arg18, Lys19, Arg24, Lys49, Lys58, and His66 have been shown to
interact with GAGs.185 (B) CXCL8 binds GAGs with residues Lys20, Arg60, Lys64, Lys67,
Arg68.186 (C) CCL3 interacts with GAGs with residues Arg18, Lys45, Arg46, Lys48.187 (D)
CXCL12 residues Lys24, His25, Lys27, Arg41, and Lys43 interact with GAGs.188 (E) CCL5
binds GAGs with residues Arg44, Lys45, and Arg47.189
2.2.3 Chemokines
Another important class of molecules that interact with HS are members of the C,
CC, CXC, and CX3C families of chemokines.109 The chemokines are a group of
small secreted proteins that signal through G-protein-coupled receptors (GPCRs) to
control cell migration associated with a multitude of processes, including development,
lymphocyte homing, inflammation, and wound repair.135 Certain chemokines require
interactions with GAGs for their in vivo function;190 and, like the morphogens, the
HS interaction is thought to provide a mechanism for retaining chemokines on cell
surfaces, facilitating the formation of chemokine gradients. These gradients serve
as directional cues to guide the migration of the appropriate cells in the context of
their inflammatory, developmental, and homeostatic functions.191 The chemokines
share a common ternary structure and engage GAGs at a similar location on the
surface of the protein (Figure 2.3). While depicted as monomers in Figure 2.3, many
chemokines form dimers or oligomers in solution, especially in the presence of HS. The
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GAG-binding sites of several chemokines have been determined through mutagenesis
studies and reveal important differences (Figure 2.3). For example, both CCL3 and
CCL5 principally interact with GAGs at a BBXB motif (where B represents either
Lys or Arg, and X represents a non-acidic amino acid), involving residues Lys45,
Arg46, and Lys48 of CCL3 and Arg44, Lys45 and Arg47 of CCL5,187,189 while in
CXCL8, the binding site is primarily localized to the C terminus.186 The differences
in the HS-binding sites may reflect a difference in preference for different HS sulfation
patterns.
In addition to the GAG-binding requirements of the protein, the chemokine bind-
ing site of HS have been determined for CCL3 and CXCL8. In both cases, the proteins
interacted with an HS sequence consisting of two highly sulfated regions 3–7 disac-
charide units long separated by a region with low sulfation ∼7 disaccharide units
long.192,193 The N -sulfated/N -acetylated/N -sulfated (SAS) domain may allow HS to
bind to an antiparallel-oriented dimer.135 SAS domains may be important for HS-
induced oligomerization and ternary complex formation in which long sequences of
up to 12 disaccharides long are thought to be required for efficient binding.132,134
2.2.4 Summary
Early studies found that several heparin-binding proteins contained XBBXBX and
XBBBXXBX motifs.194 However, as more heparin-binding sites were characterized,
it became clear that a particular primary sequence was not required, but rather
a suitable three-dimensional arrangement of residues was sufficient. The principle
determinant of a GAG-binding site seems to be regions of sufficient electropositive
charge density with favorable topology. While the examples presented here underscore
a certain amount of topological flexibility, GAGs tend to bind growth factors on the
surface of the protein or along shallow groves.
The large number of proteins that HS has been shown to interact with has led to
the belief that the interactions are non-specific. This may be true for many proteins.
For example, FGF family members share binding sites on the HS chain, and their
affinities for HS oligosaccharides generally correlate with the overall degree of sulfa-
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tion.195,196 Moreover, charge was found to be the main factor in the ability of HS
oligosaccharides to promote ternary complex formation with FGF-1 and FGF-2.197
In vivo evidence shows that mice lacking C5-epimerase or HS 2-O-sulfotransferase
showed no obvious brain phenotype.105,198,199 These mice do not have the gross mor-
phogenic defects seen in the Nestin-Cre+;Ext1lx/lx cKO or Ndst1−/− mouse brain.85,103
The elevated levels of N - and 6-O-sulfation in the Glce and Hs2st mutants was ap-
parently sufficient to satisfy the requirement for HS in VEGF and FGF signaling.200
These findings suggest that growth factor signaling is less dependent on HS fine struc-
ture than previously thought.
On the other hand, investigators have shown that some proteins have shown a
dependence for a particular type of sulfation (e.g., 2-O-sulfation) for activity.16,21
Comparing the FGF-2 and FGF-4 binding sites reveals that subtle amino acid sub-
stitutions can affect the preference for HS fine structure. In this cases and others, the
specific molecular-level interactions have been uncovered revealing an important role
for HS fine structure,201 so it may be that a subset of HS-binding proteins have strict
HS sequence requirements while other proteins are less selective. For example, Slit1
and Slit2 appear to have a preference for 2-O- and 6-O-sulfation, respectively.93,99
For some morphogens and growth factors, the distribution of regions of high sulfation
along the HS chain may be more important for activity than the specific sequence,200
while others may require certain sulfation motifs.
2.3 Heparan Sulfate as a Co-Receptor for Growth
Factors
2.3.1 FGF-FGFR
Cell-surface HSPGs have been shown to modulate the activity of extracellular protein
ligands by forming multimeric HS-protein complexes. Formation of these complexes
can enhance or reduce receptor activation, depending on the concentration of the
ligand, receptor, or HSPG. In many cases, HS is thought to influence ligand-receptor
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interactions by locally increasing the growth factor concentrations;202 however, HS
has also been shown to act as a co-receptor in FGF/FGFR interactions in a ternary
complex on the surface of the cell, suggesting HS plays a more active role in FGF
signaling.203 Although not without controversy, there are two crystal structures of
FGF-FGFR-heparin complexes.134,204 These structures differ dramatically in the sto-
ichiometry and orientation of heparin as well as the type of FGF, FGFR, and crys-
tallization conditions, all of which may have influenced the structure (Figure 2.4).205
The FGF2-FGFR1-heparin crystal structure features a deep, electropositive “canyon”
where two molecules of heparin bind, each interacting with an FGF-FGFR dimer,
with their non-reducing ends facing each other (Figure 2.4A).134
The FGF1-FGFR2-heparin crystal structure differs from the FGF2-FGFR1-heparin
structure in heparin stoichiometry and the relative orientation of the FGF-FGFR
dimers. In the FGF1-FGFR2 structure, a single decasaccharide cross-links two FGF-
FGFR dimers. This structure lacks significant protein-protein contacts between the
two FGF-FGFR dimers, and the heparin molecule makes a different set of contacts
with each dimer (Figure 2.4B).204 This structure also lacks the deep electropositive
canyon that characterizes the FGF2-FGFR1 HS-binding site, although the HS-binding
interaction is still electrostatic in nature. In both models, heparin makes similar con-
tacts in a similar spatial arrangement to one of the FGF molecules and the second
Ig domain (D2) of one of the FGFR molecules. In either case, heparin promotes the
dimerization of FGFR, thereby inducing cell signaling. HS has been shown to be
required for the high-affinity interaction between FGF-2 and FGFR1 and activation
of downstream signaling pathways.206 While the different ternary structures may be
due to artifacts in the crystallization, it is possible that different FGF/FGFR combi-
nations dimerize FGFR through different mechanisms, as other evidence suggests.201
For example, the activity of the FGF-7 receptor does not require heparin or HSPG
oligomerization for biological activity.207
The HS requirement for complex formation was found to be similar for both
structures. FGF-1 and FGF-2 were found to require similar HS oligosaccharides for
complex formation with FGFR1-3. FGF-2 was found to be slightly more efficient
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Figure 2.4: Crystal structures of FGF-FGFR-heparin ternary complexes. (A) The struc-
ture of FGF2-FGFR1-heparin with 2:2:2 stoichiometry (PDB: 1FQ9).134 (B) The structure
of FGF1-FGFR2-heparin with 2:2:1 stoichiometry (PDB: 1E0O).204 In both structures, FGF
(cyan) makes more contacts with heparin (orange) than FGFR (white), as expected based
on the relative affinities. The major differences between the structures are the number of
protein-protein contacts between the FGF-FGFR dimers, and the relative orientation of
heparin.
at recruiting HS than FGF-1, perhaps due to the electrostatic potential differences
(Figure 2.4). In all cases, the stability of the ternary complexes improved with in-
creased HS sulfation, rather than the precise distribution of sulfate groups. Given
the size of HS domains that are implicated in these complexes,132,134 it may be that
SAS domains are involved in these protein-protein-HS complexes,136 as contiguous
domains of N -sulfation longer than 8 disaccharides long are rare. It may be possible
that variations in the spacing of N -sulfated domains, rather than defined sulfation
sequences, are sufficient to regulate FGFR activation. Endogenous HS chains in the
developing mouse are capable of differential regulation of distinct FGF/FGFR pairs,
and each pair preferentially binds a distinct HS domain.158 These results suggest
that some FGFs have distinct sulfation requirements, consistent with the results of
Ashikari-Hada et al. and others.21 Therefore, a combination of SAS domain spac-
ing and the spatiotemporal regulation of general sulfation motifs (e.g., 2-O-sulfation)
may be required to fully describe HS regulation of FGF signaling.
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2.3.2 Thrombin-Antithrombin
After the FGF-FGFR complex, the interaction of heparin with thrombin/antithrombin
is perhaps the next most studied GAG ternary interaction. Together, thrombin and
antithrombin regulate hemostasis. Thrombin is the final protease generated in the
blood coagulation cascade and is responsible for the cleavage of fibrinogen to form
the fibrin clot. Effective inhibition of thrombin is essential for normal blood flow as it
is able to promote its own formation.208 Antithrombin is the primary inhibitor of the
blood coagulation proteases and circulates at high concentration, but binds poorly
to thrombin. Upon interaction with heparin-like GAGs, antithrombin becomes an
efficient inhibitor. Unlike most heparin-binding proteins,209 antithrombin requires a
specific pentasaccharide sequence found in approximately one-third of heparin chains.9
Heparin binding induces a global conformation change in antithrombin and provides
a template on which the inhibitor and protein can interact (Figure 2.5).210 While the
conformation change is important for binding Factor Xa, thrombin relies entirely on
the heparin template.211 Binding to antithrombin changes the structure of heparin,
flattening the normal helical shape at the binding site. Heparin interacts with Lys11,
Arg13, Asn45, Arg46, Arg47, Glu113, Lys114, Lys125, and Arg129 of antithrom-
bin and Arg93, Arg101, Arg233, Arg236, and Lys240 of thrombin.210 Both proteins
require a rare trisulfated GlcN for binding.
Despite the differences in sequence specificity, the thrombin-antithrombin-heparin
ternary structure shares some similarities with the FGF1-FGFR2-heparin ternary
structure. In both cases, heparin acts as a template to facilitate protein-protein
contacts. Both structures feature relatively weak protein-protein interactions (in the
case of the FGF-FGFR structure, the weak protein-protein interaction is the contacts
made between the FGF-FGFR dimers). Indeed, a plausible mechanism would be
that heparin facilitates these interactions by binding with high affinity to one protein
(antithrombin, or one of the FGF-FGFR dimers) and allowing the protein with less
specificity (thrombin, or the other FGF-FGFR dimer) to translate along the chain
until it encounters the binding partner.212
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Figure 2.5: The thrombin-antithrombin-heparin ternary structure (PDB entry 1TB6).
Heparin serves as a template for the thrombin-antithrombin interaction. Antithrombin
(white) binds with high affinity and specificity to a heparin (orange) pentasaccharide (inset,
with important residues labeled in cyan and electrostatic contacts labeled in magenta).
Thrombin (cyan) binds to heparin with less specificity.
2.3.3 Summary
The heparin sequence specificity of antithrombin seems to be unique among HS-
binding proteins. Other proteins have significantly less stringent sequence require-
ments. FGFs binding activity, for instance, seems to depend more on the overall
charge of HS, rather than a particular spatial arrangement. For chemokine binding,
the spacing of SAS domains seems more important than a specific sequence. How-
ever, many proteins seem to require a specific type of sulfation for activity. Taken
together, differentially spaced clusters of motifs may sufficiently describe the struc-
tural components of HS for efficient growth factor binding and selectivity. HS appears
to mediate complex formation in part by bridging two molecules that bind heparin
with strong affinity even in the absence of strong protein-protein interactions, such as
the thrombin-antithrombin-heparin complex, and, in part, by stabilizing the protein-
protein interactions by providing a template that can interact with multiple binding
partners simultaneously, such as the FGF-FGFR-HS complexes. While the differences
in the helical conformation (Section 1.4) and charge density between CS and HS may
contribute to differences in protein-binding selectivity between the two GAG classes,
the general properties of HS-protein binding should be similar for both GAGs. For
example, CS likely binds to electropositive surfaces of proteins in a similar manner to
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HS. Interactions with proteins and HS suggest that developing an understanding of
the spacing of heavily sulfated domains may be important for describing higher-order
CS-protein interactions (see also, Appendix B).
2.4 Chondroitin Sulfate-Growth Factors Interactions
Unfortunately, much less structural information is available for CS-protein interac-
tions than heparin. One of the only known structures with a CS oligosaccharide longer
than a disaccharide is cathepsin K bound to a CS-A hexasaccharide (Figure 2.6I).213
Cathepsin K is the major collagenolytic enzyme produced by bone-resorbing osteo-
clasts, with unique triple-helical collagen-degrading activity that depends on the for-
mation of complexes with glycosaminoglycans such as CS-A. Multiple cathepsin K
molecules bind specifically to a single CS-A chain with each protein molecule inter-
acting with a hexasaccharide sequence of CS-A distant from the active site. Like
heparin upon binding to antithrombin, the helical structure of CS-A is significantly
perturbed from the helical structure observed in fiber diffraction and computational
modeling studies.167,214 However, instead of flattening the helical structure, binding
to cathepsin K induces a sharp kink in the glycan.
Unlike many known growth factor-GAG interactions, cathepsin K binds to a low-
sulfated CS motif. Despite binding to a ligand with the lowest charge density discussed
in this chapter, the±5 kbT/e electrostatic potential surface shows that the binding site
has significant electropositive charge (Figure 2.6I). Like other GAG-binding proteins,
the key residues are basic. The cathepsin K-CS-A interaction depends on the Arg8,
Lys9, Lys10, Asn172, and Lys191 residues. No interactions are made with the sulfate
group on the final GalNAc moiety before the kink, suggesting the protein does not
require 6-O-sulfation at this site.
Cathepsin K may not be representative of CS-growth factor interactions. As
described in Section 2.2, the affinities of growth factors binding to GAGs generally
correlate with total charge of the glycan. Several known CS-binding proteins have
similar charge preferences. For example, midkine (MK); pleiotrophin (PTN); FGFs
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Figure 2.6: Growth factors with known chondroitin sulfate-binding activity. Structures are
displayed with the ±5 kbT/e electrostatic potential plotted on the solvent-accessible surface
and ribbon representations. (A) BDNF. (B) NGF. (C) FGF-16. (D) FGF-17. (E) GDNF.
(F) HB-EGF. (G) MK. (H) PTN. (I) Cathepsin K in complex with CS-A. Residues involved
in the interaction are labeled in cyan.
2, 16, and 17; and heparin-binding epidermal growth factor (HB-EGF) have been
shown to preferentially bind to oversulfated CS motifs (Figure 2.6).215,216 These
growth factors also bind to heparin, many with comparable activity.159 The equivalent
affinities heparin and CS have for these proteins is interesting because heparin has a
higher overall charge density than oversulfated CS motifs, such as CS-E. This suggests
that the spatial arrangement of charge may be important for these proteins. Like
heparin, CS interacts with electropositive surfaces of proteins via interactions with
basic or amide-functionalized residues.
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Most of the members of the FGF family that bind heparin also bind CS-E, albeit
with lower affinity, with the exception of FGF-16, which has higher affinity to CS-E.159
In addition, the fact that CS-E binds to GDNF, a member of the TGF-β superfamily,
suggests that CS-E might also bind with known HS-binding members, such as TGF-β
and BMP members. CS-E has also been shown to interact with Wnt-3 with similar
affinity to heparin.217 Taken together, these findings suggest that CS may interact
with more HS-binding proteins than previously considered. In fact, both CS-E and
heparin interact with the same GAG-binding site to RPTPσ (see also, Appendix
B).60 Therefore, lessons derived from the study of heparin-protein interactions should
be directly applicable to predicting CS-protein interactions. In Chapter 3, we apply
these lessons to the design of a computational method for predicting GAG-binding
sites.
2.4.1 Chondroitin Sulfate-Growth Factor Interactions Promote
Neuronal Growth In Vitro
CS activation of growth factors has been implicated in promoting neurite outgrowth
in some types of neurons.79 These interactions were sulfation-specific and the CS
sequences with high growth factor-binding activity also were proficient at promoting
neurite outgrowth in vitro.68,74–76 To systematically evaluate the role of sulfation
on neurite outgrowth, the three major CS sulfation motifs, CS-A, -C, and -E, were
synthesized, as well as a motif, termed CS-R, with sulfation at the 2- and 3-O positions
of GlcA. This motif has not been shown to exist in nature, but has the same overall
charge as CS-E and was designed to test the specificity of the CS-protein interactions.
Neurite outgrowth experiments were performed using the synthetic tetrasaccharides
adsorbed to the substratum. CS-E was able to promote neurite outgrowth, but the
other CS motifs, including the oversulfated CS-R motif, had no discernible effect on
the neurons (Figure 2.7).15
To probe the mechanism of CS-induced neurite outgrowth, carbohydrate microar-
rays were prepared from the synthetic tetrasaccharides.15,218 The reducing-end allyl
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C D 
Figure 2.7: Chondroitin sulfate tetrasaccharides control neurite outgrowth in a sulfation-
dependent manner. (A) Hippocampal neurons are stimulated by CS-E tetrasaccharide, but
not CS-A, -C, or -R relative to poly-ornithine control. Quantification of percent change
in neurite outgrowth relative to poly-ornithine in hippocampal (B), dopaminergic (C), and
DRG neurons. Figure adapted from Gama et al.15
group was ozonized, and the resulting aldehyde was conjugated to a bis-oxime linker.
The resulting CS molecules were printed onto glass arrays coated with an aldehyde-
functionalized dextran hydrogel. This strategy allowed for the CS molecules to be
conjugated to the surface covalently and display in a homogeneous manner.15,218,219
Using the arrays to detect MK and BDNF binding showed that both proteins bound
preferentially to CS-E, especially at lower concentrations (Figure 2.8C and D). How-
ever, both proteins bound CS-A and CS-R moderately, relative to CS-E, at slightly
higher concentrations. This pattern of binding was similar for several other growth
factors, including nerve growth factor (NGF), various FGF family members, glial-
derived neurotrophic factor (GDNF), tumor necrosis factor-α (TNF-α), and PTN
(Figure 2.6).216
To test if CS-E promotes neurite outgrowth through endogenously excreted growth
factors, such as midkine or BDNF, hippocampal neurons were grown on a substratum
containing CS-E in the presence or absence of antibodies against MK, BDNF, or their
cell-surface receptors protein tyrosine phosphatase ζ (PTPζ) and tropomyosin kinase
receptor B (TrkB), respectively. The anti-growth factor antibodies blocked the inter-
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5 mM CS, which approximates the estimated concentration of CS-E
present in physiological samples9,10,25 (Fig. 1d). As a control, we
demonstrated that none of the tetrasaccharides interacts strongly with
FGF-1 (Fig. 1e), which is consistent with studies indicating that FGF-1
is regulated by heparan sulfate but not by CS glycosaminoglycans8,16.
Having shown that distinct sulfation sequences can modulate the
interactions of CS with specific growth factors, we next investigated
the impact of sulfation on cell growth. As both midkine and BDNF
stimulate neuronal outgrowth, we compared the neuritogenic activity
of tetrasaccharides 1, 2, 3 and 4. We cultured primary hippocampal
neurons from embryonic day 18 (E18) rats on coverslips coated with
polyornithine and each of the four compounds. After 48 h, we fixed
the neurons, immunostained them with antibodies to tubulin and
examined them by confocal fluorescence microscopy. A specific
CS sulfation pattern was required for the growth-promoting activity
of CS. Whereas the CS-E tetrasaccharide stimulated neurite outgrowth
by 48.6 ± 2.3% relative to the polyornithine
control, tetrasaccharides representing other
CS subclasses found in vivo (CS-A and CS-
C) had no appreciable activity (Fig. 2a,b).
Notably, CS-R had no effect on neurite out-
growth, despite having the same overall nega-
tive charge as CS-E. These results are
consistent with previous reports that CS
polysaccharides enriched in the CS-E sulfa-
tion pattern possess neuritogenic activity8. In
this study, we extend those findings by estab-
lishing that a precise orientation of the sulfate
groups is critical for the growth-inducing
ability of CS.
We next investigated whether the effects of
the CS-E motif are unique to specific cell
types. Paradoxically, CS has been reported
both to stimulate and inhibit neuronal
growth, depending on the cellular context.
For instance, CS proteoglycans can repel
migrating neurons or extending axons during
brain development or after injury4,17. How-
ever, CS staining also coincides with develop-
ing axon pathways, and tissues expressing CS
do not always exclude axon entry27. To exam-
ine whether sulfation is important for the
growth of other neuron types, we cultured
dopaminergic neurons from the mesencepha-
lon of rat embryos on a substratum of each
tetrasaccharide. We found that the CS-E tet-
rasaccharide has similar activity toward both
dopaminergic and hippocampal neurons,
inducing the outgrowth of dopaminergic neurons by 29.6 ± 6.0%
(Fig. 2c). In contrast, the CS-C, CS-A and CS-R motifs showed no
appreciable neuritogenic activity. Similarly, we observed that the CS-E
tetrasaccharide, but not the other sulfation motifs, stimulates the
outgrowth of dorsal root ganglion (DRG) neurons derived from the
spinal cord (Fig. 2d). The ability of the CS-E sulfation motif to elicit a
response in various cell types suggests that protein receptors, shared by
many cell types, are likely present to engage the sugar. These results
indicate that the molecular structure of CS glycosaminoglycans is
critical for the function of CS, independent of neuron type.
The ability of the CS-E sulfation sequence to interact with growth
factors and modulate neuronal growth suggests that CS may recruit
specific growth factors to the cell surface, thereby activating down-
stream signaling pathways. To investigate this potential mechanism,
we cultured hippocampal neurons on a CS-E tetrasaccharide or
polyornithine substratum in the presence or absence of antibodies
–10
250 500 250 500 250 500 250 500
0
10
20
30
40
50
60
*
*
CS-E
Hippocampal neurons
Pe
rc
e
n
ta
ge
 
gr
o
w
th
–10
0
10
20
30
40
50
60
Pe
rc
e
n
ta
ge
 
gr
o
w
th
CS-C
CS-A
*
CS-R
CS-E
CS-C CS-A CS-R
Carbohydrate concentration (µg ml–1)
50 100 50 100 50 100 50 100
Carbohydrate concentration (µg ml–1)
DRG neurons
*
*
–10
0
10
20
30
40
50
60
Pe
rc
e
n
ta
ge
 
gr
o
w
th CS-E
CS-C CS-A CS-R
16 50 16 50 16 50 16 50
Carbohydrate concentration (µg ml–1)
Dopaminergic neurons
* *
b
c d
a
P-Ornithine CS-E
CS-A CS-R
50 µm 50 µm
50 µm 50 µm
50 µm
CS-C
Figure 2 The sulfation pattern directs the neuritogenic activity of CS. (a) Representative
immunofluorescence images of hippocampal neurons cultured on a substratum of polyornithine
and the synthetic tetrasaccharides. Scale bar, 50 mm. (b) The CS-E tetrasaccharide 1 stimulates
the outgrowth of hippocampal neurons. Altering the position of the sulfate groups, but not the overall
electrostatic charge, modulates the neuritogenic activity of CS. (c,d) The specific sulfation pattern
directs the activity of CS toward various neuron types. The CS-E tetrasaccharide 1 promotes the
outgrowth of dopaminergic (c) and DRG (d) neurons. We cultured neurons for 2–5 d on glass coverslips
coated with polyornithine and the tetrasaccharides at the indicated concentrations. We quantified
neurite length (mean ± s.e.m.), expressed as percentage growth relative to polyornithine control,
using NIH Image 1.62 (available online at http://rsb.info.nih.gov/nih-image) or Neurolucida 2000
(MicroBrightField Inc.) software after immunostaining with antibodies to tubulin (a,b), tyrosine
hydroxylase (c) or b-tubulin III (d). We performed statistical analysis using the one-way ANOVA
followed by the Scheffe test; n ¼ 50–200 cells. *P o 0.0001, relative to polyornithine control.
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the receptors PTPz or TrkB, but not TrkA, abolish the growth-promoting
effects of CS-E. We cultured hippocampal neurons on a substratum of
polyornithine or polyornithine plus the CS-E tetrasaccharide. After 24 h,
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cells for 24 h. We quantified neurite length (mean ± s.e.m.) using
NIH Image 1.62 software after immunostaining them with antibodies
to tubulin. *P o 0.0001, relative to the CS-E, no-antibody control;
n ¼ 150 cells.
L E T TERS
470 VOLUME 2 NUMBER 9 SEPTEMBER 2006 NATURE CHEMICAL BIOLOGY
CS tetrasaccharide favors a distinct set of torsion angles and presents a
unique electrostatic and van der Waals surface for interaction with
proteins (Fig. 1a and Supplementary Figs. 1–4 online). Whereas the
negatively charged sulfate and carboxylate groups on CS-C point
toward either the top or bottom face of the molecule, as oriented in
Figure 1a, the same charges on CS-A point in several different
directions. Similarly, although CS-E and CS-R have the same number
of sulfate groups, the relative orientation of these groups along the
carbohydrate backbone leads to distinctly different predicted solution
structures. Whereas the CS-R tetrasaccharide has the sulfate groups
distributed along several faces of the molecule, the CS-E tetrasacchar-
ide presents all four sulfate groups along a single face, which may
position the groups to interact with basic residues characteristic of
glycosaminoglycan binding sites on proteins2.
To explore the functional consequences of sulfation on growth
factor binding, we used tetrasaccharides 1, 2, 3 and 4 to construct
carbohydrate microarrays. Carbohydrate microarrays have proven to
be powerful tools for investigating the interactions of various glycans
with proteins, viruses and bacteria21–23. However, they have not been
extensively exploited for detailed structure-function analyses of
glycosaminoglycans, whose structures differ only subtly in their
sulfation pattern and are identical in stereochemistry and sugar
composition. The potential of microarrays to distinguish such closely
related structures has been unclear, as most studies have used
carbohydrates of very different composition, such as mannose versus
galactose or tetrasaccharides versus hexasaccharides21–23. To fabricate
the microarrays, we appended an aminooxy linker to the reducing end
of tetrasaccharides 1, 2, 3 and 4 by ozonolysis of the allyl group and
reaction with 1,2-(bisaminooxy)ethane. This linker enabled immo-
bilization of the oligosaccharides on aldehyde-coated slides via
formation of a covalent oxime bond. We used a high-precision
contact-printing robot to deliver nanoliter volumes of the compounds
to aldehyde-coated slides, yielding 1,000 spots approximately 200 mm
in diameter (Fig. 1b). We washed the slides before using them and
quenched the unreacted aldehyde moieties on the slide surfaces using
NaBH4. We validated the methodology by probing the microarrays
initially with a mouse monoclonal antibody selective for the CS-C
sulfation motif (Supplementary Methods online). We visualized the
binding of antibodies to the tetrasaccharides using a secondary
Cy3-conjugated goat anti-mouse antibody. The CS-C antibody
bound to the CS-C tetrasaccharide in a concentration-dependent
manner, and we observed selectivity of this antibody for the CS-C
motif with no detectable binding to the CS-A, CS-E or CS-R
tetrasaccharides (Supplementary Fig. 5 online).
Having validated the microarray methodology, we investigated the
effects of sulfation on the binding of CS to the growth factor midkine.
Midkine participates in the development and repair of neural and
other tissues24 and binds with nanomolar affinity to heterogeneous
polysaccharides enriched in the CS-E motif9. We observed selective
binding of midkine to the CS-E tetrasaccharide at CS concentrations
within the physiological range25. Notably, the midkine interaction
was highly sensitive to the position of the sulfate groups along
the carbohydrate backbone (Fig. 1c). The interaction of midkine
with CS-A and CS-C, the most abundant sulfation motifs in
the mammalian brain9, was significantly weaker than that with CS-E
(Po 0.0001). Midkine also did not interact as strongly with CS-R as
with CS-E, indicating that the midkine-CS association requires a
specific arrangement of sulfate groups and is not governed by
nonspecific, electrostatic interactions.
Access to defined sulfation sequences coupled with microarray
technologies provides a powerful, rapid means to identify new
glycosaminoglycan-protein interactions and to gain insight into the
functions of specific sulfation sequences. In addition to midkine, we
discovered that brain-derived neurotrophic factor (BDNF) selectively
binds to the CS-E sulfation sequence. The neurotrophin BDNF
controls many aspects of mammalian nervous system development
and contributes to synaptic plasticity, neurotransmission and neuro-
degenerative disease26. We found that BDNF has a 20-fold preference
for the CS-E motif relative to those of CS-C, CS-A and CS-R at
CS-E CS-C CS-A CS-R
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Figure 1 A specific sulfation patt rn promotes the interaction of CS with
neuronal growth factors. (a) Average structures from molecular dynamics
simulations of the CS tetrasaccharides in water. The sulfation pattern
influences the structure of CS, allowing it to present distinct electrostatic
and van der Waals surfaces to proteins. We generated the CS ball-and-stick
figures in PyMOL (DeLano Scientific) and created the electrostatic maps
using GRASP (available online at http://trantor.bioc.columbia.edu/grasp/).
(b) Overall scheme to detect CS-protein interactions using carbohydrate
microarrays. Each microarray contained 1,000 spots; a representative
portion of the microarray after binding to the CS-C antibody is shown. See
Supplementary Figure 5 for a description of the spotting pattern. (c,d) The
CS-E tetrasaccharide interacts with the growth factors midkine (c) and
BDNF (d). Altering the position of the sulfate groups, but not the overall
electrostatic charge, modulates the binding interaction. Each bar
(mean ± s.e.m.) represents an average of 5–10 spots. (e) None of the CS
tetrasaccharides interact with FGF-1. We compared binding data for FGF-1
to the average fluorescence intensity obtained for midkine binding to 15 mM
CS-E. We performed all statistical analyses using the one-way ANOVA
followed by the Scheffe test; n Z 5. *P o 0.0001, relative to CS-E
tetrasaccharide for a given concentration. **P r 0.001, relative to CS-E
tetrasaccharide for a given concentration.
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CS tetrasaccharide favors a distinct set of torsion angles and presents a
unique electrostatic and van der Waals surface for interaction with
proteins (Fig. 1a and Supplementary Figs. 1–4 online). Whereas the
negatively charged sulfate and carboxylate groups on CS-C point
toward either the top or bottom face of the molecule, as oriented in
Figure 1a, the same harges on CS-A point in several different
directions. Similarly, although CS-E and CS-R have the same number
of sulfate groups, the relative orientation of these groups along the
carbohydrate backbone leads to distinctly different predicted solution
structures. Whereas the CS-R tetrasaccharide has the sulfate groups
distributed along several faces of the molecule, the CS-E tetrasacchar-
ide presents all four sulfate groups along a single face, which may
position the groups to interact with basic residues characteristic of
glycosaminoglycan binding sites on proteins2.
To explore the functional consequences of sulfation on growth
factor binding, we used tetrasaccharides 1, 2, 3 and 4 to construct
carbohydrate microarrays. Carbohydrate microarrays have proven to
be powerful tools for investigating the interactions of various glycans
with proteins, viruses and bacteria21–23. However, they have not been
extensively exploited for detailed structure-function analyses of
glycosaminoglycans, whose structures differ only subtly in their
sulfation pattern and are identical in stereochemistry and sugar
composition. The potential of microarrays to distinguish such closely
related structures has been unclear, as most studies have used
carbohydrates of very different composition, such as mannose versus
galactose or tetrasaccharides versus hexasaccharides21–23. To fabricate
the microarrays, we appended an aminooxy linker to the reducing end
of tetrasaccharides 1, 2, 3 and 4 by ozonolysis of the allyl group and
reaction with 1,2-(bisaminooxy)ethane. This linker enabled immo-
bilization of the oligosaccharides on aldehyde-coated slides via
formation of a c valent oxime bond. We used a high-precision
contact-printing robot to deliver nanoliter volumes of the compounds
to aldehyde-coated slides, yielding 1,000 spots approximately 200 mm
in diameter (Fig. 1b). We washed the slides before using them and
quenched the unreacted aldehyde moieties on the slide surfaces using
NaBH4. We validated the methodology by probing the microarrays
initially with a mouse monoclonal antibody selective for the CS-C
sulfation motif (Supplementary Methods online). We visualized the
binding of antibodies to the tetrasaccharides using a secondary
Cy3-conjugated goat anti-mouse antibody. The CS-C antibody
bound to the CS-C tetrasaccharide in a concentration-dependent
manner, and we observed selectivity of this antibody for the CS-C
motif with no detectable binding to the CS-A, CS-E or CS-R
tetrasaccharides (Supplementary Fig. 5 online).
Having validated the microarray methodology, we investigated the
effects of sulfation on the binding of CS to the growth factor midkine.
Midkine participates in the development and repair of neural and
other tissues24 and binds with nanomolar affinity to heterogeneous
polysaccharides enriched in the CS-E motif9. We observed selective
binding of midkine to the CS-E tetrasaccharide at CS concentrations
within the physiological range25. Notably, the midkine interaction
was highly sensitive to the position of the sulfate groups along
the carbohydrate backbone (Fig. 1c). The interaction of midkine
with CS-A and CS-C, the most abundant sulfation motifs in
the mammalian brain9, was significantly weaker than that with CS-E
(Po 0.0001). Midkine also did not interact as strongly with CS-R as
with CS-E, indicating that the midkine-CS association requires a
specific arrangement of sulfate groups and is not governed by
nonspecific, electrostatic interactions.
Access to defined sulfation sequences coupled with microarray
technologies provides a powerful, rapid means to identify new
glycosaminoglycan-protein interactions and to gain insight into the
functions of specific sulfation sequences. In addition to midkine, we
discovered that brain-derived neurotrophic factor (BDNF) selectively
binds to the CS-E sulfation sequence. The neurotrophin BDNF
controls many aspects of mammalian nervous system development
and contributes to synaptic plasticity, neurotransmission and neuro-
degenerative disease26. We found that BDNF has a 20-fold preference
for the CS-E motif relative to those of CS-C, CS-A and CS-R at
CS-E CS-C CS-A CS-R
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Figure 1 A specific sulfation pattern promotes the interaction of CS with
neuronal growth factors. (a) Average structures from molecular dynamics
simulations of the CS tetrasaccharides in water. The sulfation pattern
influences the structure of CS, allowing it to present distinct electrostatic
and van der Waals surfaces to proteins. We generated the CS ball-and-stick
figures in PyMOL (DeLano Scientific) and created the electrostatic maps
using GRASP (available online at http://trantor.bioc.columbia.edu/grasp/).
(b) Overall scheme to detect CS-protein interactions using carbohydrate
microarrays. Each microarray contained 1,000 spots; a representative
portion of the microarray after binding to the CS-C antibody is shown. See
Supplementary Figure 5 for a description of the spotting pattern. (c,d) The
CS-E tetrasaccharide interacts with the growth factors midkine (c) and
BDNF (d). Altering the position of the sulfate groups, but not the overall
electrostatic charge, modulates the binding interaction. Each bar
(mean ± s.e.m.) represents an average of 5–10 spots. (e) None of the CS
tetrasaccharides interact with FGF-1. We compared binding data for FGF-1
to the average fluorescence intensity obtained for midkine binding to 15 mM
CS-E. We performed all statistical analyses using the one-way ANOVA
followed by the Scheffe test; n Z 5. *P o 0.0001, relative to CS-E
tetrasaccharide for a given concentration. **P r 0.001, relative to CS-E
tetrasaccharide for a given concentration.
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CS tetrasaccharide favors a distinct set of torsion angl s and presents a
unique electrostatic and van der Waals surface for interaction with
proteins (Fig. 1a and Supplementary Figs. 1–4 online). Whereas the
negatively charged sulfate and carboxylate groups on CS-C point
toward either the top or bottom face of the molecule, as oriented in
Figure 1a, the same h rges on CS-A point in several different
directions. Simil rly, although CS-E and CS-R ave the same number
of sulfate groups, the r lativ orientation of th s groups along the
carbohydrate backbon leads o distinctly different predicted solution
structures. Whereas the CS-R tetrasaccharide has the sulfate groups
distributed along several faces of the molecule, the CS-E tetrasacchar-
ide presents all four sulfate groups along a single face, which may
position the groups to interact with basic residues characteristic of
glycosaminoglycan binding sites on proteins2.
To explore th functional consequences of sulfation on growth
factor binding, we used tetrasaccharides 1, 2, 3 and 4 to const uct
carbohydrate microarrays. Carbohydrate microarray have proven to
be powerful tools for inv stigating the in era tions of various glycans
with proteins, viruses and bacteria21–23. However, they have not been
extensively exploited for detailed structure-function analyses of
glycosaminoglycans, whose structures differ only subtly in their
sulfation pattern and are identical in stereochemistry and sugar
composition. The potential of microarrays to distinguish such closely
related structures has been unclear, as most studies have used
carbohydrates of very differ nt omposition, such as mannose versus
galactose or tetrasaccharides versus hexasaccharides21–23. To bricate
the microarrays, we appended a aminooxy linker to the educing end
of tetrasaccharides 1, 2, 3 an 4 by ozonolysis of the allyl group and
reaction with 1,2-(bisaminooxy)ethane. This linker enabled immo-
bilization of the oligosaccharides on aldehyde-coated slides via
formation of a covalent oxime bond. We used a high-precision
contact-printing rob t to deliver nanoliter volumes of the compounds
to aldehyde-coated slides, yielding 1,000 spots approximately 200 mm
in diameter (Fig. 1b). We washed the slides before using them and
quenched the unreacted aldehyde moieties on the slide surfaces using
NaBH4. We validated the methodology by probing the microarrays
initially with a mouse monoclonal antibody selective for the CS-C
sulfation motif (Supplementary Methods online). We visualized the
binding of antibodies to the tetrasaccharides using a secondary
Cy3-conjug ted goat anti-mouse antibody. The CS-C antibody
bound to the CS-C tetrasaccharide in a concentration-dependent
ann r, and we obse ved selectivity of this antibody for the CS-C
m tif with no detectable binding to the CS-A, CS-E or CS-R
tetrasaccharides (Supplementary Fig. 5 online).
Having validated the microarray methodology, we investigated the
effects of sulfation on the binding of CS to the growth factor midkine.
Midkine participates in the development and repair of neural and
other tissues24 and binds with nanomolar affinity to heterogeneous
polysaccharides enriched in the CS-E motif9. We observed selective
binding of midkine to the CS-E tetrasaccharide at CS concentrations
within the physiological range25. Notably, the midkine interaction
was highly sensitive to the position of the sulfate groups along
the carbohydrate backbone (Fig. 1c). The interaction of midkine
with CS-A and CS-C, the most abundant sulfation motifs in
the mammalian brain9, was significantly weaker than that with CS-E
(Po 0.0001). Midkine also did not interact as strongly with CS-R as
with CS-E, ind cating that he midkine-CS association requires a
specific arrangement of su fate groups and is not governed by
nonspecific, electrostatic interactions.
Access to defined sulfation sequences coupled with microarray
technologies provides a powerful, rapid means to identify new
glycosaminoglycan-protein interactions and to gain insight into the
functions of specific sulfation sequences. In addition to midkine, we
discovered that brain-derived neurotrophic factor (BDNF) selectively
binds to the CS-E sulfation sequence. The neurotrophin BDNF
co trols many aspects of mammalian nervous system development
and contributes to synaptic plasticity, neurotransmission and neuro-
degenerative disease26. We found that BDNF has a 20-fold preference
for the CS-E motif relative to those of CS-C, CS-A and CS-R at
CS-E CS-C CS-A CS-R
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Figure 1 A specific sulfation pattern promotes the interaction of CS with
neuronal growth factors. (a) Average structures from molecular dynamics
simulations of the CS tetrasaccharides in water. The sulfation pattern
influences the structure of CS, allowing it to present distinct electrostatic
and van der Waals surfaces to proteins. We generated the CS ball-and-stick
figures in PyMOL (DeLano Scientific) and created the electrostatic maps
using GRASP (available online at http://trantor.bioc.columbia.edu/grasp/).
(b) Overall scheme to detect CS-protein interactions using carbohydrate
microarrays. Each microarray contained 1,000 spots; a representative
portion of the microarray after binding to the CS-C antibody is shown. See
Supplementary Figure 5 for a description of the spotting pattern. (c,d) The
CS-E tetrasaccharide interacts with the growth factors midkine (c) and
BDNF (d). Altering the position of the sulfate groups, but not the overall
electrostatic charge, modulates the binding interaction. Each bar
(mean ± s.e.m.) represents an average of 5–10 spots. (e) None of the CS
tetrasaccharides interact with FGF-1. We compared binding data for FGF-1
to the average fluorescence intensity obtained for midkine binding to 15 mM
CS-E. We performed all statistical analyses using the one-way ANOVA
followed by the Scheffe test; n Z 5. *P o 0.0001, relative to CS-E
tetrasaccharide for a given concentration. **P r 0.001, relative to CS-E
tet asaccharide for a given concentration.
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Figure 2.8: CS-E tetrasaccharide-induced neurite outgrowth requires BDNF and MK sig-
naling. (A) Adding function-blocking antibodies against growth factors BDNF and MK, or
(B) against rec ptors TrkB or PTPζ prevents the ffect of CS-E-i duc d neurite outgrowth
in hippocampal neurons. Antibodies against FGF-1 or TrkA had no effect. Microarray
analysis of MK (C), BDNF (D), or FGF-1 (E) show selective binding t CS-E, but o her
CS motifs also show significant level of b nding. Figure d pted from Gama et al.15
action between t e growth factor and CS-E, as measured by microarray anal sis. In
the presence of these antibodies, the CS-E-induced contribution to neurite outgrowth
w s abolish d. The antibodies h d no ffect on basal neurite outgrowth in the ab-
sence of CS-E, nor did class-matched ntibodies agai st FGF or TrkA (Figure 2.7A
and B).
These results are co sistent with a mech nism whereby CS-E enhances the co cen-
tration of gr wth fa to s ne r the cell su face, leading to increased signaling.202 This
is supported by the ob ervation that solubl CS-E polysaccharides inhibit hippocam-
pal neurite outgrowth in vitro.220 However, if the role of CS in neurite outgrowth
was as simple as enha cing l cal gro th factor concentration, then one might expect
CS-A or CS-R o have some growth-promoting act v ty. Alternatively, CS could play
a more specific role in growth factor sig aling, akin to the role of HS in FGF signaling,
and promote and stabilize the formation of the growth factor-receptor complex or act
as a co-receptor. This mechanism would likely impose additional structural demands
on the CS, explaining the observed specificity for CS-E. To our knowledge, such a
role has not been demonstrated for CS. The neurotrophin (NT) family of growth fac-
tors, of which BD F is a member, and their receptors were ideal candidates to test
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Figure 2.9: Structures of neurotrophin-receptor complexes. (A) The structure of the
NGF-TrkA complex (PDB 2IFG).221 A single NGF homodimer (green and cyan) binds two
molecules of TrkA (yellow) at the Ig2 domain. (B) Interactions and cross talk of the NTs
with TrkA. Primary interactions are depicted with a bold arrow. Secondary interactions are
shown as dashed arrows. (C) The structure of the NGF-p75NTR complex (PDB 1SG1).222
An NGF homodimer interacts with one molecule of p75NTR (magenta), leaving one of the
receptor-binding domains free. Note that the orientation of the N and C termini of NGF
differ significantly from the TrkA complex, making formation of a TrkA-NGF-p75NTR species
on the cell surface unlikely. (D) The structure of the NT-3-p75NTR complex (PDB 3BUK).223
The NT-3-p75NTR structure differs from (C) in p75NTR stoichiometry. Gong et al. suggest
the difference is due to the glycosylation of the receptor, which affects the structure of the
protein.223
this hypothesis. In addition to the interesting biological properties of these proteins,
the NTs bind two cell-surface receptors within their extracellular domains (ECDs),
potentially simplifying the study of the in vitro interaction (see, Chapter 3).
2.5 The Neurotrophin Family of Growth Factors
The NT family of growth factors consists of NGF, BDNF, neurotrophin-3 (NT-3), and
neurotrophin-4/5 (NT-4/5). Mature NTs are small noncovalent homodimers with
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high homology between the family members (Figure 3.11). The NTs are involved
in diverse functions related to the development and maintenance of the vertebrate
nervous system.224,225 For instance, NTs can mediate either cell survival or death,
depending on the context.226 A key function of the NTs is controlling the survival and
growth of neurons and of their branches. The NTs are synthesized and released by
neurons, and both their biosynthesis and secretion depends on neuronal activity.227
They all have very basic isoelectric points, a somewhat unusual property for secreted
proteins, which may serve the purpose of limiting their range of action and mediating
GAG binding (Figure 2.6A and B).
NTs bind to two different classes of transmembrane receptor proteins, the tropo-
myosin receptor kinases (Trks) and the neurotrophin receptor p75 (p75NTR). This
dual-receptor system allows the transduction of very different signals following ligand
binding, which can be as contrasted as signaling cell death through p75NTR or cell
survival through the Trk receptors. These two classes of receptors also directly inter-
act, allowing fine tuning and cross talk. Three Trk receptors have been identified and
each NT binds to a particular Trk receptor with high affinity. NGF binds to TrkA,
BDNF and NT-4/5 bind to TrkB, and NT-3 binds to TrkC.228 In addition, there is
considerable cross talk among the NT-Trk pairs, with NT-3 and NT-4/5 interacting
with TrkA, and NT-3 interacting with TrkB (Figure 2.9B).229 The Trks feature a
poorly conserved (∼30%) extracellular domain consisting of several leucine-rich re-
peats (LRRs) and two immunoglobulin-like (Ig) domains. The NTs interact primarily
with the second Ig, or d5, domain (Figure 2.9A). Trks have a single transmembrane
domain and a highly conserved (∼80%) tyrosine kinase domain.
All of the NTs bind to p75NTR with approximately equal affinity (K
D
∼ 1 nM).225,230
A member of the TNF receptor superfamily, the ECD of p75NTR is composed of four
cysteine repeats (CRs; Figure 2.9C). While Trk-NT and p75NTR-NT interactions have
approximately equivalent affinity in solution, p75NTR is known as the “low-affinity re-
ceptor,” due to the presence of high-affinity binding sites (∼10 pM) on Trk-expressing
PC12 cells or neurons. However, high-affinity binding cannot be explained by Trk
receptors alone, and subsequent studies have revealed that high-affinity binding sites
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for NTs can be formed by co-expression of p75NTR and Trk receptors.231,232 The
mechanism for this enhancement is unclear, but one explanation is that p75NTR acts
as a co-receptor for Trk. Recent crystallographic evidence, however, suggests such
an association is unlikely. NTs bind to Trk and p75NTR with different orientations
which may preclude the formation of an NT-p75NTR-Trk complex (Figure 2.9A, C
and D).231 Instead, the binding kinetics of p75NTR and Trks may cooperate to en-
hance the apparent affinity of NTs to neurons.231 The association of NTs to p75NTR
is immeasurably rapid by surface plasmon resonance (SPR), whereas the dissociation
from Trk is immeasurably slow by SPR (unpublished observations). Therefore, NTs
could be kept near the cell surface by virtue of the fast association with p75NTR and
the slow dissociation with TrkA. In fact, when the two receptors are co-expressed, the
apparent rate at which NGF can associate with TrkA increases by about 25-fold.231
Similarly, CS may enhance the binding affinity of the Trk receptors by acting as
a co-receptor. As discussed above, oversulfated CS is capable of stimulating neuronal
growth through the NTs. The observed selectivity of the NTs for variously sulfated
CS domains does not adequately describe the outgrowth phenotype. CS may act
similar to heparin and stabilize the formation of the NT-receptor interaction. We
test this possibility in Chapter 3.
2.5.1 Chondroitin Sulfate as a Regulator of NT Function
The multiple NTs, receptors, and ability to engage in cross talk raises the question
of how NT signaling is regulated in vivo. Reports suggest that differential activa-
tion of NT signaling pathways can lead to different cellular responses. For example,
in DRG/Schwann cell co-cultures, the NTs differentially regulate myelination. NT-3
acting through TrkC represses myelination, whereas BDNF acting through p75NTR
promotes it. Once active myelination is underway, TrkB sequesters extracellular
BDNF.233 Interestingly, CSPGs are over expressed after demyelination and have been
shown be a potent inhibitor of remyelination,234 suggesting the possibility that CS
may help regulate, or interfere, with myelination. However, mature, myelinated neu-
rons may no longer express the relevant NTs or receptors, so the inhibitory action of
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Figure 2.10: Expression of neurotrophins, their receptors, and CS-E in the E5.5 chick
retina. CS-E is expressed in the nerve fiber layer (NFL), the ganglion cell layer (GCL), and
in a graded pattern in the outer nuclear layer (ONL) with high expression near the pigment
epithelium (PE) and low expression near the inner nuclear layer (INL). (A) Expression of
the NTs. All of the NTs seem to be expressed by, or near retinal ganglion cells (RGCs),
given their localization in the NFL and GCL. NGF seems to be present at high levels in
the NFL, while the other NTs are localized near RGC cell bodies in the GCL. NT-4/5 is
expressed in the ONL. All NTs have expression profiles that considerably overlay with CS-
E. (B) Expression of NT receptors shows slightly higher levels of localization that the NTs.
TrkA is expressed highly in the NFL and TrkB is expressed highly in the NFL, GCL, and
ONL. Lastly, p75NTR has graded expression in the ONL.
CSPGs may be acting through a different mechanism.
To look at how NTs may be regulated in vivo, we looked at the expression profiles
of the NTs, their receptors, and CS-E in the developing chick retina (Figure 2.10).
Retina from E5.5 chick were examined, a time when CS-E expression was maximal
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(see also, Chapter 5). At this stage, CS-E is strongly expressed in the nerve fiber
layer (NFL), the ganglion cell layer (GCL), and in an apparent gradient in the outer
nuclear layer (ONL) with high expression near the pigment epithelium (PE) and
low expression near the inner nuclear layer (INL). Most of the NTs had congruent
expression profiles with CS-E in the retina, but many of the NTs had distinct patterns
of apparent localization. NGF, for instance, had very strong staining in the NFL,
associated with retinal ganglion cell (RGC) axons (Figure 2.10B). BDNF, on the
other hand, had minimal staining in the NFL but was associated with the GCL.
Additionally, NT-4/5 is expressed in the GCL but also in the ONL as well. All of the
NTs have expression profiles that are considerably congruent with CS-E.
Next, we looked at the expression of the Trk receptors and p75NTR (Figure 2.10B).
TrkA was localized to the NFL, and displayed very little expression elsewhere in the
retina. The expression of TrkB, on the other hand, was expressed on the NFL, GCL,
and ONL. Interestingly, the expression profile of TrkB was very similar to that of
CS-E. Signal for TrkC staining was poor (data not shown), and p75NTR displayed
modest expression in the GCL and the ONL.
An intriguing possibility suggested by the co-localization patterns of CS-E, the
NTs, and their receptors is that a CS co-receptor may help regulate NT-receptor
interactions. For example, NT-4/5 and BDNF both bind to TrkB and p75, and all
of these proteins are expressed in regions with high levels of CS-E expression. It may
be possible that CS is capable of acting as a co-receptor for one complex, such as
BDNF-TrkB, but not another, such as NT-4/5-TrkB, and thereby able to promote
the formation of one complex over the other. In Chapter 3, we examine the ability of
CS to promote specific NT-receptor complexes.
2.6 Conclusion
Major classes of GAG-binding proteins include small, secreted proteins such as growth
factors, morphogens, and chemokines. A distinct characteristic of all of these pro-
teins is regions of high electropositive surface potential, leading to the hypothesis
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that GAG-protein binding is non-specific. There is some evidence to supports this:
some proteins prefer GAGs with higher charge regardless of sequence; and, many
growth factors bind to oversulfated CS with equivalent affinity to HS or heparin,
despite the differences in structure between the GAGs. On the other hand, many
interactions depend on a particular type of sulfation (e.g., 2-O-sulfation) or motif
(e.g., CS-E), suggesting that the spatial arrangement of charge is important. Addi-
tionally, ATIII preferentially binds to a specific heparin pentasaccharide, which, taken
together, implies that there simply may be diversity in the structural requirements
for GAG-protein binding. Interestingly, data from neurite outgrowth studies with
CS suggests that the outgrowth phenotype depends on a particular sulfation motif,
CS-E. However, binding data to growth factors known to stimulate outgrowth does
not show similar specificity. The phenotype could be explained if CS-E acts as a
co-receptor for these growth factors, and only CS-E were capable of juxtaposing the
growth factor and its receptor. This would represent a new role for CS, akin to the
role of HS in FGF-FGFR signaling, and shed new light on the biological activity of
GAGs.
2.7 Appendix
2.7.1 Homology Models
Homology models were created for FGF-4, -16, -17, -18, -21, and PTN. The model
for FGF-4 was taken from Protein Data Bank (PDB) accession number 1IJT, which
shares 99% sequence homology with the target. The structure for FGF-16 was taken
from PDB 1G82 which shares 84% sequence identity, and FGF-17 was taken from
PDB 2FDB which shares 74% sequence identity. Likewise, models for FGF-18 and
FGF-21 were taken from PDB accession numbers 2FDB and 2P23, which share 63%
and 35% homology with the target proteins, respectively. The structure for PTN was
based on a template from 1MKN which shares 49% sequence identity. The models
were taken from the SWISS-MODEL repository,235,236 and used without additional
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modification. A homology model for BDNF was created by replacing the NT-4/5
monomer from the BDNF/NT-4/5 heterodimer structure (PDB 1B8M) with another
BDNF monomer. The electrostatic potential of the solvent-accessible surface was
calculated with APBS237 and visualized with PyMOL.238
2.7.2 Immunohistochemistry
The heads of embryo from E5–E7.5 chicken were fixed in a solution of 4% paraformalde-
hyde containing 10% sucrose. After fixation, the samples were placed in 20% sucrose
for 12 hours before sectioning. 20 µm transverse sections of the optic tract were
mounted on glass slides. The samples were exposed to 10% FBS in PBS for 1 h at
room temperature before staining for 3 h at room temperature with anti-CS-E (1:250
in 10% FBS in PBS) with anti-NT (1:200) or anti-NTR (1:200). The antibodies were
removed and the samples were washed five times with PBS before treatment with
secondary antibody. The samples were treated with an Alexa Fluor 488 anti-mouse
antibody (1:500 in 10% FBS in PBS) and Alexa Fluor 564 anti-rabbit (1:500). After 1
h, the samples were washed five times with PBS, treated with vectashield and sealed
with a coverslip. The samples were then imaged using confocal microscopy.
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Chapter 3
Elucidating
Glycosaminoglycan-Protein-Protein
Interactions†
3.1 Abstract
Few methods exist for the rapid identification of GAG-protein interactions and for
studying the potential of GAGs to assemble multimeric protein complexes. Here, we
report a multidisciplinary approach that combines new carbohydrate microarray and
computational methodologies to elucidate and understand GAG-protein interactions.
This approach was validated through the study of known protein partners for heparan
and chondroitin sulfate, including fibroblast growth factor 2 (FGF-2) and its receptor
FGFR1, the malarial protein VAR2CSA, and tumor necrosis factor-α (TNF-α). We
then applied our approach to identify novel interactions between CS-E and the neu-
rotrophins, a family of growth factors critical for the development and maintenance
of the vertebrate nervous system. Our studies show for the first time that CS is
capable of assembling multimeric signaling complexes and modulating neurotrophin
signaling pathways. In addition, we identify a contiguous CS-E-binding site within
the neurotrophin-tropomyosin receptor kinase (Trk) complex by computational mod-
eling that suggests a mechanism that could potentially explain how CS may promote
†Portions of this chapter were take from Claude J. Rogers, Peter M. Clark, Sarah E. Tully, Ravin-
der Abrol, K. Christopher Garcia, William A. Goddard III, Linda C. Hsieh-Wilson, “Elucidating
glycosaminoglycan-protein-protein interactions using carbohydrate microarray and computational
approaches,” Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 9747–9752.
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complex formation and neurotrophin signaling. Together, our microarray methodol-
ogy, when combined with computational modeling, provides a general, facile means
to identify new GAG-protein-protein interactions, as well as a molecular-level under-
standing of those complexes.
3.2 Introduction
While GAGs have been shown to regulate a wide variety of cellular responses, the
mechanism of how GAGs regulate many of these processes remains unclear. Per-
haps the most studied mechanism in GAG-mediated signaling is the role of HS in
FGF signaling. HS participates in the assembly of a ternary signaling complex with
FGF and FGFR, thereby modulating signal transduction pathways (see also, Chapter
2).134,204,239–241 However, few other examples of GAG-mediated multimeric protein
complexes have been elucidated, and the extent to which other GAGs such as CS
participate in similar signaling complexes is unknown. Elucidating the interactions
of specific GAG substructures with proteins and large protein-protein complexes will
be critical for understanding the structure-activity relationships of GAGs and the
mechanisms underlying important biological processes.
Several methods have been developed to study GAG-protein interactions, includ-
ing affinity chromatography, analytical ultracentrifugation, electrophoretic mobility
shift assays, competition experiments, mass spectrometry-based approaches, isother-
mal titration calorimetry, and surface plasmon resonance (SPR).240–247 Although pow-
erful, these approaches are low throughput, often labor intensive, and require signif-
icant quantities of carbohydrate and/or protein. Notably, no methods are available
to rapidly screen various GAGs for their ability to assemble multimeric protein com-
plexes. In addition, existing methods often require oligosaccharides or polysaccharides
that are relatively homogeneous in chain length and charge density, such as fraction-
ated heparin or chemically modified HS.242,243,245 As such, it has been difficult to
study the interactions of proteins with other GAG classes and physiologically rele-
vant GAG preparations, which are more heterogeneous and structurally diverse.
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Similarly, structural studies of GAG-protein interactions have been limited by
the complexity and heterogeneity of natural occurring GAGs. For example, the ma-
jority of crystal structures contain fully sulfated heparin oligosaccharides instead of
physiological HS ligands of lower charge density.209 As an alternate strategy, recent
advances in molecular modeling have provided several approaches for understand-
ing the interaction of heparin or HS with proteins, including interleukin 8 (IL-8;
CXCL8), TNF-stimulated gene 6 (TSG-6), and platelet endothelial cell adhesion
molecule 1 (PECAM-1).248–250 However, GAG-protein interactions pose a unique set
of challenges for computational modeling, such as highly flexible sugar ligands with
many rotatable bonds, interaction energies dominated by electrostatics, and shallow,
solvent-accessible binding pockets. Moreover, computational approaches have not yet
been applied to other GAGs, such as the less highly charged CS class, nor have they
been developed to investigate large GAG-protein-protein complexes.
Here, we describe an integrated approach that combines carbohydrate microar-
ray methodologies with computational modeling to provide new insights into GAG
interactions with proteins and multimeric protein complexes. We demonstrate that
carbohydrate microarrays can be used to rapidly screen proteins and protein-protein
complexes for binding to specific sulfation motifs and GAG classes. Such informa-
tion can then be used in conjecture with new computational modeling approaches
to predict GAG-binding sites within proteins and determine the potential for GAGs
to assemble multimeric protein complexes. Using this combined approach, we iden-
tify a specific interaction between CS-E and the neurotrophin (NT) family of growth
factors and receptors. Our computational modeling results suggest a contiguous CS-
E-binding site that spans the NT-Trk receptor complex, providing a potential mech-
anism to explain how CS modulates complex formation and NT signaling pathways.
Together with cellular data, we provide the first evidence that CS plays an active role
in cellular signaling by regulating the interactions between growth factors and their
receptors.
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3.3 General Microarray Approach
The binding of proteins to GAGs was examined using carbohydrate microarrays con-
taining either synthetic tetrasaccharides of defined sulfation sequence,15,218 or nat-
urally occurring polysaccharides representing various GAG classes.16 Microarrays
of synthetic tetrasaccharides displaying CS-A, CS-C, or CS-E sulfation motifs were
robotically printed on aldehyde-coated glass surfaces at varying concentrations (1–300
µM). Polysaccharide microarrays were printed on poly-dl-lysine-coated glass surfaces
and contained varying concentrations (0.25–25 µM) of chondroitin sulfate enriched in
the CS-A, CS-C, CS-D, and CS-E motifs; dermatan sulfate (CS-B), hyaluronic acid
(HA), heparin (Hep), heparan sulfate (HS), or keratan sulfate (KS; see also, Appendix
A). In all cases, the microarrays were incubated with the protein or protein-protein
complex of interest, and binding was detected using primary antibodies against the
protein(s) followed by secondary Cy3- and/or Cy5-labeled antibodies. Notably, this
miniature array format permitted the rapid detection of multiple binding events si-
multaneously and required minimal amounts (1–100 µg) of carbohydrate and protein.
As described below, the arrays allowed for comparisons of the binding of large fam-
ilies or functional classes of proteins to various GAG subtypes to provide a more
comprehensive understanding of the specificity of proteins for different GAG classes
and sulfation sequences. Notably, we also applied the microarray technology for the
first time toward the discovery of new glycosaminoglycan-protein interactions and
toward an understanding of the assembly of multimeric protein complexes.
3.4 General Computational Approach
Once GAG-protein interactions were identified using carbohydrate microarrays, we
predicted the GAG-binding sites on proteins using computational methods. First,
rigid-body docking of one oligosaccharide conformation to the entire molecular surface
of the protein was performed using the program ScanBindSite to locate the most
favorable binding sites.251 The protein region(s) with the lowest-energy structures
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were subsequently inputted into GenMSCDock for further refinement of the binding
site.252 In GenMSCDock, rigid-body docking of one oligosaccharide conformation
was continued until a diverse set of ligand orientations with respect to the protein
was obtained. The protein side chains in the binding site were then optimized by
SCREAM using a 1.0 Å rotamer library,253 and the oligosaccharide-protein complex
was minimized for 10 steps using conjugate-gradient minimization. Residues within
5 Å of the oligosaccharide in more than one of the five minimum energy structures
were considered part of the GAG-binding site. Modeling the oligosaccharides as rigid
bodies greatly simplifies the computation and is justified by observations that protein
binding typically does not change the conformation of the GAG.166
3.5 Validation of the Computational and Microarray
Approaches
3.5.1 VAR2SCA
To test the computational methods, we first examined the protein VAR2CSA, a CS-
A-binding protein involved in placental malaria pathogenesis.254 CS-A binds to the
DBL3x and DBL6 (Duffy binding-like 3x and 6) domains of VAR2CSA with micro-
molar affinity, and basic residues important for the interaction have been identified
by site-directed mutagenesis.255 In addition, 1.8 and 3.0 Å crystal structures of the
DBL3x and DBL6 domains of VAR2CSA, respectively, have been solved.255,256 We
predicted the lowest energy conformation of a CS-A tetrasaccharide by performing
molecular dynamics simulations in explicit water15 and used ScanBindSite and Gen-
MSCDock to determine the CS-A binding site on DBL3x or DBL6. CS-A was found
to interact with both of the lysine residues predicted by mutagenesis to comprise
the primary CS-A binding site on DBL6 (Figure 3.1A, Table 3.1). Moreover, five
of the seven residues determined to be important for CS-A binding to DBL3x were
successfully identified, further validating the computational approach (Figure 3.1B,
Table 3.2). The side chain of Lys1515, one of the residues not identified by compu-
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Figure 3.1: (A and B) CS-A binding site (blue) on the DBL6 (A) and DBL3x (B) domains
of VAR2CSA, as predicted by computational modeling (left) and mutagenesis (right). (C)
Heparin-binding site (blue) on FGF-2 as predicted computationally (left) and determined
crystallographically (right). (D) Heparin-binding site (blue) in the FGF2-FGFR1 complex
as predicted computationally (left) and determined crystallographically (right). The two
FGF-2 subunits are shown in green and orange, and the two FGFR1 subunits are shown
in light blue and gray. (E) Predicted CS-E binding site (blue) in the trimeric structure of
TNF-α (left). Homology model of the TNF-α-TNFR1 complex (right) shows that the CS-E
binding site overlaps with the TNFR1 binding site. TNFR1 is depicted in gray.
tational modeling, is buried in the crystal structure and makes electrostatic contacts
with two internal Glu residues (Glu1464 and Glu1518), suggesting that this residue
may not directly engage in interactions with CS-A. Together, these results show that
CS-binding sites on proteins can be correctly identified using our computational ap-
proach. Furthermore, we identify additional residues within DBL6 and DBL3x that
may engage in close van der Waals and other interactions with the sugar.
3.5.2 FGF-2 and Its Complex with FGFR1
To further test our computational methods, we modeled the heparin-binding site on
FGF-2 and extended our approach to the larger FGF2-FGFR1 complex. Using the
solution structure of FGF-2 and the crystal structure of a heparin tetrasaccharide,
we identified all of the charged residues as well as six of the seven other residues
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Table 3.1: Predicted CS-A binding site on the DBL6 domain of VAR2CSA
and associated KD values for the interaction of DBL6 mutants with purified
CS-A
Predicted CS-A Binding Site K
D
Values of DBL6 Mutantsa
Lys2388
Arg2389
Asp2390
Pro2391
Lys2392 Lys2932Ala: NDb
Phe2394
Lys2395 Lys2395Ala: NDb
Ile2452
Leu2453
Gly2454
Lys2462
Trp2462
Met2469
Asn2470
a For comparison, WT DBL6 had a K
D
value of 80 µM. Blank entries correspond
to residues whose contribution to the binding site was not tested.254
b K
D
too weak to determine
59
Table 3.2: Predicted CS-A binding site on the DBL3x domain of VAR2CSA
and associated KD values for the interaction of DBL3x mutants with purified
CS-A
Predicted CS-A Binding Site K
D
Values of DBL3x Mutantsa
Asp1236
Gly1237
Lys1238
Ile1239
Phe1240
Gly1242
Lys1243 Lys1243Ala: 367 µM
Gly1244
Gly1245
Glu1246
Gly1318
Thr1319
Ile1321
Lys1324 Lys1324Ala: 122 µM
Asn1325
Lys1328 Lys1328Ala: 89 µM
Gly1329
Gln1330
Lys1467 Lys1467Ala: 122 µM
Arg1503
Lys1504Ala: 172 µM
Lys1507
Lys1510 Lys1510Ala: 193 µM
Lys1515Ala: 488 µMb
a For comparison, WT DBL3x had a K
D
value of 33 µM. Blank entries correspond
to residues whose contribution to the binding site was not tested.254
b Corresponds to a buried lysine residue that may not directly interact with CS-A
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located within 5 Å of heparin in the co-crystal structure of FGF-2 complexed to a
tetrasaccharide (Figure 3.1C, Table 3.3).170 Two additional contacts were predicted
using our computational approach, one of which (Lys26) is found in the co-crystal
structure of FGF-2 bound to a heparin hexasaccharide.170
Having correctly predicted the heparin-binding site, we next tested whether our
computational approach could be used to provide insight into the interaction of
GAGs with large, multimeric protein complexes. Biochemical, structural, and cel-
lular studies have established that heparin forms a ternary complex with FGF-2 and
the FGFR1 receptor and makes multiple contacts with both proteins (see also, Section
2.3.1).134,257 Initial attempts to dock a heparin octasaccharide to the FGF2-FGFR1
complex identified only the heparin-binding site on FGFR1. To overcome this prob-
lem, we determined each of the heparin-binding sites on FGF-2 and FGFR1 individ-
ually and superimposed those binding sites onto the structure of the FGF2-FGFR1
complex. The majority of the residues found in the sugar-binding site of the heparin-
FGF2-FGFR1 crystal structure were identified (Figure 3.1D and Table 3.4). Most
importantly, we observed a contiguous binding site that spanned the FGF2-FGFR1
complex, consistent with the crystal structure. Thus, our computational methods can
be used to predict GAG-binding sites and to provide insights into the potential for
glycosaminoglycans to assemble multimeric protein complexes.
The ability of HS to mediate the formation of protein complexes is critical for its bi-
ological functions, enabling it to regulate growth factor, chemokine, and other key sig-
nal transduction pathways.190,239 As experimental methods for studying carbohydrate-
mediated protein-protein interactions require considerable material and are low through-
put and time consuming, we sought to expand carbohydrate microarray methodolo-
gies to rapidly screen for carbohydrate-protein-protein complexes. We chose the
well-established heparin-FGF2-FGFR1 interaction as our first test case. FGF-2,
FGFR1-Fc fusion protein, or a 1:1 mixture of FGF2:FGFR1-Fc was incubated with
the polysaccharide microarrays, and after treatment with a primary antibody against
FGF-2, growth factor or receptor binding was detected using orthogonal secondary
antibodies conjugated to Cy3 or Cy5 dyes. We found that FGF-2 bound strongly
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Table 3.3: Comparison of the heparin-binding site on FGF-
2 as determined using computational and crystallographic
methodsa
Computational Prediction Crystal Structure
Lys26b
Asn27 Asn27
Gly28
Leu118 Leu118
Lys119 Lys119
Arg120 Arg120
Thr121
Lys125 Lys125
Lys129 Lys129
Gly133 Gly133
Gln134 Gln134
Lys135 Lys135
Ala136 Ala136
Ile137
a Residues are numbered according to FGF-2 structure 1FQ9.
b Found in the heparin-binding site of the structure 1BFC
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Table 3.4: Comparison of the heparin-binding site in the FGF2-FGFR1
complex determined using computational or crystallographic methods
Computational
Prediction
Crystal
Structurea
Computational
Prediction
Crystal
Structurea
FGF-2 FGFR1
Lys26A Lys26A Lys160A Lys160A
Asn27A Asn27A Lys163A Lys163A
Gly28A Gly28A His166A His166A
Leu118A Leu118A Val168A
Lys119A Lys119A Lys172A Lys172A
Arg120A Arg120A Thr173A Thr173A
Thr121A Thr121A Val174A Val174A
Lys125A Lys125A Lys175A Lys175A
Leu126A Phe176A
Ser128A Lys177A Lys177A
Lys129A Lys129A Tyr206A
Gly133A Gly133A Lys207A Lys207A
Gln134A Gln134A Val208A
Lys135A Lys123A Arg209A Arg209A
Ala136A Ala136A Thr212A
Ile137A Ser214A
Tyr24B Ile216A Ile216A
Lys26B Lys26B Asp218A Asp218A
Asn27B Asn27B Lys160B Lys160B
Gly28B Gly28B Lys163B Lys163B
Gly29B His166B His166B
Ala117B Val168B Val168B
Leu118B Leu118B Lys172B
a Residues found within 5 Å of heparin in the heparin-FGF2-FGFR1 structure
1FQ9
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Table 3.4: Comparison of the heparin-binding site in the FGF2-FGFR1 com-
plex determined using computational or crystallographic methods (continued)
Computational
Prediction
Crystal
Structurea
Computational
Prediction
Crystal
Structurea
FGF-2 FGFR1
Lys119B Lys119B Thr173B Thr173B
Arg120B Arg120B Val174B
Thr121B Lys175B Lys175B
Lys125B Lys125B Phe176B
Leu126B Lys177B
Ser128B Tyr206B
Lys129B Lys129B Lys207B Lys207B
Thr130B Val208B
Gly131B Arg209B Arg209B
Gly133B Gly133B Thr212B
Gln134B Gln134B Ser214B
Lys135B Lys123B Ile216B Ile216B
Ala136B Ala136B Asp218B Asp218B
Ile137B
a Residues found within 5 Å of heparin in the heparin-FGF2-FGFR1 structure
1FQ9
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Figure 3.2: (A) Relative binding of FGF-2 to the indicated glycosaminoglycan (0.5, 5,
and 10 µM concentration) on polysaccharide microarrays in the presence (red) or absence
(black) of FGFR1. (B) Relative binding of FGFR1 to the indicated glycosaminoglycan (0.5,
5, and 10 µM concentration) on polysaccharide microarrays in the presence (red) or absence
(black) of FGF-2. (C) Relative binding of TNF-α to the indicated tetrasaccharide of defined
sulfation sequence in the presence (red) or absence (black) of TNFR1. (D) Relative binding
of TNFR1 to the indicated tetrasaccharide of defined sulfation sequence in the presence
(red) or absence (black) of TNF-α. Binding relative to the maximum signal for each plot is
shown. Each protein was analyzed in triplicate, and the data represent an average of 8–10
spots for a given carbohydrate concentration.
to heparin and HS polysaccharides in the absence of FGFR1 (Figure 3.2A), whereas
FGFR1 alone showed minimal binding to the array (Figure 3.2B). Notably, FGFR1
binding increased significantly in the presence of FGF-2, suggesting that binding of
the growth factor to heparin or HS enhances binding of the receptor. Moreover, co-
localization of both proteins was detected on the arrays (Figure 3.8), indicating the
formation of carbohydrate-protein-protein complexes. Complex formation was ob-
served with heparin, HS and, to a lesser extent, with CS-E-enriched polysaccharides,
consistent with the demonstrated selectivity of FGFs for these glycosaminoglycan
subclasses.16,243
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3.5.3 TNF-α and Its Complex with TNFR1
As final validation of our computational and carbohydrate microarray approaches,
we examined the interaction of CS with TNF-α, a proinflammatory cytokine involved
in autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoria-
sis.258–260 Previous studies in our laboratory have demonstrated that a tetrasaccharide
displaying the CS-E sulfation motif binds to TNF-α and antagonizes its interaction
with TNFR1, thereby inhibiting TNF-α-induced cell death.218 To test our microarray
approach, we incubated TNF-α, TNFR1-Fc, or a 1:1 mixture of TNF-α:TNFR1-Fc
with CS tetrasaccharide microarrays. Both TNF-α and TNFR1-Fc selectively bound
to CS-E tetrasaccharides when incubated alone with the microarrays (Figure 3.2C
and D). However, binding of these proteins to CS-E was abolished when the proteins
were incubated together. These data indicate that once formed, the TNF-α-TNFR1
complex cannot bind to CS-E tetrasaccharides on the array. Thus, CS-E, TNF-α
and TNFR1 do not appear to form a ternary complex, consistent with previous stud-
ies,218 and further validating the use of microarrays to rapidly probe the interactions
of glycosaminoglycans with multimeric protein complexes.
We next applied our computational approach to gain insight into the CS-E binding
site on TNF-α. We found that CS-E binds predominantly to two loops between
antiparallel β-strands c–d of monomer A and β-strands e–f of monomer B in the
TNF-α trimer structure (Figure 3.1E and Table 3.5).261 As the structure displays
3-fold symmetry, CS-E binding sites are also predicted between monomers B and
C, and C and A. We constructed a homology model of the TNF-α-TNFR1 complex
based on the known crystal structure of the TNF-β-TNFR1 complex.262 Notably,
the CS-E binding site on TNF-α overlaps with that of TNFR1, as determined by
site-directed mutagenesis263 and homology modeling. These findings are consistent
with the carbohydrate microarray results above and with previous ELISA and cellular
studies,218 further validating the computational methods. Collectively, we have shown
that the integration of computational modeling and microarray approaches can be
used to gain important insights into GAG-protein interactions and to rapidly establish
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whether specific GAG subclasses or sulfation motifs interact with multimeric protein
complexes.
3.6 Identification of New GAG-Protein Interactions:
The Neurotrophins and Their Receptors
As described in Chapter 2, the NT family of growth factors has critical functions
in many aspects of neuronal development, including neurite outgrowth, cell survival,
differentiation, and proliferation.232,264–266 They also play important roles in synaptic
plasticity and maintenance of the adult nervous system,264–266 and have been impli-
cated in neurodegenerative diseases.264 Previously, we found that a tetrasaccharide
containing a specific sulfation motif, CS-E, stimulates the outgrowth of developing
hippocampal neurons.15,70 Our studies implicated brain-derived neurotrophic factor
(BDNF) as one of the proteins responsible for mediating the effects of CS-E.15 In ad-
dition to BDNF, the NT family includes nerve growth factor (NGF), neurotrophin-3
(NT-3), and neurotrophin-4/5 (NT-4/5), which share approximately 50% sequence
homology to BDNF and strikingly similar structures, with root mean square devia-
tions (RMSD) of less than 2 Å between any two of the NTs. We used our microar-
ray approach to rapidly compare the binding specificity across this protein family.
Notably, all of the NTs showed concentration-dependent binding to CS-E tetrasac-
charides, with NGF displaying the greatest specificity (Figure 3.3A). However, the
ability of BDNF and other NTs to bind weakly to other sulfation motifs was un-
expected, given that only the CS-E motif stimulated neurite outgrowth.15,70 Thus,
we postulated that CS-E might interact with additional proteins, possibly forming
protein-protein complexes between NTs and their receptors, and that the formation
of such complexes might impart greater selectivity for the CS-E motif.
To test this hypothesis, we examined the binding of various NT-receptor pairs to
CS tetrasaccharide and polysaccharide microarrays. The NTs activate signal trans-
duction pathways by binding to the Trk receptors A, B and C.224,232,264,266 In par-
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Figure 3.3: (A) Relative binding of NGF, BDNF, NT-3, and NT-4/5 to the indicated CS
tetrasaccharide on carbohydrate microarrays. (B) Relative binding of the Trk receptors to
CS tetrasaccharides on carbohydrate microarrays in the presence (red) or absence (black)
of the indicated NTs. (C) Comparison of the relative binding of TrkA to CS-E-enriched
polysaccharides in the presence of NGF, NT-3, or NT-4/5. Binding relative to the maximum
signal for each plot is shown in A and C; binding relative to the maximum signaling for the
series of four plots is shown in B. Each protein was analyzed in triplicate, and the data
represent an average of 8–10 spots for a given carbohydrate concentration.
ticular, TrkA binds to NGF, TrkB binds to BDNF and NT-4/5, and TrkC binds to
NT-3. However, cross talk among the NT family has also been observed, whereby
certain NTs bind to additional Trk receptors with lower affinity (e.g., NT-3 and NT-
4/5 to TrkA).229,264 This cross talk raises the interesting question of how specific NT
signaling pathways are differentially activated in vivo.
We first probed the ability of CS-E to assemble NT-Trk complexes, starting with
the primary-binding partners NGF-TrkA, BDNF-TrkB, NT-3-TrkC, and NT-4/5-
TrkB. In the absence of NT, TrkA and TrkB bound weakly to the CS-E tetrasac-
charide, while TrkC showed no apparent binding to the microarray (Figure 3.3B).
Notably, the presence of NGF and BDNF significantly enhanced the binding of TrkA
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and TrkB, respectively, to CS-E (Figure 3.3B), and co-localization of the proteins was
observed on the array (data not shown), suggesting the formation of CS-E-NGF-TrkA
and CS-E-BDNF-TrkB complexes. Complex assembly was highly selective for the CS-
E sulfation motif and did not occur in the presence of CS-A or CS-C tetrasaccharides.
Similar results were obtained using polysaccharide microarrays (Figure 3.9). Thus,
the complex of NT and Trk showed greater selectivity for CS-E than each NT alone,
reinforcing the notion that formation of GAG-protein-protein complexes can impart
greater selectivity for specific sulfation motifs. Interestingly, NT-3 and NT-4/5 did
not increase the binding of TrkC and TrkB to CS-E tetra- or polysaccharides, respec-
tively, suggesting that CS-E forms complexes only with certain NT-receptor pairs.
This raises the intriguing possibility that the spatiotemporal expression of CS-E in
vivo could lead to differential activation of specific NT signaling pathways.
We next investigated the secondary cross talk between the NTs and their receptors.
Specifically, TrkA binding to the arrays was evaluated in the presence or absence of
NGF, NT-3, or NT-4/5. Selective, but weak, binding of TrkA to CS-E-enriched
polysaccharides was observed in the absence of NT (Figure 3.3C and 3.9). Addition
of NGF, NT-3, or NT-4/5 significantly increased the binding of TrkA to the array
(Figure 3.3C), suggesting that CS-E is capable of forming complexes with NGF-TrkA,
NT-3-TrkA and NT-4/5-TrkA. Interestingly, TrkA binding to CS-E was enhanced the
most by the presence of NT-4/5, followed by NT-3. In the absence of CS-E, however,
TrkA showed the greatest binding affinity for NGF, followed by NT-3, and NT-4/5,
as measured by enzyme-linked immunosorbent assays (ELISA) and consistent with
previous reports (Figure 3.10).229 Thus, the ability of CS-E to enhance receptor
binding was inversely related to the relative affinity of the NT-TrkA interaction. These
results suggest that CS-E may help to stabilize weaker NT-receptor interactions and
may enable the activation of secondary NT signaling pathways.
To gain molecular-level insights, we computationally modeled the CS-E binding
sites in the NT and NT-receptor complexes. The CS-E tetrasaccharide structure15 was
first docked to known crystal structures of human NGF, NT-3, or NT-4/5 dimers. For
the BDNF dimer structure, we built a homology model by replacing NT-3 with BDNF
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Figure S5. Predicted CS-E binding sites in the (A) BDNF, NGF, NT-4/5, and
NT-3 dimers and (B) the NT binding domain (domain 5) of TrkA and TrkB.
Top: Ribbon representation of each protein.  Middle: Connolly surface with
CS-E binding sites depicted in blue (non-basic residues) and yellow (basic
residues).  Bottom: Electrostatic maps generated by Adaptive Poisson-
Boltzmann Solver software.  All images were created in PyMOL.
NGF BDNF NT-3 NT-4/5 TrkA TrkB
A B
Figure 3.4: Predicted CS-E binding sites on the (A) BDNF, NGF, NT-4/5, and NT-
3 dimers and (B) the NT binding domain (domain 5) of TrkA and TrkB. Top: Ribbon
representation of each protein. Middle: Connolly surface with CS-E binding sites depicted in
blue (non-basic residues) and yellow (basic residues). Bottom: Electrostatic maps generated
by Adaptive Poisson-Boltzmann Solver software. All images were created in PyMOL.
in the BDNF-NT-3 dimer structure. We found that the predicted CS-E binding sites
share several common features (Figure 3.4A, 3.11, and Table 3.6). First, each site
contains a high density of basic amino acids, ranging from four in the case of the NT-
4/5 dimer to seven in the case of the NT-3 dimer. Although these basic residues are
highly conserved across many species for a given NT, they are not entirely conserved
among different NT family members (Figure 3.11), which may explain, in part, the
observed differences in selectivity and affinity for CS-E. Second, each site contains
lysine and arginine residues separated by distances that would allow them to interact
with multiple sulfate groups on the CS-E tetrasaccharide. For example, the average
distance between the sulfur atoms of the sulfate groups in the same disaccharide of
CS-E is 5.5 Å and in adjacent disaccharides is 12.9 Å. In the CS-E binding site on
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NGF, the -amino groups of Lys32 and Lys34 are 5.6 Å apart and an average distance
of 12.7 Å away from the -amino group of Lys95.
We also observed some differences in the CS-E binding sites among NT family
members. Overall, CS-E bound to the BDNF, NGF and NT-4/5 dimers in a similar
manner, interacting with residues within loop 1, loop 4, and β strand 8 of monomer
A (Figure 3.11). However, CS-E also made contacts with residues in loop 2 and β
strands 5 and 6 of monomer B in BDNF and NGF. The predicted CS-E binding site
on the NT-3 dimer was the most distinct. Many of the basic residues found in the
binding sites of BDNF, NGF and NT-4/5 were absent in NT-3 and vice versa, and
CS-E interacted primarily with residues in loop 3 and β strands 5 and 6 of monomer
A (corresponding to β strands 7 and 8 of the other NTs). Although residues in loop 3
were not well resolved in the human NGF and NT-4/5 crystal structures used for our
modeling studies, we confirmed that the CS-E interaction with loop 3 was unique to
NT-3 by modeling the CS-E binding site in the mouse NGF crystal structure and a
different human NT-4/5 structure, both of which contain a highly resolved structure
for loop 3. In both cases, the CS-E binding site was unchanged by the presence of
loop 3, reinforcing a distinct mode of binding to NT-3.
We next modeled the CS-E binding sites in the Trk receptors by docking the CS-E
tetrasaccharide structure to known crystal structures of the ligand-binding domains
of TrkA and TrkB. In contrast to the CS-E binding sites on the NTs, the binding sites
on TrkA and TrkB comprised primarily β strands (specifically β strand C, F, and
G)267 rather than loops, and they contained only two basic residues (Figure 3.4B, and
Table 3.6). The presence of fewer basic residues in the binding site may account for
the weaker binding affinity of CS-E for the Trks compared to the NTs. Importantly,
the CS-E binding sites on TrkA and TrkB showed no overlap with the NT interaction
surface, suggesting that the sugar binds to a distinct site on the receptor. Indeed,
superimposing the CS-E binding sites for each protein onto structures of the NT-
receptor complexes revealed a contiguous sugar-binding site that spanned a single
face of the complex (Figure 3.5). As the structures of the NT-Trk complex have C2
symmetry, a second CS-E binding site is predicted that would enable formation of a
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2:2:2 complex. Each sugar-binding site readily accommodates a single octasaccharide,
suggesting a molecular mechanism by which CS polysaccharides might assist in the
assembly of NT-Trk receptor complexes and promote NT signaling.
As independent confirmation of our microarray and computational results, we
performed several cellular studies. Pheochromocytoma 12 (PC12) cells express high
levels of TrkA and have been used extensively to study NGF-TrkA signaling path-
ways.268,269 We first examined whether the CS-E motif was expressed on PC12 cells
using a CS-E-specific monoclonal antibody developed by our laboratory.15,218 We ob-
served strong CS-E-positive staining on the cell surface, which could be removed using
chondroitinase ABC (ChABC), an enzyme that hydrolyzes CS chains (Figure 3.3E).
Notably, removal of endogenous CS-E polysaccharides on PC12 cells significantly at-
tenuated TrkA activation by NGF or NT-4/5 by 24± 7% and 37± 3%, respectively,
as measured using a phospho-TrkA antibody (Figure 3.6A). The greater effect of
CS on NT-4/5-induced activation of TrkA compared to NGF is consistent with our
microarray data (Figure 3.3C) indicating that CS-E enhances the NT-4/5-TrkA in-
teraction more than that of NGF-TrkA. These results further support the notion that
CS-E promotes the formation of specific NT-Trk complexes and the activation of NT
signaling pathways.
Similarly, we found that CS-E-enriched polysaccharides adsorbed onto a substra-
tum activated NT-4/5-mediated TrkA signaling by 42±6%, but had no appreciable ef-
fect on NGF-mediated TrkA signaling at the CS-E concentration tested (Figure 3.6B).
Furthermore, the addition of exogenous CS-E-enriched polysaccharides to the media
interfered with NT signaling, reducing NGF- and NT-4/5-mediated TrkA activation
by 19± 2% and 49± 11%, respectively, (Figure 3.6C). A greater reduction (81± 1%)
in NGF-induced TrkA activation was achieved by using ten-fold higher concentra-
tions of polysaccharide, indicating that CS-E can modulate NGF-TrkA interactions,
albeit less effectively compared to NT-4/5-TrkA interactions. Finally, we found that
prolonged exposure of PC12 cells to NGF increased the co-localization of TrkA and
CS-E by 2.3± 0.1-fold (Figure 3.6D), further suggesting that CS-E is a component of
the NGF-TrkA signaling complex. Together, these data are consistent with the model
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NGF-TrkA BDNF-TrkB NT-4/5-TrkA NT-3-TrkA 
NGF-TrkA BDNF-TrkB NT-3-TrkA NT-4/5-TrkA A 
B 
Figure 3.5: Predicted CS-E binding sites in the NGF-TrkA, BDNF-TrkB, NT-3-TrkA,
and NT-4/5-TrkA complexes. (A) Top: Ribbon representation of each protein. Middle:
Connolly surface with CS-E binding sites depicted in blue (non-basic residues) and yellow
(basic residues). Bottom: Electrostatic maps generated by Adaptive Poisson-Boltzmann
Solver software. All images were created in PyMOL. (B) Predicted CS-E binding sites (blue
(non-basic residues) and yellow (basic residues)) in the BDNF-TrkB, NGF-TrkA, NT-4/5-
TrkA, and NT-3-TrkA complexes. The CS octasaccharides were manually docked.
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Figure 3.6: CS-E modulates NGF- or NT-4/5-mediated TrkA activation in cells. (A) Re-
moval of endogenous CS-E on PC12 cells using ChABC reduced NGF- and NT-4/5-mediated
TrkA phosphorylation. (B) CS-E-enriched polysaccharides enhanced TrkA phosphorylation
by NT-4/5, but not NGF, when coated on a substratum at 500 ng·ml−1. (C) Addition
of exogenous CS-E (500 ng·ml−1) to the media reduced NGF-induced and NT-4/5-induced
TrkA phosphorylation. NGF-induced activation was further inhibited by higher concentra-
tions (5000 ng·ml−1) of CS-E. For (A-C), TrkA activation is plotted relative to the signal
of untreated cells in the presence of the indicated NT. n = 4, ∗P < 0.05, ∗∗P < 0.005.
(D) Prolonged NGF treatment (60 min), increases the co-localization of CS-E and TrkA.
Representative images show minimal co-localization in untreated cells and increased co-
localization (yellow) after treatment with NGF. The extent of co-localization was quantified
as described in Materials and Methods and plotted relative to that of untreated cells. n = 24
cells. ∗∗P < 5 × 10−6. (E) Treatment of PC12 cells with ChABC results in loss of CS-E
positive immunostaining.
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that CS-E polysaccharides on cell-surface proteoglycans or coated on a substratum
recruit NTs to the cell surface, thereby promoting complex formation and stimulat-
ing NT signaling pathways. By adding exogenous CS-E in solution, the NTs are
presumably sequestered away from the cell surface, thereby disrupting NT-mediated
signaling.270
Collectively, our microarray, computational and cellular studies demonstrate that
NT-Trk interactions and signaling pathways are modulated by CS-E polysaccharides.
Furthermore, we suggest that NT-4/5-TrkA pathways should be more sensitive than
NGF-TrkA pathways to CS-E levels. More broadly, these results provide the first
evidence that CS GAGs regulate this important family of growth factors and function
in the assembly of multimeric signaling complexes.
3.7 Conclusion
We have developed carbohydrate microarray and computational modeling approaches
for the rapid screening and understanding of glycosaminoglycan interactions with
proteins and multimeric protein complexes. Using these methods, we identify novel
interactions between a specific sulfated epitope, CS-E, and the neurotrophin family of
growth factors. Moreover, we show for the first time that CS is capable of assembling
multimeric signaling complexes and modulating interactions between specific NTs and
their receptors. Our computational modeling studies identify potential CS-binding
sites on NTs and other proteins. We also discover a contiguous CS-E-binding site
within the NT-Trk receptor complex, which suggests a potential mechanism for how
CS promotes complex formation and modulates NT signaling. Taken together, we
have developed a general method for studying GAG-protein-protein interactions that
can be applied to screen various GAG subclasses (HS, DS, CS, etc.) and particular
sulfation motifs (CS-A, CS-E, etc.) for the ability to assemble specific multimeric
complexes. When combined with the computational methods demonstrated herein,
this strategy provides new molecular-level insights into the diverse biological functions
of glycosaminoglycans.
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3.8 Materials and Methods
3.8.1 Microarray Analysis
Tetrasaccharide and polysaccharide microarrays were prepared as described previ-
ously.16,218 Microarray experiments with the individual NTs were performed using
methods described previously.15 To measure glycosaminoglycan-protein-protein in-
teractions using the tetrasaccharide microarrays, a perimeter was drawn around 3
microarrays with a hydrophobic marker (PapPen) for each protein-receptor pair. The
microarrays were treated with NaBH4 (5 min, 66 mM in PBS) and washed five times
with PBS. The first microarray was incubated with the protein ligand of interest
(TNF-α, NGF, BDNF, NT-3, or NT-4/5; R&D Systems, 1 µM in 0.1% Triton X-
100 in PBS). The second microarray was incubated with the receptor of interest
(TNFR1-Fc, TrkA-Fc, TrkB-Fc, TrkC-Fc, or TrkB-Fc, respectively; R&D Systems, 1
µM in 0.1% Triton X-100 in PBS). The third microarray was incubated with a 1:1
mixture of both the protein ligand and receptor (1 µM each in 0.1% Triton X-100 in
PBS). After 3 h, the microarrays were washed (5 × PBS) and treated with a rabbit
primary antibody against the protein ligand (R&D Systems, 1:1000 in 0.1% Triton
X-100 in PBS). After 1 h, the microarray was washed (5 × PBS) and incubated with
Cy3-conjugated anti-human Fc IgG and Cy5-conjugated anti-rabbit IgG antibodies
(Invitrogen, 1:5000 in 0.1% Triton X-100 in PBS) for 1 h. The microarrays were then
washed (3 × PBS, 2 × H2O) and dried under a stream of air. A similar procedure
was employed for the polysaccharide microarrays. After drawing perimeters around
the array regions, the microarrays were incubated in 10% fetal bovine serum (FBS)
in PBS for 1 h at 37 ◦C. The remainder of the procedure was identical, except that
1% FBS in PBS was used as the incubating buffer instead of 0.1% Triton X-100 in
PBS. All microarrays were analyzed using a GenePix 5000a scanner, and fluores-
cence quantification was performed using GenePix 6.1 software with correction for
local background. Each protein was analyzed in triplicate, and the data represent an
average of 8–10 spots for a given carbohydrate concentration. As controls, the mi-
croarrays were treated with the protein ligand (NT, TNF-α or FGF-2), followed by
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the anti-ligand antibody and Cy3 anti-human Fc IgG. Similarly, the microarrays were
incubated with the receptor (Trk-Fc, TNFR1-Fc or FGFR1-Fc), followed by the corre-
sponding anti-ligand antibody (rabbit species) and Cy5 anti-rabbit IgG. In all cases,
no signal was observed, confirming that the antibodies showed no cross-reactivity
(Figure 3.7).
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Figure S8. Microarray controls to confirm lack of antibody cross-reactivity.
(A) NGF binding to the microarray was detected using an anti-NGF rabbit
primary antibody and anti-rabbit IgG secondary antibody conjugated to
Cy5. (B) No signal was observed with the anti-Fc antibody conjugated to
Cy3 used to detect Trk-Fc receptors. (C) TrkA-Fc binding to the microarray
was detected using an anti-Fc antibody conjugated to Cy3. (D) No signal
was observed with the anti-rabbit antibody conjugated to Cy5 used to
detect NGF.
Figure 3.7: Microarray controls to confirm lack of antibody cross-reactivity. (A) NGF
binding to a microarray detected using a rabbit anti-NGF primary antibody and anti-rabbit
Cy5 secondary antibody. (B) No signal was observed with the anti-Fc Cy3 antibody used to
detect Trk-Fc receptors. (C) TrkA-Fc binding to mi roarra detected using anti-Fc Cy3
antibody. (D) No signal was observed with anti-rabbit Cy5 antibody or rabbit anti-NGF
followed by anti-rabbit Cy5 antibody, used to detect NGF.
3.8.2 Computational Methods
3.8.2.1 Structure and Homology Models
The following PDB files were used: DBL3x (3BQK), DBL6 (2WAU), FGF-2 solution
structure (1BLA), FGF2-heparin co-crystal structure (1BFB), FGFR1 (1FQ9, chain
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C), FGF2-FGFR1 quaternary complex (1FQ9, chains A, B, C, D), FGF2-FGFR1-
heparin co-crystal structure (1FQ9), TNF-α trimer (1TNF), TNF-β-TNFR1 (1TNR),
NT-4/5 dimer (1B98 and 1HCF, chains A, B), human NGF dimer (2IFG, chains E,
F), mouse NGF dimer (1BET), NT-3 dimer (1NT3), BDNF monomer (1BND, chain
A), TrkA ligand-binding domain (1WWW chain X), TrkB ligand-binding domain
(1HCF, chain X), NGF-TrkA complex (1WWW).
The TNF-α-TNFR1 homology model was determined by aligning chain B of TNF-
α in the TNF-α trimer crystal structure with TNF-β in the TNF-β-TNFR1 crystal
structure (TNF-α, TNF-β RMSD = 1.08 Å) and replacing TNF-β with the TNF-α
trimer structure. The BDNF dimer homology model was constructed by replacing the
NT-3 monomer with the BDNF monomer in the BDNF-NT-3 dimer structure from
the PDB file 1BND (BDNF, NT-3 RMSD = 0.967 Å). The NT-4/5-TrkA homology
model was created by replacing TrkB in the PDB file 1HCF with TrkA (TrkA, TrkB
RMSD = 0.804 Å). The BDNF-TrkB homology model was created by replacing the
NT-4/5 dimer in the PDB file 1HCF with the BDNF dimer homology model (NT-4/5
dimer, BDNF dimer RMSD = 0.757 Å). The NT-3-TrkA homology model was created
by replacing the NT-4/5 dimer and TrkB in the PDB file 1HCF with the NT-3 dimer
and TrkA, respectively, (NT-4/5 dimer, NT-3 dimer RMSD = 1.042 Å).
The DREIDING FF was used throughout the modeling.271 Protein files were
downloaded from the RCSB Protein Data Bank (http://www.pdb.org) and loaded
into the Swiss PDB Viewer to fix incomplete side chains.272 The WhatIF program was
used to add hydrogen atoms.273 CHARMM22274 charges were added, and the protein
was fully minimized in the presence of sodium and chloride ions under conditions of
Surface Generalized Born (SGB) continuum solvation.275
The structures of a heparin tetrasaccharide and octasaccharide were extracted
from the PDB files 1BFB and 1FQ9, respectively, (heparin ‘A’). Hydrogen atoms
were added and charges were assigned to each atom using the charge equilibration
(QEq) method.276 The ligands were then fully minimized under conditions of Surface
Generalized Born (SGB) continuum solvation.275 The solution structures of the CS-A
and CS-E tetrasaccharides were determined using molecular dynamics as reported.15
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3.8.2.2 Putative Binding Site Determination
Coarse binding sites were first determined by rigid-body docking with the crystal
or solution structure ligand conformation as described previously,251 except with the
following modifications. The parameters radmax = 5.0 and dotlim = −0.5 were
used for the autoMS program in Dock4.0 when creating the molecular surface. To
determine the potential binding site, the twenty-five lowest-energy docked structures
and corresponding binding sites were tabulated and ranked by energy. Next, the sum
of the inverse energy ranks for each binding site was determined. Any binding site
with a value of 1 or greater was considered a potential GAG-binding site.
3.8.2.3 Final Binding Site Determination
The potential glycosaminoglycan-binding sites were inputted into GenMSCDock,252
and rigid-body docking with the crystal or solution structure ligand conformation
was performed with standard input parameters. Briefly, up to 120 different docked
orientations were obtained in the first step, which represented the 40 lowest-energy
orientations each, as measured by Coulombic interaction energy, van der Waals in-
teraction energy, and total interaction energy. Next, for each of these structures,
residues within 4 Å of any of the bound oligosaccharides were rotated, the com-
plexes were briefly minimized, and the energy was calculated. Finally, the universal
cavity energy, which consists of the energy of the oligosaccharide and those protein
residues within 5 Å of the oligosaccharide, was determined. Residues within 5 Å
of the oligosaccharide in more than one of the five minimum energy structures were
considered part of the glycosaminoglycan-binding site. Images were created using Py-
MOL,238 and the electrostatic maps were derived using Adaptive Poisson-Boltzmann
Solver (APBS) software.237
3.8.3 Cellular Assays
PC12 cells were propagated on collagen-coated 10-cm dishes in DMEM (Gibco) sup-
plemented with 6.5% FBS, 6.5% horse serum, 2 mM l-glutamine, 100 U·ml−1penicillin,
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and 100 U·ml−1streptomycin. Cells were grown at 37 ◦C in a humidified atmosphere
enriched with 5% CO2 and sub-cultured at a 1:3 ratio every 5–6 days. For the as-
says, PC12 cells were cultured on poly-dl-lysine-coated 60-mm dishes and grown as
described above. After 4–5 days (70–80% confluence), the media was replaced with a
minimal media composed of DMEM supplemented with 0.5% FBS, 1% horse serum,
2 mM l-glutamine, 100 U·ml−1penicillin, and 100 U·ml−1streptomycin. Cells were
incubated for 12 h before use in the following experiments.
For chondroitinase experiments, 1 U·ml−1chondroitinase ABC (Seikagaku) was
added to the media. After 2 h, the cells were gently washed with fresh media three
times before treatment. For experiments with adsorbed CS-E on the dish, cells were
split 1:1 and plated on poly-dl-lysine dishes that had been incubated with a solution
of CS-E-enriched polysaccharides (500 ng·ml−1 in PBS; Seikagaku) for 12 h at 37
◦C and then washed (3 × PBS). The cells were allowed to adhere to the dish for
2–3 h prior to treatment. For experiments with exogenous CS-E in solution, cells
were exposed to fresh media containing CS-E-enriched polysaccharides (500 ng·ml−1
or 5000 ng·ml−1) for 2 h prior to treatment. In all cases, cells treated with NTs
were exposed to NGF (5 ng·ml−1) for 5 min, NT-4/5 (0.5 µg·ml−1) for 15 min, or a
vehicle control. The cells were subsequently washed (3 × PBS), lysed, and analyzed
as previously described.277
3.8.4 Immunohistochemistry
PC12 cells were grown on poly-dl-lysine-coated coverslips and treated with chon-
droitinase as described above. For the co-localization studies, cells were treated with
NGF for 60 min. Following each treatment, cells were fixed with 4% paraformalde-
hyde in PBS for 20 min, washed (2 × PBS), and permeabilized with 0.5% Triton
X-100 for 5 min. After washing (2 × PBS), cells were blocked with 10% FBS in
PBS for 1 h and then incubated with an anti-CS-E mouse antibody15,218 (1:500) and
an anti-tubulin rat antibody (Sigma, 1:1000) in 10% FBS in PBS for 3 h. The cells
were washed (5 × PBS), treated with anti-mouse-AlexaFluor488 (Invitrogen, 1:1000)
and anti-rat-AlexaFluor546 (Invitrogen, 1:1000) secondary antibodies for 1 h, washed
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again (5 × PBS), mounted onto slides, and then imaged by confocal fluorescence mi-
croscopy. Images were analyzed using ImageJ (http://rsbweb.nih.gov/ij/) using
the RG2B Co-localization plugin, which returns a pixel in the blue channel for each
pixel with signal from both the red and green channel. The total number of pixels in
the blue channel were counted for each cell and normalized with respect to area.
3.8.5 ELISA
TrkA (3.3 µg·ml−1 in 50 mM Na2CO3, pH 9.6; 25 µl per well) was added to a 384-
well plate (Maxisorp) and incubated in a humidified chamber at 4 ◦C for 12 h. The
wells were blocked with 1% BSA in PBS at 25 ◦C for 2 h. Varying concentrations
of NGF, NT-3, or NT-4/5 (0.45–230 nM in 0.1% BSA in PBS) were added to each
well. After 2 h, the wells were incubated with a rabbit antibody against the NT of
interest (1:1000 in 0.1% BSA in PBS) at 25 ◦C for 1 h, followed by an anti-rabbit
antibody conjugated to horseradish peroxidase (Invitrogen, 1:10,000 in 0.1% BSA in
PBS) at 25 ◦C for 1 h. Between each incubation, the wells were washed three to five
times in 0.05% Tween-20 in PBS. NT binding was detected using a TMB Substrate
Kit (Pierce) according to the manufacturer’s protocol.
3.9 Supporting Figures
Figure S1. Co-localization of FGF2 (red) and FGFR1 (green) on the
polysaccharide microarray
Figure 3.8: Co-localization of FGF-2 (red) and FGFR1 (green) on the polysaccharide
microarray
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Figure S2. Binding  of Trk receptors in the presence (red) and absence (black) of the 
indicated NT to the indicated polysaccharides at 0.5, 5, and 10 !M. 
Figure 3.9: Binding of Trk receptors in the presence (red) and absence (black) of the
indicated NT to the indicated polysaccharides at 0.5, 5, and 10 µM
Table 3.5: Predicted CS-E bind-
ing site on TNF-α
Monomer A MonomerB
Ser71 Lys65
Thr72 Gln67
His73 Gly108
Val74 Ala109
Leu75 Glu110
Arg103 Ala111
Thr105 Lys112
Arg138 Pro113
Tyr115
Ile137
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Table 3.6: Predicted CS-E binding sites on the NTs and Trks
NGF BDNF NT-3 NT-4/5 TrkA TrkB
Ile31A Met31A Arg56A Arg34A Ala310 Ala314
Lys32A Ser32A Cys57A Arg36A Pro311 Gln316
Lys34A Arg88A Glu59A Asp103A Ser312 Phe318
Asp93A Arg97A Ala60A Ala104A Leu313 Ala322
Gly94A Trp100A Arg61A Gln105A Arg314 Ile322
Lys95A Arg101A Asn76A Arg107A Leu316 Leu324
Gln96A Phe102A Ser77A Gly109A Gly319 Asn325
Ala97A Trp19B Gln78A Trp110A Val321 Ile362
Ala98A Thr21B Cys79A Arg111A Asn323 Lys364
Trp99A Lys41B Lys80A Glu324 Lys369
Arg100A Val44B Thr81A Thr330
Asn46B Lys46B Gln83A Glu331
Ser47B Gly47B Arg103A Thr330
Val48B Gln48B Ala111A Glu331
Phe49B Leu49B Leu112A Phe332
Lys50B Lys50B Ser113A Arg342
Tyr52B Tyr52B Arg114A Thr360
Tyr54B Lys115A Leu362
Arg8B Ala364
Glu10B Asn365
Tyr11B Pro366
Gly368
Gln369
Ser371
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Figure S3. Binding of the indicated NTs to
immobilized TrkA, as determined by ELISA. NGF
has the strongest affinity for TrkA. NT-3 and NT-
4/5 also bind, but with >100-fold weaker affinity.
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Figure 3.10: Binding of the indicated NTs to immobilized TrkA as determined by ELISA.
NGF has the strongest affinity for TrkA. NT-3 and NT-4/5 also bind, but over 100-fold
weaker affinity.
Figure S4.  Comparison of predicted CS-E binding sites (yellow and green)
on the BDNF, NGF, NT-4/5, and NT-3 dimer.  Residues highlighted in green
correspond to monomer A of the dimer; residues highlighted in yellow
correspond to monomer B.  NT-3 does not contain !-strands 4 and 5.
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Figure 3.11: Comparison of predicted CS-E binding sites (yellow and green) on the BDNF,
NGF, NT-4/5, and NT-3 dimers. Resi ues highlighted in reen correspond to monomer A,
and residues highlighted in yellow correspond to monomer B of the dimer. NT-3 does not
contain β-strands 4 and 5.
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Chapter 4
The Molecular Determinants in
Guiding the Retinotopic Projection
4.1 Introduction
An essential feature in the function and organization of the brain is the efficient and
ordered connections between sensory and target neurons. These connections occur
during a formative stage in brain development when axons are guided to target neu-
rons to form neuronal circuits. These circuits maintain a topographical mapping of
the receptor surface from the sensory tissue to the receiving tissue. Map develop-
ment has been studied in several vertebrate projection systems, including thalamo-
cortical,278,279 hippocamposeptal,280,281 olfactory/vomeronasal,282,283 motor axons to
muscles,284,285 and retinotectal (the focus of this chapter). However, the visual pro-
jection has been far and away the predominant model for studying the development
of topographic maps and the mechanisms by which gradients of guidance molecules
that control their formation.
The maps can be qualitatively described as continuous or discrete. In a discrete
map the spatial organization in one field reflects a non-spatial quality in the other
field (Figure 4.1B). For example, in the glomerular map of the olfactory system,
olfactory receptor neurons that express the same odorant receptors project to the
same glomerular units in the brain.286 In continuous neuronal maps, such as the
visual and auditory projections, the nearest neighbor relationships from the input field
are preserved in the target field (Figure 4.1A). In the visual system, nearby retinal
85
ganglion cells (RGCs) make nearby connections to neurons in their most prominent
midbrain target–the optic tectum (OT) of fish, amphibians, and chick, or the superior
colliculus (SC) in mammals.287 Other projections, such as the somatosensory and
motor maps, contain both continuous and discrete components.
The continuous maps of the visual system are formed by molecular gradients
of guidance cues, an idea first proposed by Sperry, in 1963, decades before such a
molecule was discovered.288 Based on this hypothesis, the termination position of
a projecting axon would be identifiable in the receiving tissue by molecular labels
(receptors) corresponding to complementary labels (ligands) on the axon determined
by its position in the projecting tissue. In the intervening years, a number of graded
guidance molecules have been identified, most of which are members of the ephrin
family of ligands and their corresponding Eph receptor tyrosine kinases.289 The repre-
sentation of the retina on to the OT or SC can be simplified to the mapping of two sets
of orthogonally oriented Cartesian axes: the temporal-nasal (TN) axis of the retina
along the anterior-posterior (AP) axis of the OT/SC, and the dorsal-ventral (DV)
axis of the retina along the lateral-medial (LM) axis of the OT/SC (Figure 4.1C).† A
topographical guidance molecule in the retinotectal projection must be expressed in a
graded or restricted manner in the retina or OT/SC, RGC axons from different parts
of the retina must exhibit distinct responses to it, and it must affect RGC mapping
in vivo.
In the visual system, gradients of ephrin-A/EphA molecules along the AP axis of
the SC guide RGC cells which express opposing ephrin-A/EphA gradients. Similarly,
ephrin-B/EphB gradients are expressed along the LM axis of the SC and the DV of
the retina (Figure 4.1C). A small number of additional molecules, such as repulsive
guidance molecule (RGM), semaphorins, and heparan and chondroitin sulfate proteo-
glycans, have been shown to play a role in guidance and mapping.290 Herein, the roles
of these guidance molecules will be discussed along with the current understanding
of the molecular mechanisms by which topographical order is maintained.
†The LM axis corresponds to the ventral-dorsal axis in non-mammalian vertebrates.
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Figure 4.1: Topographic maps and guidance cues. Qualitatively, topographic maps can be
described as continuous (A) or discrete (B). In a continuous map, the spatial relationship
between axons (represented as differently colored dots) in the projecting tissue is preserved
in the receiving tissue. In a discrete map, a non-spatial quality, such as neuron type, in the
projecting tissue is mapped to a spatial field in the receiving tissue. (C) The retinotopic
projection is a continuous map. The position of axons in the retina is determined, in part,
by orthogonal EphA/ephrin-A and EphB/ephrin-B gradients along the TN and DV axes,
respectively. Guidance through the chiasm is controlled by ephrin-B2 (orange triangle),
and Slit1/2 (yellow oval). In the OT/SC, axons find the correct position by virtue of the
corresponding ephrin-A/EphA and ephrin-B/EphB gradients along the AP and LM axes,
respectively.
4.2 Retinal Development and Ganglion Cell Path-
finding
The vertebrate eye originates from bilateral telencephalic optic groves. Optic vesi-
cles emerge and contact the surface ectoderm to induce lens formation. When the
lens placode invaginates to form the lens vesicle, the distal part of the optic vesicle
begins to invaginate to form the optic cup. As the optic vesicles grow, the proximal
ends expand and their connections with the forebrain constrict to form optic stalks.
Through the retinal fissure, a groove at the inferior aspect of the optic vesicle, the
hyaloid artery, enters the eye and nourishes the optic cup and lens vesicle. The reti-
nal fissure closes and proximal parts of the hyaloid vessels persist to form the central
artery and vein of the retina, a branch of the opthalmic artery. The retina develops
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from the walls of the optic cup with the outer, thinner pigmented layer forming the
retinal pigmented epithelium (RPE) and the inner, thicker neural layer differentiating
into the neural retina. The neural layer contains photoreceptors (rods and cones) and
other neural cell types, such as bipolar and ganglion cells. The axons of RGC cells
residing in the surface layer of the neural retina grow proximally into the wall of the
optic stalk to the brain, and gradually form the optic nerve.291
The vertebrate retina is composed of six types of neurons and one type of glia,
which constitute three nuclear layers: RGCs in the ganglion cell layer (GCL); hori-
zontal, amacrine, and Müller glia cells in the inner nuclear layer (INL); and rod and
cone photoreceptors in the outer nuclear layer (ONL). During retinogenesis, these
seven cell types derive from a common population of retinal progenitor cells residing
in the inner layer of the optic cup. The RGC is the only retinal neuron that projects
and conveys visual information to the brain. RGCs extend axons to the optic nerve
head at the central retina, form the optic nerve and chiasm, and establish retinotopic
maps in the SC.
During the long distance of axon pathfinding, RGC growth cones are navigated
by a succession of different guidance cues expressed in their local environment.292–295
The first pathfinding task is to exit the eye through the optic nerve, assisted by axon
guidance molecules such as L1, netrin-1, and laminin-1.294 The axons continue toward
the optic chiasm, the structure where partial contralateral crossover of RGC axons
occurs. This process requires the repulsive guidance of Sema5A, Slit/Robo, and HS.
Sema5A is expressed at the optic disk and along the optic nerve,291 and blockade
of Sema5A function causes retinal axons to stray out of the optic nerve bundle.292
Slit/Robo are required to define the site of the optic chiasm formation (Figure 4.1C).
RGCs express Robo2, a receptor for the Slits, and Slit1 and Slit2 are present in
the ventral diencephalon. Double knockout of both Slit1 and Slit2 in mice develop
a large ectopic chiasm anterior to the true chiasm, and many RGC axons project
into the contralateral optic nerve and some extend dorsal or lateral to the chiasm.96
HS promotes Slit/Robo binding and is important for the repulsive activity of Slit2
protein.98 Mice that do not express HS display a similar phenotype to the Slit1;Slit2
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double-mutant mice (see also, Section 4.8.1).85,96
At the optic chiasm, RGC axons can either cross the midline or project ipsilater-
ally. In most mammals, RGC axons from the temporal retina avoid and do not cross
the midline,296 however, the extent of uncrossed axons varies by species. For example,
less than five percent of axons fail to cross in mice while nearly fifty percent do not
cross in humans. This arrangement at the level of the optic chiasm is necessary for
acquiring high-quality binocular vision and stereopsis. Ephrin-B2 and EphB1 control
axon divergence at the chiasm (Figure 4.1C).297 Ephrin-B2 is expressed in radial glia
cells at the optic chiasm concurrent with the development of the ipsilateral projec-
tions, and the blockade of ephrin-B2 eliminates the ipsilateral projection in mice.
The EphB1 receptor is expressed in the ventrotemporal (VT) quadrant of the retina
and EphB1 mutants reveal a significant decrease in the number of ipsilateral projec-
tions.297 Upon crossing the midline, RGC axons project to the OT/SC and come
under the influence of topographical guidance molecules.
4.3 The Discovery of Graded Topographic Guidance
Molecules
A mechanistic understanding of the molecular basis of retinotopic mapping has be-
gun to emerge in recent years after decades of intense study. In 1963, Roger Sperry
proposed the chemoaffinity hypothesis whereby molecular tags on the projecting ax-
ons and their target cells determine the specificity of axonal connections within a
neural map. Further, he suggested that these molecular tags might be distributed in
complementary gradients that mark corresponding points in both sensory and target
structures. Amazingly, the basic tenet of Sperry’s hypothesis has largely been borne
out.298 Subsequent mathematical refinement of the hypothesis by Fraser and Gierer
added countergradients of attractants and graded repellents to the model and were
able to describe topographic map development more accurately.299–302 On the basis of
the chemoaffinity hypothesis, each point in the OT/SC would have a unique “address”
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determined by the graded distribution of topographical guidance molecules along the
two tectal axes. Similarly, each RGC would have a unique profile of receptors for
those molecules that would point the axon to the correct address.
Searches for guidance molecules have been carried out by many labs using numer-
ous approaches. The strongest early evidence for topographical guidance molecules
came from Bonhoeffer’s group using in vitro growth cone collapse and membrane
stripe assays. In the membrane stripe assay, carpets of tectal membranes from ei-
ther anterior or posterior regions were printed in alternating stripes. Membranes
from the either region of the tectum supported the growth of RGC axons; however,
Bonhoeffer and colleagues demonstrated that chick RGC axons from the temporal
retina preferred to grow on their topographically appropriate anterior membranes.
Nasal RGC showed no preference for either stripe. Importantly, the group was able
to show that the growth preference of temporal axons is not due to an attractant or
growth-promoting activity associated with anterior tectal membranes but instead to
a repellent activity associated with posterior tectal membranes.303,304
Posterior tectal membranes also preferentially collapse the growth cones of tem-
poral axons, a feature that facilitated biochemically isolating the repellent activity
to a 33-kDa GPI-anchored protein referred to as RGM.305,306 RGM is expressed from
low to high along the AP axis of the OT, and its guidance activity was confirmed
in vitro by the specific inactivation of RGM using chromophore-assisted laser inac-
tivation (CALI). Free radical-mediated destruction of RGM resulted in the loss of
the selective repellent effect of posterior OT membranes on temporal RGC axons.307
Furthermore, protein stripe assays demonstrated that recombinant chick RGM has a
repellent effect on chick RGC axons.308 RGC axons transfected to express neogenin,
an RGM receptor, are also repelled by RGM.309 Therefore, it was reasonable to assume
that RGM has a required role in retinotopic mapping. However, targeted deletion of
the RGM isoform expressed in the SC in mice, RGMa, one of three RGM isoforms,
did not have any apparent mapping defects in the retinocollicular projection,310 pos-
sibly because of a functional redundancy with the other RGM family members or
with ephrin-As.
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The first description of graded molecules that proved to have topographic guidance
activity in vivo came in the mid-1990s with the cloning of two related genes, ephrin-
A2, originally called Eph ligand family-1 (ELF-1), by Flanagan and colleagues,311,312
and ephrin-A5, originally called repulsive axon guidance signal (RAGS), by the Bon-
hoeffer group,313 both of which are ligands of the receptor tyrosine kinase EphA3
(originally named MEK4), expressed in a graded pattern in the retina.311 These
molecules were shown to illicit differential responses of RGC axons;313–315 and, subse-
quent in vivo studies demonstrated that both ephrin-A2 and ephrin-A5 were required
for topographic mapping (Figure 4.3).314,316,317
4.4 Mechanisms of Map Formation
Determining the process by which axons establish topographic connections is critical
for understanding the molecular basis by which disparate tissues self-organize to form
the complex circuitry of the brain. Furthermore, defining the minimum requirements
for map development has important medical and bioengineering applications. Com-
mon model systems for studying retinotopic development include lower vertebrates
such as frogs and fish, and higher vertebrates such as chicks and rodents. There are
important differences in the development of the visual system and retinotopic maps
between these species, particularly between the higher and lower vertebrates, as well
as substantial differences in the absolute size of the OT/SC. For example, the AP
axis of the chick OT is about five times greater than the mouse SC, and 50 times
greater than that of the frog and fish OT (Figure 4.2A). RGC axons target their
correct termination zone (TZ) according to remarkably different mechanisms.
In lower vertebrates, topographically directed targeting of axonal growth cones is
the primary mechanism of map development. Development of retinotectal topography
in chicks,318,319 and rodents,320–323 however, is a multistep process that involves axon
overshoot and interstitial branching (Figure 4.2B). Detailed quantitative analyses by
O’Leary and others have demonstrated that this is the exclusive mechanism for map
development and have begun to differentiate roles of guidance molecules in controlling
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Figure 4.2: Development of the retinotopic map and relative scale of the OT/SC in mouse
and chick. (A) In mouse and chick, RGC axons enter the OT/SC and initially extend well
posterior to the location of their future TZ (circle). Interstitial branches form along the
primary axon shaft in a distribution biased for the AP location of the TZ and subsequently
exhibit bidirectional growth along the LM axis toward their correct TZ. Upon reaching their
TZ, branches elaborate complex arbors and the initial overshoot is eliminated. All arbors
are formed by interstitial branches. (B) Mechanisms and molecules controlling retinotopic
mapping in chicks and rodents. The names and/or distributions of molecules known, or
potentially able, to control the dominant mechanisms at each stage are listed.
directed extension versus branching.319,320,324 In mice and chick, the primary growth
cone of RGC axons enter the OT/SC and extend posteriorly past the location of their
future TZ.319,321,323 RGC axons from a given DV location have a broad distribution
along the LM tectal axis, with a peak centered on the location of the future TZ,
mirroring the coarse ordering within the optic tract.319,322,325 In rodents, these two
features result in RGC axons originating from a focal source in the retina covering
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virtually the entire SC at perinatal ages and covering a sizable fraction of the chick
OT from E10 to E13.290
Topography is established by a period of interstitial branch formation. Branches
form de novo along the axon shaft hundreds of microns or even millimeters behind
the growth cone (Figure 4.2B). Interstitial branching exhibits a significant degree of
topographic specificity along the AP axis. Branches, emerging roughly perpendicular
from the axon, are distributed along the AP axis, with the majority of branches
centered around the AP location of the future TZ,319 and preferentially extend along
the LM axis toward their future TZ.318,320,324 The branches arborize when they reach,
or approach, their topographically correct location of their TZ and form permanent,
ordered connections.319 DiI and DiO tracing studies have shown that RGC axons
originating from the same focal source in the retina distribute broadly across the
LM axis of the OT/SC, with most axons located well outside the LM position of
their appropriate TZ. As the map is refined, a substantial number of RGC axons are
eliminated; however, the process does not favor axons with a particular LM location
and the overall distribution of axons does not change.320,322 Therefore, the position
of an RGC axon along the LM axis relative to its TZ does not bias its ability to make
a connection to the TZ and to be maintained.
In frogs and fish, initial DV mapping along the LM axis is much more accurate
than in chicks and rodents. In addition, RGC axons extend along the AP axis directly
to the correct location of their TZ. As the growth cone of the primary RGC axon
reaches the location of the future TZ, it stops and exhibits a phenomenon termed
backbranching. During this process, short terminal branches are formed at or near
the base of the growth cone, which itself acquires a branch-like morphology. Together,
these branches locally elaborate a terminal arborization of the distal part of the
primary axon.326–328 Thus, backbranching, as originally defined in frogs and fish, is
a phenomenon distinct in scale, location, and purpose from interstitial branching in
chicks and rodents.
The small size of the tectum and the relatively early stage in which axons invade
in frog and fish may have functional consequences for guidance. In these species, an
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individual arbor is much larger relative to the OT than in chick and mouse. In frog
and fish, tectal neurogenesis progresses after axons have invaded. Therefore, while
RGC axons seem to directly target the TZ in lower vertebrates, their RGC axonal
arbors are disproportionately large compared with the OT, particularly along the AP
axis, and cover a greater percentage of its surface in later stages. As development
progresses, arbors cover progressively less of the AP axis over the period of map
development because the OT expands substantially more than the arbors, and some
arbor refinement occurs.329 As a result, map refinement in these species is temporally
substantial and occurs throughout life.330 In contrast, the surface area of the OT/SC
of chick and rodents expands relatively little over the period of map development,
and the duration of map refinement is confined to development.
4.5 Anterior-Posterior Retinotopic Mapping
4.5.1 Axon Extension and Overshoot
The EphAs and ephrin-As are the main regulators of AP mapping. Ephrin-As are
expressed in an overall low-to-high AP gradient in the OT/SC,311,313,335,336 and affect
guidance of RGC axons via corresponding gradients of EphAs from low to high in the
retina. RGC axons enter the OT/SC at its anterior border and grow parallel to the
AP axis as they extend posteriorly. The degree of posterior invasion of these axons is
controlled, in large part, by repellent EphA/ephrin-A interactions (Figure 4.1C and
4.2B) in both higher and lower vertebrates.313,314,316,337 RGC growth cones travel
directly to, or just past, the eventual TZ in amphibians and fish.326 In these species,
a single repellent gradient is sufficient to explain the guidance of RGC axons to their
topologically correct TZs. The expression profiles and in vitro guidance activity of
two ephrin-A homologs in zebrafish suggest that ephrin-As help limit the posterior ex-
tension of invading RGC axons. One homolog is expressed in a band in the midbrain,
delimiting the posterior border with the OT, and the other is expressed in the OT in
a low-to-high AP gradient. Growth cone collapse and stripe assays demonstrate the
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Figure 4.3: Phenotypic defects in temporal-nasal to anterior-posterior topographic map-
ping in mutant animals. (A) Wild-type mapping function and the EphA/ephrin-A gradients
in the retina and OT/SC. (B–D) Temporal RGC axons in ephrin-A2−/− mice (B), ephrin-
A5−/− mice (C), and ephrin-A2−/−/ephrin-A5−/− mice (D) have, in addition to a normally
positioned termination zone (TZ), ectopic TZs in the posterior OT/SC. The mildest defects
occur in ephrin-A2 mutants and the most severe occur in ephrin-A2/A5 double mutants.
Nasal axons show defects in mapping in mice lacking ephrin-A5.316,317 (E) Exogenous ex-
pression of ephrin-A2 in the chick OT can halt the extension of temporal RGC axons. Nasal
axons are not affected.314 (F) Exogenous expression of EphA3 in a subset of RGC axons
on top of the endogenous EphA gradient results in two distinct maps. RGCs expressing
EphA3 form a map compressed into the anterior SC, whereas wild-type RGCs form a map
compressed into the posterior SC. Neither map forms at the expected location.331 (G) Ex-
ogenous expression of ephrin-A2 or -A5 in the chick retina on top of the normal high-to-low
NT gradient results in severe mapping defects. Temporal axons do not form a normal TZ
and maintain axonal extensions and arborizations in posterior positions.332 (H) EphA7 is
expressed in a high-to-low AP OT/SC gradient, and ephrin-As are expressed in a low-to-
high TN gradient in RGCs. EphA7 mutant mice have mapping defects in mapping were VN
RGCs display ectopic termination zones anterior to the correct TZ.333 (I) Reverse signaling
through ephrin-As can be effected by p75NTR, which is expressed in the retina without an
apparent gradient. Mutation of p75NTR causes the TZs of nasal RGCs to shift anteriorly
from its correct location.334
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inhibitory activity of the molecules.338 In addition, the in vitro action and in vivo
distribution of Sema3A in posterior OT and neurophilin-1 in RGCs in frog suggest
that it may be involved in controlling the posterior extension of RGC axons.339
Pathfinding of the primary axon in mice and chick is not nearly as precise. In-
stead, almost all RGC axons extend well posterior to the topographically appropriate
location of the future TZ in higher-order vertebrates, overshooting it by a millime-
ter or more.318,319,321,323 In species with an extended posterior overshoot, the shape
of the ephrin-A gradient in the OT/SC corresponds to the degree of the resulting
overshoot. For example, in chick, temporal RGC axons extend further beyond their
future TZ than do nasal RGC axons, which is consistent with the relatively shallow
slope of ephrin-As in anterior and central OT and the steep slope of ephrin-As in
posterior OT.319 In chick, the overall shape of the ephrin-A gradient is determined
by ephrin-A2, which is expressed in a low-to-high AP gradient that spans the length
of the OT, and ephrin-A5, which is expressed in a steep AP gradient confined to the
posterior OT. Mice have a similar overall ephrin-A gradient shape, and their RGCs
respond similarly. In mice, ephrin-A2 expression is restricted to the mid-posterior
SC, with little expression in the anterior or far posterior regions of the SC. Ephrin-
A5 expression in the mouse SC is similar to ephrin-A2 in the chick OT. Mice also
express ephrin-A3 in low, uniform levels across the SC.340 Interestingly, in vitro and
in vivo data indicate that RGC axons are sensitive to incremental change in ligand
concentration rather than the absolute concentration of the guidance cue.331,341
As such, the ephrin-A/EphA interaction limits the advance of the primary growth
cone through a repulsive response, dependent on the amount of EphA present and
the shape of the ephrin-A gradient it encounters. Deletion of ephrin-A2, -A5,317 or
both,316 shows that these ligands are required for normal mapping of the TN retinal
axis along the AP axis of the OT/SC (Figure 4.3B–D). The reduced signaling through
EphAs expressed by RGCs in these mutants results in a decrease in the repellent
response of temporal RGC axons to ephrin-As in vitro,316,317,337,342 and an increase
in the extent of posterior overshoot in vivo resulting in posterior ectopic TZ(s).317,343
Similarly, blocking EphA/ephrin-A interactions in vitro also results in a decreased
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repellent response.316,337,342 Surprisingly, ephrin-A deficient mice still form a TZ in
the correct location, even in the ephrin-A2/A3/A5 triple mutant lacking all ephrin-A
expression in the SC, indicating that additional signals,340 such as RGM, are required
for proper AP mapping.
Similarly, increasing the levels of EphA signaling in RGCs by overexpression, or
ectopic expression of EphAs or ephrin-As either in the retina or the OT/SC, results
in an increase in the repellent response of EphA expressing axons to ephrin-As in
vitro and decreased extension of RGC axons along the AP axis in vivo (Figure 4.3E–
G).314,331,342 Gain-of-function genetic studies in which ectopic expression of EphA3
scattered throughout retina, through knock in of an IRES-EphA3 cDNA construct
appended to the 3’ UTR of the homeodomain Isl2 gene, resulted in two independent
maps in the SC. RGC subpopulations with elevated levels of EphAs formed a map
compressed in the anterior SC, and the wild-type RGCs map was compressed posteri-
orly. The authors suspect that the posterior shift is likely due to competitive interac-
tions with EphA-overexpressing axons.331 The findings suggest that TN mapping is
controlled by relative, not absolute, levels of EphA signaling between RGCs, and that
EphA repulsive signaling dominates over activity-dependent patterning mechanisms
based on neighbor relations and correlated patterns of neuronal activity.
4.5.2 Topographic Branching
As described in Section 4.5.1, RGC axon extension along the AP axis is determined
in part by EphAs and ephrin-As in fish and frog. RGC axons stop at or very near
the appropriate topographic location and undergo terminal arborization, in part via
backbranching.326,327 In vitro studies suggest that backbranching may be causally
linked to the halting of axonal extension. For example, a neuropilin-1-mediated col-
lapse of the growth cones of frog RGC axons in response to Sema3A leads to an
increase in backbranching around the collapsed growth cone.339 RGC axon arboriza-
tion via terminal branching is also likely controlled, at least in part, by TrkB/BDNF
interactions.344–346
Instead of being guided directly to the eventual TZ, growth cones of RGC axons
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in birds and mammals typically grow well over a millimeter posterior to their future
TZ before they halt extension. To make the appropriate connections at the topo-
graphically correct location, RGCs form stable interstitial branches that point to the
future TZ (Figure 4.2B).319,321–323 Branches extend from the axon shaft in a fairly
tight distribution centered near the AP location of the nascent TZ, with a paucity
of branches anterior or posterior to it.319,321–323 Restricting interstitial branching to
this topographical AP band near the future TZ requires at least two distinct activi-
ties. One activity must restrict branching posterior to the TZ and one activity must
restrict branching anterior to the TZ.319,336,347 A single graded activity, whether neg-
ative or positive, cannot do both, though a single molecule with two activities could,
in theory.
Limiting branching posterior to the TZ is accomplished by the inhibitory action of
ephrin-As, as demonstrated by in vitro branching assays,319,348 and by in vivo studies
that show enhanced RGC axon branching in the OT coincident with a local inacti-
vation of ephrin-As using CALI.343 Consistent with these data, temporal axons form
ectopic TZs in aberrantly posterior locations in ephrin-A-deficient mice (Figure 4.3A–
C).316,317 These findings indicate that the low-to-high AP gradient of ephrin-As in
the OT/SC exposes RGC axons posterior to their correct TZ to levels of ephrin-As
that inhibits their branching and thereby helps generate the topographic basis in
branching along the AP axis of the OT/SC observed in vivo (Figure 4.2B).319,321
This mechanism of branch formation is a primary role for ephrin-As in retinotopic
map development.319
4.5.2.1 Mechanisms for Anterior-Posterior Branch Specificity
While ephrin-As acting through EphAs is sufficient to explain the observed restriction
in branch formation posterior to the future TZ, modeling suggests that a second
activity must limit the extent of branching in the anterior OT/SC.319 Several potential
candidates have been identified.319,334,336,347 The observed branching activity could
simply be explained by the correlated lateral extension of filopodia and lamellipodia
that has been shown to occur distally on the axon upon ephrin-A-mediated growth
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cone collapse.349 Alternatively, the activity may be due to activation of branch-
promoting and/or branch-inhibiting signaling pathways by AP graded ligands binding
to their receptors along the axon shaft. Straightforward examples would include a
low-to-high AP gradient of a signal that promotes branching along each RGC axon
or a high-to-low proximal AP gradient of a signal that inhibits branching along each
RGC axon. These alternatives are not mutually exclusive and could cooperate to
develop AP-specific branching.
4.5.2.2 Parallel Anterior-Posterior Gradients of Promoters and Inhibitors
of Branching
One potential model to explain the observed distribution of interstitial branching is
that graded branch-promoting activity exists parallel to the ephrin-A gradient at a
level sufficient to overcome the ephrin-A inhibitory activity in an AP region near the
future TZ. Posterior to the TZ the ephrin-A branch-inhibitory activity is dominant,
and anterior to the TZ its level is insufficiently strong to promote branching.319,336
BDNF/TrkB signaling has been shown to promote the formation of primary branches
in vitro and BDNF and TrkB expression patterns have been shown to be consistent
with this role in chick (Figure 4.4B).350,351 Other potential candidates include the
ephrin-As, -A2 and -A5, if they acted bifunctionally as branch promoters at low
concentrations in addition to their demonstrated roles as branch inhibitors.319
Recent findings are consistent with this proposed bifunctional action for ephrin-As.
Other guidance molecules, such as ephrin-B1, netrin, semaphorins, have been shown
to have both attractive and repulsive functions, depending on the developmental
context. For example, ephrin-A5 can act as either an attractant or a repellent for
frog RGC axons in vitro, depending on the substrate,352 and can have positive or
inhibitory effects on distinct subsets of EphA4-expressing motor neurons.353 More
directly relevant is a recent in vitro study concluding that ephrin-A2 can have an
adhesive, attractive, or growth-promoting effect on RGC axons at concentrations
below those that result in its previously defined repellent effect.354
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Figure 4.4: Mechanisms for restricting AP branch formation. (A) Interstitial RGC
branches converge to the topographically correct AP region of the SC. The action of a
single overall low-to-high AP inhibitory ephrin-A gradient would not adequately restrict
branch formation. Another guidance cue must restrict anterior branch formation. (B) A
parallel branch-promoting gradient could explain wild-type map formation. Here, branch-
promoting BDNF signal could restrict branch formation to the topographically correct AP
region. (C) Opposing branch-inhibitory gradients could also explain wild-type AP branch
specification. Complimentary gradients of ephrin-As in the retina and EphAs in the SC
could inhibit branch formation via reverse signaling. Note that the mechanisms in B and C
are not mutually exclusive.
4.5.2.3 Opposing Anterior-Posterior Gradients of Branch Inhibitors
An alternative model for restricting interstitial branching is a set of opposing gra-
dients along the AP axis, each of which inhibits branching.319,347 For example, one
gradient is low-to-high AP gradient of ephrin-A2 and -A5, which inhibits branching
along RGC axons posterior to their TZ. Opposing it is a high-to-low AP signal gra-
dient that inhibits branching along RGC axons anterior to their TZ. High-to-low AP
gradients of EphA interacting with low-to-high TN gradients of ephrin-As through
reverse signaling may provide the necessary function.319,332,338,347,355,356 Some ephrin-
As and EphAs have expression profiles that suggest that they act in map development
predominantly via reverse signaling. For example, ephrin-A6 is expressed in a high-
to-low NT gradient by chick RGCs but is sparsely expressed in the OT.357
EphB-ephrin-B binding is well established to initiate both forward and reverse sig-
naling,358–360 and EphAs and ephrin-As have been shown to transduce signal bidirec-
tionally as well.361–363 Reverse signaling into ephrin-A-expressing cells upon binding
EphAs has been implicated in topographic mapping in the accessory olfactory system,
although in this system axonal ephrin-As act as attractant receptors for EphAs in the
targets.361,364 Computational modeling of retinotopic mapping shows that opposing
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gradients of EphAs and ephrin-As can act as branch inhibitors through bidirectional
signaling and generate the major phases of map development in chick and mouse, in-
cluding progressive increases in the topographic specificity of AP branching exhibited
by RGC axons originating from all TN positions, and can recapitulate the phenotypes
reported for ephrin-A knockout and EphA knock-in (KI) mice.347
Unlike ephrin-Bs, which are transmembrane proteins and have been shown to
transduce signal via their intracellular domains,365,366 ephrin-As are GPI-linked to
the cell membrane and require a transmembrane effector. A recent study identified
p75NTR as co-receptor for ephrin-As, and mice that do not express p75NTR feature
anteriorly shifted TZs, consistent with this model (Figure 4.3I). Additionally, nasal
RGC axons branch more anteriorly in ephrin-A5 KO mice (Figure 4.3B),316 and mice
that do not express EphA7, normally patterned in a high-to-low AP gradient, also
have anteriorly shifted mapping defects in nasal RGCs (Figure 4.3H).333 Taken to-
gether, the data suggests that opposing gradients of EphAs and ephrin-As are capable
of restricting branching to the correct topographical region (Figure 4.4C). However,
the described models are not mutually exclusive, and elements from both may be
necessary.
4.6 Lateral-Medial Retinotopic Mapping
Unlike zebrafish and frog, in which the growth cones of RGC axons are directed to
the appropriate LM location of their future TZ, RGC axons from the same retinal
location in higher vertebrates invade and grow in a broad distribution across the LM
axis of the OT/SC, with the average axon centered near the correct LM location
of the future TZ (Figure 4.2).320–323,325 Directing the connections to the correct
topographical location on the LM axis occurs through the bidirectional guidance of
the interstitial branches that form along RGC axons within a specific AP region as
described in Section 4.5.318,320,324 Branches on either the lateral or the medial side of
the future TZ extend towards the correct location. That is, branches from an axon
medial to the future TZ will extend laterally and branches extending from lateral
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axons will grow medially. Branches extending from RGC axons located within the
LM extent of the future TZ do not have an average directional bias,318,320,324 and,
at least initially, nor do branches distal from the eventual TZ. Instead, directional
bias is established as the branches extend, with longer branches exceedingly likely to
be growing in the proper direction.319 Branches form complex arbors upon reaching
the area of the nascent TZ. The directional guidance of interstitial branches is the
key feature in specifying the LM topographical position of the TZ in the same way as
restricting the AP position of branch formation is key to AP topographic specification.
4.6.1 Branch Guidance and Arborization
Understanding of the molecular mechanisms that control the DV mapping along the
LM axis of the OT/SC has lagged behind that of TN mapping along the AP axis of the
OT/SC, in part because in vitro assays, such as membrane stripe assays, that reveal
strong TN responses to endogenous AP target tissue fail to reveal differential DV
responses from RGC axons. This could be that GPI-linked guidance inhibitors, such
as RGM or the ephrin-As, are particularly suited for these assays. In the past decade,
the EphBs and ephrin-Bs have been identified as key mediators of DV mapping, and
are implicated in both bidirectional signaling and bifunctional action.
RGCs express EphB receptors in an overall low-to-high DV gradient, compli-
mented by an overall high to low gradient of ephrin-Bs during the period of retinotopic
mapping.287 Similarly, ephrin-B1 is expressed in a low-to-high LM gradient in the
OT/SC,320,371 complimented by and overall high-to-low LM EphB gradient in both
chick and mice (Figure 4.1B and 4.5A).320 EphB2 and EphB3 double-knockout mice,
show aberrant LM mapping due to defects in the guidance of interstitial branches.
Similarly, mice that lack EphB3 and the intracellular domain of EphB2 (EphB2∆Ki)
but can still participate in reverse signaling due to the intact ECD domain, have a
similar phenotype to the double mutant, as do EphB3-null mice that are heterozy-
gous for either EphB2 or EphB2∆Ki, albeit with lower penetrance.320 These mice
have an ectopic TZ lateral to the correct TZ (Figure 4.5B). These findings show that
ephrin-B1 acts as a branch attractant via EphB2/B3 forward signaling. However,
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Figure 4.5: Phenotypic defects in dorsal-ventral to lateral-medial topographic mapping.
(A) In wild-type mice, the lateral-medial position of axon terminations depends on comple-
mentary EphB/ephrin-B gradients in the retina and OT/SC. (B) Deletion of EphB2 and
EphB3 leads to defects in the topographic mapping of ventral RGC axons. An ectopic TZ
positioned lateral to the TZ (asterisk) is present in most mice. A similar phenotype was
observed in mice lacking the intercellular domain of EphB2 (EphB2 ∆Ki) and EphB3 knock-
out.320 (C) Deletion of the homeobox transcription factor Vax2 leads to major LM mapping
errors. Vax2 is normally expressed high to low along the VN to DT axis. VT axons are
mapped exclusively to the lateral SC.367,368 (D) Misexpression of ephrin-B2 in the ventral
retina, which normally has low-levels of expression that region of the retina, in Xenopus
results in ventral axons with aberrantly medial trajectories and projections.369 (E) Misex-
pression of ephrin-B1 in the chick OT affects axon branching behavior of RGC axons but
not axonal trajectory. In regions with high ectopic ephrin-B1, branches are preferentially
oriented laterally, and, at later stages, these regions are devoid of dense arborizations.324 (F)
Wnt3 is expressed from low to high along the LM axis of the OT/SC, and its receptors Ryk
and Frizzled (Fzd) are overall expressed low to high along the DV axis in the retina. Ectopic
expression of dominant-negative Ryk in the dorsal retinal causes a diffuse TZ extending
significantly medial.370
the attractant function of ephrin-B1 alone is not sufficient to describe mapping, and
modeling of these data indicates that bidirectional branch extension requires a branch
repellent in a distribution paralleling ephrin-B1.320
Bifunctional ephrin-B1 activity could account for directional branch extension,
and is supported by the demonstration that high levels of ephrin-B1, achieved through
virus-mediated ectopic expression of ephrin-B1 in the chick OT, repels interstitial
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branches in a selective manner (Figure 4.5E).324 Although the nature of the evidence
is for ephrin-B bifunctionality is significantly different from that for ephrin-As, when
taken together, these studies are consistent with a model whereby ephrin-B1 acts
through EphB forward signaling as both an attractant and repellent. A branch lo-
cated lateral to its nascent TZ is attracted up to the gradient of ephrin-B1 toward
its future TZ, whereas a branch located medial to its nascent TZ is repelled down
the ephrin-B1 gradient toward its future TZ.320,324 Importantly, the trajectories of
primary RGC axons are not changed in wild-type OT/SC nor in the SC of EphB mu-
tant mice or when encountering domains of ectopic ephrin-B1 expression in chick OT,
demonstrating that in vivo EphBs and ephrin-Bs affect the guidance of interstitial
branches, not the primary growth cone.320,324
While forward signaling is dominant in chick and mice, ephrin-B reverse signaling
plays a dominant role in retinotopic mapping in frog.369,372 Expression of dominant-
negative ephrin-B, incapable of reverse signaling in the retina, results in medially
shifted terminations (Figure 4.5D).369 However, it remains to be determined if reverse
signaling has a role in mapping in mice and chicks and that forward signaling has a role
in mapping in frog. In zebrafish, ephrin-B2a expressed in the OT has a repellent effect
on RGC axons via forward signaling through EphB receptors,373 and DV retinotopic
mapping is also likely controlled, in part, by Sema3D, which is expressed primarily
in ventral (lateral) OT and repels ventral RGC axons that map to dorsal (medial)
OT.374
4.6.2 Distinctions in Guidance of Primary Axons and Inter-
stitial Branches Require Unique Mechanisms
A major difference in EphB/ephrin-B-mediated mapping in higher versus lower verte-
brates is that in frog and zebrafish, EphBs/ephrin-Bs affect the primary axon growth
cone in vivo and in vitro,369,372,373 whereas EphBs/ephrin-B1 do not influence the
trajectories of primary RGC axons but direct the growth of interstitial branches in
mice and chick.320,324 A priori, a potential explanation is that RGC axons extend
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parallel to the ephrin-B1 gradient and thus do not encounter a gradient along their
primary direction of extension, whereas interstitial branches extend perpendicular to
the gradient and therefore extend either directly up or directly down the ephrin-B1
gradient. This is supported by observations with the ephrin-As which indicate that
axons are sensitive to incremental changes in ligand concentration, and not abso-
lute levels.331,341 However, primary RGC axons do not respond even when crossing
steep ectopic ephrin-B1 gradients achieved by electroporation of ephrin-B1 retroviral
expression vectors in the OT (Figure 4.5E),324 whereas they do stop posterior exten-
sion across the OT when they confront an ectopic domain of ephrin-A2 created by
retroviral infection (Figure 4.3E).314 A potential explanation is that growth cones of
primary RGC axons lack sufficient levels EphB receptors and signaling to respond
to ephrin-B1 in the OT/SC, or that EphB transcription and translation is upregu-
lated in interstitial branches as they form.290 Such differential mRNA transport, local
translation, and protein export to selected parts of the axon have been described for
other proteins and RNAs.339,375
4.6.3 Multiple Actions and Models of EphBs and Ephrin-Bs
in Dorsal-Ventral Map Development
In order to affect LM mapping in the OT/SC, EphBs and ephrin-Bs likely act both
bifunctionally and bidirectionally. Bifunctional activity refers to one molecule acting
either as an attractant or a repellent simply based on the context, and bidirectional
activity refers to a molecule acting as both a ligand and a receptor. Although sev-
eral guidance molecules have been shown to be bifunctional,376 and EphB/ephrin-Bs
have long been known to signal bidirectionally,358–360 an individual RGC axon has the
unique ability to exhibit a response to all of these signaling possibilities simultane-
ously. For example, two neighboring RGCs may extend axons with multiple EphBs
and ephrin-Bs on their membranes and may encounter multiple ephrin-Bs and EphBs
in the OT/SC. The responses to these cues, being transmitted by forward signal-
ing through EphBs and reverse signaling through ephrin-Bs, are dependent on the
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location of each RGC axon in relation to its future TZ, which defines the relative
levels of EphBs and ephrin-Bs. One RGC axon may be located medial to its future
TZ and extends branches laterally toward its future TZ through a combination of a
repellent response of EphBs binding ephrin-B1 in the OT/SC. Its neighboring RGC,
which may have extended lateral to their future TZ, will respond in the exact op-
posite manner, despite expressing an identical compliment of EphBs/ephrin-Bs and
responding to identical guidance cues, though at different concentrations, reflecting
its different location on the LM axis and therefore gradients of EphBs and ephrin-B1.
The bifunctional action of ephrin-B1 through EphBs present along RGC axons
may be due to the balance of distinct responses through each receptor type (i.e.,
EphB2 signaling results in attraction and EphB1 signaling in repulsion) or, alterna-
tively, to a combinatorial thresholding mechanism in which the combined signaling
through all EphBs results in either attraction or repulsion, controlled by a transition
of EphB signaling between attraction and repulsion to ephrin-B1 that is balanced
at the TZ, with lower signaling levels occurring lateral to the TZ and resulting in
branch attraction and higher levels occurring medial to the TZ resulting in branch
repulsion.320,324 It has been shown that EphB1, B2, and B3 all have similar effects
on branch guidance, suggesting that ephrin-B1 activity is determined by its relative
concentration.377 This thresholding model is based on studies showing that EphB1-
induced attachment of cell lines to a substrate of extracellular matrix molecules is
dependent on the concentration of ephrin-B1 in the substrate.378 Within a critical
concentration range, cells attach to their substrate in an integrin-dependent manner
at a much higher density. If ephrin-B1 concentration is either above or below this
optimal level, cell attachment is decreased. Trans-endocytosis of EphBs and ephrin-
Bs may be responsible for the switch from attraction to repulsion.379,380 At signaling
levels above threshold, endocytosis, which initiates repulsion is favored, whereas at
low signaling levels attraction is favored.379,380
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4.6.4 Wnt3 Signaling Plays a Role in Dorsal-Ventral Mapping
Unlike EphAs and ephrin-As in controlling AP topography, which have been shown
to act with two counteracting forces, the counteracting force of EphBs and ephrin-
Bs is not well characterized. Indeed, EphB1, B2, B3 triple mutant mice do not
show a complete absence of topography along the LM axis,377 confirming that other
signaling molecules must contribute to mapping along this axis. Wnt signaling has
been shown to play an important role in mapping the DV axis. In mouse and chick,
expression of Wnt3 is graded from low to high along the LM axis of the OT/SC and
members of the related to receptor tyrosine kinase (Ryk) and Frizzled families of Wnt
receptors are expressed in an overall low to high gradient along the LM axis of the
retina. In vitro, Wnt3 signaling inhibits RGC axons through Ryk, and stimulates RGC
axons through Frizzled members. In vivo, ectopic expression of Wnt3 in the chick
OT repelled RGC axons, causing shifted TZs. Moreover, expression of dominant-
negative Ryk causes a medial shift in the TZ and skews interstitial branches medially
(Figure 4.5F).370 Therefore, Wnt3, a classic morphogen, acts as an axon guidance
molecule counterbalancing the ephrin-B1 activity. Unfortunately, the contribution of
Wnt3-Ryk signaling to LM guidance cannot be assessed from these data.
4.7 Map Refinement
As interstitial branches converge on the eventual location of the TZ in higher ver-
tebrates, the branches arborize preferentially at or near the topographically correct
location. At first, the arbors are loosely organized around the topographically ap-
propriate position of the future TZ and must be significantly reorganized to develop
the precise connections that are a hallmark of the mature retinotopic map. In this
process, the region of the primary axon that extends posterior from the branch is
pruned, as well as misdirected arbors and branches.
Map refinement in fish and frogs is a precise shaping of arbors rather than the
large-scale remodeling of diffuse projections observed in rodents and chicks. In frog,
refinement of individual arbors is a dynamic process involving the addition and sub-
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traction of higher-order branches.344,381 In these species, the retina and OT continue
to grow throughout life, which requires continuous small-scale remodeling.330 These
processes are dependent on TrkB/BDNF signaling, which promotes both axon ar-
borization and synapse number, and neural activity via N -methyl-d-aspartate recep-
tors (NMDARs), which removes topographically incorrect branches.344,381
Mice form a retinotopic map that resembles its mature form by P8, days before
the opening of the eyes and the onset of visually evoked activity.382 The majority of
topographic mapping occurs before the opening of the eyes and is coincident with a
period of spontaneous neural activity that propagates as waves of action potentials
across the retina.383–385 Throughout the first postnatal week, these waves are driven
by a network of cholinergic amacrine cells and correlate the activity of neighboring
RGCs, thereby relating an RGCs position to its pattern of activity.386 Correlated
activity has long been thought to refine topographic connections by strengthening
coordinated inputs and/or weakening uncorrelated inputs.329,387–389 Pharmacological
activity blockade in mice and chicks indicates that neural activity plays a role in map
remodeling.321,390
Analysis of mice lacking cholinergic-mediated retinal waves indicates that corre-
lated patterns of RGC activity are required for the refinement of retinal projections
into a refined map in the SC.391–393 Mice lacking the β2 subunit of the nicotinic acetyl-
choline receptor maintain spontaneous activity, but the correlation evident in nearby
RGCs in wild-type retina is lost.392 The topographic projection in β2 mutant mice
is aberrant in that RGC axons form a loose collection of diffuse arborizations around
the appropriate location of their TZ.392 Rather than forming a dense TZ, the map of
visual space in these mutants was expanded anteriorly and compressed posteriorly.393
Studies indicate that there is a brief early critical period for retinotopic map remod-
eling in mice, as correlated activity in β2 mutant mice resumes during the second
postnatal week through a glutamatergic process, and visually evoked activity begins
soon thereafter, but neither process is able to affect map remodeling.392
Patterned retinal activity acts together with ephrin-As to establish topographic
maps. While ephrin-A2, -A3, -A5 triple mutant mice (the three ephrin-As expressed
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in the mouse visual system), have extreme mapping defects, they do not lack topog-
raphy. Also, β2−/− mice have nearly normal topography, but do not refine axonal
arbors. Mice lacking both ephrin-As and β2 have synergistic mapping defects that ab-
late nearly all topography in the retinocollicular projection.340,394 Additional studies
indicate that ephrin-As and correlated RGC activity together account almost com-
pletely for the formation of the TN mapping of the retinotopic projection.395 Together
the data suggest that ephrin-As guide the formation of topography in the SC and pat-
terned neuronal activity clusters cells based on their correlated firing patterns.394
4.7.1 Additional Activities and Interactions Potentially Re-
quired for Map Development
The action of the Ephs and ephrins is not sufficient to completely explain topographic
mapping. For example, all mutant mice deficient for Ephs or ephrins required for
retinotopic mapping form a topographically correct TZ in addition to ectopic TZs in
the SC,316,317,320,342 including mice lacking all EphBs (EphB1, B2, B3 triple mutants)
and ephrin-As (ephrin-A2, -A3, and -A5).340,377,394 This indicates that the action of
additional guidance activities along both the AP and LM axes are also required.
The dramatic LM mapping defects observed in mice deficient for the homeodomain
protein Vax2 also suggests the action of DV guidance molecules other than EphBs
and ephrin-Bs (Figure 4.5C). Vax2 is expressed in a tilted gradient in the developing
retina, being highest in nasal-ventral RGCs and lowest in temporal-dorsal RGCs.367
Targeted deletion of Vax2 in mice results in flattened or diminished gradients of retinal
EphBs and ephrin-Bs and a complete shift in the TZs of temporal-ventral RGCs from
anterio-medial SC to anterio-lateral SC,367,396 a phenotype much more dramatic than
EphB2/B3 double mutants or even EphB triple mutants, which still have a TZ in the
correct topographic location.320
As described above, Wnt3, acting through Ryk, also contributes to guidance along
the LM axis of the SC, and RGM acting through neogenin are potential guidance
cues for mapping along the AP axis. Finally, the functional interactions of Ephs
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and ephrins are still being detailed and new ones uncovered. For example, cross talk
between EphB2 and ephrin-A5, guidance molecules critical for LM and AP mapping,
respectively,317,320 activates EphB2 signaling pathways.397 Such interactions could
potentially influence retinotopic mapping along both axes of the OT/SC.
Though guidance molecules play critical roles in map formation, other interactions,
such as axon-axon interactions, are likely critical for mapping. Mice deficient for
the cell adhesion molecule, L1, which is transiently expressed on RGC axons during
pathfinding and mapping, reportedly have defects in both AP and LM mapping in
the SC.398 Interestingly, a single point mutation in the ankyrin binding region of
L1 (Y1229H) causes DV mapping defects but limited AP defects.399 Why L1 is
required for proper retinotopic mapping is not known, but considering its roles in other
systems, the investigators suggest that it modulates RGC axon-axon interactions
required for mapping or the appropriate function of Ephs and ephrins.400,401
Other interactions suggested to influence mapping include competitive interactions
for limiting diffusible factors, such as BDNF, or synaptic sites, as well as the interplay
between neural activity, response to guidance molecules, and branch dynamics.344,381
One example of evidence of this type of secondary interaction comes from analysis of
EphA3 KI mice described above. In these mice, Isl2-negative temporal RGCs form
TZs in aberrant locations, despite having wild-type levels of topographic guidance
molecules, e.g., Ephs and ephrins.331 One explanation for this result is that the TZs
of Isl2-positive, EphA3 KI RGCs are limited to anterior SC, owing to their enhanced
sensitivity to the low-to-high AP gradient of ephrin-A repellents, and exclude Isl2-
negative RGC TZs through axon-axon interactions and/or competitive interactions
resulting in their orderly, ectopic mapping in posterior SC.331
4.8 Glycosaminoglycans in Retinal Axon Guidance
The glucidic moieties of glycosaminoglycans have been known to guide ganglion cells
for over twenty years.402 The effect of GAGs on RGC cells was demonstrated in vitro
shortly thereafter.403 Since then, evidence has emerged that points to a significant
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role for GAGs in the development of the visual system. As with many other processes,
HS has been demonstrated to play an important role in RGC guidance in vivo, but
the role for CS is poorly understood and only inferred from its in vitro activity. HS
has been shown to cause RGC misrouting through the optic chiasm using EXT1-null
mice. CS has been shown to inhibit RGC growth and affect repulsive guidance in
vitro, however, discovering a role for CS has proven elusive. Several CSPGs have been
identified with expression along the optic tract that have repulsive guidance activity.
However, it is often unclear if it is the carbohydrate chains or the core protein that
is responsible for the activity, and how important the repulsive activity of molecule
is to guiding axons in vivo.
4.8.1 Heparan Sulfate in Pathfinding Through the Chiasm
Heparan sulfate plays a prominent, and fairly well-understood role in guiding RGC
axons through the optic chiasm (see also, Section 1.2.2.2). Mutant mice that lack the
ability to synthesize heparan sulfate due to the conditional knockout of the EXT1
enzyme (Nes-EXT1−/−) display significantly higher levels of RGC projection into the
contralateral eye.85 This guidance phenotype is strikingly similar to that of Slit1/Slit2
double-knockout mice. Slits are expressed around the chiasm and act repulsively to
confine the trajectory of retinal axons to a specific route across the midline.96 While
similar, RGC axons display pathfinding errors after the midline chiasm in EXT1 cKO
mice whereas Slit1/Slit2 double-knockout mice display defects at the chiasm. Cell-
surface HS has been shown to promote Slit-Robo binding and is important for the
repulsive activities of Slit2.98 Knockout of Slit2 alone, however, does not produce a
phenotype, presumably because Slit1 is able to functionally compensate. However,
reduction of one allele of EXT1 in Slit2 knockout mice causes similar axon misguidance
at the optic chiasm as the Slit double mutant.85
The sulfation pattern of HS has been shown to be important in guidance at the
chiasm. Inhibition of HS sulfation with chlorate causes axons to bypass the tectum,
and treatment with chemically modified heparins reveals that 2-O- and 6-O-sulfate
groups are also able to cause RGC misrouting.404 The dependence of RGC rout-
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ing through the optic chiasm on HS sulfation has been demonstrated in vivo using
heparan sulfate sulfotransferase (HST) mutant embryos, Hs2st−/− and Hs6st−/−.93,99
Interestingly, the Hs2st−/− and Hs6st−/− mice each had a distinct guidance pheno-
type at the optic chiasm. In Hs2st−/− mice, RGC axons grow up the ventral midline,
whereas in Hs6st−/− mice, RGC axons project into the contralateral optic nerve.
In both cases, axon misrouting occurred in regions where the respective sulfotrans-
ferase is otherwise expressed.99 Studies with purified heparin oligosaccharides suggest
that structures containing a combination of 2-O- and 6-O-sulfation are particularly
active.404 Unfortunately, manipulating the structure of HS at the sulfation-sequence
level is not possible, given our current understanding of HS biosynthesis and available
genetic tools. However, mass-deletion of sulfation at a particular position across all
HS saccharides provides additional mechanistic information that Nes-Cre; EXT1−/−
mice cannot provide. For example, the global deletion of HS results in severe devel-
opmental defects,85 presumably due to the loss or reduction of FGF and morphogen
signaling, that precludes the study of the role of HS in RGC guidance beyond the
optic chiasm.
Indeed, heparan sulfate may be involved in other aspects of retinal axon guidance
including topographic mapping. Evidence from in vitro studies suggests that HS is
involved in axonal guidance through Sema5A,100 and ephrin-A3/EphA signaling.101
As discussed above, Sema5A plays a role in guidance through the optic disk and along
the optic nerve and ephrin-A/EphA signaling is required for topographic mapping.
4.8.2 Chondroitin Sulfate in Retinal Axon Guidance
Chondroitin sulfate has been known to guide RGC axons in vitro for over twenty
years.69,402,403,405,406 In fact, CSPGs were the first molecules demonstrated to act
as repulsive guidance cues for RGC cells. RGC axons cultured in vitro from retinal
explants avoided growing on a CSPG-containing surface, however ChABC digestion
rescued this effect.403 One of the first groups to address the mechanism of CSPG-
mediated guidance in vivo was Silver and coworkers who, in a series of reports,403,407
showed strong CS staining along the peripheral retina adjacent to projecting RGC
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cells by staining for CSPGs using the CS-56 antibody,408 which binds to the CS-A and
-C sulfation moieties of CSPGs.403,407,409 As early retinal development progresses, the
CS-56-positive staining recedes further towards the periphery of the retina.407 These
observations led the authors to suggest that CSPGs promote the development of neu-
ronal polarity, since, at the time, no other repulsive guidance cue was known to explain
the directional growth of axons out of the retina through the optic fissure.69,403,407
However, it is unclear if CS is responsible for this activity, as it was later shown
that CS-56 binds the proteoglycan form of collagen IX,410 which is only present in
the retina, primarily peripheral to the growing RGC axons.64 Moreover, using the
anti-CS-A and anti-CS-C antibodies 2B6 and 3B3,411 McLoon and coworkers, as well
as other investigators, were able to show that CS is present throughout the retinofugal
pathway, including on the surface of RGC cells, during the entire period of retinal
axon growth.64,412,413 Thus, retinal stereotyping is likely not dependent on CSPGs,
although it is sometimes attributed this role in recent literature.291
Additional evidence suggests that the activity of CSPGs depends on the CS chains
in some cases, and the core protein in others. For example, some CSPGs retain in-
hibitory activity after ChABC digestion,405,406,414 while others loose activity.52,55 In
fact, a CSPG derived from the SC of neonatal rats was shown to promote the growth
of neonatal rat RGCs.415,416 Indeed, CS is present in the optical tectum in chicks dur-
ing the period in which RGC axons invade, ramify, and make synapses.64,417 Based
on this evidence, it seems that the activity of CS in RGC axon guidance depends on
the chemical composition of the glycan chain. CS-A and -C have been shown to be
present throughout the visual pathway during the time that retinal axons grow. Given
that research in our laboratory suggests that oversulfated CS motifs such as CS-D and
CS-E are much more biologically active than the monosulfated patterns,15,41,70,218–220
it is possible that a barrier mechanism could still be viable if the expression of over-
sulfated CS was spatiotemporally restricted in the visual system. McLoon and other
investigators demonstrated spatiotemporal differences in the expression of the CS-
A and CS-C sulfation patterns,64,412,413 thus, it may be possible that RGC axons
are guided by highly sulfated CS patterns with a spatiotemporal expression profile
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consistent with RGC growth patterns.
4.8.3 Summary
GAGs have been shown to play an important role in retinal development. Both
HS and CS were shown to affect RGC guidance in vitro, over twenty years ago.
Since that time, however, our understanding of the role of HS in vivo has advanced
considerably, chiefly due to the application of genetic tools to investigate the role
of HS chains and sulfation.85,99 Our understanding of CS has lagged behind due
to the lack of such an approach. As it stands, it is unclear what role CS plays in
the development of the visual system. Previous studies have relied too heavily on
crude tools, such as immunohistochemistry using antibodies with poor specificity,
and potentially non-specific inference of cellular processes by treating tissue with
exogenous CSPGs. Furthermore, in many studies it is unclear if the core protein or
the carbohydrate is responsible for the guidance activity, or if the CSPG has any
effect on guidance in vivo in the first place. Recent studies have shown that the
sulfation patterns of CS profoundly affect the activity.15,41,70,218–220 In the future,
genetic studies targeting CS sulfation could be brought to bear in order to advance
our understanding of the role of CS in vivo.
4.9 Conclusion
Retinal primary axons are guided out of the retina and through the optic tract to
reach the chiasm. At the chiasm, the axons are directed to ipsilateral or contralat-
eral OT/SC. There, axons are directed mapped to their appropriate topographical
location, where they form arbors and further refine their position and synaptic connec-
tions. Each stage of this process involves numerous, redundant guidance cues. While
our understanding of the molecular mechanisms that underlie these complex processes
has improved considerably since Sperry proposed the chemoaffinity hypothesis nearly
half a century ago, much remains to be understood. For instance, it is understood
that at least two counteracting forces are required for establishing topographic maps.
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The Eph/ephrin families are required for mapping, however the necessary counter-
acting forces are not well characterized. Understanding the molecular determinants
controlling the formation of topographic maps is critical for understanding the how
the nervous system is able to efficiently self-organize into a functional structure. This
could have a profound impact on our ability to treat spinal cord injury in the future.
In Chapter 5, we examine the sulfation dependence of CS-mediated axon guidance
in vitro and the spatiotemporal expression of the oversulfated motif in vivo to iden-
tify a functional role. Given the repulsive action of CSPGs and the importance of
CS-binding proteins such as BDNF and Wnt3, it may be possible that CS assists in
topographic mapping of RGCs in the OT/SC.
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Chapter 5
Chondroitin Sulfate E Is Required
For Retinotopic Mapping†
5.1 Abstract
Here, we show that a specific CS sulfation motif, CS-E, is required for establishing
proper retinotopic maps. CS-E, but not the other major CS sulfation patterns, is
capable of guiding RGC axons. The Rho/ROCK-dependent guidance activity of
CS-E is graded from low to high along the DV axis of the retina with an activity
profile congruent with EphB3 expression. EphB3 bound to CS-E with high affinity
and specificity, and is required for CS-E-mediated axon guidance. CS-E null mice
displayed misguided axonal connections in the superior colliculus (SC), with aberrant
RGC projections in the medial SC, indicating that CS-E is required for retinotopic
mapping the LM axis. This is first demonstration of a non-protein guidance cue for
topographic mapping.
5.2 Introduction
Chondroitin sulfate proteoglycans (CSPGs) have been known to affect RGC guid-
ance for 20 years;69,402,403,405,406 however, the role of CS in vivo is still unclear, and
the molecular determinants responsible for CSPG function have not been thoroughly
†Portions of this chapter were taken from Claude J. Rogers, Jost Vielmetter, Adam Griffith,
Ravinder Abrol, BinQuan Zhuang, William A. Goddard III, Linda C. Hsieh-Wilson, “Chondroitin
sulfate E influences retinotopic mapping via EphB3,” Manuscript in preparation.
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explored. One of the first groups to address the mechanism of CSPG-mediated guid-
ance in vivo was Silver and coworkers who, in a series of reports, showed that CS
expression in the retina is most pronounced in the periphery during the course of de-
velopment, adjacent to the area where newly differentiated RGC cells emerge.403,407
These studies relied on the CS-56 antibody408 that recognizes CS-A and -C sulfation
motifs (Figure 5.1A).403,407,409 These observations, coupled with in vitro boundary
assay data which demonstrated that CSPGs inhibit RGC outgrowth, led to the con-
clusion that the role of CS in vivo may be to guide developing axons out of the retina
towards the optic fissure. However, it is unclear if CS is responsible for this activity,
as it was later shown that CS-56 also binds the proteoglycan form of collagen IX,410
which is only present in the retina peripheral to the growing axons.64 Using the anti-
CS-A and anti-CS-C antibodies 2B6 and 3B3,411 McAdams and McLoon, and other
investigators, were able to show that CS is present throughout the retina, including
on the surface of RGC cells, during the entire period of RGC growth.64,413
Additional evidence suggests that the activity of CSPGs depends on the CS chains
in some cases, and the core protein in others. For example, some CSPGs retain
inhibitory activity after ChABC digestion of the carbohydrate chains,405,406,414 while
others lose activity.52,55 In fact, a CSPG derived from the SC of neonatal rats was
shown to promote the growth of neonatal rat RGCs.415,416 Indeed, CS is present in
the optic tectum in chicks during the period in which RGC axons invade, ramify, and
make synapses.64,417 Based on this evidence, it seems that the activity of CS in RGC
guidance depends on the chemical composition of the chain.47,55,402,403,405,406,409,418–420
However, the precise structural determinants responsible for CS activity are not well
understood as heterogeneous proteoglycans were used for those studies. Given our
recent investigations into the role of sulfation on CS activity,15,41,70,218–220 it is possible
that highly sulfated CS motifs might be responsible for the guidance activity of many
CSPGs, and may be expressed in only a subset of the CS-A/CS-C population in a
manner consistent with a boundary inhibition mechanism.
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Figure 5.1: Chondroitin sulfate E is expressed throughout the developing visual system,
inconsistent with a boundary mechanism in early retinal development. (A) Structures of
the major CS sulfation motifs. (B) Transverse cryosections of the embryonic chick retina
and optic nerve during early retinal development. CS-E (green) is highly expressed during
the period of RGC growth and differentiation (∼E5.5). The expression of CS-E decreases as
development progresses. (C) A transverse cross section of the E5.5 chick optic tract shows
abundant CS-E expression (green) overlapping with developing axons in the retina, optic
tract (OT), and optic chiasm (OC), as indicated by GAP43 staining (red).
5.3 Chondroitin Sulfate Expression in the Develop-
ing Visual System
We previously demonstrated that a specific sulfated epitope on CSPGs, the CS-E mo-
tif (Figure 5.1A), stimulates the outgrowth of a variety of embryonic neuron types, at
least in part, by regulating the neurotrophin family of growth factors.15,41,70,219,220,421
On the other hand, CS-E inhibits axon outgrowth of postnatal and adult dorsal root
ganglion (DRG) and cerebellar granule neurons (CGN) through interactions with
PTPσ, NgR, and possibly other receptors.41,58–60 To investigate whether the CS-
E motif plays a role in RGC guidance, we examined the spatiotemporal expression
patterns of CS-E in the developing retinotectal system. Transverse sections of em-
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bryonic chick retina and optic tract between E5–E7.5 (Hamburger-Hamilton stages
26–31)422 were labeled using an antibody selective for the CS-E motif (Figure B.2
and B.3).15,218 We observed strong immunostaining throughout the retina and op-
tic tract, with CS-E expression peaking at E5.5, which coincides with the period in
which the rate of RGC genesis is maximal.64 CS-E expression declined as embryonic
development progressed (Figure 5.1B). To identify cell types that express CS-E, we co-
immunostained E5.5 optic tract sections for growth-associated protein 43 (GAP43),
a marker of developing axons (Figure 5.1C and 5.2A).423 We found that the CS-E
motif was associated with developing RGC axons, cell bodies, as well as cells in the
outer nuclear layer of the retina (Figure 5.2A–C). CS-E was also present in the optic
tract, chiasm, and on cells adjacent to these structures (Figure 5.1C). To confirm fur-
ther that CS-E expression co-localizes with RGC cell bodies, we co-immunostained
with an antibody selective for Islet-1, a LIM homeodomain transcription factor and
RGC marker (Figure 5.2C).424 As expected, CS-E expression was present along the
perimeter of Islet-1-positive cells. Both RGCs and adjacent cells in developing mice
(E18.5) also displayed high expression levels of CS-E (Figure 5.2E). Based on the
expression profile of CS-A/C reported by McLoon and coworkers, we expected that
CS-E expression should overlap with that of CS-C. Indeed, co-immunostaining with
a highly selective CS-C antibody15,216 showed a high degree of co-localization in the
RCG and nerve fiber layers of the retina (Figure 5.2B). On the other hand, cells in
the outer nuclear layer of the retina showed more CS-E than CS-C staining indicating
that CS-E is more ubiquitously expressed in the E5.5 retina.
A barrier mechanism for neurite growth during vertebrate embryogenesis or neu-
ronal regeneration is frequently evoked when considering the action of CS in vivo,
especially in spinal cord injury model systems.52,405,406,425 Indeed, CS has been shown
to prevent RGC axons traveling to the tectum from invading the telencephalon an-
teriorly in developing chick.426 Barrier mechanisms have also been evoked to explain
the establishment of retinal axon polarity via collagen IX,69,407 and guidance around
the optic fissure and disc via the Te38 proteoglycan.405 In both of these cases, the
protein core may be responsible for the inhibitory effects of these molecules. However,
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Figure 5.2: Expression of chondroitin sulfate E in the developing retina. (A) A cross section
of the E5.5 chick retina shows that CS-E (green) and GAP43 (red) expression significantly
overlay, particularly i the nerve fib r lay r of h retina, suggesting CS-E is expressed by
RGC axons. (B) RGC axons also appear to expr ss CS-C (red), consistent with previous
findings. (C CS-E (green) expression also app ars to overlay with RGC cell bodies, as
indicated by islet-1 staining (red), as a comparison, see (D) with islet-1 (green) and GAP-43
(red) staining. (E) E18.5 mice also express CS-E (green), which also appears to overlay with
axonal fibers, as indicated with GAP-43 (red).
we found CS-E to be widely expressed near or around areas of active RGC neurite
growth, an expression profile not consistent with a barrier mechanism, during a phase
of axonal pathfinding in early retinal development (Figure 5.1C). In fact, the expres-
sion pattern of the CS-E sulfation motif was congruent with the expression patterns
of the CS-A and CS-C sulfation motifs as observed by of McLoon and coworkers.64
Furthermore, we show that CS-E is expressed throughout the visual tract during RGC
axonal growth, and apparently by RGC axons themselves. We employed immunohis-
tochemistry instead of in situ hybridization techniques since we are interested in the
display of a particular sulfation motif on the cell surfaces, not the mere presence of the
transcripts of the enzymes responsible for the elaboration of the glycan. Differences
in spatiotemporal expression of sulfation patterns of various other proteoglycans have
been observed in the visual system,64,413 and CS-E expression seems to follow a sim-
ilar pattern, peaking in early retinal development, then tapering off as development
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Figure 5.3: Chondroitin sulfate E guides ventral RGC cells. (A) CS-E, but not CS-A, -C, or
-D, guides ventral-temporal chick RGC axons. E6–7 retinal explants (green) were grown for
1–2 days on a substratum containing alternating stripes of the indicated CS polysaccharide
and laminin (red) or laminin alone. Only CS-E-containing stripes induce a preference for
one of the sets of stripes. (B) The guidance activity of CS-E is dependent on Rho/ROCK
signaling. Addition of the ROCK inhibitor Y27632 to ventral-temporal retinal explants
showed no preference for stripes consisting CS-E or laminin alone, as compared to control,
which were administered vehicle alone. (C) The coefficient of choice for RGC axons for each
condition in A and B. RGCs strongly avoid CS-E (coefficient of choice = 0.77, p < 0.0005,
n = 12), while the preference of RGC axons for either stripe in the presence other sulfation
patterns, or CS-E in the presence of Y27632 is not significant (coefficients of choice = 0.07,
0.13 and −0.03, respectively, n = 8–10).
progresses.
5.4 Chondroitin Sulfate E Guides Retinal Axons In
Vitro
Given the ubiquitous expression of CS and the CS-E epitope in the developing retina,
we investigated the effects of specific sulfation motifs in RGC guidance using stripe
assays. No one, to our knowledge, has demonstrated the role of the CS chains alone,
or the importance of sulfation per se, in RGC guidance. CSPGs are potentially
challenging to study, as some proteoglycans retain inhibitory properties even after
ChABC treatment,405,406,414 while others are rendered inactive.52,308 Moreover, some
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CSPGs have been shown to promote RGC outgrowth and survival. These proteogly-
cans have been shown to be positive for CS-A, CS-C, and CS-A/CS-D motifs.68,415,416
Therefore, it is unclear to what extent the core protein or the CS chains affect CSPG
activity. To overcome this problem, we tested the activity of commercially available
CS polysaccharides, rather than PGs, enriched in a particular sulfation pattern.
Retinal explants from E6–7.5 chicks were grown in the presence of alternating
stripes of CS polysaccharides and laminin, or laminin alone.303,304,364,427 RGC axons
were strongly repelled by polysaccharides enriched in the CS-E motif, greatly prefer-
ring the laminin-only stripes (Figure 5.3A). Guidance was quantified using a modified
Sholl intersection analysis in which the number of axons associated with each type
of stripe was quantified at set distances from the explant.334,428 The coefficient of
choice (see Materials and Methods) for CS-E (0.77, p < 0.0005, n = 12) is consistent
with a strongly repulsive cue (Figure 5.3B). In contrast, polysaccharides enriched in
the CS-A, -C and -D motifs had no effect on RGC guidance (coefficients of choice =
0.07, 0.13 and −0.03, respectively), even when used at 20-fold higher concentrations
than CS-E. Thus, the repulsive activity of CS-E polysaccharides is not likely due to
non-specific effects related to their high overall negative charge or to the carbohydrate
blocking the growth permissiveness of the CS-positive stripes. As the RGC guidance
activity of CSPGs requires the activation of Rho kinase (ROCK),55 we examined
whether inhibiting this pathway affects CS-E-mediated RGC guidance. Addition of
the ROCK inhibitor Y27632 abolished the axon repulsion activity of CS-E (coefficient
of choice = 0.06, n.s., n = 10; Figure 5.3B and C), indicating that both CS-E and
CSPGs mediate axon guidance via Rho/ROCK.
This finding is consistent with previous studies in which CS-E is uniquely active
compared to the other major CS sulfation motifs, including the neurite growth inhibi-
tion of dorsal root ganglion neurons.15,41,70,219,220 Surprisingly, the guidance activity
of CS-E was graded along the DV axis of the retina, with axons from the dorsal retina
showing significantly less repulsion (Figure 5.4A and 5.12). The coefficient of choice
was 0.90 (p < 5 × 10−5, n = 12) for ventral axons, compared to 0.21 (p < 0.005,
n = 16) for dorsal axons, in the presence of CS-E polysaccharide-containing stripes
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Figure 5.4: CS-E-mediated axon guidance activity is graded along the dorsal-ventral axis of
the retina. (A) Dorsal RGC axons show significantly less avoidance for the CS-E-containing
stripes compared to ventral axons. There were no nasal-temporal differences, as quantified
in (B) with temporal-ventral (black) and nasal-ventral (red) axons showing high preference
for the laminin-only stripes (coefficient of choice = 0.90, p < 5 × 10−5, n = 12), while
temporal-dorsal (blue) and nasal-dorsal (green) have low preference for the laminin-only
stripes (coefficient of choice = 0.21, p < 0.005, n = 16). (C) The morphology of growth
cones on CS-E-containing stripes significantly differed between the dorsal and ventral retina,
as quantified in (D).
(Figure 5.4B). This was unexpected because a previous report of a stripe assay us-
ing CSPGs made no mention of differential dorsal-ventral responses,55 although the
authors explicitly note that no nasal-temporal differences were observed, which is
consistent with our findings. The repellent activity of CS-E was independent of the
distance of the axons from the explant, suggesting that secreted factors from RGC
cell bodies or other retinal cells, whose effects diminish with distance,429,430 such as
BDNF or Wnt3,350,351,370 are not required for CS-E-mediated RGC guidance. Instead,
local conditions surrounding the growth cone appear to be sufficient for the guidance
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activity of CS-E.
Moreover, CS-E apparently induced position-dependent growth cone collapse along
the DV axis (Figure 5.4C and D). Approximately 83% of growth cones originating
from the ventral retina displayed a collapsed morphology in CS-E-containing stripes.
In contrast, only 15% of growth cones originating from the dorsal retina were collapsed
in CS-E-containing stripes. Consistent with previous studies using CSPGs,55,431 CS-E
induced growth cone collapse occurred only when the axon traveled a sufficient dis-
tance into the stripe. Ventral RGC axons were able to sample the CS-E-containing
substratum without the immediate induction of growth cone collapse, as indicated
by the presence of healthy growth cones from the ventral retina making contact with
the CS-E stripes. Taken together, these results indicate that CS polysaccharides are
sufficient to recapitulate the repulsive activities of CSPGs toward RGC neurons, and
this activity depends critically on the CS sulfation pattern. Moreover, the activity
profile of CS-E implicates the presence of potential binding partner(s) with graded
expression on RGC axons. To our knowledge, CS-E is the first non-protein molecule
shown to elicit a differential response with RGC axons along the DV axis. The dif-
ferential response to CS-E led us to consider that CS-E might not just be a molecule
generally acting as a non-permissive or repulsive agent acting as a simple barrier to
growing axons, but that some neurite populations might be non-responsive to its ef-
fect as a barrier to neurite extension and thereby give it the potential of a differential
guidance molecule comparable to other known guidance molecules.
5.5 Chondroitin Sulfate E Interacts with EphB3
Before the question of mechanism could be addressed, we examined if any of the
molecules expressed from low to high along the DV axis of the retina might be can-
didates for receptors to CS-E. The EphB2 and EphB3 members of the Eph fam-
ily of tyrosine receptor kinases are expressed from low to high along the DV axis
in both mouse and chick retina,287,290,320,355,359,371,396,432–434 and effect axon guid-
ance through the Rho/ROCK pathway.358,435,436 Therefore, we investigated whether
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Figure 5.5: EphB3 binds strongly and specifically to CS-E. (A) Binding of EphB3 to a
glycosaminoglycan microarray shows the specificity of the interaction with CS-E. The other
major CS sulfation motifs and other important GAG classes show very little EphB3 binding.
EphB2, on the other hand, did not bind to CS-E or any of the other major GAGs. (B) Surface
plasmon resonance of the EphB3-CS-E interaction. A series of 2-fold dilutions of EphB3,
starting at 3 µM was passed over a sensor chip containing CS-E. The resulting sensorgrams
were fit to a Langmuir 1:1 binding interaction (black). SPR confirms that EphB2 does
not significantly interact with CS-E. EphB2, at equivalent concentrations to EphB3 had no
observable response. (C) The electrostatic potential surface of EphB3 suggests that CS-E
binds between the two FNIII domains, in the region of high electropositive potential (blue).
EphB2 does not have an equivalent electropositive region.
EphB2 and EphB3 interact with CS-E polysaccharides using glycosaminoglycan mi-
croarrays.15,16,218,219,437 The extracellular domains of EphB2 and EphB3 expressed as
Fc fusion proteins (EphB2-Fc and EphB3-Fc) were incubated with robotically printed
microarrays containing varying concentrations (0.25–25 µM) of CS enriched in the CS-
A, CS-C, CS-D, CS-E motifs, dermatan sulfate (DS), hyaluronic acid (HA), heparin,
heparan sulfate (HS), or keratan sulfate (KS). Protein binding was detected with a
Cy3-labeled Fc antibody. We observed strong, selective binding of EphB3 to CS-E
polysaccharides on the array (Figure 5.5A). Only minor binding of EphB3 to HS and
heparin, and no significant binding to other glycosaminoglycan classes, was observed,
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highlighting the specificity of the interaction. Moreover, EphB2, which shares 70%
homology to EphB3, did not bind to glycosaminoglycans on the array.
We next examined the kinetics of the interaction between EphB3 and CS-E by sur-
face plasmon resonance (SPR). CS-E polysaccharides were mono-biotinylated438,439
and affixed to the surface of a streptavidin-coated sensor chip. EphB3-Fc was passed
over the surface at varying concentrations, and the resulting sensorgrams were fit to
a one-to-one Langmuir binding model. The data revealed a physiologically relevant
dissociation constant (K
D
) of 85 nM (ka = 3012 M−1 · s−1 and kd = 2.56× 10−4 · s−1)
and an estimated three EphB3 binding sites per CS-E molecule (Figure 5.5B). As
expected, EphB2-Fc did not show any measurable interaction with CS-E by SPR,
even at high protein concentrations.
To gain insight into the molecular basis of the EphB3-CS-E interaction, we per-
formed computational modeling studies. The large extracellular domain of the EphB
family of proteins consists of an N-terminal ephrin-binding domain, an epidermal
growth factor (EGF)-like cysteine-rich region and two fibronectin (FN) type-III do-
mains (Figure 5.5C). As only the ephrin-binding domains have been crystallized for
EphB2 and EphB3, we constructed a homology model of the full ectodomain of each
protein based on the crystal structure of EphA2, which shares 41% sequence identity
with EphB2 and 47% with EphB3. The atomic structures for human EphB2 and
EphB3 were obtained by combining models from the SWISS-MODEL repository that
contains homology models for different subsets of the target protein sequence based
on sequence homology to known protein structures from the PDB database.235,236
The constructed models for EphB2 and EphB3 were then minimized using the Drei-
ding force field271 to a force threshold of 0.5 (kcal · mol−1)/Å. Surface electrostatic
potential calculations revealed a region of strong positive potential between the FNIII
domains on EphB3 that was missing on EphB2, suggesting a basis for the difference
in CS-binding activity (Figure 5.5C).
While the electrostatic potential surface provides a basis for the observed differ-
ences between EphB2 and EphB3 in CS-binding activity, the potential-binding area
is large and does not suggest where CS-E binds to the protein. Additionally, the
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Figure 5.6: The docked structure of CS-E octasaccharide bound to EphB3. (A) The
electrostatic potential surface of the ligand-bound protein. (B) CS-E (magenta) interacts
with EphB3 (white ribbon) along the upper portion of the first FN type III domain of
the protein. Interacting residues within 5 Å of the ligand are represented in cyan. Closer
examination of the binding site reveals that CS-E makes a number of specific contacts with
polar EphB3 residues.
electrostatic potential surface does not provide an explanation for the selectivity of
EphB3 for CS-E, nor how CS-E may activate the protein. To answer these ques-
tions, we docked CS-E to the protein. The large surface area of EphB3 and no prior
knowledge of the location of the CS-binding site presents a significant challenge for
docking. We reasoned that we could eliminate large portions of the protein surface
from consideration due to unfavorable electrostatics. Only electropositive regions of
the protein above an arbitrary threshold value were considered for analysis. This step
reduced the regions needed to consider from over one hundred to thirty-five. Next, a
coarse-level docking of the CS-E tetrasaccharide, in which possible ligand poses are
broadly sampled, was performed for both EphB2 and EphB3. As expected, EphB3
had favorable interactions with CS-E tetrasaccharide at several sites on the protein,
with the lowest-energy binders clustered in the electropositive region between the two
FN type-III domains. EphB2, on the other hand, had poor binding energies with CS-
E. Interestingly, attempting to buffer the charge of the ligand and protein through
neutralization gave unrealistic binding-energy profiles for the complex (Figure 5.13).
Finer-level docking of CS-E tetrasaccharide with the top-ten EphB3 binding sites
identified via coarse docking revealed that CS-E preferentially bound along two shal-
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Table 5.1: Predicted CS-E binding sites on
EphB3
High-Affinity Site Low-Affinity Site
Arg309
Asn322
Asn323
Tyr325
Ser341
Arg344 Arg344
Arg363 Arg363
Lys378
Arg391
Arg420
Glu424
Lys434
Leu437
Arg440
Ala442
Ala443
Asn445
Ile446
Thr447
Thr448
Gln450
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Figure 5.7: A model for CS-E-induced dimerization of EphB3. In addition to the high-
affinity site (A, cyan, CS-E in magenta), docking identified another binding site with less
favorable binding energy (B, green, CS-E in orange). (C) A single molecule of CS-E may
be capable of bringing two molecules of EphB3 together in a mode similar to the proposed
mode of dimerization via the ephrin ligands.440
low grooves along the protein surface (Figure 5.14). The interactions of the tetrasac-
charides suggested that a longer CS oligosaccharide is necessary for binding to EphB3,
which is supported by the SPR data (see also, Chapter B). Because of this, ranking
the potential binding sites was not feasible. To overcome these challenges, a model for
a CS-E octasaccharide was created using the crystal structure of CS-A hexasaccharide
as a template.214 The conformation of the sugar was determined by molecular dy-
namics, and the resulting ligand was docked into EphB3. Docking the octasaccharide
revealed a single low-energy interaction along a groove formed by the first FN domain
and the EGF domain and extending along the electropositive surface of the first FN
domain. The single binding site identified by docking is consistent with the apparent
one-to-one kinetics of the in vitro interaction identified by SPR. CS-E makes several
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specific contacts with the protein, the most important being electrostatic interactions
with Arg309, Arg344, Arg363, Lys434, and Arg440 (Figure 5.6 and Table 5.1). Both
the 4-O- and 6-O-sulfates of the GalNAc moieties of CS-E make contacts with the
protein, with the exception of the second GalNAc moiety from the reducing end that
only makes contacts with the 6-O-sulfate group, which helps explain the selectivity of
this protein to CS-E. Indeed, binding energies for docked CS-A octasaccharide were
∼100 kcal ·mol−1 less favorable than CS-E.
Intriguingly, a number of charged groups of the bound ligand are presented away
from the protein in a manner that suggests that the may be able to engage another
protein molecule, indicating a potential mechanism for activation of EphB3. However,
due to the angle the bound octasaccharide makes with the vertical axis of the protein,
it is unlikely that CS-E engages with another molecule of EphB3 at the predicted high-
affinity binding site, as this would presumably force the intracellular domains of the
protein too far apart to achieve activation. Interestingly, docking also identified a low-
affinity CS-E-binding site that interacts with EphB3 in a conformation that would
allow for dimerization of the receptor (Figure 5.7). A similar mode of dimerization
has been proposed for the Eph proteins based on the crystal structure of the ephrin-
A5-EphA2 complex.441 Therefore, it is possible that CS-E is sufficient to activate
EphB3 signaling, consistent with the stripe assay data.
5.6 EphB3 is Required for Chondroitin Sulfate-E-
Mediated RGC Guidance
Given the strong, specific interaction between EphB3 and CS-E, the EphB3 expression
pattern in the retina congruent with the CS-E activity profile, and the convergence to
the same downstream signal transducers for both molecules, we reasoned that EphB3
may act as a receptor for CS-E. Indeed, both RPTPσ and NgR have been shown to af-
fect repulsive guidance via a direct interaction with CS-E in other contexts.41,59,60 To
test whether EphB3 is required for CS-E-induced axonal guidance, we compared the
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Figure 5.8: EphB3 is required for CS-E-induced RGC guidance. Stipe assays with alter-
nating stripes of a mixture of CS-E and laminin (red) and laminin (black) alone showed
that E14–15 mice retinal explants displayed a preference for laminin-only stripes only for
EphB3+/+ and EphB3+/− mice. EphB3−/− littermates had significantly less preference for
the laminin-only stripe. **p < 10−5.
propensity of RGC axons from wild-type (WT, EphB3+/+), EphB3+/− or EphB3−/−
mice to be repelled by CS-E using stripe assays. RGC axons from WT and EphB3+/−
mice strongly avoided stripes containing CS-E polysaccharides (coefficient of choice
= 0.68 and 0.67, respectively; p < 5× 10−7; n = 12, 10) and displayed graded behav-
ior along the DV axis, as observed in chicks (Figure 5.8 and 5.15). Importantly, RGC
axons from EphB3−/− mice had no apparent preference for either laminin or CS-E
polysaccharides plus laminin, readily crossing into CS-E-containing stripes (coefficient
of choice = 0.02, n.s., n = 11; Figure 5.8). These results indicate that CS-E-induced
axon guidance requires EphB3. Collectively, the data gathered in vitro strongly sug-
gest that CS-E may be involved in mapping DV retinal axons along the LM axis of
the SC.
5.7 Chondroitin Sulfate E is Required for Retino-
topic Mapping
EphB receptors and their ephrin-B ligands are the only guidance cues that have been
demonstrated to preserve the dorsal-ventral neighbor relationships in the projecting
retinal axons along the LM axis of the receiving neurons in the SC.287,290,320 However,
the action of ephrin-B1 acting either solely as an attractant or solely as a repellent
through the EphBs is not sufficient to explain the bidirectional interstitial branching
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in the SC observed in wild-type and EphB-deficient mice,320 suggesting the existence
of an additional guidance cue. Ephrin-B1 has been shown to have repellent activity
at high concentrations,324 but it remains unclear if the repellent activity of ephrin-B1
is sufficient to achieve proper mapping. Similarly, a Wnt3 gradient in the SC has been
implicated as a repellent LM guidance cue through Ryk.370 Unfortunately, both of
these repellent activities were demonstrated by ectopically overexpressing ephrin-B1
or Wnt3 in the chick OT, or a dominant-negative Ryk in the retina. Therefore, the
extent to which either of these repellent cues affect mapping in vivo remains unclear.
To determine whether CS-E might serve as a repulsive guidance cue in vivo, we
first investigated the spatiotemporal expression of CS-E in the SC. Experimental and
modeling studies have shown that a repulsive guidance cue expressed from low to
high along the LM axis of the SC is required to account for mapping in wild-type and
mutant mice.320 We employed immunohistochemistry to probe for CS-E expression,
instead of using in situ hybridization to detect the presence of the relevant sulfotrans-
ferases, because we are interested in determining when the actual motif is displayed
at the cell surface. CS-E expression was not observed during embryonic development
when RGC axons are growing into the SC (E18.5). By contrast, strong, graded CS-E
staining was observed along the LM axis of the SC in P3 mice, and CS-E levels in-
creased by over 50% traveling medially from the lateral SC (Figure 5.9A and C). At
this stage, RGC axons have formed interstitial branches directed toward an emerging
TZ. Lower levels of CS-E expression were observed as development progressed. By
P5, expression of CS-E was dramatically reduced, until it was no longer apparent
at P8, at which point RGC axons have converged to form a discrete TZ.320 These
results indicate that graded expression of CS-E is present in the SC at the relevant
developmental stage and in the appropriate pattern to participate in LM mapping.
In the SC, the spatiotemporal expression of CS-E seems important. CSPGs are
expressed in the SC before birth. In fact, a proteoglycan from neonatal rat SC positive
for CS-A and CS-C was shown to promote outgrowth in neonatal rat RGCs.415,416 In
contrast, we found that the inhibitory CS-E motif is not expressed in the neonatal SC.
CS-E does not seem to be expressed in the SC until after the RGC axons have invaded,
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Figure 5.9: CS-E is required for normal retinotopic mapping. (A) Focal DiI injection in
the TV retina of P8 Nestin-Cre−;Chst11 lx/− (Chst11 Ctl) mice labels a discrete termination
zone (TZ) in the contralateral superior colliculus (SC). At P3, CS-E expression (green) is
graded from low to high along the lateral-medial (LM) axis of the P3 SC. Axonal tracing of
Nestin-Cre+;Chst11 lx/− (Chst11 cKO) mice indicate abnormal termination of RGC axons.
Focal injection of DiI in the TV retina of P8 mice labeled a TZ in the correct location
of the SC but also an ectopic TZ (eTZ) positioned medial to the correct TZ. At P3, little
observable CS-E staining was observed in cKO mice. Similarly, Chst15−/− mice have defects
in retinotopic mapping, with medial eTZs similar to cKO mice and apparent loss of CS-E
expression in the P3 SC. (B) CS-E sulfation requires the action of two sulfotransferases.
Chst11 sulfates the 4-O position of the galactosamine monomer (gray circle) to give CS-
A. Chst15 then sulfates CS-A motifs at the 6-O position of galactosamine. Sulfation and
glucuronic acid are represented as red and orange circles, respectively. (C) Quantification
of the CS-E expression gradient in the P3 SC in Ctl, cKO and Chst15−/− mice. (D)
The frequency of animals with an ectopic TZ at P8 by genotype. The number of cases is
noted above each bar. The aberrant phenotype in cKO and Chst15−/− mice is significantly
different than Ctl or Chst15+/−(p < 1.2× 10−5 and 2.8× 10−4; Chi-square).
and it is mainly present during RGC arborization and branching.320 Furthermore,
the low-to-high graded expression of CS-E along the LM axis is significant because
EphB2;EphB3 double KO mice show that a low-to-high repulsive LM cue is required
to explain the homing behavior of interstitial branches from axons, specifically those
originating from the ventral part of the retina. The portion of these axons that project
to the medial SC must direct these branches laterally toward the nascent TZ. This
could be mediated by their higher EphB3-mediated susceptibility to the repulsive
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CS-E, more heavily present in the medial collicular areas. An axon from the same
retinal location projected into the lateral retina would not experience significant CS-
E-mediated repulsion, and instead, interstitial branches would be guided medially due
to the attractive ephrin-B1 gradient. Consistent with this role, previous studies have
shown that CSPG activity is concentration dependent and that low concentrations of
CSPG do not affect axon guidance.308
To determine whether CS-E is required for retinotopic mapping, we used two
mouse lines deficient in CS-E biosynthesis, Chst11−/− and Chst15−/−.125,442 Chst11−/−
mice lack the 4-O-sulfotransferase required for the biosynthesis of CS-A,111,120,442 the
biosynthetic precursor to CS-E, while Chst15−/− mice lack the 4-sulfate 6-O-sulfo-
transferase that converts CS-A to CS-E (Figure 5.9B, see also, Section 1.3.1).125 As
constitutive deletion of Chst11 is perinatal lethal, we generated a neuron-specific
conditional Chst11 knockout line (Nestin-Cre+;Chst11lx/−, Chst11 cKO) by cross-
ing Chst11 lox mice with Nestin-Cre mice.443 Levels of Chst11 expression positively
correlate with CS-E disaccharide content,444 and the CS-E motif is undetectable in
Chst15-null mice.125 Both Chst11 cKO and Chst15−/− mice appeared normal, with-
out any obvious developmental defects to the brain or visual system. As expected,
these mice showed little detectable expression of CS-E at P3 (Figure 5.9A and C),
confirming that genetic manipulation of CS-E biosynthetic genes leads to ablation of
CS-E expression in the SC.
To visualize the effect that loss of CS-E has in retinotopic mapping, a subpopu-
lation of RGC cells in the ventral-temporal quadrant of the retina was labeled with
a focal injection of the fluorescent retrograde axon tracer DiI in P7–P9 mice (Fig-
ure 5.9A). Similar labeling studies have been successfully performed to identify RGC
guidance cues.316,317,320,321 After 24 hours, labeled mice were sacrificed and the reti-
nas and SCs dissected, flat-mounted, and analyzed by fluorescence microscopy. For
all genotypes, axons exited the retina and entered the SC normally (Figure 5.16).
No differences in the distribution of axons across the LM axis at the anterior border
of the SC were observed. In all cases, the labeled RGC axons converged to form a
TZ in the expected location in the SC (Figure 5.9A and 5.17A). As expected,320 the
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Figure 5.10: Diversity of ectopic TZ phenotype in Nestin-Cre+;Chst11 lx/− (cKO) and
Chst15−/− mice. (A) The diversity of phenotypes in Chst11 cKO and Chst15−/− mice:
(i, v) Extreme phenotype, a distinct eTZ clearly separated from the main TZ located in
the extreme medial SC (n = 4 and 5); (ii, vi) disjointed TZ where it appears that the TZ
segregates into two regions (n = 4 and 2); (iii, vii) disjointed TZ with an eTZ appearing to
bud off medial to the main TZ (n = 3 and 1); (iv, viii) no apparent eTZ (n = 2 and 3).
These were scored as Ctl phenotype in Figure 6D. Branches of axons extending medially
from the TZ (arrowheads) are apparent in many cKO and Chst15−/− mice. (B) Normalized
position and size of eTZs in cKO (green shades) and Chst15−/− mice (blue shades) with
respect to the correct TZ, represented as a black circle. (C–E) Boxplots of the distance of
the eTZ from the TZ (C), the angle of the TZ with respect to the LM axis (D), and the
relative area of the eTZ compared to the correct TZ for Chst11 cKO (11) and Chst15−/−
(15) mice.
labeled RGCs from Nestin-Cre−;Chst11 lx/− (Chst11 Ctl), WT, and Chst15+/− mice
(n = 17, 10, and 16, respectively) labeled in the VT retina produce a single, dense
TZ in the anterior SC. However, mice lacking Chst11 or Chst15 often displayed an
ectopic TZ (eTZ) that was skewed medially to the main TZ (Figure 5.9A). Labeled
axons in Chst11 cKO and Chst15−/− mice (n = 11 and 13, respectively) resulted in
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a similar TZ in all cases and an ectopic TZ in 84% and 72% of the animals tested
(Figure 5.9D). Interestingly, TZs of axons from the nasal-dorsal portion of the retina
were not significantly affected by the loss of CS-E sulfation, even in animals with eTZs
from temporal-ventral axons (Figure 5.17B). Presumably, low expression of EphB3
makes dorsal axons less sensitive to CS-E, consistent with our in vitro findings.
While the ectopic TZs were always positioned medial to the correct TZ, there was
some variation in its location along the anterior-posterior (AP) axis and its distance
from the correct TZ (Figure 5.10). In some cases (n = 4 for Chst11 cKO, n = 5 for
Chst15−/−), the ectopic TZ was distinct and separated from the correct TZ by as
much as 650 µm. In other cases (n = 4 for Chst11 cKO, n = 2 for Chst15−/−), a
distinct ectopic TZ was positioned immediately medial to the correct TZ, resulting in
a disjointed appearance. The phenotype was sometimes less severe (n = 3 for Chst11
cKO, n = 1 for Chst15−/−), with an ectopic TZ appearing closer to the main TZ.
Lastly, some cKO mice (n = 2 for Chst11 cKO, n = 3 for Chst15−/−) did not have
an apparent ectopic TZ. In the less severe phenotypes, branches of axons extend-
ing medially from the TZ were often observed (Figure 5.10A). The eTZs for either
sulfotransferase mutant had similar distributions in size and position (Figure 5.10B–
E). The observed phenotypes indicate that CS-E is required for proper formation of
retinotopic maps.
Interestingly, although the Chst11 knockout is more severe in terms of loss of CS
sulfation, both sulfotransferase knockout animals display similar phenotypes, suggest-
ing that CS-E sulfation in particular, and not merely sulfation in general, is required
for activity. This is consistent with our in vitro data in which CS-E is uniquely active
with respect to the other major CS sulfation motifs.
5.8 Discussion
The determination of axonal topographic mapping mechanisms on a molecular level
along the LM axis remains less defined than along the AP axis. Only in the last
several years have specific molecules been implicated in DV mapping (see Chapter
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4). Only the EphB family of receptors, and the ephrin-B family of ligands have
been shown to be required for normal LM mapping.287,320,324,369 In mice, using an
EphB2 and EphB3 double-knockout, evidence suggests that forward signaling through
the EphB receptors is responsible for medially directing axonal connections to their
TZs.320 In this context, ephrin-B1 seems to act as an attractant. Modeling studies
suggest that the attractant activity of ephrin-B1 must cooperate with a repulsive
activity expressed in a gradient that resembles that of ephrin-B1 in order to explain
the double-knockout phenotype.320 CS-E is expressed in a similar low-to-high LM
gradient as ephrin-B1, and might require EphB3 as a receptor to act as a repulsive
guidance cue. While there is some evidence to suggest that ephrin-B1 may have a
concentration-dependent bifunctional effect, attractive at lower concentrations and
repulsive at higher concentrations to axons from ventral retinal origin,324 mapping in
the visual system is remarkably redundant, and CS-E may complement the role of
ephrin-B1 in the SC.
In fact, the data seems to support a mechanism that employs both ephrin-B1 and
CS-E to affect repulsive guidance in the medial SC. If CS-E were entirely responsible
for repulsive guidance from the medial SC, we would expect the eTZ to be positioned
further in the medial SC than we observed. Instead, the eTZ was positioned in the
far medial SC in only a few cases in the CS-E deficient mice. The median distance
of the eTZ was only 185–350 µm compared to a maximal distance of ∼650 µm. This
relatively modest shift of the eTZs in CS-E-null mice may be due to the functional
redundancy of the inhibitory effect of high ephrin-B1 concentrations in the medial
SC. Indeed, the data suggest that CS-E and ephrin-B1 may cooperate to repel axons
from the medial SC. Therefore, our findings are consistent with those of McLaughlin,
et al.,324 but suggest that ephrin-B1 repulsive guidance alone is not sufficient for
proper map formation. Repulsive guidance through Wnt3-Ryk may also contribute
to mapping along this axis.370 It is unclear how loss of CS-E may affect this activity.
On the one hand, Wnt3 has been shown to interact with CS-E, and Chst11 modulates
Wnt3 activity.217 On the other hand, HS or other GAGs may functionally compensate
for the loss of CS-E sulfation, as morphogenic defects would be expected with loss
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Figure 5.11: Directional guidance of interstitial branching of RGC axons along the LM
axis of the OT/SC depends on gradients of EphB/ephrin-B. However, ephrin-B1 acting as
either an attractant or a repellent alone cannot explain the wild-type phenotype. Ephrin-
B1 acting with both attractive and repulsive guidance activity could potentially explain the
phenotype in both wild-type and EphB-null animals. CS sulfotransferase mutants show that
ephrin-B1 alone is not sufficient for LM mapping, but still may have bifunctional guidance
activity. A mechanism consistent with all of the data is that CS-E and ephrin-B1 cooperate
to repel RGC axons from the medial OT/SC.
of Wnt3 signaling.445 In any case, the data presented here seems to indicate that an
additional, short-range repulsive guidance cue also affects mapping along this axis.
Together, our data suggest a mechanism where interstitial branches of RGC ax-
ons are repelled from the medial SC by the presence of a low-to-high LM gradient
of CS-E, which may induce forward signaling in EphB3. This action complements
EphB/ephrin-B1 forward signaling, which is possibly also repulsive in the medial
SC.324 There are numerous other examples of redundant molecular mechanisms act-
ing in the same direction along the more highly understood AP axis.290,377 Supporting
this mechanism, CS-E activity is graded from low to high along the DV axis of the
retina, therefore the CS-E receptor must be expressed along the same gradient. It
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is unlikely that other secreted protein factors, such as BDNF or Wnt3,344–346,370 are
required for the interaction, otherwise, we would see a distance dependence on guid-
ance activity as the axons extend beyond the explant.429,430 Therefore the ligand
probably interacts with CS-E directly. This is not unprecedented, as cell-surface re-
ceptors such as RPTPσ or NgR have been shown to induce signaling upon binding
to CS-E.58–60 EphB3 is expressed in the appropriate retinal gradient and binds CS-
E specifically and with physiologically relevant affinity, further supporting the idea
that CS-E interacts directly with the EphB3 receptor. Most importantly, EphB3
is required for CS-E induced guidance, based on the EphB3 KO stripe assay data.
Therefore, the minimum mechanism to account for the role of CS-E in retinotopic
mapping is that CS-E directly induces EphB3 forward signaling resulting in repulsive
guidance of interstitial branches of ventral axons in the medial SC.
5.9 Conclusion
Establishing a role for chondroitin sulfate in axonal guidance has proven elusive. De-
spite having discovered that CSPGs were capable of guiding RGC axons over twenty
years ago, little was understood about its role in retinal development. Here, we have
shown that sulfated CSPGs are required for retinotopic mapping. By examining the
role of sulfation in guidance, we were able to show that a particular sulfation motif,
CS-E, retains the guidance activity of the CSPG while the other common sulfation
motifs, CS-A, CS-C, and CS-D show no apparent activity. Importantly, we have
shown that the activity is graded along the dorsal-ventral axis of the retina. We have
shown that CS-E binds with physiologically relevant affinity to EphB3, an important
guidance molecule with graded expression along the DV axis. EphB3−/− RGC cells
were not guided by CS-E, suggesting a role in mapping. The suggestion was con-
firmed using axonal tracing studies that showed that CS-E-null mice have defects in
mapping.
These results demonstrate a new role for CSPGs, which are commonly thought
to act as a simple blockade through which axons cannot cross. While CSPGs in-
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deed have this effect on regenerating axons after nerve injury,41,47–50 the expression of
CS throughout the retinotectal system precludes this simple mechanism. Others have
shown that exogenous CSPGs can influence guidance towards the OT/SC,446–448 how-
ever, the challenges of studying CSPGs in vivo have hampered significant progress.
Only by examining specific sulfation sequences, were we able to bring the appropri-
ate tools to bear in order to study this problem. As a result we have shown that
CS-E is a necessary guidance molecule for the normal development of the visual sys-
tem. This is the first demonstration of a role for a non-protein molecule influencing
topographic guidance and adds to mounting evidence that GAGs are sophisticated
signaling molecules with diverse roles in vivo.
5.10 Materials and Methods
5.10.1 Animals
Conditional knockout of the Chst11 gene in mice was obtained using Chst11−/− and
Chst11 lx/lx mice provided by from Dr. Melitta Schachner. These mice were crossed
with Chst11−/− mice, and the Chst11 lox/− progeny were further crossed Nestin-Cre+/−
mice to obtain breeding pairs with Nestin-Cre+/−;Chst11lx/− genotype. EphB3−/−
mice were a gift from Dr. Mark Henkemeyer, and Chst15 KO mice were a gift from
Dr. Osami Habuchi.
5.10.2 Immunohistochemistry
The heads of embryo from E5–E7.5 chicken or E18.5 mice were fixed in a solution
of 4% paraformaldehyde containing 10% sucrose. Whole brains from P0 and older
mice were dissected before fixation. After fixation, the samples were placed in 20%
sucrose for 12 hours before sectioning. 20 µm transverse sections of the optic tract,
or coronal sections of the retina, were mounted on glass slides. The samples were
exposed to 10% FBS in PBS for 1 h at room temperature before staining for 3 h at
room temperature with anti-CS-E (1:250 in 10% FBS in PBS) alone, or with anti-
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GAP43 (1:500), anti-Islet1 (1:50), or anti-CS-C (1: 250). The antibody was removed
and the samples were washed five times with PBS before treatment with secondary
antibody. The samples were treated with an Alexa Fluor 488 anti-mouse antibody
(1:500 in 10% FBS in PBS) when treated with anti-CS-E alone, Alexa Flour 488 anti-
mouse (1:500) and Alexa Fluor 564 anti-rabbit (1:500) when treated with anti-CS-E
and anti-GAP43, or Alexa Fluor 488 anti-mouse IgG3 (1:500) and Alexa Fluor 564
anti-mouse IgG1 (1:500) when treated with anti-CS-E and anti-Islet1 or anti-CS-C.
After 1 h, the samples were washed five times with PBS, treated with vectashield and
sealed with a coverslip. The samples were then imaged using confocal microscopy.
Images were analyzed using ImageJ.
5.10.3 Stripe Assay
Coverslips for the stipe assay were prepared by incubating sterilized 22 × 22 mm
coverslips with poly-dl-lysine (0.1 mg · ml−1 in 50 mM borate buffer, pH 10) for 1
h at 37 ◦C. The coverslips were washed three times in sterile PBS and twice with
sterile water and were allowed to dry in a tissue culture hood. Each dry coverslip
was carefully placed onto a 25 × 25 × 5 mm silicon microfluidic device featuring a
10 × 10 mm region etched with a series of 50 µm parallel channels separated from
each other by 50 µm connected by an inlet and outlet. The inlet of the device was
connected to a reservoir containing the printing solution (0–20 µg ·ml−1 chondroitin
sulfate polysaccharide, 10 µg ·ml−1 laminin, 10 µg ·ml−1 BSA-488, 0.05% Tween 20
in PBS) and the outlet connected to a syringe pump that drew the solution over
the surface of the coverslip at a rate of 0.05 ml · h−1 overnight. The coverslips were
gently removed from the microfluidics device, and washed three times with PBS,
then incubated with laminin (10 µg · ml−1 in PBS) for 2 h at 37 ◦C. The coverslips
were washed three times with PBS and placed in culture dishes containing the media
(DMEM/F12 supplemented with 0.4% methylcellulose, 6.5% FBS, 6.5% chick serum,
2 mM l-glutamine, 100 U ·ml−1 penicillin, and 100 U ·ml−1 streptomycin for chick
explants, or F12 supplemented with 0.4% methylcellulose, 10% FBS, 2% chick serum,
1× B-27, 2 mM l-glutamine, 100 U ·ml−1 penicillin, and 100 U ·ml−1 streptomycin
141
for mouse explants)449 and incubated at 37 ◦C in an atmosphere enriched with 5%
CO2 while the retinal explants were prepared.
Retina from E7 chick embryo or E14 mouse embryo were dissected in HBSS con-
taining calcium and magnesium (Invitrogen), and flat-mounted on to a sterile nitro-
cellulose membrane (Pall Corporation). In our hands, young mouse embryos were
required to achieve sufficient axonal growth. Consistent with previous studies, the
use of older embryo resulted in sparse growth.449 The retinas were sectioned along
the DV axis into 150 µm strips using a tissue chopper (McIlwain). A strip of retinal
tissue from the nasal and temporal portions of the retina were placed on the cover-
slips perpendicular to the direction of the stripes and held in place by sterilized rods
(stainless steel, 2 × 2.5 × 12 mm). The explants were incubated for 1–2 days at 37
◦C in an atmosphere enriched with 5% CO2 before the tissue was fixed by adding a
solution of 2% gluteraldehyde in 10% sucrose in PBS directly into the media. After 2
h at ambient temperature, the coverslips were washed three times in water, and then
allowed to dry for ten minutes. Axons were labeled by incubating the coverslips with
a solution of rhodamine B isothiocyanate (0.1 mg · ml−1 in PBS) for 10 min. The
coverslips were washed three times with PBS, once with 70% ethanol for one minute,
and once with 100% ethanol for 1 min, then allowed to dry. The coverslips were then
mounted on glass slides with vectashield, sealed with nail polish, and imaged using
confocal microscopy.
Microarrays were analyzed using a modified Sholl intersection assay.334,428 The
number of pixels associated with axons was quantified for each set of stripes at 100
µm intervals away from the explant up to a distance of 900 µm using custom software
written in C (Section 5.11.2). The coefficient of choice, c, is given by
c =
TC − TE
TC + TE
(5.1)
where TC is the total number of pixels on the control (laminin-only) stripes and TE
is the total number of pixels on the experiment (CS-positive) stripes. A coefficient of
choice of one represents a complete preference for the control stripes, a value of zero
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represents no preference, and negative one represents a complete preference for the
experiment stripes.
5.10.4 Carbohydrate Microarrays and EphB Surface Plasmon
Resonance
Microarrays were prepared and performed as previously described (Chapter 3 and
Appendix A).219,437 Briefly, a perimeter was drawn around the printed region of a
microarray with a hydrophobic marker (PapPen). The array was then incubated
with 10% FBS in PBS for 1 h at 37 ◦C. The solution was removed and a 2 µM
solution of EphB2-Fc or EphB3-Fc (R & D Systems) in 1% FBS in PBS was added to
the printed region. After 3 h, the protein solution was removed and the microarray
was washed five times with PBS. Bound protein was labeled by incubating the array
with a solution of Cy3-conjugated anti-human Fc IgG (1:5000 in 1% FBS in PBS)
for 1 h. The arrays were washed three times with PBS, twice with water, the dried
under gentle stream of air before being analyzed using a fluorescent array scanner.
Biotinylated CS-E or CS-C was attached to a Biacore CM5 sensor chip as pre-
viously described (Appendix B).439 EphB2-Fc or EphB3-Fc (R & D Systems) were
passed over the surface of the chip at a flow rate of 80 µl · min−1 for 240 s. The
bound protein was allowed to dissociate for 600 s before the surface of the chip was
regenerated with a 30 s pulse of 1 M MgCl2.
5.10.5 Homology Modeling
The human EphB2 model was constructed for the sequence corresponding to protein
residues 20–529 by using the 2.3 Å resolution structure for human EphB2 (PDB:
2QBX)440 for protein residues 20–194 and combining it with a homology structure for
residues 195–529 based on a lower resolution (4.3 Å) human EphA2 structure (PDB:
2X11).441 This required aligning the 2QBX structure to the full 2X11 homology
structure and extracting residues 195–529 to attach to the 2QBX structure. This was
followed by minimizing hinge residues 192–197 using the Dreiding force field while
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keeping all other residues fixed and then minimizing all the residues. The human
EphB3 model was constructed for the sequence corresponding to protein residues
39–544 by using the 2.1 Å resolution structure for human EphB3 (PDB: 3P1I) for
protein residues 39–209 and combining it with a homology structure for residues 210–
544 based on human Ephrin type-A receptor 2 (EphA2) structure (PDB: 2X11). This
required aligning 3P1I structure to the full 2X11 homology structure and extracting
residues 210–544 to attach to 3P1I structure.450 This was followed by minimizing
hinge residues 207–212 using the Dreiding force field while keeping all other residues
fixed and then minimizing all the residues.
Using CS-A hexasaccharide (PDB: 1C4S) as a template for the carbohydrate back-
bone,214 a dodecasaccharide was prepared using Maestro. The sulfation pattern was
modified to that of CS-E. Ligand conformations were sampled using MacroModel with
the sugar backbone fixed. Mulliken charges were then generated for the lowest energy
structure using Jaguar (B3LYP/6-31G**). Using these charges, all structures passing
the 10 kcal · mol−1 energy cutoff (OPLS_2005 force field, water solvent) were then
minimized again using MPSim and Dreiding force field (100 steps, no solvation).451
The lowest energy conformation was selected for molecular dynamics.
Molecular dynamics on the CS-E dodecasaccharide was performed using NAMD
with AMBER force field.452 The sugar was placed in a water box with 12 Å cutoffs
and sodium counterions using tleap. Relaxation of the system was performed in four
steps: minimization of water and counterions for 5000 steps, 0.5 ns of dynamics of
water and counterions, minimization of the complete system for 5000 steps, and 5 ns of
dynamics of the complete system. The trajectory of the final dynamics was analyzed,
and the structure closest to the average of the trajectory was selected. To generate
an octasaccharide, two sugars were removed from each end of the dodecasaccharide.
Charges were prepared for the resulting structure using Jaguar, and the structure was
minimized to 0.25 (kcal ·mol−1)/Å RMS force.
144
5.10.6 EphB3 Docking
Alanized EphB structures, in which Val, Leu, Ile, Phe, Tyr, Trp, and Met residues
were converted to Ala, were prepared from the homology model. Regions for docking
were determined for the protein using the standard DOCK/sphgen approach with
parameters modified for protein surface docking.453 Starting with the center of mass
of the generated spheres, the spheres were placed into 20 × 20 × 20 Å boxes with
5 Å overlap between the boxes until all of the spheres were placed into boxes. The
electrostatic potential surface of each protein was determined using APBS using the
non-alanized structure.237 Due to the strong negative charge of CS ligands, regions
with the largest number of positively charged spheres were selected for docking. The
spheres in the selected boxes were thinned using clustering until the number of spheres
was less than 150 per box.
Docking of the CS-E tetra- or octasaccharide to the alanized EphB proteins in the
selected sphere regions was performed using DarwinDock, a program that thoroughly
samples a binding site through repeated cycles of pose generation with DOCK6 and
ligand clustering.453 The sampling is determined to be “complete” when the percent
of new clusters, is less than a given value. At this point, the center pose of each cluster
is evaluated using MPSim and Dreiding force field.451 The clusters were ranked by
binding energy, and all of the members of the 10% of families with the lowest energies
are scored again with MPSim and Dreiding. The 120 poses with the lowest energy
from this set are then analyzed further.
The nonpolar residues of these structures removed during alanization were re-
placed using the sidechain optimization program SCREAM.253 The residues in the 5
Å-binding site were optimized simultaneously with SCREAM. The optimized struc-
tures were then minimized for 10 steps using MPSim and the Dreiding force field.
The structures were ranked using the single-point energy of the complex minus the
single-point energies of the isolated protein and isolated ligand. Half of the structures
were kept based on this binding energy. The structures were then minimized for an
additional 25 steps and were re-scored. Comparison of the binding energies across the
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different ligand poses in the different regions identified the preferred CS-E binding
site in EphB3.
5.10.7 Axonal Tracing
Pulled glass needles were coated with a solution of DiI (5 mg ·ml−1 in ethanol) and
allowed to dry. The needle was then inserted into the temporal-ventral quadrant of
the eye of an anesthetized P8 mouse. After 24 h, the mouse was euthanized and the
retina and the superior colliculus were dissected, the retina was flat-mounted, and the
tissue fixed in 4% paraformaldehyde. The retina was examined under fluorescent and
light microscopy, and the superior colliculus was examined with confocal microscopy.
Images were analyzed using ImageJ.
5.11 Supporting Information
5.11.1 Supporting Figures
D V 
Figure 5.12: The repulsive RGC axon guidance-activity gradient of CS-E visualized in
a single retinal strip. Four images from a stripe of tissue from the temporal E6.5 chicken
retina, located near the middle of the DV axis. Here, the repulsive guidance activity of CS-E
(red stripes) increases for axons (green) traveling from the dorsal to the ventral sides of the
retina.
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Figure 5.13: Coarse-level docking reveals an energetic difference between EphB2 and
EphB3 binding to CS-E. (A) Simple rigid docking (DarwinDock) of CS-E onto EphB3 finds
several 20 Å regions of the protein with favorable interaction energy scores. (B) Allowing
the protein side chain atoms in the binding site (SCREAM) to move improves the absolute
energy scores for most of the sites, but the relative difference between EphB2 and EphB3
binding is consistent with A. (C) Neutralizing the charges of the ligand and the protein
return unrealistic differences in binding energy between EphB2 and EphB3, highlighting
the importance of charge in CS binding. (D) The top ten regions of EphB3 identified in
A–C are depicted as differently colored regions on the surface of the protein represented by
its electrostatic potential surface. Note that the top binding regions correlate with highly
electropositive regions of the protein.
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Figure 5.14: Preliminary docking with CS-E tetrasaccharides suggests two potential CS-
binding sites. (A) Binding energies for CS tetrasaccharide poses docked to different regions
of EphB3 (labeled with an arbitrary numerical value prefixed by the letter “r”). The four
lowest-energy poses (r39, r30, r11, and r19) make up two distinct potential binding sites on
the protein (B). (B) The lowest-energy pose for every region in A. The size of the label is
proportional to the absolute binding energy of the pose. The color of the label corresponds
to the color of the carbon atom of the tetrasaccharide.
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Figure 5.15: Wild-type mice also display dorsal-ventral differences in CS-E-mediated guid-
ance activity. Ventral axons show a strong preference for laminin stripes compared to dorsal
axons.
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Figure 5.16: Axonal guidance from the retina was unaffected by genotype. Both Chst11-
and Chst15-deficient mice had normal RGC axon guidance out of the retina.
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Figure 5.17: (A) Wild-type and heterozygous Chst15 mice do not have mutant phenotype.
(B) Dorsal axons from Chst15−/− mice do not have a mutant phenotype, but ventral axons
from the same animal have an eTZ (arrowhead). These examples are typical.
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5.11.2 Stripe Assay Analysis Source Code
5.11.2.1 jpegio.h
1 //
2 // jpegio.h
3 // edge_detect
4 //
5 // Created by Claude Rogers on 7/7/11.
6 // Copyright 2011 California Institute of Technology. All rights reserved.
7 //
8
9 # include <stdio.h>
10 # include <stdlib.h>
11 # include <jpeglib.h>
12 # include <setjmp.h>
13
14 # define IMAGE_HEIGHT 512
15 # define IMAGE_WIDTH 512
16 # define ROW_STRIDE (512*3)
17
18 struct my_error_mgr {
19 struct jpeg_error_mgr pub;
20 jmp_buf setjmp_buffer;
21 };
22
23 typedef struct my_error_mgr * my_error_ptr;
24
25 METHODDEF(void)
26 my_error_exit(j_common_ptr cinfo);
27
28 GLOBAL(int)
29 read_JPEG_file(char * filename, JSAMPLE *image_data,
30 int analyze_only, int r_thrs, int g_thrs);
31
32 GLOBAL(void)
33 write_JPEG_file (char *filename, int quality, JSAMPLE *image_buffer);
5.11.2.2 jpegio.c
1 //
2 // jpegio.c
3 // edge_detect
4 //
5 // Created by Claude Rogers on 7/7/11.
6 // Copyright 2011 California Institute of Technology. All rights reserved.
7 //
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8
9 # include "jpegio.h"
10
11 METHODDEF(void)
12 my_error_exit(j_common_ptr cinfo)
13 {
14 my_error_ptr myerr = (my_error_ptr) cinfo->err;
15
16 (*cinfo->err->output_message) (cinfo);
17 longjmp(myerr->setjmp_buffer, 1);
18 }
19
20 GLOBAL(int)
21 read_JPEG_file(char * filename, JSAMPLE *image_data,
22 int analyze_only, int r_thrs, int g_thrs)
23 {
24 struct jpeg_decompress_struct cinfo;
25 struct my_error_mgr jerr;
26
27 FILE *infile;
28 JSAMPARRAY buffer;
29 int row_stride;
30
31 if ((infile = fopen(filename, "rb")) == NULL) {
32 fprintf(stderr, "can’t open %s\n", filename);
33 return 0;
34 }
35
36 cinfo.err = jpeg_std_error(&jerr.pub);
37 jerr.pub.error_exit = my_error_exit;
38
39 if (setjmp(jerr.setjmp_buffer)) {
40 jpeg_destroy_decompress(&cinfo);
41 fclose(infile);
42 return 0;
43 }
44
45 jpeg_create_decompress(&cinfo);
46
47 jpeg_stdio_src(&cinfo, infile);
48
49 (void) jpeg_read_header(&cinfo, TRUE);
50
51 (void) jpeg_start_decompress(&cinfo);
52
53 row_stride = cinfo.output_width * cinfo.out_color_components;
54
151
55 buffer = (*cinfo.mem->alloc_sarray)
56 ((j_common_ptr) &cinfo, JPOOL_IMAGE, row_stride, 1);
57
58 while (cinfo.output_scanline < cinfo.output_height) {
59 int y, i, j;
60 unsigned char r, g, b;
61 y = cinfo.output_scanline;
62 (void) jpeg_read_scanlines(&cinfo, buffer, 1);
63 for (i = 0; i < cinfo.output_width; i++) {
64 r = buffer[0][i * 3];
65 r = (r < r_thrs) ? 0 : r;
66 g = buffer[0][i * 3 + 1];
67 g = (g < g_thrs) ? 0 : g;
68 b = buffer[0][i * 3 + 2];
69 j = (y * IMAGE_HEIGHT) + i;
70 image_data[j * 3] = r;
71 image_data[j * 3 + 1] = g;
72 if (analyze_only) {
73 image_data[j * 3 + 2] = b;
74 } else {
75 image_data[j * 3 + 2] = 0;
76 }
77 }
78 }
79
80 (void) jpeg_finish_decompress(&cinfo);
81
82 jpeg_destroy_decompress(&cinfo);
83
84 fclose(infile);
85 return 1;
86 }
87
88 GLOBAL(void)
89 write_JPEG_file (char *filename, int quality, JSAMPLE *image_buffer)
90 {
91 struct jpeg_compress_struct cinfo;
92
93 struct jpeg_error_mgr jerr;
94
95 FILE *outfile;
96 JSAMPROW row_pointer[1];
97
98 cinfo.err = jpeg_std_error(&jerr);
99
100 jpeg_create_compress(&cinfo);
101
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102 if ((outfile = fopen(filename, "wb")) == NULL) {
103 fprintf(stderr, "can’t open %s\n", filename);
104 (void) exit(0);
105 }
106 jpeg_stdio_dest(&cinfo, outfile);
107
108 cinfo.image_width = IMAGE_WIDTH;
109 cinfo.image_height = IMAGE_HEIGHT;
110 cinfo.input_components = 3;
111 cinfo.in_color_space = JCS_RGB;
112
113 jpeg_set_defaults(&cinfo);
114 jpeg_set_quality(&cinfo, quality, TRUE);
115
116 jpeg_start_compress(&cinfo, TRUE);
117
118 while (cinfo.next_scanline < cinfo.image_height) {
119 row_pointer[0] = &image_buffer[cinfo.next_scanline * ROW_STRIDE];
120 (void) jpeg_write_scanlines(&cinfo, row_pointer, 1);
121 }
122
123 jpeg_finish_compress(&cinfo);
124 fclose(outfile);
125 jpeg_destroy_compress(&cinfo);
126 }
5.11.2.3 edge_detect.h
1 //
2 // edge_detect.h
3 // edge_detect
4 //
5 // Created by Claude Rogers on 7/7/11.
6 // Copyright 2011 California Institute of Technology. All rights reserved.
7 //
8
9 void apply_mask (int mask[3][3],
10 JSAMPLE *image_buffer,
11 JSAMPLE *edge_buffer, int x, int y);
12
13 void detect_edges (JSAMPLE *image_buffer, JSAMPLE *edge_buffer);
14
15 void draw_lines (JSAMPLE *image_buffer, JSAMPLE *edge_buffer);
16
17 void analyze_image (JSAMPLE *image_buffer);
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5.11.2.4 edge_detect.c
1 //
2 // edge_detect.c
3 // edge_detect
4 //
5 // Created by Claude Rogers on 7/7/11.
6 // Copyright 2011 California Institute of Technology. All rights reserved.
7 //
8
9 # include "jpegio.h"
10 # include "edge_detect.h"
11
12 void apply_mask (int mask[3][3],
13 JSAMPLE *image_buffer,
14 JSAMPLE *edge_buffer, int x, int y)
15 {
16 int i, j, min, max, sum, index;
17 min = 0;
18 max = 255;
19 sum = 0;
20 index = 0;
21 for (i = -1; i < 2; i++) {
22 for (j = -1; j < 2; j++) {
23 sum += image_buffer[x+(i*3)+y+(j*ROW_STRIDE)] * mask[i+1][j+1];
24 }
25 }
26 if (sum < 0)
27 sum = 0;
28 if (sum > max)
29 sum = max;
30 if (sum > edge_buffer[x+y] && sum > 250)
31 edge_buffer[x+y] = sum;
32 }
33
34 void detect_edges (JSAMPLE *image_buffer, JSAMPLE *edge_buffer)
35 {
36 int i, x, y;
37 int sobel_mask_0[3][3] = {
38 { 1, 2, 1},
39 { 0, 0, 0},
40 {-1, -2, -1} };
41
42 int sobel_mask_3[3][3] = {
43 { 0, -1, -2},
44 { 1, 0, -1},
45 { 2, 1, 0} };
46
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47 int sobel_mask_7[3][3] = {
48 { 0, 1, 2},
49 {-1, 0, 1},
50 {-2, -1, 0} };
51 int max_x, max_y;
52 max_x = 0;
53 max_y = 0;
54 for (i = 0; i < IMAGE_HEIGHT * ROW_STRIDE; i++)
55 edge_buffer[i] = 0;
56 for (y = (ROW_STRIDE); y < IMAGE_HEIGHT*ROW_STRIDE; y += (ROW_STRIDE)) {
57 for (x = 3; x < ROW_STRIDE; x += 3) {
58 if (x > max_x)
59 max_x = x;
60 if (y > max_y)
61 max_y = y;
62 apply_mask(sobel_mask_0, image_buffer, edge_buffer, x, y);
63 apply_mask(sobel_mask_3, image_buffer, edge_buffer, x, y);
64 apply_mask(sobel_mask_7, image_buffer, edge_buffer, x, y);
65 }
66 }
67 }
68
69 void draw_lines (JSAMPLE *image_buffer, JSAMPLE *edge_buffer)
70 {
71 int i, j, sum;
72 int summary[IMAGE_WIDTH], peaks[IMAGE_WIDTH];
73 for (i = 0; i < ROW_STRIDE; i += 3) {
74 sum = 0;
75 for (j = 0; j < IMAGE_WIDTH*ROW_STRIDE; j+=(ROW_STRIDE)) {
76 sum += edge_buffer[i+j];
77 }
78 summary[i / 3] = (sum / IMAGE_HEIGHT);
79 }
80 for (i = 0; i < IMAGE_WIDTH; i++)
81 peaks[i] = 0;
82 int last_index, last_value, this_value, flag;
83 last_index = 0;
84 last_value = 0;
85 flag = 0;
86 for (i = 0; i < IMAGE_WIDTH-2; i++) {
87 this_value = abs(summary[i+2] - summary[i]);
88 if (this_value > 20) {
89 if (flag) {
90 if (((i - last_index) < 50) && (last_index != 0)) {
91 if (this_value > last_value) {
92 peaks[i] = this_value;
93 peaks[last_index] = 0;
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94 last_index = i;
95 last_value = this_value;
96 }
97 } else if (i > 5) {
98 peaks[i] = this_value;
99 last_index = i;
100 last_value = this_value;
101 }
102 } else {
103 peaks[i] = this_value;
104 flag = 1;
105 last_index = i;
106 last_value = this_value;
107 }
108 }
109 }
110 int x, y;
111 for (y = (ROW_STRIDE); y < IMAGE_HEIGHT*ROW_STRIDE; y+=(ROW_STRIDE)) {
112 for (x = 3; x < ROW_STRIDE; x += 3) {
113 if (peaks[x/3])
114 image_buffer[x+y+2] = 255;
115 }
116 }
117 }
118
119 void analyze_image (JSAMPLE *image_buffer)
120 {
121 int x, y, r, g, b;
122 int g_pix;
123 int flag;
124 int lb;
125 for (y = 100*ROW_STRIDE; y < IMAGE_HEIGHT*ROW_STRIDE; y+=100*ROW_STRIDE) {
126 g_pix = 0;
127 flag = 0;
128 lb = 0;
129 printf("%d:\t", (y / ROW_STRIDE));
130 for (x = 0; x < ROW_STRIDE; x += 3) {
131 r = image_buffer[x + y];
132 g = image_buffer[x + y + 1];
133 b = image_buffer[x + y + 2];
134 if (b == 255) {
135 flag += 1;
136 }
137 if (flag % 2) {
138 if (g) {
139 g_pix++;
140 }
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141 } else {
142 printf("%d\t", g_pix);
143 g_pix = 0;
144 flag++;
145 lb = x;
146 }
147 }
148 printf("%d\n", g_pix);
149 }
150 }
5.11.2.5 main.c
1 //
2 // main.c
3 // edge_detect
4 //
5 // Created by Claude Rogers on 7/7/11.
6 // Copyright 2011 California Institute of Technology. All rights reserved.
7 //
8
9 # include <unistd.h>
10 # include "jpegio.h"
11 # include "edge_detect.h"
12
13 int main (int argc, char * argv[])
14 {
15 int c;
16 char *filename = NULL;
17 char *outname = NULL;
18 int draw_flag = 1;
19 int analyze_only = 0;
20 int green_thrs = 120;
21 int red_thrs = 120;
22
23 opterr = 0;
24
25 while ((c = getopt(argc, argv, "f:o:dar:g:")) != -1)
26 switch (c)
27 {
28 case ’f’:
29 filename = optarg;
30 break;
31 case ’o’:
32 outname = optarg;
33 break;
34 case ’d’:
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35 draw_flag = 0;
36 break;
37 case ’a’:
38 analyze_only = 1;
39 break;
40 case ’g’:
41 green_thrs = atoi(optarg);
42 break;
43 case ’r’:
44 red_thrs = atoi(optarg);
45 break;
46 default:
47 abort();
48 }
49 if (!filename) {
50 fprintf(stderr, "Input filename required\n");
51 return 1;
52 }
53 if (!outname && !analyze_only) {
54 fprintf(stderr, "Output filename required\n");
55 return 2;
56 }
57 JSAMPLE image_data[IMAGE_HEIGHT * IMAGE_WIDTH * 3];
58 JSAMPLE edge_data[IMAGE_HEIGHT * IMAGE_WIDTH * 3];
59 (void) read_JPEG_file(filename, image_data,
60 analyze_only, red_thrs, green_thrs);
61 if (analyze_only) {
62 analyze_image(image_data);
63 return 0;
64 }
65 detect_edges(image_data, edge_data);
66 if (draw_flag)
67 draw_lines(image_data, edge_data);
68 analyze_image(image_data);
69 write_JPEG_file(outname, 100, image_data);
70 return 0;
71 }
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Appendix A
Microarray Method for the Rapid
Detection of Glycosaminoglycan-
Protein Interactions†
A.1 Abstract
Glycosaminoglycans (GAGs) perform numerous vital functions within the body. As
major components of the extracellular matrix, these polysaccharides participate in
a diverse array of cell signaling events. We have developed a simple microarray
assay for the evaluation of protein binding to various GAG subclasses. In a single
experiment, the binding to all members of the GAG family can be rapidly determined,
giving insight into the relative specificity of the interactions and the importance of
specific sulfation motifs. The arrays are facile to prepare from commercially available
materials.
A.2 Introduction
GAGs are a large family of linear polysaccharides that fulfill diverse functions in vivo,
such as joint lubrication and movement,2 cell signaling and development, angiogene-
sis,3 axonal growth,4 viral invasion,454 spinal cord injury,455,456 tumor progression,5,6
†Portions of this chapter were taken from Claude J. Rogers, Linda C. Hsieh-Wilson “Microarray
method for the rapid detection of glycosaminoglycann-protein interactions,” Carbohydrate Microar-
rays: Methods and Protocols, Methods in Molecular Biology, Yann Chevolot (ed.), 2011, vol. 808,
321–336.
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Figure A.1: (A) Structures of glycosaminoglycan family members. Indicated hydroxyl
groups can either be protonated or sulfated (R = H or SO–3). Indicated amino groups can
be either protonated, acetylated, or sulfated (R’ = H, Ac, or SO–3). (B) The common CS
sulfation patterns.
metastasis,5,7 and anti-coagulation.8,9 GAGs are large (typically 10–100 kDa), highly
charged, and heterogeneously sulfated molecules composed of repeating disaccharide
units. Members of the GAG family vary subtly in stereochemistry, length, and sulfa-
tion pattern (Figure A.1A). For instance, chondroitin sulfate (CS), the most abundant
GAG in the body is composed of the repeating disaccharide d-glucuronic acid (GlcA)
and N -acetyl-d-galactosamine (GalNAc). CS is further classified by the sulfation
pattern of its disaccharides, the most common of which are termed CS-A, -C, -D, and
-E (Figure A.1B). Dermatan sulfate (DS), also known as CS-B, differs from CS in the
stereochemistry of the C -5 position of the uronic acid. Heparin and heparin sulfate
(HS) are composed of d-glucosamine (GlcN) and either GlcA or its C -5 epimer l-
iduronic acid (IdoA). The GlcN can either be N-sulfated, protonated, or acetylated.
In general, HS has more GlcA and N-acetylated GlcN then heparin, and heparin has
a much higher charge density and more N -sulfated GlcN than HS. Keratan sulfate
(KS) is composed of d-galactose and N -acetyl-d-glucosamine (GlcNAc) and is the
only GAG that does not contain uronic acid. Hyaluronic acid (HA), the only un-
sulfated GAG, is composed of GlcA and GlcNAc. The chemical diversity of GAGs
is believed to have important functional consequences, enabling a large number of
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protein-binding motifs to be generated from a relatively simple scaffold.163,457 For
instance, HS is important for growth factor signaling, inflammation, and blood co-
agulation,8,9, 458,459 while chondroitin sulfate has been shown to interact with various
growth factors involved in stem cell proliferation, neurogenesis and gliogenesis, and
is a major component of the glial scar, an inhibitory barrier that forms after spinal
cord injury.456,460
A major challenge in understanding GAG function has been the lack of high-
throughput methods to identify protein-GAG interactions. While effective, methods
such as affinity chromatography, electrophoretic mobility shift assays, competition
experiments, mass spectrometry-based approaches, isothermal titration calorimetry,
and surface plasmon resonance are frequently labor intensive and require significant
quantities of carbohydrate and/or protein. Given the diverse structure of GAGs and
the large number of potential protein-binding motifs, a high-throughput approach for
the discovery and study of protein-GAG interactions is needed. Moreover, the highly
anionic character and other structural similarities among GAGs necessitate a method
to compare the relative affinities of proteins for different GAG family members and
for different sulfation patterns within a GAG class.
The recent development of GAG microarrays has enabled many of these chal-
lenges to be addressed.15,16,218,219,247,461 Microarrays allow for the rapid, simultane-
ous detection of multiple protein-GAG binding events and require minimal amounts
of carbohydrate and protein. Methodologies have been developed for studying the
binding of growth factors, cell-surface receptors, and chemokines to sulfated variants
of CS and HS,15,218,247 and for comparing the binding specificities of proteins across
various GAG classes.16,461 Microarrays have been constructed using chemically syn-
thesized CS and HS oligosaccharides, which have the advantage of defined sulfation
patterns,15,218,247 or from naturally occurring polysaccharides.16,461 Here, we describe
a microarray-based approach for the study of protein-GAG interactions that employs
commercially available sugars and simple adsorption to affix the sugars to the array
surface. The microarrays are relatively inexpensive, easy to prepare and enable the
rapid evaluation of protein-binding specificities across the entire GAG family in a
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single assay.
A.3 Materials
A.3.1 Slide Preparation
1. Microslides (25× 75× 1.0 mm) from VWR; West Chester, PA (see Note 1).
2. Phosphate buffered saline (PBS): Prepare 10X stock with 1.37 M NaCl, 27 mM
KCl, 54 mM Na2HPO4, 18 mM KH2PO4, pH 7.4. Dilute 100 mL of 10X stock
with 900 mL water for use (see Note 2).
3. Glass staining dishes with removable racks (105×70×85 mm, Wheaton Science
Products, Millville, NJ).
4. Poly-l-lysine solution: combine 80 mL of 0.1% (w/v) poly-l-lysine solution in
H2O from Sigma-Aldrich, St. Louis, MO with 80 mL PBS and 640 mL water.
5. Etch solution: dissolve 150 g solid NaOH in 600 mL water. Mix in 900 mL of
95% ethanol (see Note 3).
6. Slide Box. Prior to use, blow compressed air into the box to remove any dust
particles.
7. Chondroitin sulfate A, C, D, E from Seikagaku America; Fallmouth, MA, are
dissolved at 500 µM in water and stored at 4 ◦C (see Note 4).
8. Chondroitin sulfate B (known also as dermatan sulfate) from Sigma-Aldrich;
St. Louis, MO, is dissolved 500 µM in water and stored at 4 ◦C.
9. Hyaluronic acid from Sigma-Aldrich; St. Louis, MO, is dissolved at 500 µM in
water and stored at 4 ◦C.
10. Heparin polysaccharides from Neoparin; Alameda, CA, are dissolved at 500 µM
in water and stored at 4 ◦C.
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11. Keratan sulfate from Seikagaku America; Fallmouth, MA, is dissolved at 500
µM in water and stored at 4 ◦C.
12. High Sample Recovery 384-well plate and covers (Genetix; Boston, MA).
13. Microplate Sealing Film (VWR; West Chester, PA).
14. Lint-free paper: Bluesorb 750, 4× 4, non-woven polyester/cellulose (Berkshire;
Surrey, UK).
15. Microgrid II (Biorobotics; Cambridge, UK) or other suitable arrayer.
A.3.2 Carbazole Assay Reagents
1. Acid borate reagent: A solution of 0.80 g sodium tetraborate (Sigma-Aldrich)
dissolved in 16.6 mL water and 83.3 mL sulfuric acid is stored at room temper-
ature.
2. Carbazole reagent: 0.1% (w/v) carbazole is dissolved in 100% ethanol, protected
from light and stored at 4 ◦C.
3. Glucuronolactone standard: d-Glucuronic acid lactone from Sigma-Aldrich; St.
Louis, MO at 1 mg/mL in water, stored at 4 ◦C.
A.3.3 Protein-Binding Assay
1. Super Pap Pen (Research Products International Corp.; Mount Prospect, IL).
2. Blocking buffer: 3% (w/v) Bovine serum albumin (BSA, Fisher Scientific; Pitts-
burgh, PA) in PBS. Alternatively, 10% (w/v) fetal bovine serum (FBS, Gibco;
Bethesda, MD) in PBS can be used. In either case, filter through a 0.20 µm
membrane and store at 4 ◦C.
3. Protein dilution buffer: PBS supplemented with 1% (w/v) BSA, filtered through
a 0.20 µm membrane and stored at 4 ◦C.
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4. Protein(s) of interest. For example: Recombinant human β-NGF (Peprotech;
Rocky Hill, NJ).
5. Incubation box: DVA211 6-compartment plastic box (7×3.75×1.25 in., Durphy
Packaging Co.; Ivyland, PA).
6. Primary antibody: Primary antibody/antibodies against protein of interest at 1
mg/mL. For example: Rabbit anti-human β-NGF (Peprotech; Rocky Hill, NJ).
7. Secondary antibody: Cy3- or Cy5-conjugated secondary antibody at 1 mg/ml
(see Note 5). For example: Cy3 goat anti-rabbit IgG (Invitrogen; Carlsbad,
CA).
8. GenePix 5000a scanner with GenePix 6.1 software (Affymetrix; Fremont, CA).
A.4 Methods
The carbohydrate microarray methodology described herein exploits the high charge
density of GAGs to affix the sugars to the array surface. Adsorption is simple and
effective and allows GAGs to be used directly, without additional modification. As
members of the GAG family can vary considerably in length, GAG concentration
must be determined in terms of uronic acid concentration. It is necessary to normal-
ize binding data with respect to the uronic acid concentration because longer GAG
molecules may have more binding sites per mole.
The carbohydrate microarray methodology is robust and provides reproducible
and consistent results. The microarrays are very sensitive and even weak protein-
GAG interactions (e.g., K
D
> 10 µM) can be detected. Therefore, it is important
to interpret results with caution and use independent methods to confirm that the
observed binding is strong and physiologically relevant. Carbohydrate microarrays
provide a powerful, rapid method to screen for novel protein-GAG interactions, but as
with any method, they must be used in combination with other techniques. Further-
more, care should be taken when comparing the relative affinity of a given protein-
GAG interaction to another based on the difference in fluorescence intensity between
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two microarrays. The difference could be due to any number of factors and does
not necessarily reflect a difference in affinity. A quantitative assay should be used to
compare differences in affinity from protein to protein.
A.4.1 Preparation of Poly-l-Lysine Coated Slides (see Note
1)
1. Place the microslides into the removable racks of the staining dishes. Examine
each slide, checking for markings that cannot be removed by Kim-Wipes. Place
19 slides in each rack and place the rack into the empty dish (see Note 6).
2. Carefully pour approximately 200 mL of the etch solution into the dishes (see
Note 7). Make sure the slides are completely covered. Cover the dish with the
lid and incubate the slides in the etch solution for 1 hr.
3. Remove the etch solution (see Note 8), and rinse the slides in the dishes five
or more times in approximately 200 mL of water for approximately 10 seconds,
moving the rack in an up-and-down motion at a constant and consistent speed.
It is critical that all of the etch solution is removed before continuing to the
next step.
4. Pour approximately 200 mL of the poly-l-lysine solution into each dish, making
sure the slides are covered. Place the dishes on an orbital shaker at a speed low
enough that none of the poly-l-lysine solution will splash out. Incubate with
shaking for 1 hr.
5. Remove the poly-l-lysine solution and rinse the slides with water as described
in step 3.1.3 above. After the final rinse, leave the slides in water for the next
step.
6. One dish at a time, remove the rack from the water and dry the rack and the
slides under a stream of compressed air to remove most of the water. Then,
without touching the surface, dry the slides individually under a stream of
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compressed air, making sure the slides are completely dry. Place the slides into
the slide box (see Note 6). Once all the slides have been dried and transferred
to the slide box, label and date the box and place the box in a desiccator. Allow
at least two weeks before printing the slides to ensure complete dryness.
A.4.2 Preparation of Sugar Samples
1. Make a series of samples containing 0, 1, 3, 5, 7.5, and 10 µL of the glucurono-
lactone standard. Adjust the final volume to 50 µL with water.
2. For each GAG, prepare 1, 3 and 5 µL samples from the 500 µM stocks. Adjust
the final volume to 50 µL with water.
3. For each sample (both the glucuronolactone and GAG dilutions, 33 samples in
total), add 1 mL of acid borate reagent to a test tube, followed by the 50 µL
samples prepared in steps 3.2.1 and 3.2.2. Mix by vortexing, cover each tube
with foil or Parafilm, and place the samples in a boiling water bath for 10 min.
4. After cooling the samples to room temperature, add 50 µL of carbazole reagent,
mix by vortexing, cover, and return the mixtures to the boiling water bath for
an additional 15 min.
5. After cooling the samples, measure the absorbance at 530 nm. For the d-
glucuronolactone standards and the GAG samples, plot volume of stock used
versus absorbance, and determine the slope of the resulting curve using linear
regression analysis. Determine the molarity of each sample by dividing the
slope of the GAG dilution series by that of the d-glucuronolactone standard,
then divide the quotient by the average molecular weight of the GAG.
A.4.3 Printing Slides
1. These instructions assume the use of a Microgrid II arrayer. If using another
instrument to print arrays, follow the manufacturer’s instructions. It is critical
167
A B! C
Figure'2'
Figure A.2: (A) The dimensions of the array on the 25 × 75 mm slide. The gray boxes
represent the array region. (B) Detail of the array regions from (A). The array features 16
blocks with 10 replicates of four concentrations of GAGs. The concentrations and GAGs
are labeled within each block. (C) A detail of the layout of a block. This is the block in the
third row from the top, second column from the left.
that the arrays have multiple replicates of each concentration of GAG and that
the spot morphology is consistent. Maintaining the dimensions of the array and
the location of the GAGs within the array is less important.
2. Using the concentration of the GAG samples determined above, prepare 15 µL of
0.5, 1, 2, 5, 10, 15, 20 µM samples of each GAG in water from the standardized
stocks.
3. Place the samples into the high sample recovery 384-well plate. Start filling
the plate at well A1, and fill the remaining wells such that a minimal number
of 4 × 4 grids are filled. For example, if 16 samples are used, fill the wells
A1–D4, inclusive. For these arrays, with 7 concentrations of 9 GAGs, use the
wells between A1 and P4, with one well empty as a blank. Cover the plate
with the microplate sealing film and lid and store at 4 ◦C until use. Record the
location of each sample, including the blank, in an Excel spreadsheet. Export
the file as a tab delimited text file. If using an operating system that uses end-
of-line characters (EOLs) different from the Windows operating system (such
as Unix-based systems, including Mac OS X), change the EOLs to be Windows
compatible (see Note 9).
4. Transfer the tab separated text file with Windows compatible EOLs to the
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computer that operates the Microgrid II Arrayer. Open the TAS application
suite program on this computer to set up the print run.
5. From the file menu, select New Microarray. In the new window that appears,
under the Options tab, under Group: select 2. MicroSpot (384 well) and
under Tool: select 4 × 4 configuration.
6. Click the Source tab. Under Microplate Group: select Generic, under Microplate
Type: select 384 well (low profile), under Number of Plates: type 1.
Confirm the Number of Samples matches the number of samples in the 384-
well plate in 3.3.2. Under Lid Removal check Replace lid immediately.
Select Remove one lid at a time. Under Source action select dwell.
7. Under the Target tab, under Tool array definition change the size to be
6× 5, and the pitch to be 0.500 mm.
8. Under the Format section, select the n radio button and enter 10 for the number
of replicates to print and edit the location of each replicate within the print block
in the Edit window. After the layout is saved, the selected radio button will
become Custom. Under Adapter Plate and Slide Layout, enter the number
of slides to print in the targets field.
9. Enter the dimensions of the array. Press the Slide layout button. Make
sure the option Mirror vertical margins option is unchecked. Enter 18.15
mm for the top margin, and 12.90 mm for the bottom margin (see Note 10).
Check the Mirror horizontal margins options and type 3.40 mm for Left
margin, 0.00 mm for x spacing and 11.00 mm for y spacing. The resulting
array will have two identical array regions per slide with dimensions as shown in
Figure A.2. A representative array with sample GAG concentrations is depicted.
The concentrations, GAGs and layout of the array can be tailored to the protein
of interest.
10. Under the Target action tab, type 0 s under Delay before spotting, 0.6
mm under Target Height, 0 s under Dwell time, 1 under Multiple strikes.
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Make sure the soft touch option is checked and that the Pre-spotting option
remains unchecked.
11. Close this window, when prompted save the method.
12. From the file menu of the TAS application suite program, select Clone tracking
wizard... Click Next twice, then select No, plates do not have barcodes,
and then click Next again. In the type of output file dialog window, select I
already know what file type I need and choose Axon GAL from the pull-
down menu. Select the Import name and ID option and type 80 µm under
the field labeled Typically the spots I am printing are. Click Next, and
then select the tab delimited text file with Windows compatible EOLs that was
saved on the computer in step 3.3.3. Check the Tab option below.
13. After clicking Next, the wizard will display the contents of the imported text
file. Confirm that the imported file is correct and that there are no errors. Click
Next. Check again that the file is correct, if so, press Output file. Give the
file a name and select a location to save it. Click Save, then Next. Transfer
this file to the computer that runs the GenePix Scanner.
14. Select 16 pins from the Microgrid II arrayer accessories. Make sure the pins
are not bent or damaged in any way. Submerge the tips of the pins in 15 mM
KOH in water. After 5 min, remove the pins from this solution and sonicate the
tips of the pins for 5 min while submerged in 0.01% Tween-20 in water. Rinse
the pins by submerging the tips in water and sonicating for 5 min. Replace
the water and repeat two more times. Rinse the pins by dipping them in 95%
ethanol in water and place them on the lint-free paper to dry (see Note 11).
15. Fill the large bottle supplied with the arrayer with water. Click the Fill
6-litre reservoir icon on the TAS application suite program. The progress
can be monitored with the icon to the left of this button. Turn on the recy-
cling water bath pump and wait for the coolant temperature to drop to 8 ◦C
(approximately 30 min).
170
16. Under the Housekeeping menu in the TAS application suite program, click
load/unload tray 1. Clean tray with compressed air to make sure that it is
dust free. Carefully place the poly-l-lysine coated slides onto the tray after
checking that they are dust free. Remove any dust with a stream of compressed
air, if needed. Continue loading slides into the remaining trays if necessary.
Each tray must contain exactly 30 slides. If printing a number of slides that
is not divisible by 30, use dust-free plain glass slides to fill the remaining slots
in the tray. Nothing will be printed on these slides, but they are necessary
to maintain the vacuum applied to the tray to keep the slides in place during
printing.
17. Select the Load tool option under the Housekeeping menu. Load the clean
and dry pins in the orientation shown by the wizard.
18. Next, select Load biobank from the Housekeeping menu. After removing the
film and placing the cover on the 384-well sample plate, place into machine.
19. On the bottom panel of the chamber in the robot, there should be three reser-
voirs. Fill the left hand reservoir with water and the middle with 70% ethanol
in water. Lastly, to maintain humidity in the chamber take three 384-well plate
lids, place a few paper towels into each lid, cutting them to fit as necessary. Fill
the lids with water, making sure the paper towels are saturated. Place the lids
on the bottom of the chamber. Close the chamber lid, and press the GO icon in
the TAS application suite program. This will initiate printing.
20. When the printing is finished, unload the slides via the wizard in the Housekeeping
menu. Transfer slides into a dust-free slide box. Label the top-right corner of the
slide using a diamond-tipped pen (see Note 6). Store arrays in a low-humidity,
dust-free desiccator.
21. Unload pins via the wizard in the Housekeeping menu and repeat the cleaning
procedure detailed in step 3.3.13.
171
22. Remove the 384-well sample plate via the wizard in the Housekeeping menu.
If sufficient volume remains, the plate can be re-sealed with film, covered and
stored at −20 ◦C for an additional print run.
23. Drain the reservoir, shut down the robot.
A.4.4 Protein-Binding Assay
1. Using a hydrophobic marker, such as a PapPen, draw a perimeter around the
printed region of the slide according to the dimensions for the array region
given in step 3.3.8. This perimeter allows much less protein to fully cover
the array region. However, take care not to mark the slide too close to the
printed region, leaving up to 0.5 cm of space when possible. This is important
because the hydrophobic marker can prevent the protein from interacting with
the carbohydrate spots near the edge of the array.
2. Place the slide in the incubation box and cover the slide with 2.5 mL of blocking
buffer at 37 ◦C for 1 hr with gentle rocking. This step is necessary to prevent
non-specific interactions between the proteins and the surface of the array.
3. Remove the blocking buffer and add the protein sample (0.5–2 µM in protein
dilution buffer, see Note 12) to the printed region of the slide. Make sure the
slide does not dry out before adding the protein. Also, make sure there are no
water “bridges” over the hydrophobic pen markings. If so, carefully blot dry
with a Kim-Wipe. Be sure to add sufficient volume to fully cover the region
(100–200 µL). Incubate at room temperature for 1–3 hr.
4. Wash the slide 5 times for 30 s each with 2.5 mL PBS with gentle rocking.
5. Incubate the slide in 2.5 mL of a 1:1000 or appropriate dilution (see Note 13)
of primary antibody in protein dilution buffer for 1 hr at room temperature
with gentle rocking. Alternatively, 100–200 µL of the antibody solution can be
added to the array region as described in step 3.4.3.
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6. Remove the antibody solution and wash the slide 5 times for 30 s each with 2.5
mL PBS with gentle rocking.
7. Incubate the slide in 2.5 mL of a 1:5000 or appropriate dilution (see Note 13)
of secondary antibody in protein dilution buffer for 1 hr at room temperature
with gentle rocking.
8. Remove the antibody solution and wash the slide 3 times for 30 s each with 2.5
mL PBS and 2 times for 30 s each with 2.5 mL water with gentle rocking.
9. Immediately after the final wash step, dry the slide(s) under a gentle stream
of air or nitrogen. This prevents water droplets from evaporating on the array,
which could potentially obscure the signal.
10. (Optional) Add a droplet (∼ 5 µL) of a fluorescence-specific mounting medium,
such as VectaShield, to the printed area of the array. Carefully place a coverslip
over the drop, taking care to avoid forming any bubbles, and seal the coverslip
with nail polish.
A.4.5 Recording Data
1. These instructions are specific for the GenePix 5000a scanner using GenePix
6.1 software. They are easily adaptable to other microarray scanners. Follow
the manufacturer’s instructions. It is critical that the dye on the secondary
antibody is compatible with the filters on the scanner (see Note 5), and that
the array is scanned using appropriate laser power and gain.
2. On the computer controlling the GenePix 5000a scanner, open the GenePix 6.1
software and wait for the scanner to initialize.
3. Place the slide into the GenePix 5000a scanner. Orient the slide such that the
printed region of the slide is facing down and the top of the array is pointed
into the scanner. If the slides were labeled according to step 3.3.19, the label
will be in the back left of the scanner.
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Figure A.3: (A) A representative image of nerve growth factor (NGF) binding to a GAG
microarray as visualized using a Cy3-conjugated secondary antibody against anti-NGF. (B)
An expansion of a region of the microarray from (A). The columns, from left to right, in
(B) are 2 µM CS-C; 15 µM CS-D; 1 µM CS-D; 10 µM CS-E; 2 µM CS-C; 15 µM CS-D;
1 µM CS-D; 10 µM CS-E. Each concentration is repeated 5 times down the column. (C)
Quantification of the data in (A) for binding of NGF to various GAG subclasses
4. In the GenePix 6.1 program, click the Hardware Settings icon. In the menu
that appears, there will be two fields labeled Select Wavelength select one
by clicking the checkbox on the left, and make sure the other is not checked.
Under the pull-down menu to the right of the Select Wavelength field, select
the wavelength used for the experiment (532 nm for Cy3, or 635 nm for Cy5).
Under PMT Gain: enter the desired value for the gain. A reasonable place to
start is 400. Under Power (%): begin at a low percent power, such as 5–10%.
Under Filter: select the corresponding filter for the wavelength (Standard
Green for 532 nm/Cy3, or Standard Red for 635 nm/Cy5). Lastly, change
Pixel Size (µm) to 5, Lines to Average to 1, and Focus Position to 0, if
necessary.
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5. Click the Preview Scan icon. This will take a quick scan of the array. Adjust
the brightness and contrast in the Tools section if necessary. While it may not
be possible to distinguish the signal from the background at this resolution, the
preview scan is helpful for determining if the PMT Gain or Power needs to be
increased or decreased. If so, repeat the preview scan.
6. If the preview scan is acceptable, click the View Scan Area icon under the
Tools panel. Using the mouse, highlight the array region of the slide. A white
rectangle will appear. Resize or move the rectangle with the mouse if necessary.
7. When the array region of the slide is within the area delimited by the rectangle,
click the Data Scan icon. This takes a high-resolution image of the array region
of the slide. After the scan has finished, click the File... icon and select Save
Images. After saving, zoom into the array region to see the signal, which should
look like small, ordered spots. Adjust the brightness and contrast as needed, or
rescan the image after adjusting the PMT Gain and Power if necessary. The
image should look similar to Figure A.3A, B.
8. If the data scan is acceptable, click the View Blocks icon. Then, under the
File... menu, click Load Array List... Find the .gal file that was created
in steps 3.3.11–12 and click Open. A series of boxes with small circles inside
will appear. Using the mouse, select all of the boxes and move them roughly
into position (i.e., over the spots corresponding to protein bound to GAG). To
more precisely position the blocks, select one block at a time, zoom into the
region and move the block such that the spots (i.e., the signal) are centered in
the circles. When the ideal adjustment has been achieved, press F5. Repeat for
the remaining blocks (see Note 14).
9. Click the Analyze icon. Under the File... menu, click Save Results As...
Name the file and click Save. This .gpr file can be opened in Excel and ana-
lyzed, as in Figure A.3C (see Note 15).
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A.5 Notes
1. Alternatively, poly-l-lysine coated slides are available from Erie Scientific, Ports-
mouth, NH. If pre-coated slides are used, ignore method 3.1 and start the
procedure at 3.2.
2. Throughout the text, “water” refers to water that has a resistivity of 18.2 MΩ-cm
and total organic content of less than five parts per billion.
3. CAUTION: Wear lab coat and safety glasses when preparing this solution.
This solution becomes hot when the reagents are mixed. Ensure the solution is
carefully vented if mixing in a sealed container.
4. Due to the heterogeneity of GAG samples in terms of chain length, degree of
sulfation, and number and type of counter ions (both within a sample and
between different GAGs), the molecular weights for each sample are only ap-
proximate. Prepare 500 µM samples based on the average molecular weight for
each sample. In order to compare different GAGs to one another, we measure
the average uronic acid concentration for each sample using the carbazole assay
described in the methods section.
5. The choice of Cy3 and Cy5 dyes was based on the scanner wavelengths of the
GenePix 5000a scanner. If using a different scanner, check the manufacturer’s
specifications and use dyes compatible with the instrument’s filters.
6. Wear gloves whenever handling the slides. Make sure the slides are arranged in
the rack such that both sides of the slide are exposed to solution.
7. CAUTION: Wear lab coat and safety glasses when handling the etch solution.
8. It is possible to reuse the etch solution. The solution is good for up to one
month, although if discoloration is observed, the solution should be remade.
9. If using Mac OSX, it is possible to convert the tab separated file to be windows
compatible by using the following command in Terminal:
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tr ’\r’ ’\n’ < inputfile > outputfile
10. The asymmetric margins will help determine the proper orientation of the slide
if necessary.
11. Handle the pins very carefully and only with tweezers.
12. When testing a protein with unknown affinity to GAGs, a good starting con-
centration is 2 µM, although less protein can be used if the sample is precious.
Some proteins have very high affinity to GAGs, and will saturate the signal
when incubated at 2 µM, even when scanned at extremely low laser power. If
this is the case, it is necessary to reduce the concentration of protein to obtain
useful data.
13. When using unknown antibodies, a good starting dilution is 1:1000 for the pri-
mary antibody and 1:5000 for the secondary antibody. However, particularly
strong antibodies may require a higher dilution, and weak antibodies may re-
quire a lower dilution.
14. If the program has difficulty adjusting the grid to the signal, right click on
a box and select Block Properties, and adjust the diameter of the circles
accordingly.
15. Analysis of the resulting .gpr files can be automated using the ruby script listed
in Section A.6. The script will only run on Mac OSX, and requires that the
appscript package be installed on the system.
A.6 Microarray Analysis Script
1 #!/usr/bin/ruby
2 # == Synopsis
3 #
4 # microarrayAnalyzer0.3: analyzes tetrasaccharide microarray data
5 #
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6 # == Usage
7 #
8 # ruby microarrayAnalyzer0.3.rb [OPTION] ... GPRFILE
9 #
10 # -h, --help:
11 # shows this help message.
12 #
13 # -c, --ternary-color:
14 # Optional. If analyzing an array with both Cy3 and Cy5, providing an
15 # argument is required. Use "green" or "g" for Cy3, "red" or "r" for
16 # Cy5.
17 #
18 # -f, --file [GPRFILE]:
19 # Required. Path to gpr file to analyze.
20 #
21 # GPRFILE: The path to the gpr file.
22
23
24 require "getoptlong"
25 require "rdoc/usage"
26 require "rubygems"
27 require "appscript"
28 include Appscript
29
30 class Microarray
31 attr_accessor :sugar, :conc, :values
32 def initialize(sugar_name, sugar_conc, *the_values)
33 @sugar = sugar_name
34 @conc = sugar_conc
35 @values = *the_values
36 end
37
38 def average
39 sum = 0
40 @values.each{ |i| sum += i }
41 return sum.to_f/@values.length.to_f
42 end
43
44 def stdev
45 total = 0
46 @values.each do |i|
47 total += (i - average) ** 2
48 end
49 return Math.sqrt(total.to_f/(@values.length - 1.0).to_f)
50 end
51
52 def sem
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53 stdev/Math.sqrt(@values.length)
54 end
55 end
56
57 class MicroarrayAnalyzer
58 attr_accessor :infile, :outfile, :color
59 def initialize(gprFile, color)
60 @infile = gprFile
61 @outfile = File.basename(gprFile, ".gpr") + "_results.xls"
62 @color = color
63 end
64
65 def get_results
66 results = []
67 data1 = {}
68 data2 = {}
69 regex = /([\w\-]+(\s\w+)?)\s([0-9]{1,3}(\.[0-9])?)/
70
71 File.open(@infile, ’r’) do |f|
72 while line = f.gets
73 row = line.split(/\t/)
74 if row.length > 33
75 if regex.match(row[3]) != nil
76 if row[0].to_i < 17
77 if @color == ’red’
78 (data1.has_key?(row[3])) ? (data1[row[3]] << row[45].to_f) :
79 (data1[row[3]] = [row[45].to_f])
80 elsif @color == ’green’
81 (data1.has_key?(row[3])) ? (data1[row[3]] << row[46].to_f) :
82 (data1[row[3]] = [row[46].to_f])
83 else
84 (data1.has_key?(row[3])) ? (data1[row[3]] << row[34].to_f) :
85 (data1[row[3]] = [row[34].to_f])
86 end
87 else
88 if @color == ’red’
89 (data2.has_key?(row[3])) ? (data2[row[3]] << row[45].to_f) :
90 (data2[row[3]] = [row[45].to_f])
91 elsif @color == ’green’
92 (data2.has_key?(row[3])) ? (data2[row[3]] << row[46].to_f) :
93 (data2[row[3]] = [row[46].to_f])
94 else
95 (data2.has_key?(row[3])) ? (data2[row[3]] << row[34].to_f) :
96 (data2[row[3]] = [row[34].to_f])
97 end
98 end
99 end
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100 end
101 end
102 end
103 return results << data1 << data2
104 end
105
106 def summarize
107 regex = /([\w\-]+(\s\w+)?)\s([0-9]{1,3}(\.[0-9])?)/
108 input = get_results
109 excel = app("Microsoft Excel")
110 doc = excel.make(:new => :workbook)
111 w = excel.worksheets[1]
112 i = 0
113 input.each do |data|
114 if !data.empty?
115 i += 1
116 smry = []
117 data.each_pair do |key, value|
118 sugar_label = regex.match(key)[1].to_s
119 sugar_conc = regex.match(key)[-2].to_f
120 results = Microarray.new(sugar_label, sugar_conc, value)
121 smry << [results.sugar, results.conc, results.average,
122 results.stdev, results.sem]
123 end
124
125 if i == 2
126 w = excel.make(:new => :worksheet, :at => doc)
127 end
128 w.name.set("Region #{i}")
129 header = %w[GAG Conc Avg STDEV SEM]
130 curr_row = 1
131 curr_col = 1
132 header.each do |x|
133 w.rows[curr_row].cells[curr_col].value.set(x)
134 curr_col += 1
135 end
136
137 curr_row += 1
138 curr_col = 1
139 dummy = ’’
140 smry.sort.each do |item|
141 item.each do |x|
142 if x == item[0] && dummy != item[0]
143 w.rows[curr_row].cells[curr_col].value.set(x)
144 dummy = item[0]
145 elsif x == item[0] && dummy == item[0]
146 w.rows[curr_row].cells[curr_col].value.set(’’)
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147 else
148 w.rows[curr_row].cells[curr_col].value.set(x)
149 end
150
151 curr_col += 1
152 end
153
154 dummy = item[0]
155 curr_row += 1
156 curr_col = 1
157 end
158
159 rng = "C2:C#{curr_row - 1}"
160 lblrng = "A2:B#{curr_row - 1}"
161 excel.cells[rng].select
162 excel.make(:new => :chart_sheet, :at => doc)
163 c = excel.active_chart
164 c.has_legend.set(false)
165 c.chart_groups[1].gap_width.set(50)
166 x = c.get_axis(:axis_type => :category_axis,
167 :which_axis => :primary_axis)
168 x.category_names.set(w.cells[lblrng])
169 y = c.get_axis(:axis_type => :value_axis,
170 :which_axis => :primary_axis)
171 y.has_major_gridlines.set(false)
172 s = c.series_collection[1]
173 s.chart_solid
174 end
175 end
176 excel.save(excel.active_workbook, :in => @outfile)
177 end
178 end
179
180 opts = GetoptLong.new(
181 [ ’--help’, ’-h’, GetoptLong::NO_ARGUMENT ],
182 [ ’--file’, ’-f’, GetoptLong::REQUIRED_ARGUMENT ],
183 [ ’--ternary-color’, ’-c’, GetoptLong::OPTIONAL_ARGUMENT ]
184 )
185
186 filename = nil
187 color = nil
188 opts.each do |opt, arg|
189 case opt
190 when ’--help’
191 RDoc::usage
192 when ’--file’
193 filename = arg
181
194 when ’--ternary-color’
195 if arg == ’’
196 color = arg
197 elsif arg.downcase == "red" or arg.downcase == "r"
198 color = "red"
199 elsif arg.downcase == "green" or arg.downcase == "g"
200 color = "green"
201 else
202 RDoc::usage
203 end
204 end
205 end
206
207 if !filename
208 puts "File name required!\n"
209 RDoc::usage
210 end
211
212 if File.extname(filename) == ".gpr"
213 out = MicroarrayAnalyzer.new(filename, color)
214 out.summarize
215 end
216
217
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Appendix B
Analysis of Chondroitin
Sulfate-Protein Interactions by
Surface Plasmon Resonance
B.1 Introduction
Carbohydrate microarrays provide a rapid and inexpensive means to screen for GAG-
protein interactions. In addition, the tools described in Chapter 3 and Appendix A
provide useful information about the relative specificity of the protein across the
GAG family members, and/or the relative effect of sulfation on the interaction. This
knowledge is important; however, it is not always sufficient. Quantitative information
on the affinity, kinetics or thermodynamics of the interaction is sometimes necessary.
Unfortunately, probing the dynamics of GAG-protein interactions is not necessarily
straightforward. Heterogeneity in the length and degree or pattern of sulfation could
potentially affect the fidelity of the kinetic or thermodynamic measurements. An-
other potential problem is that the length of the GAG chain may be large enough
to accommodate multiple, simultaneous protein-binding events. Depending on the
interaction, GAG molecules could display a few discrete protein-binding sites, or the
entire length could present a continuous binding surface (a ligand-binding lattice).
With very little information on the sequence of CS polysaccharides, especially
heavily sulfated sequences important for protein binding. The potential distributions
of patterns of high sulfation are bounded by two extremes: sulfation could be clustered
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in a single continuous block, or it could be completely random. Because it is difficult
to imagine the consequences of random sulfation on potential protein-binding sites, in
aggregate, we calculate the probability distributions of regions of continuous sulfation
of length n occurringm times along the length of a polysaccharide. The results suggest
that if sulfation were random it may be possible to treat CS polysaccharides as ligands
with multiple, discrete protein-binding sites.
Next, we measured the kinetics of multiple CS-binding proteins by surface plasmon
resonance. We found that large CS-binding proteins, such as cell-surface receptors,
typically have interactions with CS polysaccharides well-described by simple binding
models. On the other hand, growth factor-binding interactions appeared more com-
plex. Using a combination of kinetic and structural data, we test the predictions of
the model for the random distribution of CS sulfation. Surprisingly, this model is
quite consistent with the data.
B.2 Modeling the Distribution of CS Sulfation
The pattern of sulfation along the length of an average GAG molecule could radically
affect the mechanism of GAG-protein interactions. If CS-E motifs are expressed in
discrete chunks, we might expect that a standard multisite-binding model would be
sufficiently descriptive. On the other hand, if CS-E is expressed in a monolithic se-
quence, protein binding might be better described by a ligand-lattice model.462 Such
a pattern may not sound very likely, but CS-A sulfation is restricted to a block of
disaccharides at the reducing end of the glycan in bikunin.156 Additionally, Cathepsin
K binds to CS-A with 1:n stoichiometry in a manner consistent with a ligand-lattice
interaction.213 On the other hand, CS-A and -C sulfation motifs isolated from bovine
trachea had an apparently random distribution, while CS-C motifs from shark car-
tilage polysaccharides were organized in non-random, discrete chunks.463 Unfortu-
nately, the distribution of heavily sulfated patterns have not been described.
However, given that CS-A is the biosynthetic precursor for CS-E, these data in-
dicate that it is possible that CS-E motifs could be distributed according to either
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Table B.1: Resolved disaccharide sulfation patterns from
commercially available CS polysaccharides49
Disaccharide type 0S 4S 6S 2,6S 4,6S
(%) (%) (%) (%) (%)
Squid cartilage (CS-E) 5.9 22.9 9.6 - 61.5
Shark cartilage (CS-C) 1.7 15.4 72.9 9.3 0.6
extreme: a monolithic block or completely randomly. We decided to model the the-
oretical average distribution of sulfation on commercially available CS-E polysac-
charides (hereafter referred to simply as CS-E, Seikagaku America; Fallmouth, MA)
assuming random CS-E sulfation. The composition of CS-E has been analyzed by
high-performance liquid chromatography (HPLC) of unsaturated disaccharide iso-
forms obtained by enzymatic digestion of the polysaccharide.49,464 The 4,6S (CS-E)
disaccharide is the prominent species, comprising 61.5% of the total disaccharides.
The monosulfated 4S (CS-A) and 6S (CS-C) disaccharides accounts for 22.9% and
9.6% of the total, respectively. The remaining disaccharides are unsulfated. No sig-
nificant traces of 2,6S (CS-D) disaccharides were observed (Table B.1).
As described in Section 1.3, the CS-A motif is the biosynthetic precursor for CS-E;
therefore, the substrate for the 4-S, 6-O-sulfotransferase (Chst15) is approximately
85% 4S sulfated. There is evidence to suggest that CS-C sulfation is interspersed
randomly in CS-A polysaccharides.463 Therefore, Chst15 may encounter a relatively
even distribution of CS-A across the length of the polysaccharide. As a first approx-
imation, if we assume that CS-E sulfation occurs randomly along the length of the
polysaccharide (i.e., CS-E sulfation at one position does not affect the probability of
adjacent CS-E sulfation), we can construct a simple model for determining the dis-
tribution of CS-E sulfation clusters based only on the final sulfation ratios. We can
also assume, based on the evidence from the preceding chapters, that only the CS-E
motif has protein-binding activity. With these assumptions, we can represent the
CS-E polysaccharide as a binary tree where 1 and 0 represents CS-E and non-CS-E
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Figure B.1: Calculated distribution of CS-E n-mers in CS-E polysaccharides with a min-
imum length ranging from tetrasaccharide (n ≥ 2) to tetrakaidecasaccharide (n ≥ 7). For
each n-mer, the number of occurrences of the n-mer per average polysaccharide is plotted
against its probability.
disaccharide motifs, respectively. Let us further assume that there is minimal con-
tiguous length of CS-E disaccharides, or threshold, required to form a protein-binding
site. This is based on observations that there is a minimal unit for CS-E activity,70
and that the affinity of proteins to heparin oligosaccharides increases in proportion
to the oligosaccharide length until the it is sufficiently long and affinity no longer
increases.171,192,465
To model this CS-E polysaccharide we merely construct all 2length possible binary
representations of CS polysaccharides, where length is the total number of disaccha-
rides, and count (cnt) the number of contiguous “CS-E” disaccharides whose length
(tail) is at least as long as the threshold (thrsh). Each of the generated polysac-
charides is assigned a probability based on the probability that a disaccharide is
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CS-E or not and the total CS-E disaccharide content of the final chain. The function
get_dist_r declared on line 5 is an implementation of this algorithm in python.
Next, the probability that a sequence of contiguous CS-E disaccharides of length
greater or equal to thresh is present on a polysaccharide exactly n times is calculated
by the get_dist function declared on line 21 below. This function calls get_dist_r
(line 23), and serves as an application programming interface for the algorithm. The
program is evoked simply by passing appropriate values for length and thrsh.
1 #!/usr/bin/env python
2
3 import sys
4
5 def get_dist_r(store, length, thrsh, tail, cnt):
6 key = (length, thrsh, tail, cnt)
7 if length == 0:
8 store[key] = {(tail, cnt): 1.0}
9 if key not in store:
10 t0 = get_dist_r(store, length - 1, thrsh, 0, cnt)
11 t1 = get_dist_r(store, length - 1, thrsh, tail + 1,
12 cnt + (1 if tail + 1 == thrsh else 0))
13 r = {}
14 for k, v in t0.iteritems():
15 r[k] = r.get(k, 0.0) + 0.385 * v
16 for k, v in t1.iteritems():
17 r[k] = r.get(k, 0.0) + 0.615 * v
18 store[key] = r
19 return store[key]
20
21 def get_dist(length, thrsh):
22 store = {}
23 r = get_dist_r(store, length, thrsh, 0, 0)
24 s = {}
25 for k, v in r.iteritems():
26 s[k[1]] = s.get(k[1], 0.0) + v
27 return s
28
29 if __name__ == ’__main__’:
30 length, thrsh = map(int, sys.argv[1:3])
31 s = get_dist(length, thrsh)
32 for k, v in s.iteritems():
33 print "%d\t%f" % (k, v)
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The average molecular weight of CS-E polysaccharide is ∼70,000 KDa. Given
the distribution of disaccharides, the average length of the polysaccharide is approx-
imately 125 disaccharide units long. With this, we calculated the distribution of
potential protein-binding sites at or above a threshold length (Figure B.1). Based on
the model, the average modeled CS-E polysaccharide (mCS-E) has approximately 30
sites of contiguous CS-E motifs at least as long as a disaccharide. As expected, long,
contiguous CS-E n-mers are rare. For example, the average mCS-E polysaccharide
does not have a contiguous octakaidecasaccharide, or longer, with 4,6S sulfation. On
the other hand, the average mCS-E polysaccharide has 18 units of contiguous CS-
E sulfation at least as long as a tetrasaccharide, although the shorter n-mers have
broader distributions. Between these extremes, octa-, deca-, and dodecasaccharides
are displayed 6, 3, and 1 times per polysaccharide, on average. These results sug-
gest that contiguous regions of CS-E motifs are relatively sparsely distributed along
the length of the modeled polysaccharide. Unpublished protein-binding data from
our lab suggests that CS-E tetrasaccharides have affinities several-fold weaker than
the polysaccharide, while the affinities with disaccharides were too weak to deter-
mine.218 In addition, binding studies with heparin oligosaccharides show that the
protein-binding affinity increases with length.192 This may suggest that GAG-protein
binding depends on cooperative interactions between functional groups on the GAG
and specific amino acid residues of the protein.
Taken together, the results of the modeling studies suggest that it may be possible
to treat CS-E as a randomly sulfated polysaccharides as a ligands with multiple,
discrete, protein-binding sites, especially for proteins that require long, contiguous
CS-E motifs. For proteins that only require a tetrasaccharide motif to achieve high-
affinity binding, the potential protein-binding sites will be significantly less discrete,
these interactions with CS-E polysaccharides may not be interpretable using standard
binding mechanisms. Therefore, the assumptions of this model should be testable in
protein-binding assays. At the other extreme, CS-E sulfation may be contained in a
single, continuous block. In this case, protein binding should conform to a ligand-
lattice mechanism, with recognizable consequences, such as slow saturation.462 More
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likely, if CS-E sulfation is not random, but the presence of CS-E sulfation at some
location in the biosynthetic intermediate increases the probability of adjacent CS-E
sulfation, the distribution of binding sites on the resulting polysaccharides could be
significantly different from the predictions of this model.
B.3 Measuring CS-Protein Interactions With SPR
Measuring the interactions of proteins with heterogeneous ligands such as CS is po-
tentially extremely difficult. For example, if the protein interacts with different motifs
on CS with slightly different affinities, the resulting binding isotherms may be im-
possible to fit to conventional models. This could occur if the CS-binding site of a
protein could accommodate an octasaccharide, but the hexasaccharide, or an octasac-
charide with one non-CS-E disaccharide somewhere in the chain could also bind, but
with different kinetics. If the proteins have multiple CS-binding sites, the challenge
in understanding the interactions would be further exacerbated. Indeed, almost all
examples of SPR using GAGs in the literature do not fit to standard mechanisms,
although, given the challenges of SPR in general, it is possible that the problems with
these data is not inherent to GAGs.
B.3.1 Validation of SPR with the CS-E Antibody 2D11-2A10
To try and avoid these problems, we first tested if the CS-E tetrasaccharide could be
used for SPR. The short length and homogeneous sulfation of the tetrasaccharides
should make the protein-binding analysis simpler, and SPR would be an ideal tool
because the precious synthetic molecules would be affixed to the sensor and used
in sparing quantities. However, we anticipated that there may be some technical
challenges with using these molecules. For one, the tetrasaccharides may not have
enough affinity with most CS-binding proteins to be detected by SPR, which has a
window of ∼ 10−10 M < KD <∼ 10−5 M. Another problem could be that getting the
right amount of ligand on the surface would be too challenging. In SPR, the amount
of a molecule bound to the surface of the sensor is proportional to its mass. Too much
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Figure B.2: (A) Kinetics of the interaction of the CS-E antibody with CS-E tetrasaccha-
ride. A twofold dilution series of antibody concentrations starting at 400 nM were allowed to
bind and dissociate. The resulting curves were fit to a bivalent analyte model, summarized
in Table B.2. (B) The affinity of the CS-E antibody-CS-E tetrasaccharide interaction. The
CS-E antibody was allowed to flow over the sensor until an equilibrium level of binding was
obtained. The resulting curve was fit to the Langmuir equation to give an apparent KD of
4.3 nM.
surface ligand can cause mass transport effects which can make interpreting binding
kinetics difficult or impossible. The small size of the tetrasaccharide, relative to its
binding proteins, means that adding the appropriate amount of ligand to the surface
is difficult because of the detection limit of the instrument.
We decided we could eliminate the problem of low affinity by first studying the
interaction of CS-E tetrasaccharide with the CS-E antibody. Since the tetrasaccha-
ride was the antigen for this antibody, we reasoned the affinity should be within the
operating range. The tetrasaccharides could be affixed to the surface of the sensor
chip by “aldehyde capture.” The carboxymethylated dextran hydrogel on the sur-
face of the commercially available CM5 chips were treated with EDC:NHS followed
by a hydrazine derivative to afford a hydrazide functionalized surface. Passing the
aldehyde-functionalized CS-E tetrasaccharide over the surface followed by reduction
of the resulting hydrazone with NaBH4 resulted in an irreversible covalent bond with
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a uniform mode of display. To prevent over addition, the tetrasaccharide was added
in series of brief pulses (10 s) until sufficient response with the antibody was achieved.
An advantage of using this capture technique was that we could freely employ rela-
tively harsh denaturing conditions for regenerating the surface.
Indeed, the antibody interacted strongly with CS-E tetrasaccharide and required
strong denaturing conditions (6 M guanidine HCl) to regenerate the surface. Fortu-
nately, the integrity of the surface was unaffected by these conditions and we were
able to measure the kinetics of the CS-E antibody interaction. As expected, the data
fit to a bivalent analyte model (Equations B.8–B.12), common for antibody-antigen
interactions, in which the antibody can bind to two molecules of CS-E simultaneously
(Figure B.2A).
Table B.2: Kinetic parameters for the interaction of the CS-E anti-
body with its tetrasaccharide antigen or CS-E polysaccharide
Parameter CS-E Tetrasaccharide CS-E Polysaccharide
ka1 (M
−1s−1) 3.77 (±0.00)× 104 1.36 (±0.00)× 104
kd1 (s
−1) 6.41 (±0.01)× 10−4 7.94 (0.03)× 10−4
ka2 (RU
−1s−1) 4.71 (±0.84) 4.20 (±0.04)× 10−5
kd2 (s
−1) 11.9 (±2.1) 8.00 (±0.08)× 10−3
Rmax (RU) 22.6 (±0.02) 653.2 (±1.0)
χ2 (RU2) 0.059 32.9
Unfortunately, since the rate of association for this second binding event (ka2) is
expressed in units of RU−1 · s−1 (see Table B.2), deriving the K
D
from these results
would be difficult. Instead, we measured the affinity directly by passing the antibody
over the surface of the chip until an equilibrium response is achieved. The resulting
response at equilibrium (Req) was fit to the Langmuir equation B.1.
Req =
Rmax × [Protein]
KD + [Protein]
(B.1)
The approximate overall affinity of the antibody to the tetrasaccharide was 4.3 nM,
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suggesting that the interaction may be pharmacologically useful. Indeed, we were
able to show that this antibody is capable of promoting RGC regrowth past the glial
scar in adult mice following optic nerve crush.41
Encouraged by these results, we tested if the tetrasaccharide sensor chips could
be used with other CS-binding proteins. As we were still concerned about the rela-
tively low affinity of the tetrasaccharide, we chose Nogo Receptor (NgR) as our first
candidate, because microarray studies suggested this protein had particularly strong
affinity to CS-E.41,216 Unfortunately, we were not able to observe a response. Instead,
we decided to use the natural polysaccharide as the ligand, but we were concerned
that the heterogeneity of the polymer might make the interpretation of the resulting
data difficult. To test this, we used the CS-E antibody, as the CS-E-binding site
should be well defined for this protein, hopefully simplifying the interaction.
To prepare CS-E polysaccharide-conjugate sensors, we decided to employ a strept-
avidin-capture approach with mono-biotinylated CS-E. This approach has been used
previously by other groups,466,467 and has the advantage that the GAGs are displayed
in a homogeneous fashion on the surface. Streptavidin was covalently bound to the
NHS-activated surface. After blocking any remaining NHS esters with ethanolamine,
biotinylated CS-E was carefully titrated onto the surface until an RL = 25 RU was
achieved. Unlike the tetrasaccharide, the natural polysaccharide had a high enough
molecular weight (∼ 70 kDa) to allow the direct observation of its attachment. New
regeneration conditions were also required, since 6 M guanidine could potentially
denature the streptavidin and inactivate the surface. We found that MgCl2 was
capable of regenerating the surface after 1–3 pulses of 30–90 s each, depending on the
protein, but was sufficiently mild to maintain surface activity.
With the experimental parameters in hand, we tested the kinetics of the CS-E
antibody (Figure B.3). Reassuringly, the data fit well to the bivalent analyte model
as expected, and seen for the interaction with the tetrasaccharide. Unsurprisingly,
given the specificity of the antibody to the CS-E motif, the initial interaction of the
antibody with CS-E polysaccharide (ka1 and ka2) has very similar kinetic parame-
ters with the antibody (Table B.2). The secondary interaction of the other binding
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Figure B.3: Kinetics of the CS-E antibody interaction with CS-E polysaccharide. A
twofold series of CS-E antibody dilutions, starting at 512 nM, was passed over the CS-E
polysaccharide surface for 240 s, then allowed to dissociate for 600 s at a flow rate of 80
µl ·min−1. The resulting sensorgrams (red) were fit to a bivalent analyte model (black).
arm of the antibody differs by several orders of magnitude between the tetra- and
polysaccharides. This is not necessarily surprising either, since the antibody could
potentially bind to nearby motifs on the same molecule. The significantly slower kd2
may be due to fact that the second bindi g events are more likely to occur on ad-
jacent motifs than on adjacent molecules, suggesting the antibodies may be able to
“walk down” the length of the chain. Another distinguishing difference between the
polysaccharide and the tetrasaccharide is the Rmax which differs by nearly 30 fold.
Rmax is proportional to the stoichiometry of the ligand-analyte interaction. The dif-
ference between the expected Rmax for a single binding site and the observed Rmax for
the polysaccharide is approximately 15 fold, suggesting a stoichiometry of ∼15. This
estimate is expected to be low, and is consistent with the predicted average number
of tetrasaccharides per polysaccharide as calculated in Section B.2 (Figure B.1). The
data is not consistent with CS-E sulfation restricted to a single block, as the sensor-
grams would not fit to the bivalent model. Kinetic studies with Fab fragments would
provide better results.
B.3.2 Kinetics of CS-E Binding to Cell-Surface Receptors
The results of the polysaccharide-antibody interaction suggest that SPR is a viable
approach to studying the interaction of CS-E with proteins. We next examined if we
could use SPR to determine the kinetics of CS-E binding to cell-surface receptors.
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We have determined that several cell-surface receptors, such as NgR, and members
of the Eph and Ephrin families of receptors, and RPTPσ, bind GAGs by microar-
ray analysis.16,216 Interestingly, these proteins are involved in axonal guidance or
inhibition after injury, so understanding the strength of their interaction with CS
could be an efficient means to filter for likely candidates in CS-mediated guidance
and inhibition. First, we examined NgR, which had a particularly strong interaction
with CS by microarray.216 Indeed, NgR-CS-E binding dynamics are characterized
by a very slow rate of dissociation, and required multiple injections of regeneration
reagent between injections. A key feature of the interaction is the distinctive bimodal
shape of the sensorgrams. This is distinct from the bivalent model, especially in the
dissociation phase, where instead of a gradual, almost linear, dissociation, a fraction
of the bound analyte dissociates at a faster rate than the remaining portion. Simi-
larly, during the injection, there appears to be an initial fast association, followed by
a slower association (Figure B.4A).
This type of binding is consistent with a two-site ligand or analyte. Because of
the heterogeneity of the polysaccharide, and because both in silico modeling (Fig-
ure B.4C)468 and analysis of NgR truncation mutants59 indicate that multiple CS-E
binding sites on NgR are be unlikely, we reasoned that NgR may engage two types
of distinct domains of the polysaccharide with different kinetics to the same CS-
binding site on the protein. We fit the sensorgrams to the heterogeneous ligand
model (Equations B.13–B.18), which, despite the name, is a general two-site model.
The resulting fit was very good (χ2 = 17.3 RU2), with a high-affinity interaction with
an apparent K
D2
= 1.83 ± 1.65 pM, and a low-affinity interaction with an apparent
K
D2
= 8.69 ± 0.05 nM (Table B.3). The very significant error associated with the
high-affinity interaction is due to the very slow apparent kd2 which approaches the
detection limit of the instrument. The low-affinity interaction was characterized by
faster association and dissociation rates. The ratio of high-affinity to low-affinity
binding sites of 3.8.
Based on the model described in Section B.2, a naïve interpretation of a binding
interaction with independent sites is that a low-affinity site L on CS-E would have a
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Figure B.4: SPR analysis of the interaction of NgR and EphB3 to CS-E polysaccharide.
(A) Kinetics of the NgR interaction. NgR was passed over the sensor in a series of twofold
dilutions starting at 128 nM. The resulting sensorgrams (red) were fit to the heterogeneous
ligand model (black). (B) Affinity analysis of the NgR interaction. NgR was passed over the
sensor until reaching Req. The resulting curve was fit to the Langmuir equation B.1, giving
a value of KD = 4.3± 0.2 nM. (C) The predicted structure of NgR (white) bound to CS-E
(orange). NgR residues predicted to interact with CS-E are depicted as cyan spheres. (D)
Kinetics of the EphB3 interaction. A series of twofold dilutions of EphB3 starting at 3072
nM were passed over the sensor. The resulting sensorgrams (red) were fit to a 1:1 Langmuir
binding model. The approximate KD of the interaction is 84.9± 0.03 nM.
lower threshold tL of contiguous CS-E motifs, and a high-affinity site H would have
a higher threshold tH . Thus, the number of high-affinity sites would be the average
number of regions with contiguous CS-E sulfation of length greater or equal to the
high-affinity threshold (equation B.2). The number of low-affinity protein-binding
sites, on the other hand would be the sum of the average number of regions with
contiguous CS-E sulfation of length greater or equal to the low-affinity threshold up
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Table B.3: Kinetic parameters for the interaction of NgR, ephrin-A3 and RPTPσ with
CS-E polysaccharide by SPR according to the heterogeneous ligand model
Parameter NgR Ephrin-A3 RPTPσ
ka1 (M
−1s−1) 5.56 (±0.02)× 105 1.52 (±0.01)× 105 3.06 (±0.02)× 104
kd1 (s
−1) 4.83 (±0.02)× 10−3 1.30 (±0.01)× 10−3 1.50 (±0.01)× 10−2
K
D1 (M) 8.69 (±0.05)× 10−9 8.53 (±0.07)× 10−9 4.89 (±0.04)× 10−7
Rmax1 (RU) 63.7 (±0.1) 15.9 (±0.0) 53.8 (±0.2)
ka2 (M
−1s−1) 8.51 (±0.00)× 104 4.72 (±0.05)× 103 4.54 (±0.16)× 102
kd2 (s
−1) 1.55 (±1.40)× 10−7 1.20 (±0.02)× 10−3 3.11 (±0.02)× 10−3
K
D2 (M) 1.83 (±1.65)× 10−12 2.52 (±0.25)× 10−8 6.85 (±0.24)× 10−6
Rmax2 (RU) 240.5 (±0.1) 14.8 (±1.0) 384 (±12)
χ2 (RU2) 17.3 0.49 1.72
to the high-affinity threshold (equation B.3)
H =
n≤N∑
i=tH
x¯n (B.2)
L =
n<tH∑
i=tL
x¯n (B.3)
where N is the total length of CS-E polysaccharide and x¯n is the average number of
sites of contiguous CS-E sulfation of length n. Thus, we would expect there to be a
higher statistical frequency of high-affinity sites. To calculate the expected number,
we could modify the conditional expression on line 12 of the code in Section B.2 to
decrement the value of cnt by one if the value of tail exceeds thrsh. The modified
line of code, with whitespace removed for clarity, should appear as follows.
12 cnt + (1 if tail+1 == thrsh else -1 if tail+1 == thrsh+1 else 0))
With this modification, the code will calculate the distribution of sites with contiguous
sulfation of length exactly equal to thrsh (Figure B.5). Only when tH = tL + 1 does
H/L ≈ Rmax2/Rmax1, but even then, the ratios differ by nearly twofold for reasonable
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Figure B.5: Calculated distribution of CS-E n-mers in CS-E polysaccharides with an exact
length ranging from tetrasaccharide (n = 2) to tetrakaidecasaccharide (n = 7). For each
n-mer, the number of occurrences of the n-mer per average polysaccharide is plotted against
its probability.
values of n. A nearly equivalent mechanism, in terms of H/L ratio would be if
both binding sites required the same length of CS-E oligosaccharide, but the low-
affinity site could contain a non-CS-E sulfated disaccharide at a specified position.
It is possible that the Rmax ratio for the NgR binding sites is inexact due to the
difficulty in accurately determining a value for kd2, or CS-E sulfation may not be
purely random, and E sulfation at the ith position increases the probability of E
sulfation at the (i+ 1)th position.
Next, we tested EphB3 binding, previously discussed in Chapter 5. Unlike NgR,
the resulting sensorgrams fit to a one-to-one binding model (Equations B.4–B.7; Fig-
ure B.4). The kinetics featured a relatively slow ka and, again, a slow kd with good
overall affinity (K
D
≈ 85 nM, Table B.4). Consistent with the kinetics, the Rmax for
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EphB3 is approximately 3-fold less than NgR (which should be approximately equal,
if each had a stoichiometry of one), suggesting that EphB3 requires a longer region
of contiguous CS-E sulfation for high-affinity binding.
Table B.4: Kinetic parameters of the one-to-one interaction of
EphB3 and ephrin-B1 with CS-E polysaccharide
Parameter EphB3 Ephrin-B1
ka (M
−1s−1) 3.01 (±0.00)× 104 2.48 (±0.01)× 104
kd (s
−1) 2.56 (±0.01)× 10−4 2.70 (±0.00)× 10−3
KD (M) 8.49 (±0.03)× 10−8 1.09 (±0.00)× 10−7
Rmax (RU) 94.3 (±0.05) 34.1 (±0.1)
χ2 (RU2) 1.1 0.851
Next, we tested members of the EphA family of receptors. Members of this
family have been shown to affect axonal guidance,469 and have weak interactions with
heparin.101 It is possible, given the strong and specific interaction between EphB3
and CS-E, that EphAs might have a similar preference. First, we screened EphA1–
A8 for GAG binding by microarray analysis. Half of the EphAs (EphA1, A3, A4,
and A6) displayed some binding to CS-E by microarray, with EphA4 and EphA6
showing the strongest apparent affinity. Consistent with the microarray studies, the
relatively weak binders had either no apparent interaction with CS-E (EphA1), or
interacted very weakly (EphA3, Table B.5). The receptors with stronger affinity by
microarray had dissociation constants with CS-E polysaccharide in the nanomolar
range. Interestingly, EphA3, A4 and A6 all interacted with CS-E approximately
according to a one-to-one binding model (Figure B.6), like EphB3. Both EphA4
and A6 had approximately equal rates of association, but EphA6 had the strongest
apparent affinity with an rate of dissociation nearly two orders of magnitude slower
than EphA4 (Table B.5). The rate of dissociation for EphA4 is significantly faster
than any of the other CS-binding protein with significant affinity described here. The
EphAs interacted with CS-E with relatively low stoichiometry, perhaps suggesting
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Figure B.6: Sensorgrams of the interaction of EphA family members with CS-E polysaccha-
ride. (A) EphA3, (B) EphA4, and (C) EphA6 all bound to CS-E polysaccharide according
to the one-to-one model
that long contiguous regions of CS-E are required for binding.
In addition to the EphA and EphB receptors, both the ephrin-A and ephrin-B
families of ligands are thought to have a role in axonal guidance and inhibition after
injury.470 We screened ephrin-A1–A5 and ephrin-B1–B3 by microarray analysis, and
found ephrin-A1, -A3, -A5 and ephrin-B1 had some interaction with CS-E. Using
SPR, only ephrin-A3 and -B1 were found to have interactions with physiologically
relevant affinities. Unlike the EphA receptors, the interaction with ephrin-A3 could
not be described by the one-to-one binding model. In fact, the kinetics were difficult
to describe in general, as the heterogeneous ligand model had did not describe the
initial dissociation phase of the sensorgram (Figure B.7A, Table B.3). To obtain an
overall K
D
for the interaction, an affinity analysis was performed. The data fit well
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to the Langmuir equation B.1 (Figure B.7B) and gave an apparent K
D
of 49.3± 5.0
nM.
Table B.5: Kinetic parameters of the one-to-one interaction of EphA family mem-
bers with CS-E polysaccharide
Parameter EphA3 EphA4 EphA6
ka (M
−1s−1) 1.19 (±0.26)× 103 1.14 (±0.00)× 104 1.69 (±0.01)× 104
kd (s
−1) 1.61 (±0.02)× 10−2 1.61 (±0.05)× 10−2 7.81 (±0.05)× 10−4
KD (M) 1.35 (±0.30)× 10−5 8.55 (±0.04)× 10−7 4.62 (±0.03)× 10−8
Rmax (RU) 62.4 (±13) 34.2 (±0.1) 16.8 (±0.0)
χ2 (RU2) 0.322 0.242 1.83
Like ephrin-A3, ephrin-B1 was difficult to fit to standard models. While, the
ephrin-B1 sensorgrams fit reasonably well to the one-to-one model (χ2 = 0.851 RU2),
the initial association phase was poorly described, suggesting another interaction with
a faster rate of association might be affecting the kinetics (Figure B.7C). The hetero-
geneous ligand model, however, could not adequately fit the data. It is possible these
slight deviations are due to short-lived protein-protein interactions. Both ephrin-A3
and -B1 interact with similar stoichiometries, based on their respective Rmax values
(Tables B.3 and B.4).
Another important CS-binding protein is the type IIa receptor protein tyrosine
phosphatase sigma (RPTPσ). Like the Ephs/ephrins, members of this protein family
localize to axonal growth cones and regulate neuronal guidance, growth, and synapse
formation and maintenance.62,471–475 Type IIa RPTP family members, including
RPRPσ, have been shown to interact with both HSPGs and CSPGs.58,60,61,472,474
Activation of RPTPσ with the different classes of proteoglycans has opposite effects
on neuronal growth. HSPGs mediate growth promotion and CSPGs mediate growth
inhibition.60 Interestingly, the bimodal action of RPTPσ is mediated through a com-
mon binding site for both GAG classes.58,61
The GAG-binding site is located near the interface of the Ig1 and Ig2 domains
at the N terminus of the protein. Residues Lys67, Lys68, Lys70, Lys71, Arg96, and
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Figure B.7: Sensorgrams of the interaction of ephrin-A3 and ephrin-B1 with CS-E polysac-
charide. (A) Ephrin-A3 interacting with CS-E, fit to the heterogeneous ligand model. (B)
Affinity analysis of the ephrin-A3/CS-E polysaccharide interaction. (C) Ephrin-B1 interacts
with CS-E polysaccharide according to the one-to-one model.
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Arg99 are known to be involved in GAG binding, and form a positively charged sur-
face. Using the RPTPσ crystal structure, we computationally modeled the binding
of the protein to CS-E tetrasaccharide. Modeling identified the correct identified the
known GAG-binding site, and suggested a low-energy pose for bound CS-E (Fig-
ure B.8B). All of the residues previously shown to interact with GAGs were within
5 Å of bound CS-E, including Arg76, which was identified in the crystal structure of
SOS, a heparin analog, with LAR (Table B.6).60 Interestingly, all of the CS-E sul-
fates interact directly with the protein, leaving a relatively uncharged solvent-exposed
surface, suggesting CS-E is not capable of mediating receptor dimerization at this in-
terface. A single heparin oligosaccharide, with its higher charge density and helical
twist (Figure 1.7), on the other hand, may be able to bind two RPTPσ molecules
(Figure B.13B). This may account for the difference in mechanism between the two
GAGs.
The binding site for CS-E is only slightly larger than a tetrasaccharide, suggesting
a high stoichiometry by SPR. As predicted, the estimated binding stoichiometry was
higher than that of NgR (Table B.3). Like NgR, the interaction with CS-E polysac-
charide and RPTPσ was well described by the heterogeneous ligand model. Unfor-
tunately, contaminates in the protein sample (likely degradation products) makes
interpreting the kinetic parameters difficult. For example, the estimated K
D
was
approximately 100-fold higher than the literature value.58,60 Confirming the protein
was active, an ELISA with bound RPTPσ and varying concentrations of biotinylated
CS-E gave a correct estimate for the K
D
(Figure B.13A). Qualitatively, the associa-
tion was relatively rapid compared to the other receptors examined, and similar to
NgR. In contrast to NgR, the dissociation was rapid, but probably not as fast as the
dissociation of CS-E and EphA3 or EphA4. It would be interesting to compare these
kinetics with the interaction with heparin. Given the rate of dissociation of RPTPσ
from CS-E, there may be a kinetic basis for the phenotypic difference between the
GAGs.
In summary, we have shown that several cell-surface receptors interact strongly
with CS-E polysaccharide with kinetics that follow known models of protein-ligand
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Figure B.8: Sensorgrams and predicted binding pose of RPTPσ with CS-E. (A) The
binding of RPTPσ with CS-E polysaccharide was well described by the heterogeneous ligand
model. (B) The computationally predicted binding pose for CS-E tetrasaccharide. CS-E was
predicted to bind in the known GAG-binding region of RPTPσ. All of the residues known to
interact with GAGs (green) were within 5 Å of the ligand (colored residues). Arg76 (yellow)
was shown to interact with SOS,60 a heparin analog.
binding. Interestingly, despite the heterogeneity of CS-E polysaccharide, the cell-
surface proteins tested here interact discretely with CS-E, many according to the
one-to-one model. The actual stoichiometry was often several-fold greater than the
expected value for one-site binding, and the variance in apparent stoichiometry be-
tween the proteins was similar in magnitude. The variance in stoichiometry could
be due to the different requirements for a protein to make cooperative contacts with
CS-E-sulfated regions of the polysaccharide. Together, this supports the naïve model
for CS-E sulfation proposed in Section B.2, which predicts different distributions of
motifs with a contiguous block of CS-E sulfation for a given block length. The ratio
of high and low-affinity sites on NgR, however, suggests that one of the assumptions
of the model—that E sulfation is completely random—may be incorrect; however, the
deviations from the random model are small. Although, the binding species for NgR
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Figure B.9: Isoelectric potential surfaces of CS-E-binding cell-surface receptors. The
isoelectric potential surfaces for NgR (A), EphB3 (B), EphB2(C), EphA3 (D), EphA4 (E),
EphA6 (F), ephrin-A3 (G), ephrin-B1 (H) and RPTPσ reveals differences in the likely CS-
binding sites between the proteins.
and other CS-E-binding proteins must be better understood before drawing too many
conclusions from a simple model. Detailed computational modeling should help in
this regard. Importantly, kinetic binding data was extremely helpful in understanding
the nature of the CS-E-protein interaction.
B.3.3 CS-E Binding to Growth Factors
Growth factors have traditionally been considered the principle binding partners for
CS. CS has been shown to bind a number of growth factors, including the NT family
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Figure B.10: Sensorgrams of the interaction of CS-E with growth factors. (A) NGF seems
to bind CS-E according to a one-to-one Langmuir model, however higher concentrations are
needed to accurately describe the kinetics. (B) NT-4/5 binding to CS-E is characterized
by rapid association and dissociation of the bulk of NT-4/5, with a slower binding event
with lower stoichiometry. (C) GDNF binding to glycopolymer 1 is inconsistent with simple
binding mechanisms. (D) GDNF binding to the CS-E polysaccharide. Note the significant
differences in binding to the polysaccharide compared to glycopolymer 1 in (C).
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members, MK, PTN, heparin-binding epidermal growth factor (HB-EGF), GDNF,
and select FGF family members (see Chapter 2).216 To better understand the mech-
anism of interaction between CS-E and growth factors, we examined the binding of
CS-E with NT family members NGF and NT-4/5. In Chapter 3, we noted the relative
enhancement of TrkA binding to CS-E polysaccharide was several-fold higher in the
presence of NT-4/5 than in the presence of NGF. To determine the molecular basis
of this difference, we measured the kinetics of these interactions by SPR.
Interestingly, the kinetics and the stoichiometry of the interactions of NGF and
NT-4/5 with CS-E were startlingly different, despite the high homology between the
proteins. Both NGF and NT-4/5 interact with CS-E polysaccharide with an estimated
affinity of ∼1 µM; however, it was not possible to fully describe the affinity or kinetics
of either protein due to the poor solubility of the growth factors at high concentrations
at physiological pH. NGF interacted with a relatively slow apparent on and off rate,
and with relatively low stoichiometry. While it was not possible to fully describe the
kinetics of the interaction due to poor coverage of the effective concentration range,
the data appear to fit to a one-to-one binding model.
NT-4/5, on the other hand, interacted with extremely high stoichiometry and
rapid on and off rates. The apparent rates of association and dissociation are too
rapid to be quantified by SPR. Additionally, a second slower interaction is apparent.
After the bulk of NT-4/5 associates to CS-E during the initial phase of the injection,
additional NT-4/5 associates at a much slower rate and lower stoichiometry. A sim-
ilar and proportional effect can also be seen during the dissociation. This suggests
that NT-4/5 can weakly associate at several locations on the polysaccharide, but the
protein has a tighter interaction at less frequently expressed motifs.
These findings are consistent with the differences between NGF and NT-4/5 seen
in Chapter 3 in terms of relative selectivity between CS sulfation motifs and can
help explain some of the relative ability of each NT to enhance TrkA binding to
the ternary complex. The high stoichiometry of NT-4/5 binding to CS-E suggests
a relative ambivalence of this protein to regions of high contiguous CS-E sulfation,
consistent with the lower relative selectivity of NT-4/5 to CS-E tetrasaccharide (Fig-
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ure 3.3A). The slow, tight binding interaction of NGF, on the other hand, suggests
that NGF requires binding sites rich in CS-E sulfation, which is consistent with the
high selectivity observed by microarray analysis. The difference in the ability of each
NT to recruit TrkA in ternary complexes, as seen in Figure 3.3C, may be due to
the differences in stoichiometry of the NTs bound to CS-E. In other words, NT-4/5
may be able to recruit more TrkA to CS-E than NGF simply because there is more
NT-4/5 bound to CS.
Finally, we examined the binding of glial-derived neurotrophic factor (GDNF) with
CS-E polysaccharide and synthetic CS-E glycopolymer 1. The glycopolymer exploits
multivalency to enhance the affinity of proteins to the disaccharide monomers, which
alone have poor affinity.220 Using glycopolymer 1, we would expect complex kinetics
because the CS repeating unit of 1 implies lattice-like binding.462 However, kinetics
according to the McGhee-von Hippel model would only be applicable if GDNF had
a simple mode of disaccharide binding. Unfortunately, given the electrostatic poten-
tial map of the protein (Figure 2.6E), it is likely that there are several disaccharide
binding sites with variable affinity. Indeed, The resulting sensorgrams suggest a com-
plex mechanism (Figure B.10C). The binding is made more difficult to understand
by apparent secondary effects, for example protein-protein aggregation, which are
especially prevalent at high protein concentrations.
Our studies with NGF, NT-4/5, and GDNF, as well as several examples in the
literature suggest that growth factor-GAG interactions have complex binding interac-
tions. For example, SPR studies with CS and MK,79,215 chemokines,466 Wnt,217 PTN
and FGFs,215 or heparin with FGFs,21,240,257 chemokines,188 Slits,476 have demon-
strated that a variety of growth factors or other excreted proteins have complex
interactions with GAGs. Perhaps this is not surprising given the small size, high
proportion of electropositive surface area, and the poor GAG sequence specificity of
these proteins (see Chapter 2). These proteins may engage GAGs in a variety of
poses at different locations on the protein, each with various affinities for different
GAG sequences. The resulting sensorgrams, the average of all of these interactions,
are simply too complex to decipher.
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B.4 Conclusion
While growth factors, the archetypal CS-binding partners, have apparently complex
kinetic interactions with CS-E, cell-surface receptors, only recently recognized as in-
teracting with CS, have readily interpretable kinetics. Of the cell-surface proteins
tested, those with measurable affinity to CS-E by SPR bound according to one-to-
one binding (EphB3, EphAs, ephrin-B1) or according to a heterogeneous ligand model
(NgR, ephrin-A3, RPTPσ), which can be rationalized as the interaction of the protein
with two different lengths of CS subsequences, each with different kinetics. A com-
mon feature of CS-E-receptor interactions is the relatively low binding stoichiometry
relative to growth factors, suggesting that these proteins engage long regions of CS.
This is largely borne out by examining the relative size of positive regions on the
electrostatic potential surface of these proteins. Low binding stoichiometry tends to
correspond to proteins with large regions of electropositive charge. The differences
between growth factors and receptors in how they engage CS may reflect mechanistic
differences between the two binding events. For example, GAG-growth factor binding
is typically associated with the stimulation of neuronal growth, whereas GAG-receptor
interactions are associated with repulsive guidance or inhibition.
B.5 Materials and Methods
SPR experiments were performed on a Biacore T100 at 25 ◦C using Sensor Chip CM5
and running buffer composed of 0.01 M Hepes, pH 7.4, 0.15 M NaCl, 3 mM EDTA,
0.05% Surfactant P20 (HBS-EP+).
B.5.1 Preparation of Biotinylated CS Polysaccharide
Chondroitin sulfate C and E polysaccharide was purchased from Seikagaku America
and conjugated with biotin as previously described.438 Briefly, 2 mg of CS-C or CS-E
were dissolved in 1 ml of 0.05 M NaHCO3 for 30 min at room temperature. EZ-Link
Sulfo-NHS-LC-LC-Biotin (0.25 mg; Pierce) was dissolved in 1 ml H2O and added to
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each CS sample. The solution was mixed at room temperature for 3 h, lyophilized,
and resuspended in H2O. Excess biotin was removed by gel filtration using Sephadex
G-50 (Amersham) or dialysis.
B.5.2 Preparation of CS-E Tetrasaccharide Conjugated Chips
Both active and control flow cells of a CM5 sensor chip were exposed to a 1:1 mixture
of N -hydroxysuccinimide (NHS) and 1-ethyl-3-(3-diethylaminopropyl)carbodiimide
(EDC) for 3 min at a flow rate of 10 µl · min−1. Next, 5 mM carbohydrazine was
injected at the same flow rate for 7 min. CS-E tetrasaccharide, with an aldehyde-
functionalized reducing end, prepared as previously described,15,218 was covalently
attached to the surface by injecting a 0.5 mM solution of tetrasaccharide onto the
flow cell in a short pulse (0.05 mg · ml−1, 10 s, 60 µl · min−1), followed by a 20 min
injection of 0.1 M sodium cyanoborohyride in 0.1 M sodium acetate buffer, pH 4.0
at 2 µl ·min−1. Because of the low molecular weight of the CS-E tetrasaccharide, it
was not possible to observe the amount of ligand bound to the surface. Instead, 500
nM of the CS-E antibody 2D11-2A10 was injected onto both the control and active
flow cells to test the response. The amount of ligand on the surface was increased, as
described above, until an adequate response (50–150 RU) was observed.
B.5.3 Preparation of CS Polysaccharide/Glycopolymer Con-
jugated Chips
Both control and active flow cells were activated with a 1:1 mixture of EDC:NHS
for 3 min at µl · min−1, according to the manufacturer’s amine coupling protocol.
Streptavidin (1 µM, 0.01 NaOAc, pH 5.0) was conjugated to the activated surface
until saturation, followed by ethanolamine blocking. Biotinylated CS polysaccharide
or glycopolymer, prepared as previously described,439 was immobilized onto the active
flow cell (2 or 4) to give an RL of 25 RU.
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B.5.4 Analysis of CS-Protein Interactions
For the CS-E antibody, concentrations of 2D11-2A10 was injected over control and
active flow cells for 300 s at 30 µl ·min−1. The dissociation was monitored for 900 s
before the surface was regenerated using a 30 s injection of 6 M guanidine HCl. The
resulting sensorgrams were fit to a bivalent analyte model.
Affinity analysis was measured by injecting the antibody for 3,600 s at 5 µl·min−1.
After 600 s, the surface was regenerated with a 60 s injection of guanidine HCl at 10
µl · min−1. The data were analyzed by plotting the response at equilibrium versus
CS-E antibody concentration and fitting the resulting curve to the Langmuir equation
B.1. For CS polysaccharides or glycopolymers, proteins were injected over both the
control and active flow cells for 240 s at a flow rate between 50–80 µl·min−1, depending
on the protein. The dissociation was monitored for 600–800 s before the surface was
regenerated by one to three 30–90 s injections of 2.5 M MgCl2 at a flow rate of 30
µl ·min−1. When possible, the resulting sensorgrams were fit to either a one-to-one
binding or heterogeneous ligand model. In other cases, the response at equilibrium
was fit to the Langmuir equation B.1.
B.6 Supplementary Information
B.6.1 Models
The Biacore SPR evaluation software globally fits kinetic sensorgrams to the user-
chosen model. Each model is a system of rate equations with limiting conditions.
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The one-to-one Langmuir binding model:
d[A]
dt
= tcf
1/3 ([A]soln − [A])− (ka[A][B]− kd[AB]) , [A](0) = 0 (B.4)
d[B]
dt
= − (ka[A][B]− kd[AB]) , [B](0) = Rmax (B.5)
d[AB]
dt
= ka[A][B]− kd[AB], [AB](0) = 0 (B.6)
Rtotal = [AB] +RI (B.7)
The bivalent analyte model:
d[A]
dt
= tcf
1/3([A]soln − [A])− (2ka1[A][B]− kd1[AB]), [A](0) = 0
(B.8)
d[B]
dt
= − ((2ka1[A][B]− kd1[AB])− (ka2[AB][B]− 2kd2[AB2])) , [B](0) = Rmax
(B.9)
d[AB]
dt
= (2ka1[A][B]− kd1[AB])− (ka2[AB][B]− 2kd2[AB2]), [AB](0) = 0
(B.10)
d[AB2]
dt
= ka2[AB][B]− 2kd2[AB2], [AB2](0) = 0
(B.11)
Rtotal = [AB] + [AB2] +RI (B.12)
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The heterogeneous ligand model:
d[A]
dt
= tcf
1/3([A]soln − [A])− (ka1[A][B1]− kd1[AB1])−
(ka2[A][B2]− kd2[AB2]), [A](0) = 0 (B.13)
d[B1]
dt
=− (ka1[A][B1]− kd1[AB1]), [B1](0) = 0 (B.14)
d[B2]
dt
=− (ka2[A][B2]− kd2[AB2]), [B2](0) = 0 (B.15)
d[AB1]
dt
= ka1[A][B1]− kd1[AB1], [AB1](0) = 0 (B.16)
d[AB1]
dt
= ka2[A][B2]− kd2[AB2], [AB2](0) = 0 (B.17)
Rtotal = [AB1] + [AB2] +RI (B.18)
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B.6.2 Supplementary Figures
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Figure B.11: Preparation of sensors for SPR studies. (A) Aldehyde coupling. The surface
was activated with an injection of a 1:1 mixture of EDC:NHS. The NHS esters were exposed
to carbohydrazine to form the hydrazide derivative. Unreacted NHS esters were quenched
with ethanolamine. A small amount of ligand at a predetermined concentration was injected
onto the surface, then the resulting hydrazone groups were reduced with NaBH4. (B) Strep-
tavidin capture. Streptavidin was passed over the activated surface at low pH to saturate
the sensor. Ethanolamine was injected to react with any remaining NHS esters. (C, D)
Capture of mono-biotinylated CS-E polysaccharide (C) or end-capped CS-E glycopolymer
(D). An injection of the desired compound at a predetermined concentration, flow rate and
injection time achieved the desired RL.
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Figure B.12: Human Fc was passed over the CS-E polysaccharide in a series of 2-fold
dilutions starting at 3072 nM under conditions identical to those used for EphB3. No
response over baseline was observed.
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Figure B.13: RPTPσ binding to CS polysaccharides by ELISA and computational model
with heparin. (A) RPTPσ was absorbed to the surface and incubated with the indicated
CS polysaccharide at the indicated concentration. The resulting curves were fit to obtain
an estimated value for the KD . (B) The lowest-energy pose for heparin bound to RPTPσ.
Heparin bound in a similar conformation to CS-E (Figure B.8B), but due to the higher
charge density and helical twist, heparin has more charge density exposed to solvent than
CS-E.
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Table B.6: Comparison of RPTPσ
residues identified to interact with
GAGs and residues found within 5
Å of docked structures of CS-E and
heparin
Literature60 CS-E Heparin
Lys67 Lys67 Lys67
Lys68 Lys68 Lys68
Lys70 Lys70 Lys70
Lys71 Lys71
Val72 Val72
Asn73 Asn73
Ser74 Ser74
Gln75 Gln75
Arg76 Arg76 Arg76
Phe77 Phe77
Ile92
Pro94
Arg96 Arg96 Arg96
Arg99 Arg99 Arg99
Asp100 Asp100
Asn102 Asn102
Tyr104 Tyr104
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Appendix C
Incremental Improvement of the
Synthesis of CS-E Tetrasaccharide
C.1 Introduction
The heterogeneity of naturally obtained CS-E polysaccharides in both length and
sulfation precludes its use in several kinds of experiments. The direct comparison of
the effect of sulfation, x-ray crystallographic, or 1H NMR structural studies require
homogeneous samples to get an unambiguous answer. Therefore, homogenous samples
of CS-E were synthesized, using a highly convergent route that efficiently exploits the
modular properties inherent in the target molecule, as previously developed in the
lab.15,70 CS-E tetrasaccharide 1 was derived from the fully protected tetrasaccharide
2 in only five steps. The arrangement of the protecting groups in 2 also allows for
the facile generation of other sulfation patterns, and can be generated by coupling
the disaccharide acceptor 3 with the donor 4. The structural similarity of acceptor
3 and donor 4 allow their synthesis from the key disaccharide 5 in only one and
three chemical steps, respectively. The need for only a single disaccharide is a major
advantage of the synthesis, necessitating the preparation of only two monosaccharides,
GlcA donor 6 and GalN acceptor 7 (Figure C.1). Herein, we report the synthesis of
CS-E tetrasaccharide 1 with minor modifications to the published procedure.
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Figure C.1: Retrosynthesis of CS-E tetrasaccharide 1
C.2 Synthesis of the GlcA Monomer
Due to the length of the synthesis, the monomers must be prepared on a large scale
from readily available starting materials. The synthesis of the GlcA donor began
by converting commercially available glucose pentaacetate 8 to the corresponding β-
thioglycoside by Lewis acid-catalyzed displacement of the anomeric acetate, followed
by nucleophilic attack of the resulting oxocarbenium ion with p-tolSH at −20 ◦C.
Developed over 40 years ago, this reaction was effective at scales as high as 100
g.477 Subsequent hydrolysis of the remaining acetate groups with NaOMe in MeOH
returned 9 in 90% yield over two steps. Next, the 4- and 6-hydroxyl groups were
selectively protected with p-anisaldehyde dimethyl acetal and catalytic CSA in an
adaptation of a known procedure.478 Benzoylation of the 2- and 3-hydroxyl groups
with BzCl and DMAP afforded 10 as white needles after recrystallization from EtOAc.
The regioselective opening of the benzylidene ring was provided by treatment of 10
with NaBH3CN and TFA to return the less substituted PMB ether.479 TBS protection
of the 4-hydroxyl, followed by PMB hydrolysis with DDQ in the dark afforded the
alcohol 11 in 88% yield.480 Next, the primary hydroxyl group of 11 was oxidized
to the acid. In previously reported versions of this synthesis, pyridinium dichromate
was used to affect this transformation. However, this reaction had serious drawbacks:
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Figure C.2: Synthesis of GlcA donor 6. Reagents and conditions: (a) i. SnCl4, p-TolSH,
CH2Cl2, −20 ◦C, 91%; ii. NaOMe, MeOH, rt. 2 h, 99%; (b) i. Anisaldehyde dimethy acetal,
CSA, CH3CN, DMF, 15 h, 84%; ii. BzCl, DMAP, CH2Cl2, 30 min, 84%; (c) i. NaBH3CN,
TFA, DMF, 25 h; ii. TBSOTf, DMAP, CH2Cl2, 1 h, 85%; iii. DDQ, CH2Cl2, H2O, 15 h,
88%; (d) BAIB, TEMPO, CH2Cl2, 30 min; CH2N2, Et2O, CH2Cl2, 81%; (e) i. NIS, TfOH,
CH2Cl2, THF, H2O. ii. Cs2CO3, Cl3CCN, CH2Cl2, 89%
the reaction was extremely slow, taking 3 days to complete, the reagent is highly
toxic and required an extra chromatographic step to remove the chromium salts.
Instead, the oxidation was accomplished with BAIB and catalytic TEMPO in 30
min.481 Exposure of the crude acid with CH2N2 returned ester 12 in 81% yield
over two steps. This oxidation reagent is sufficiently mild to allow for the selective
oxidation of a primary alcohol in the presence of a secondary alcohol. Therefore, it
could be possible to reduce the synthesis by a step by hydrolyzing 10 with catalytic
acid, the treating the resulting diol with BAIB and catalytic TEMPO, followed by
diazomethane esterification. TBS protection of the 4-hydroxyl group would afford 12.
The increase in efficiency may be offset by the potential difficulty of installing the 4-O
protecting group in the presence of the electron withdrawing methyl ester. Hydrolysis
of the anomeric protecting group, followed by treatment of the resulting hemiacetal
with Cs2CO3 and Cl3CCN returned the desired GlcA donor 6 (Figure C.2).482
C.3 Synthesis of the GalNAc Monomer
In a modified route from our previously reported synthesis, the GalNAc acceptor
7 was synthesized by converting tri-O-acetyl-d-galactal 13 to the corresponding α-
azidoselenide 14 using PhSeSePh, TMSN3, and BAIB in 65% yield.483 Next, the azide
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Figure C.3: Synthesis of GalN Acceptor 7. Reagents and conditions: (a) (PhSe)2, TMSN3,
BAIB, CH2Cl2, 65%; (b) i. 1,2-dithiopropane, Et3N; ii. TCACl, Et3N, CH2Cl2, 70% over
two steps; (c) i. NaOMe, MeOH; ii. Anisaldehyde dimethyl acetal, CSA, CH2Cl2, 95% over
two steps; (d) Allyl alcohol, TMSOTf, CH2Cl2, 53%
was reduced with 1,3-dithiopropane, and the resulting amino sugar was converted
to the TCA derivative 15 in 70% yield. Due to the electron withdrawing nature
of the three acetate groups of 15, attempts to install the anomeric allyl group at
this point proceeded poorly. Instead, the acetates were removed with NaOMe in
MeOH, and the 4,6-benzylidene ring was selectively prepared with p-anisaldehyde
dimethyl acetal and catalytic CSA to give 16 in 95% yield over two steps. The β-
allyl group was installed by TMSOTf-mediated elimination of the selenophenyl moiety
and subsequent attack of allyl alcohol, present in excess. Exclusive generation of the
β-isomer was accomplished due to anchimeric assistance from the trichloroacetamido
group in the 2-position. Unfortunately, this reaction suffered from low yield, due
to poor solubility and because of the inherent lability of the p-methoxybenzylidene
group in acidic conditions, providing the GalN acceptor 7 in 53% yield. Despite these
challenges, this route is a significant improvement over the previous method because
it avoids redundant manipulations of the anomeric protecting groups required in the
published synthesis.
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C.4 Generation and Elaboration of CS-E Tetrasac-
charide Through a Key Disaccharide Intermedi-
ate
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Figure C.4: Synthesis of CS-E tetrasaccharide 1. Reagents and conditions: (a) TMSOTf,
4 Å molecular sieves, CH2Cl2, −45→ −20 ◦C, 74%; (b) HF · pyridine, THF, pyridine. 88%;
(c) i. Grubb’s 2nd gen. cat. (10 mol%), CH2Cl2; ii. I2, pyr, THF, H2O, iii. Cl3CCN,
DBU, CH2Cl2, 86%; (d) TMSOTf, 4 Å molecular sieves, CH2Cl2, −78→ −20 ◦C, 54%; (e)
i. Bu3SnH, AIBN, PhH, DMA, 80
◦C; ii. DDQ, CH2Cl2, H2O, 86% over two steps; (f) i.
SO3 · TMA, DMF, 50 ◦C, 84%; ii. HF · pyridine, THF, pyridine, H2O; iii. 1 M LiOH, 30%
H2O2, THF, H2O; 4 M NaOH, MeOH, 64% over two steps
With the final monomers in hand, a mixture of GlcA donor 6 and GlcN acceptor
7 were exposed to anhydrous TMSOTf in the presence of 4 Å molecular sieves un-
der a carefully controlled temperature gradient of −45 → −20 ◦C to return the key
disaccharide 5 in 74% yield. Exposure of the resulting disaccharide to HF · pyridine
provided the disaccharide acceptor 3. Alternatively, isomerization the anomeric allyl
group of 5 with Grubb’s second-generation catalyst, followed by hydrolysis with io-
dine, and treatment of the resulting hemiacetal with Cl3CCN in DBU afforded the
disaccharide donor 4. Coupling of 3 and 4, using catalytic by TMSOTf in a temper-
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ature gradient from −78 to −20 ◦C returned tetrasaccharide 2 in yields as high as
54%. This coupling step generates a disaccharide byproduct that is difficult to sep-
arate from the product. Gel filtration through Sephadex LH-20 resin prior to silica
gel chromatography cleanly removed this impurity, expediting purification. Radical-
mediated reduction of the C−Cl bonds of the TCA groups with Bu3SnH catalyzed by
AIBN,484 followed by hydrolysis of the benzylidene rings gave the tetraol 17. Sulfa-
tion by SO3 · TMA in elevated temperature for 3 days followed by deprotection of the
non-reducing-end TBS group and saponification under mild conditions485 returned
the desired CS-E tetrasaccharide 1.
C.5 Materials and Methods
Unless otherwise stated, all reactions were performed in flame-dried glassware under
an atmosphere of argon using freshly distilled solvents. Thin-layer chromatography
(TLC) was performed using 0.25 mm E. Merck silica gel 60 F254 plates, and visualized
with cerium ammonium molybdate stain. 1H and 13C NMR spectra were recorded
on Varian Mercury 300 (300 MHz), Inova 500 (500 MHz), or 600 Mercury (600 MHz)
instruments. NMR data are reported as follows: chemical shift (δ ppm), multiplicity
(s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant,
and integration. Mass spectra were obtained from the Protein/Peptide MicroAnalyt-
ical Laboratory at the California Institute of Technology.
p-Methylphenyl-1-thio-β-d-glucopyranoside (9). To a solution of glucose pen-
taacetate (50 g, 128 mmol), p-TolSH (17.5 g, 141 mmol) in CH2Cl2 (500 ml) at −20◦C
was added SnCl4 (10.5 ml, 90 mmol). After stirring 5.5 h, the reaction was quenched
with saturated aqueous NaHCO3, and the mixture was warmed to room temperature.
The organic layer was extracted, dried (MgSO4), filtered, and concentrated to afford a
yellow-white solid. Purification by flash chromatography (25%→30% EtOAc:hexanes)
returned a white solid (53 g, 91%).
The tetraacetate (26.5 g, 58.3 mmol) was dissolved in MeOH (800 ml) and CH2Cl2
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(117 ml), and NaOMe (4 ml, 17.5 mmol) was added. After stirring 1h, the reaction
was quenched by the addition of Dowex 50X8-200 resin, filtered and concentrated to
afford 9 (16.6 g, 99%) as a white solid. 1H NMR (300 MHz, CD3OD): δ = 7.26 (d,
J = 8.5 Hz, 2H), 7.12 (d, J = 8.5 Hz, 2H), 4.57 (d, J = 9.6 Hz, 1H), 3.73 (dd, J =
12, 1.5 Hz, 1H), 3.58 (dd, J = 12, 5 Hz, 1H), 3.34–3.21 (m, 3H), 3.11 (t, J = 9.5 Hz,
1H), 2.28 (s, 3H). ESI MS [M + Na]+m/z calc: 309.08, found: 309.0.
p-Methylphenyl 2,3-di-O-benzoyl-4,6-O-p-methoxybenzylidene-1-thio-β-d-
glucopyranoside (10). To a solution of 9 (64.2 g, 224 mmol) in CH3CN (1750 ml)
and DMF (156 ml) was added p-anisaldehyde dimethyl acetal (96.5 ml, 561 mmol)
and (±)-10-camphorsulfonic acid (15.6 g, 67 mmol). After stirring for 12 h, the re-
action was quenched with Et3N and the mixture was concentrated in vacuo. The
crude oil was purified by SiO2 chromatography (50%→70% EtOAc/hexanes) to give
a white solid (76 g, 84%).
The resulting solid (90.8 g, 224 mmol) and DMAP (96 g, 786 mmol) were dissolved
in CH2Cl2 (1300 ml) and cooled to 0 ◦C. BzCl (83 ml, 715 mmol) was added drop-
wise. After stirring for 25 min, the reaction was quenched with saturated aqueous
NaHCO3. The aqueous layer was extracted with CH2Cl2 and the combined organic
layers were washed with brine and dried with Na2SO4. The mixture was filtered and
concentrated to afford a pale yellow solid. The crude solid was washed with MeOH
and recrystallized from EtOAc to afford the product 10 as colorless needles (115 g,
84%). 1H NMR (300 MHz, CDCl3): δ = 7.98–7.90 (m, 4H), 7.56–7.30 (m, 10H), 7.12
(d, J = 8 Hz, 2H), 6.82 (d, J = 9 Hz, 2H), 5.76 (dd, J = 9.5, 9.5 Hz, 1H), 5.49 (s,
1H), 5.43 (dd, J = 9.5, 9.5 Hz, 1H), 4.95 (d, J = 10.5 Hz, 1H), 4.43 (dd, J = 4.5,
11 Hz, 1H), 3.90–3.82 (m, 2H), 3.76–3.67 (m, 4H), 2.35 (s, 3H). 13C NMR (75 MHz,
CDCl3: δ = 165.6, 165.2, 160.1, 138.8, 133.8, 133.3, 133.1, 129.9, 129.8, 129.4, 129.3,
129.2, 128.4, 128.3, 127.9, 127.5, 113.6, 101.5, 87.3, 78.5, 73.4, 71.1, 71.0, 68.5, 55.3,
21.3. FAB MS [M + H]+m/z calc: 613.1896, found: 613.1879.
p-Methylphenyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-1-thio-β-d-
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glucopyranoside (11). To a flask containing 10 (40.5 g, 66 mmol), NaBH3CN
(20.8 g, 331 mmol), activated 3 Å molecular sieves (40.5 g) in DMF (800 ml) at 0
◦C, TFA (51 ml, 610 mmol) was added dropwise. After stirring 1 h, the mixture
was warmed to room temperature and stirred an additional 24 h. The resulting
mixture was filtered, diluted with CH2Cl2, and quenched with the addition of cold
saturated aqueous NaHCO3. The aqueous layer was separated and washed twice with
CH2Cl2. The combined organic layers were washed with saturated aqueous NaHCO3
and brine, then dried with Na2SO4. After the mixture was filtered and concentrated,
the resulting material was dissolved in CH2Cl2 and washed three times with brine.
The organic layer was dried with Na2SO4, filtered, and concentrated to return the
crude alcohol.
The resulting alcohol was dissolved in CH2Cl2 (1.6 L) and cooled to 0 ◦C. Et3N
(27.5 ml, 198 mmol) was added, followed by the dropwise addition of TBSOTf (38 ml,
165 mmol). The reaction was warmed to room temperature and stirred an additional
3 h. The reaction was quenched with NaHCO3 and diluted with CH2Cl2. The aqueous
layer was separated and extracted three times with CH2Cl2. The combined organic
layers were washed with brine and dried over MgSO4, filtered, concentrated and
purified by SiO2 chromatography (10%→ 15% EtOAc/hexanes) to give a white solid
(65 g, 85% over two steps).
The resulting TBS ether (65 g, 89 mmol) was dissolved in CH2Cl2 and H2O (110
ml) and protected from light. DDQ (24.3 g, 107 mmol) was added, and the reaction
was stirred in the dark for 15 h. The reaction was quenched with saturated aqueous
NaHCO3 and diluted with H2O. The aqueous layer was extracted three times with
CH2Cl2 and the combined organic layers were washed with brine. After the solu-
tion was dried with MgSO4, filtered, and concentrated, the resulting peach solid was
purified by SiO2 chromatography (40% CH2Cl2/hexanes → 100% CH2Cl2 → 70%
EtOAc/CH2Cl2) to afford 11 as a colorless foam (47.8 g, 88%). 1H NMR (300 MHz,
CDCl3): δ = 7.92–7.88 (m, 4H), 7.52–7.45 (m, 2H), 7.38–7.32 (m, 6H), 7.12 (d, J =
8 Hz, 2H), 5.62 (dd, J = 9.5, 9.5, 1H), 5.29 (dd, J = 9.5, 9.5, 1H), 4.93 (d, J = 10
Hz, 1H), 4.02–3.92 (m, 2H), 3.81–3.73 (m. 1H), 3.57 (d, J = 11.5, 1H), 2.35 (s, 3H),
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1.95 (bs, 1H), 0.76 (s, 9H), 0.07 (s, 3H), −0.20 (s, 3H). 13C NMR (75 MHz, CDCl3):
δ = 169.5, 165.4, 138.7, 133.5, 133.3, 133.2, 130.0, 129.9, 129.8, 129.4, 128.5, 128.4,
86.4, 81.1, 77.2, 71.3, 69.0, 62.0, 25.9, 21.6, 18.2, −3.9, −4.3. FAB MS [M+H]+ m/z
calc: 609.2342, found: 609.2321.
p-Methylphenyl methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-1-
thio-β-d-glucopyranosyluronate (12). To a solution of alcohol 11 (32.1 g, 53
mmol), DAIB (42.5 g, 132 mmol) in CH2Cl2 (395 ml) and H2O (132 ml), TEMPO
(1.65 g, 10.5 mmol) was added. The mixture was allowed to stir 30 min before the
addition of 1 M aqueous Na2S2O3. The aqueous layer was separated, acidified with
1 M HCl, and extracted three times with CH2Cl2. The combined organic layers were
dried with MgSO4, filtered, and evaporated. To a solution of the crude acid in CH2Cl2
(530 ml) at 0 ◦C, CH2N2 (605 ml, ∼0.2 M in Et2O, 121 mmol) was added dropwise.
After stirring 1 h, AcOH was added dropwise to quench any remaining CH2N2. The
mixture was then concentrated and purified by SiO2 chromatography (10% → 15%
EtOAc/hexanes) to yield the ester 12 as a white solid (27.3 g, 81%). 1H NMR (300
MHz, CDCl3): δ = 7.90–7.86 (m, 4H), 7.52–7.46 (m, 2H), 7.38–7.31 (m, 6H), 7.10
(d, J = 8 Hz, 2H), 5.59 (dd, J = 9.5, 9.5 Hz, 1H), 5.30 (dd, J = 9.5, 9.5 Hz, 1H),
4.90 (d, J = 10 Hz, 1H), 4.26 (dd, J = 9, 9 Hz, 1H), 4.08 (d, J = 8.5 Hz, 1H), 3.82
(s, 3H), 2.33 (s, 3H), 0.71 (s, 9H), −0.05 (s, 3H), −0.22 (s, 3H). 13C NMR (75 MHz,
CDCl3): δ = 168.3, 165.9, 165.3, 138.8, 133.7, 133.4, 130.0, 129.7, 129.5, 128.5, 128.2,
87.2, 80.4, 76.6, 70.9, 70.7, 52.8, 25.6, 21.4, 18.0, −4.2, −4.9. FAB MS [M+H]+ m/z
calc: 637.2291, found: 637.2284.
Methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-α-d-glucopyranosyl-
uronate trichloroacetimidate(6). To a solution of NIS (6.6 g, 29.2 mmol), and
TfOH (0.2 ml, 2.2 mmol) in CH2Cl2 (290 ml) and THF (7.5 ml) was added a mixture
of 12 (14.3 g, 22.5 mmol) in CH2Cl2 (160 ml) and H2O. After 5.5 h, the mixture was
quenched by the addition of 1 M Na2S2O3 and diluted with CH2Cl2. The aqueous
layer was extracted three times with CH2Cl2, and the combined organic layers were
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washed with brine and dried over Mg2SO4. After the mixture was filtered and con-
centrated, the resulting material was purified by SiO2 chromatography (15% → 30%
EtOAc:hexanes).
The resulting material was dissolved in CH2Cl2 (173 ml). Cl3CCN (13.5 ml, 135
mmol) and Cs2CO3 (2.9 g, 9 mmol) were added and the mixture was allowed to
stir at room temperature. After 8 h, the solution was concentrated and purified by
SiO2 chromatography (10% EtOAc/hexanes + 0.1% Et3N) to afford the GlcA donor
6 (13.5 g, 89%) as a white foam. 1H NMR (300 MHz, CDCl3): δ = 8.60 (s, 1H),
7.96–7.87 (m, 4H), 7.53–7.29 (m, 6H), 6.74 (d, J = 4 Hz, 1H), 5.99 (dd, J = 9, 10
Hz, 1H), 5.43 (dd, J = 4, 10 Hz, 1H), 4.51 (d, J = 9.5 Hz, 1H), 4.38 (dd, J = 9.5,
9.5 Hz, 1H), 3.81 (s, 3H), 0.74 (s, 9H), −0.01 (s, 3H), −0.15 (s, 3H). 13C NMR (75
MHz, CDCl3): δ = 168.7, 165.7, 165.7, 160.8, 133.7, 133.5, 130.1, 129.9, 129.7, 128.6,
93.4, 74.6, 72.5, 70.9, 70.8, 53.0, 25.7, 18.0, −4.1, −4.9. ESI MS [M+Na]+ m/z calc:
696.1, found: 696.2.
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-d-gluco-
pyranosyluronate)-(1→3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-tri-
chloroacetamido-β-d-galactopyranoside (5). A mixture of GlcA donor 6 (1.25 g,
1.85 mmol) and GlcN acceptor 7 (0.745 g, 1.54 mmol) was coevaporated three times
in toluene and dried in vacuo overnight. The mixture was dissolved in CH2Cl2 (16.5
ml) and activated 4 Å powdered molecular sieves (3 g) were added. After stirring at
room temperature for 1 h, the mixture was cooled to −40 ◦C and stirred an addi-
tional 30 min. A solution of TMSOTf (1 M in CH2Cl2, 1.16 ml, 1.16 mmol) at −40
◦C was added to the reaction dropwise. After 30 min, the reaction was warmed to
−20 ◦C over a period of 30 min at which point Et3N was added and the mixture was
warmed to room temperature. The mixture was filtered through a plug of celite and
concentrated. The resulting yellow syrup was purified by SiO2 chromatography (5%
→ 50% EtOAc:hexanes + 0.1 Et3N) to afford the key disaccharide 5 (1.13 g, 74%)
as a white solid. 1H NMR (300 MHz, CDCl3): δ = 7.87–7.82 (m, 4H), 7.48–7.39 (m,
4H), 7.35–7.26 (m, 4H), 6.86 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 7 Hz, 1H), 5.89–5.76
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(m, 1H), 5.45 (s, 1H), 5.52–5.39 (m, 2H), 5.22 (dd, J = 1.5, 17.5 Hz, 1H), 4.67 (dd, J
= 3.5, 11 Hz, 1H), 4.36–4.27 (m, 4H), 4.10 (d, J = 9.5 Hz, 1H), 4.07–4.01 (m, 2H),
3.79 (s, 6H), 3.77–3.68 (m, 1H), 3.48 (s, 1H), 0.72 (s, 9H), −0.08 (s, 3H), −0.23 (s,
3H). 13C NMR (75 MHz, CDCl3): δ = 168.7, 165.7, 165.2, 162.3, 160.0, 133.8, 133.4,
130.5, 130.0, 129.9, 129.2, 128.5, 127.7, 118.2, 113.6, 100.7, 100.6, 97.8, 92.3, 76.4,
75.8, 75.6, 73.6, 72.0, 70.9, 69.2, 66.8, 55.6, 55.4, 52.9, 25.7, 18.1, −4.0, −4.7. FAB
MS [M]+ m/z calc: 992.2250, found: 992.2255.
Allyl (methyl 2,3-di-O-benzoyl-β-d-glucopyranosyluronate)-(1→3)-4,6-O-
p-methoxybenzylidene-2-deoxy-2-trichloroacetamido-β-d-galactopyranoside
(3). To a solution of 5 (1.0 g, 1.0 mmol) in THF (16 ml) and pyridine (16 ml) at
0 ◦C was added HF · pyridine (5.2 ml). The reaction mixture was warmed to room
temperature and stirred an additional 18 h. The mixture was diluted with EtOAc
and washed with 10% aqueous CuSO4. The aqueous layer was extracted three times
with EtOAc and the combined organic layers were washed with saturated aqueous
NaHCO3 and dried with MgSO4. After filtration, the mixture was concentrated and
purified by SiO2 chromatography (30% → 60% EtOAc:hexanes) to afford the disac-
charide acceptor 3 as a white solid (0.774 g, 88%). 1H NMR (300 MHz, CDCl3): δ =
7.93–7.87 (m, 4H), 7.50–7.42 (m, 4H), 7.36–7.26 (m, 4H), 7.01 (d, J = 6.5 Hz, 1H),
6.89 (d, J = 8.5 Hz, 2H), 5.89–5.77 (m, 1H), 5.47 (m, 3H), 5.26–5.12 (m, 4H), 4.73
(dd, J = 3.5, 11.5 Hz, 1H), 4.41–4.28 (m, 3H), 4.19 (m, 1H), 4.12–4.02 (m, 3H), 3.83
(s, 3H), 3.81 (s, 3H), 3.48 (s, 1H), 3.45 (d, J = 3.5 Hz, 1H), 13C NMR (75 MHz,
CDCl3): δ = 169.3, 166.6, 165.2, 162.3, 160.1, 133.8, 133.6, 133.5, 130.4, 130.1, 130.0,
129.2, 129.1, 128.7, 128.6, 127.5, 118.2, 113.7, 100.8, 100.7, 97.7, 76.1, 75.4, 74.3, 74.1,
71.4, 70.7, 69.3, 66.8, 55.7, 53.4. ESI MS [M− H]− m/z calc: 880.1, found: 880.2.
Methyl (2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-d-glucopyranosyl-
uronate)-(1→3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-trichloroacetamido-
α-d-galactopyranoside trichloroacetimidate (4). To a solution of 5 (303.7 mg,
0.305 mmol) in CH2Cl2 (4.9 mL) was added Grubb’s second-generation catalyst (52
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mg, 0.061 mmol) and the mixture was allowed to stir at room temperature. After 2
h, the solvent was removed and the brown residue was redissolved in THF (5.8 ml),
water (1.2 ml), and pyridine (92 µl). Iodine (153 mg,) was added, and the mixture
was stirred at room temperature. After 2 h, the solvent was removed and the residue
was dissolved in EtOAc and washed with 5% aqueous Na2SO3, saturated aqueous
NaHCO3, brine, and dried over MgSO4. After filtration, the solvent was removed
and the residue was purified by SiO2 chromatography (40% → 60% EtOAc/hexanes)
to give a white solid (276.8 mg, 95%).
To a solution of pure hemiacetal (166.5 g, 0.17 mmol) and Cl3CCN (0.26 ml, 2.6
mmol) in CH2Cl2 (6.8 ml) at 0 ◦C was added DBU (10 µl, 0.07 mmol). After 15
min, Et3N was added and the solvent was removed in vacuo. Purification via SiO2
chromatography (50% EtOAc/hexanes + 0.1% Et3N) returned disaccharide donor 4
(168.3 mg, 90%) as a yellow foam. 1H NMR (300 MHz, CDCl3): δ = 8.69 (s, 1H),
7.90 (m, 4H), 7.51 (m, 2H), 7.42–7.26 (m, 4H), 7.00 (d, J = 9 Hz, 2H), 6.93 (d, J =
5.5 Hz, 1H), 6.77 (d, J = 2 Hz, 1H), 6.68 (d, J = 9 Hz, 2H), 5.52 (dd, J = 8.5, 8.5
Hz, 1H), 5.45 (dd, J = 8.5, 8.5 Hz, 1H), 5.27 (d, J = 8 Hz, 2H), 5.17 (s, 1H), 4.62
(m, 2H), 4.49 (m, 1H), 4.31 (m, 2H), 4.18 (d, J = 9 Hz, 1H), 4.00 (d, J = 12.5 Hz,
1H), 3.94 (s, 1H), 3.75 (s, 3H), 3.74 (s, 3H), 0.73 (s, 9H), −0.06 (s, 3H), −0.19 (s,
3H). 13C NMR (75 MHz, CDCl3): δ = 168.1, 165.9, 165.6, 162.0, 160.4, 133.9, 133.6,
130.1, 129.9, 129.4, 128.7, 128.6, 127.6, 113.6, 101.1, 98.4, 95.3, 77.2, 75.5, 74.4, 71.2,
70.9, 69.2, 69.0, 65.5, 55.6, 53.0, 50.5, 46.5, 25.7, −4.0, −4.8.
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-d-gluco-
pyranosyluronate)-(1→3)-(4,6-O-p-methoxybenzylidene-2-deoxy-2-tri-
chloroacetamido-β-d-galactopyranosyl)-(1→4)-(methyl 2,3-di-O-benzoyl-4-
O-tert-butyldimethylsilyl-β-d-glucopyranosyluronate)-(1→3)-4,6-O-p-
methoxybenzylidene-2-deoxy-2-trichloroacetamido-β-d-galactopyranosyl (2).
A mixture of donor 4 (0.10 g, 0.088 mmol) and acceptor 3 (0.065 g, 0.074 mmol) was
coevaporated three times with toluene and placed under vacuum overnight. The
mixture was dissolved in CH2Cl2 (3.O ml) and activated 4 Å powdered molecular
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sieves were added. After stirring at room temperature, the mixture was cooled to
−78 ◦C and stirred an additional 30 min. A solution of TMSOTf (0.5 M solution in
CH2Cl2, 30 µl, 0.015 mmol) at −78 ◦C was added dropwise to the mixture. After
10 min, the solution was warmed to −20 ◦C, and stirred for 30 min, then quenched
with Et3N. The mixture was filtered through a pad of celite and concentrated. The
residue was purified by Sephadex LH-20 gel filtration (1:1 CH2Cl2:MeOH) followed
SiO2 chromatography (40%→ 50% EtOAc/hexane + Et3N) afforded tetrasaccharide
2 (74 mg, 54%) as a white solid. 1H NMR (600 MHz, CDCl3): δ = 7.88–7.80 (m, 8H),
7.49–7.45 (m, 4H), 7.38–7.28 (m, 8H), 7.22–7.20 (m, 2H), 7.06 (d, J = 8.4 Hz, 2H),
6.93 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 6.6 Hz, 1H), 6.74 (d, J = 8.4 Hz, 2H), 6.66 (d,
J = 7.2 Hz, 1H), 5.87–5.81 (m, 1H), 5.58 (dd, J = 8, 8 Hz, 1H), 5.49 (s, 1H), 5.44
(dd, J = 8.5, 8.5 Hz), 5.35 (m, 2H), 5.23 (d, J = 18 Hz, 1H), 5.20 (s, 1H), 5.15–5.12
(m, 2H), 5.11 (d, J = 8 Hz, 1H), 5.03 (d, J = 7 Hz, 1H), 5.00 (d, J = 8.5 Hz, 1H),
4.68 (dd, J = 3.5, 11 Hz, 1H), 4.58 (dd, J = 9.0, 9.0 Hz, 1H), 4.39–4.30 (m, 5H),
4.14 (m, 2H), 4.06–3.91 (m, 3H), 3.83 (s, 3H), 3.81–3.68 (m, 4H), 3.80 (s, 3H), 3.80
(s, 3H), 3.79 (s, 3H), 3.48 (s, 1H), 3.10 (s, 1H), 0.72 (s, 9H), −0.09 (s, 3H), −0.24 (s,
3H). 13C NMR (75 MHz, CDCl3): δ = 168.8, 168.4, 165.7, 165.4, 165.2, 165.1, 162.2,
161.9, 160.0, 159.8, 133.8, 133.4, 133.3, 133.1, 130.5, 130.4, 130.2, 130.1, 130.0, 129.9,
129.6, 129.5, 129.2, 129.1, 128.6, 128.5, 128.4, 127.9, 127.8, 118.2, 113.7, 113.4, 100.8,
100.5, 100.4, 100.2, 98.6, 97.7, 77.4, 76.4, 75.9, 75.8, 75.3, 75.0, 74.2, 74.1, 73.5, 73.4,
72.1, 71.9, 70.8, 70.6, 69.3, 68.4, 66.9, 55.7, 55.6, 54.8, 53.5, 52.8, 25.7, 18.1, -4.1, -4.8.
ESI MS [M + H]+ m/z calc: 1819.4, found: 1819.5.
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-d-gluco-
pyranosyluronate)-(1→3)-(2-deoxy-2-acetamido-β-d-galactopyranosyl)-
(1→4)-(methyl 2,3-di-O-benzoyl-β-d-glucopyranosyluronate)-(1→3)-2-
deoxy-2-acetamido-β-d-galactopyranoside (17). To a solution of 2 (98 mg,
0.054 mmol) in benzene (1.7 mL) and N,N -dimethylacetamide (0.43 mL) were added
Bu3SnH (0.20 mL, 0.97 mmol) and AIBN (5.2 mg). The reaction was stirred at room
temperature for 30 min and then was heated at 80 ◦C. After stirring 5 h, the mixture
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was cooled to room temperature, concentrated, and purified by SiO2 chromatography
(50% EtOAc/hexanes + 0.1% Et3N, then 99.9% EtOAc/Et3N) to give the product
as a white solid (80 mg, 92%). In a flask protected from the light, the resulting white
solid (42 mg, 0.026 mmol) was dissolved in CH3CN (840 µl) and H2O (90 µl). DDQ
(24 mg, 0.10 mmol) was added and the reaction stirred for at room temperature. The
reaction mixture was purified by Sephadex LH-20 gel filtration chromatography (1:1
CH2Cl2:MeOH) to afford 17 as a pale yellow solid (34 mg, 93%). 1H NMR (300 MHz,
CD3OD): δ = 7.85–7.76 (m, 8H), 7.47–7.42 (m, 4H), 7.36–7.27 (m, 8H), 5.79–5.66
(m, 1H), 5.52 (dd, J = 8.5, 8.5 Hz, 1H), 5.51 (dd, J = 8.5, 10 Hz, 1H), 5.27–5.19 (m,
3H), 5.12 (dd, J = 1.5 Hz, 17.5 Hz), 5.00–4.96 (m, 4H), 4.43–4.42 (m, 1H), 4.32–4.26
(m, 2H), 4.20–4.10 (m, 5H), 4.00 (d, J = 2.4 Hz, 1H), 3.96–3.88 (m, 3H), 3.70 (s,
3H), 3.69 (s, 3H), 3.41–3.35 (m, 2H), 3.17–3.10 (m, 3H), 3.04–3.00 (m, 1H), 1.20 (s,
3H), 1.18 (s, 3H), 0.66 (s, 9H), −0.10 (s, 3H), −0.26 (s, 3H). ESI MS [M+Na]+ m/z
calc: 1397.5, found 1397.6.
Allyl (sodium β-d-glucopyranosyluronate)-(1→3)-(4,6-di-O-sodium
sulfonato-2-deoxy-2-acetamido-β-d-galactopyranosyl)-(1→4)-(sodium
β-d-glucopyranosyluronate)-(1→3)-4,6-di-O-sodium sulfonato-2-deoxy-
2-acetamido-β-d-galactopyranoside (1: CS-E). To a solution of 17 (23 mg,
0.017 mmol) in DMF (600 µl) was added SO3 · TMA (90 mg, 0.64 mmol). The
reaction was stirred at 50 ◦C for 2 d, at which time additional SO3 · TMA (50 mg,
0.36 mmol) was added. After stirring an additional 1 d at 50 ◦C, the mixture was
quenched with MeOH, and concentrated to afford a yellow solid. Purification via
Sephadex LH-20 gel filtration (1:1 CH2Cl2:MeOH), followed by SiO2 chromatography
(6:2:1 EtOAc:MeOH:H2O) afforded the product as a white solid (24 mg, 84%).
The resulting sulfated compound (24 mg, 0.014 mmol) in a plastic centrifuge tube
was dissolved in pyridine (585 µl), THF (585 µl), and H2O (50 µl). The mixture was
cooled to 0 ◦C and HF · pyridine (94 µl, 5.2 mmol) was added. After stirring at 0
◦C for 1 h, the mixture was warmed to room temperature and stirred overnight. The
reaction mixture was purified by Sephadex LH-20 gel filtration (1:1 CH2Cl2:MeOH).
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The product was concentrated to afford a white solid (20 mg, 91%) that was imme-
diately used in the next reaction.
To a solution of the resulting alcohol (20 mg, 0.013 mmol) in THF (2.3 ml) and
H2O (1.7 mL) at 0 ◦C, were added 1 M aq. LiOH (330 µl, 0.33 mmol) and 30%
H2O2 (170 µl, 0.0015 mmol). The reaction was stirred at 0 ◦C for 1 h then allowed
to warm to room temperature. After stirring 12 h, 4 M NaOH (230 µl, 0.46 mmol)
and MeOH (1.7 mL) were added and the reaction stirred for another 12 h. The pH
of the reaction mixture was carefully lowered to ∼6 with Amberlyst IR-120 resin,
filtered, and lyophilized to afford an orange solid. Purification by Sephadex G-25 UF
gel filtration chromatography (0.9% NaCl in H2O) and desalting with Sephadex G-25
UF (100% H2O) to afforded 1 (CS-E) as a white solid upon lyophilization (10.7 mg,
70%). 1H NMR (600 MHz, D2O): δ = 5.94–5.88 (m, 1H), 5.33 (dd, J = 1.5, 17 Hz,
1H), 5.27 (d, J = 10 Hz, 1H), 4.85 (s, 1H), 4.79 (d, J = 1 Hz, 1H), 4.61 (dd, J = 4,
8 Hz, 1H), 4.59 (d, J = 8 Hz, 1H), 4.49 (d, J = 8 Hz, 1H), 4.47 (d, J = 8 Hz, 1H),
4.35 (dd, J = 5.5, 13 Hz, 1H), 4.29 (dd, J = 3, 11.5 Hz, 2H), 4.24–4.18 (m, 4H), 4.13
(dd, J = 2.5, 8.5 Hz, 1H), 4.09–4.05 (m, 4H), 3.77 (dd, J = 9.5, 9.5 Hz, 1H), 3.69 (d,
J = 9.5 Hz, 1H), 3.67 (d, J = 9.5 Hz, 1H), 3.61 (dd, J = 9, 9.5 Hz, 1H), 3.52 (dd, J
= 9, 9 Hz, 1H), 3.47 (dd, J = 9, 9.5 Hz, 1H), 3.41 (dd, J = 8.5, 9 Hz, 1H), 3.34 (dd,
J = 8, 9 Hz, 1H), 2.04 (s, 3H), 2.01 (s, 3H). ESI MS [M − Na]− m/z calc: 1245.0,
found 1245.0.
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